StreetAccount

AstraZeneca (AZN.LN) Full SA coverage

Description Website Subsidiaries Edgar Filings Sector: Healthcare Industry: Major Drugs Industry Data: Pharmaceuticals Market Cap (USD): 248.88 B

Earnings Profile

Last Earnings Call Transcript
Q2 2026 - 27-Jul-26

Next Earnings ReleasePreview Pending
30-Oct-26 Pre-Mkt (Confirmed)

Earnings Central

FactSet Consensus	Current Q3 (Sep)	Next Q4 (Dec)	Current Year	Next Year
EPS	$2.63	$2.45	$10.23	$11.50
Revenue	$16.05B	$16.65B	$63.35B	$67.63B

Show Company Data

TAGRISSO

	Actual	Cons	Actual	Cons	Actual	Cons	Actual	Cons
	Q1		Q2		Q3		Q4
2026	1833.0000	1877.0000	1941.0000	1971.0000
2025	1679.0000	1754.0000	1810.0000	1752.0000	1864.0000	1851.0000	1902.0000	1891.0000
2024	1595.0000	1493.0000	1608.0000	1593.0000	1674.0000	1620.0000	1703.0000	1651.0000
2023	1424.0000	1401.0000	1491.0000	1480.0000	1465.0000	1500.0000	1419.0000	1475.0000
2022	1304.0000	1309.0000	1400.0000	1398.0000	1398.0000	1390.0000	1342.0000	1437.0000
2021	1149.0000	1162.2000	1306.0000	1280.0000	1247.0000	1384.0000	1314.0000	1351.0000
2020	982.0000	879.0000	1034.0000	1006.5000	1155.0000	1111.6000	1157.0000	1134.3000
2019	630.0000	623.0000	784.0000	697.0000	891.0000	854.0000	679.2000	730.4000
2018	338.0000	324.0000	422.0000	392.0000	506.0000	478.0000	594.0000
2017	132.6000	170.4000	177.3000	150.9000	248.0000	258.0000	304.0000	290.0000
2016	41.3000	27.4000	74.5000	59.1000	107.6000	99.2000	117.3000	126.3000

IMFINZI

	Actual	Cons	Actual	Cons	Actual	Cons	Actual	Cons
	Q1		Q2		Q3		Q4
2026	1694.0000	1781.0000	1854.0000	1935.0000
2025	1261.0000	1368.0000	1455.0000	1434.0000	1601.0000	1572.0000	1747.0000	1703.0000
2024	1113.0000	1158.0000	1147.0000	1230.0000	1203.0000	1247.0000	1254.0000	1246.0000
2023	900.0000	728.0000	1076.0000	923.0000	1126.0000	1064.0000	1135.0000	1165.0000
2022	599.0000	644.0000	695.0000	662.0000	737.0000	700.0000	752.0000	756.0000
2021	556.0000	581.0000	604.0000	626.0000	618.0000	645.0000	634.0000	651.0000
2020	462.0000	438.0000	492.0000	473.0000	533.0000	545.0000	555.0000	573.0000
2019			338.0000	328.0000	412.0000	374.0000	424.0000	456.0000

LYNPARZA

	Actual	Cons	Actual	Cons	Actual	Cons	Actual	Cons
	Q1		Q2		Q3		Q4
2026	781.0000	782.0000	829.0000	869.0000
2025	726.0000	776.0000	838.0000	803.0000	837.0000	851.0000	878.0000	882.0000
2024	705.0000	701.0000	744.0000	762.0000	778.0000	757.0000	1444.0000	795.0000
2023	651.0000	701.0000	717.0000	729.0000	702.0000	721.0000	741.0000	737.0000
2022	617.0000	648.0000	673.0000	676.0000	659.0000	690.0000	689.0000	703.0000
2021	543.0000	528.0000	588.0000	579.0000	588.0000	608.0000	629.0000	622.0000
2020	397.0000	362.0000	419.0000	409.0000	464.0000	453.8000	496.0000	498.0000
2019	237.0000		283.0000	261.0000	327.0000	303.0000	351.0000	359.0000
2018							209.0000

ZOLADEX

	Actual	Cons	Actual	Cons	Actual	Cons	Actual	Cons
	Q1		Q2		Q3		Q4
2026	315.0000	292.0000	316.0000	292.0000
2025	293.0000	267.0000	294.0000	274.0000	296.0000	278.0000	266.0000	256.0000
2024	285.0000	218.0000	282.0000	230.0000	278.0000	254.0000	252.0000	256.0000
2023	227.0000	221.0000	233.0000	226.0000	239.0000	230.0000	254.0000	219.0000
2022	240.0000	219.0000	236.0000	232.0000	240.0000	230.0000	210.0000	220.0000
2021	221.0000	227.0000	244.0000	224.0000	250.0000	231.0000	232.0000	231.0000
2020	228.0000	195.0000	217.0000	199.0000	233.0000	228.0000	216.0000	211.0000
2019	194.0000	175.0000	197.0000	188.0000	226.0000	197.0000	196.0000	203.0000
2018	184.0000	178.0000	192.0000	172.0000	194.0000	176.0000	182.0000
2017	185.0000	180.8000	178.0000	190.0000	185.0000	181.0000	187.0000	211.0000
2016	178.0000	191.4000	204.0000	203.0000	199.0000	204.0000	235.0000	194.3000
2015	194.0000	193.3000	215.0000	199.0000	186.0000	208.0000	198.0000	214.4000
2014	221.0000	226.0000	236.0000	253.6700	240.0000	231.0000	227.0000	227.0000
2013	240.0000	257.1000	263.0000	248.4000	246.0000	253.3000	247.0000	249.1000
2012	273.0000	274.2000	275.0000	289.3900	274.0000	284.0000	271.0000	272.5000
2011	275.0000	268.0000	302.0000	291.2000	304.0000	243.7500	298.0000	307.8000
2010	265.0000	248.2000	280.0000	269.2900	268.0000	275.0000	302.0000	262.2500
2009	232.0000	242.0000	272.0000	271.0000	282.0000	273.4000	300.0000	278.8900
2008	255.0000	273.0000	310.0000	279.0000	295.0000	277.0000	278.0000	308.7140
2007	249.0000		275.0000	254.0000	273.0000	271.0000	307.0000	291.0000
2006	231.0000	242.0000	250.0000	264.0000	255.0000	265.0000	272.0000	266.0000

FARXIGA

	Actual	Cons	Actual	Cons	Actual	Cons	Actual	Cons
	Q1		Q2		Q3		Q4
2026	2193.0000	1965.0000	1804.0000	1784.0000
2025	2058.0000	1982.0000	2151.0000	2101.0000	2135.0000	2072.0000	2060.0000	1981.0000
2024	1892.0000	1592.0000	1945.0000	1842.0000	1943.0000	1945.0000	1938.0000	1963.0000
2023	1299.0000	1263.0000	1505.0000	1359.0000	1554.0000	1469.0000	1606.0000	1588.0000
2022	1000.0000	831.0000	1103.0000	1021.0000	1101.0000	1100.0000	1177.0000	1155.0000
2021	625.0000	565.0000	734.0000	644.0000	797.0000	765.0000	849.0000	840.0000
2020	407.0000	404.0000	443.0000	423.0000	525.0000	479.0000	587.0000	546.0000
2019	349.0000	359.0000	377.0000	391.0000	398.0000	404.0000	419.0000	447.0000
2018	299.0000	285.0000	340.0000	330.0000	355.0000	361.0000	397.0000
2017	207.0000	239.6000	250.0000	252.0000	285.0000	285.0000	332.0000	299.0000
2016	165.0000	161.0000	211.0000	189.1000	220.0000	213.0000	239.0000	239.8000
2015	76.0000		129.0000		135.0000	95.0000	152.0000	155.2000

BRILINTA

	Actual	Cons	Actual	Cons	Actual	Cons	Actual	Cons
	Q1		Q2		Q3		Q4
2026	105.0000	146.0000	80.0000	92.0000
2025	305.0000	293.0000	215.0000	256.0000	146.0000	167.0000	158.0000	146.0000
2024	323.0000	320.0000	342.0000	315.0000	327.0000	315.0000	341.0000	313.0000
2023	334.0000	314.0000	331.0000	343.0000	331.0000	331.0000	329.0000	335.0000
2022	325.0000	358.0000	350.0000	353.0000	338.0000	351.0000	345.0000	330.0000
2021	374.0000	381.0000	375.0000	396.0000	375.0000	372.0000	348.0000	372.0000
2020	408.0000	403.0000	437.0000	416.0000	385.0000	450.0000	363.0000	427.0000
2019	348.0000	338.0000	389.0000	364.0000	416.0000	394.0000	428.0000	448.0000
2018	293.0000	291.0000	316.0000	335.0000	336.0000	337.0000	376.0000
2017	224.0000	241.0000	272.0000	260.5000	284.0000	271.0000	299.0000	307.0000
2016	181.0000	185.0000	214.0000	197.4000	208.0000		236.0000	226.7000
2015	131.0000	137.4000	144.0000	152.6000	170.0000	160.5000	174.0000	181.0000
2014					127.0000	129.0000	133.0000	139.5000

CRESTOR

	Actual	Cons	Actual	Cons	Actual	Cons	Actual	Cons
	Q1		Q2		Q3		Q4
2026	355.0000	326.0000	332.0000	335.0000
2025	317.0000	292.0000	320.0000	304.0000	306.0000	312.0000	276.0000	288.0000
2024	297.0000	289.0000	293.0000	269.0000	304.0000	270.0000	261.0000	261.0000
2023	305.0000	247.0000	280.0000	273.0000	275.0000	265.0000	247.0000	229.0000
2022	267.0000	250.0000	280.0000	245.0000	277.0000	261.0000	224.0000	243.0000
2021	274.0000	261.0000	265.0000	256.0000	298.0000	264.0000	259.0000	260.0000
2020	302.0000	277.0000	282.0000	263.0000	301.0000	284.0000	298.0000	274.0000
2019	335.0000	323.0000	310.0000	286.0000	337.0000	301.0000	296.0000	311.0000
2018	289.0000	446.0000	338.0000	346.0000	353.0000	338.0000	353.0000
2017	631.0000	525.5000	560.0000	572.0000	580.0000	513.0000	594.0000	493.0000
2016	1156.0000	1083.4000	926.0000	993.0000	688.0000	690.0000	631.0000	623.4000
2015	1167.0000	1212.5000	1310.0000	1280.0000	1218.0000	1200.0000	1322.0000	1260.2000
2014	1332.0000	1250.0000	1450.0000	1384.6700	1342.0000	1333.0000	1388.0000	1383.6000
2013	1323.0000	1438.3000	1480.0000	1436.4000	1356.0000	1438.3000	1463.0000	1475.6000
2012	1500.0000	1581.8800	1587.0000	1.6500	1544.0000	1540.0000	1622.0000	1602.5000
2011	1480.0000	1541.9200	1710.0000	1626.6300	1660.0000	1615.6300	1771.0000	1748.1400
2010	1300.0000	1234.8800	1430.0000	1369.3800	1370.0000	1420.5000	1590.0000	1445.2500
2009	969.0000	969.2220	1130.0000	1092.4300	1150.0000	1099.7500	1260.0000	1234.3000
2008	772.0000		916.0000		922.0000	912.0000	987.0000	991.2500
2007	628.0000		678.0000	688.0000	691.0000	714.0000	799.0000
2006	387.0000	393.0000	480.0000	442.0000	536.0000	531.0000	625.0000	585.0000

SYMBICORT

	Actual	Cons	Actual	Cons	Actual	Cons	Actual	Cons
	Q1		Q2		Q3		Q4
2026	747.0000	716.0000	671.0000	696.0000
2025	723.0000	737.0000	715.0000	714.0000	742.0000	685.0000	704.0000	711.0000
2024	769.0000	555.0000	722.0000	566.0000	705.0000	586.0000	684.0000	632.0000
2023	688.0000	604.0000	600.0000	581.0000	555.0000	555.0000	520.0000	535.0000
2022	674.0000	654.0000	614.0000	628.0000	630.0000	601.0000	620.0000	616.0000
2021	691.0000	702.0000	680.0000	642.0000	676.0000	617.0000	681.0000	664.0000
2020	790.0000	571.0000	653.0000	555.0000	599.0000	624.0000	680.0000	674.0000
2019	585.0000	563.0000	585.0000	594.0000	613.0000	560.0000	712.0000	604.0000
2018	534.0000	643.0000	372.0000	648.0000	619.0000	611.0000	636.0000
2017	677.0000	675.9000	706.0000	699.0000	668.0000	656.0000	752.0000	696.0000
2016	749.0000	798.2000	803.0000	795.0000	697.0000	816.0000	740.0000	755.9000
2015	845.0000	873.2000	842.0000	846.0000	848.0000	872.0000	859.0000	884.0000
2014	928.0000	889.0000	928.0000	949.6700	967.0000	903.0000	978.0000	1022.9000
2013	826.3000	791.1000	842.0000	864.8000	839.0000	837.1000	976.0000	945.2000
2012	723.0000	799.5700	795.0000	793.6300	785.0000	773.0000	891.0000	872.2000
2011	752.0000	789.3000	802.0000	764.1300	755.0000	733.2500	839.0000	822.5700
2010	701.0000	646.8800	664.0000	683.8800	640.0000	663.7500	741.0000	710.1300
2009	515.0000	519.7500	551.0000	560.8600	562.0000	559.3800	666.0000	625.5500
2008	471.0000	482.0000	518.0000	529.0000	504.0000	512.0000	514.0000	536.2500
2007	354.0000		414.0000	378.0000	371.0000	384.0000	436.0000	424.0000
2006	277.0000	290.0000	308.0000	293.0000	276.0000	308.0000	323.0000	321.0000

PULMICORT

	Actual	Cons	Actual	Cons	Actual	Cons	Actual	Cons
	Q1		Q2		Q3		Q4
2026	149.0000	142.0000	120.0000	100.0000
2025	158.0000	211.0000	106.0000	145.0000	93.0000	113.0000	161.0000	125.0000
2024	224.0000	207.0000	155.0000	123.0000	138.0000	156.0000	164.0000	183.0000
2023	221.0000	168.0000	124.0000	128.0000	148.0000	133.0000	219.0000	156.0000
2022	217.0000	236.0000	116.0000	151.0000	145.0000	139.0000	166.0000	150.0000
2021	330.0000	304.0000	167.0000	194.0000	217.0000	146.0000	248.0000	220.0000
2020	380.0000	377.0000	97.0000	322.0000	151.0000	172.0000	368.0000	223.0000
2019	383.0000	352.0000	333.0000	307.0000	337.0000	297.0000	413.0000	416.0000
2018	346.0000	380.0000	287.0000	239.0000	264.0000	259.0000	389.0000
2017	337.0000	323.3000	226.0000	253.0000	242.0000	234.0000	371.0000	302.0000
2016	310.0000	286.0000	239.0000	248.0000	224.0000	242.0000	288.0000	280.9000
2015	286.0000	198.6000	232.0000	207.0000	222.0000	215.0000	274.0000	259.8000
2014	263.0000	224.0000	209.0000	235.3300	205.0000	188.0000	269.0000	245.9000
2013	233.0000	224.4000	213.0000	207.1000	176.0000	194.6000	245.0000	225.6000
2012	227.0000	234.9300	206.0000	211.4300	191.0000	179.0000	242.0000	218.2900
2011	248.0000	204.2900	236.0000	211.7100	185.0000	191.8300	223.0000	226.8600
2010	243.0000	221.5700	216.0000	207.6300	180.0000	200.3800	233.0000	199.4300
2009	292.0000	304.5710	311.0000	304.9100	320.0000	285.2700	387.0000	346.0000
2008	411.0000	420.0000	383.0000	336.0000	304.0000	305.0000	397.0000	322.3330
2007	401.0000		320.0000	337.0000	286.0000	285.0000	447.0000	415.0000
2006	328.0000	324.0000	301.0000	296.0000	263.0000	259.0000	400.0000	353.0000

Hide Company Data

Portfolios Manage

AZN.LN appears in 1 portfolio:

Blank

Upcoming Events

Start Date	End Date	Event
18-Aug-26		SEB Nordic Large Cap Seminar Stockholm
mid 2026		NDA submission-- Wilson Disease ALXN1840
02-Sep-26		Jefferies Swiss Healthcare Summit Zurich
Display All 47 Events

08-Sep-26		Kepler Autumn Conference Paris
14-Sep-26		Morgan Stanley Global Healthcare Conference New York
17-Sep-26		AstraZeneca Investor Meeting - SEB
22-Sep-26		Bank of America Global Healthcare Conference Charlotte
during Q3 2026		Delayed: Datroway – non-squamous NSCLC (1L) (TROPION-Lung07) DATROWAY
during Q3 2026		Delayed: Regulatory approval -- Calquence – MCL (1L) (ECHO) in Japan Calquence
10-Nov-26		UBS European Conference Zurich
11-Nov-26		AstraZeneca Investor Meeting - TD Cowen
30-Nov-26		Berenberg European Conference Hamburg
during Q4 2026		Phase 2 proof of concept ZORYVE-----Vitiligo ZORYVE
during H2 2026		Phase 3 data readout for Imfinzi combination oleclumab/monalizumab ---unresectable stage III NSCLC (PACIFIC-9) IMFINZI
during H2 2026		Regulatory approval --- high-risk non-muscle invasive bladder cancer (POTOMAC) (JP) IMFINZI
during H2 2026		Phase 3 data readout for Ultomiris – CSA-AKI (ARTEMIS) Ultomiris
during H2 2026		Phase 3 data readout for tozorakimab – LRTD (TILIA) tozorakimab
during H2 2026		gefurulimab – generalised myasthenia gravis (PREVAIL) gefurulimab
during H2 2026		Anselamimab – AL amyloidosis (CARES) IN (US) CAEL-101
during H2 2026		Phase 3 readout for Tezspire – eosinophilic esophagitis (EoE) (CROSSING) TEZSPIRE
during H2 2026		Enhertu – 1L HER2+ mBC (DESTINY-Breast09) (EU, JP, CN) Enhertu
during H2 2026		Topline results from the Phase 3 SAFFRON study--2nd-Line (2L) Non-Small Cell Lung Cancer (NSCLC) Orpathys
during H2 2026		Submission for regulatory approval -- ENPP1 deficiency BMN 401
during H2 2026		Saphnelo – systemic sclerosis (DAISY) SAPHNELO
during H2 2026		Saphnelo – lupus nephritis (IRIS) SAPHNELO
during H2 2026		camizestrant – HR+ HER2- met. breast cancer (1L) (SERENA 4) ETCAMAH
during H2 2026		Datroway + Tagrisso – EGFRm NSCLC (2L) (TROPION-Lung15) DATROWAY
during H2 2026		Datroway + Imfinzi – non-squamous/non-squamous TROP2+ NSCLC (1L) (AVANZAR ) DATROWAY
during H2 2026		Data read-out from PACIFIC-9 in non-small cell lung cancer monalizumab
during H2 2026		Expected topline results from TEBE-AM - trial in Cutaenous melanoma KIMMTRAK
during 2026		Expected topline results from ATOM- trial in uveal (or ocular) melanoma KIMMTRAK
by the end of 2026		Topline results from the Phase 3 SANOVO study--1st-Line (1L) Non-Small Cell Lung Cancer (NSCLC) Orpathys
23-Feb-27		PDUFA -- sNDA for ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months ZORYVE
during Q1 2027		Phase 2 proof of concept ZORYVE-----hidradenitis suppurativa ZORYVE
during H2 2027		Phase 3 data readout for Imfinzi ---unresectable stage I/II NSCLC (PACIFIC-4) IMFINZI
during H2 2027		Topline data from ACCEL phase 3 study of IBSRELA in chronic idiopathic constipation Ibsrela
during 2027		Phase3 data readout for cliramitug – ATTR-CM (DepleTTR-CM) AZD0171
during 2027		Phase 3 data readout for laroprovstat – dyslipidemia (AZURE-LDL/AZURE-HeFH) AZD0780
during 2027		Phase 3 data readout for volrustomig – mNSCLC (1L) (eVOLVE-Lung02) volrustomig
during 2027		Phase 3 data readout for volrustomig – high-risk locally advanced cervical cancer (eVOLVE-Cervical) volrustomig
during 2027		Phase 3 data readout for Saphnelo – CLE (LAVENDER) SAPHNELO
during 2027		Phase 3 Data readout for Saphnelo – myositis (JASMINE) SAPHNELO
during 2027		Regulatory decision for Saphnelo – SLE (subcutaneous) (TULIP-SC) (CN) SAPHNELO
during 2027		Phase 3 readout for Truqap– 1L early relapse/ET resistant advanced HR+ BC (CAPItello-292) TRUQAP
during 2027		camizestrant – adj. switch HR+ HER2- early breast cancer (CAMBRIA-1) ETCAMAH
during 2027		Phase 3 Readout for TROPION-Breast05 in Datroway + Imfinzi 1L PD-L1 CPS = 10 in TNBC DATROWAY
during 2027		Phase3 readout of TROPION-Breast03 in Datroway + Imfinzi post-neoadj for TNBC DATROWAY
Hide Additional Events

Company News Date Range: 100 Days

Filtered by: All

Records Returned: 205
Related Company News

07-Aug-2026 19:13	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities finished broadly higher and a modest outperformer overall on Friday. Advancers beat decliners by nearly 4:1 on the XLV. Healthcare +0.78% vs S&P 500 +0.62%. All major health groups ended with gains for the session; most were higher by +1% to +2%. Pharma lagged the tape, the DRG only an inline +0.56% with Animal Health pullback resumed on pricing battle concerns. ZTS (6.0%) biggest decliner on XLV one-day after reporting results. ELAN also down another (8.6%). Managed Care today's leading gainer led by HUM +4.8%, bested only by MRNA +9.9% and VEEV +5.8% on the XLV. Vaccine maker saw its best week in a month. RMD (5.1%) after an inline print. The XBI +1.86% on Friday, green five-straight days, to extend its weekly performance above +7%. SMID-cap earnings again dominate newsflow, as well as the new FDA flexibility that led to Replimune's TUDRIQEV crossing the finish line. IPO streak also continued with two more debuts on the Nasdaq today; returns subpar however for BLSM (flat) and LTGO +1.4%. Macro: Stocks posted solid weekly gains, with a risk-on tone carrying into the weekend amid strong Q2 earnings/guidance, cleaner positioning following July's momentum unwind, solid macro data, and de-escalatory US-Iran headlines. Bad news is good news dynamics also in play following weak July NFP, with September rate-hike odds down 10pp+ to ~44%. Software earnings were another bright spot. Oil logged a sharp weekly decline as expectations for a near-term SoH reopening deal persist. Latest headlines point to Oman-Iran progress, with a US official saying a deal is expected soon and would see the US lift its blockade of Iranian ports. Earnings calendar gets much quieter next week before the shift to the Jul Q reporters though macro in focus with July CPI, PPI and retail sales. Notable Gainers on Friday: +63.6% RCEL - earnings; upgraded at BTIG +21.4% NTRA - earnings; best performer on XBI +21.1% OMDA - earnings +20.2% HALO - earnings; upgraded at Leerink +19.1% TNDM - earnings +11.4% CON - earnings +10.9% ICUI - earnings +10.4% GRDN - earnings +10.1% AGL - shares were down (20%) yesterday +9.9% MRNA - best performer on XLV; shares +8% for the week +9.6% GRAL - FDA formally schedules Adcomm for September; shares were down (15%) yesterday +6.9% GH - shares were down (3%) yesterday +6.2% NTLA - upgraded at Evercore ISI +5.8% VEEV - follow-through, shares +13% for the week +5.1% STRO - initiation +4.8% HUM - shares +50% YTD +3.8% BMRN - earnings Notable Decliners on Friday: -59.8% CVRX - earnings, guidance; downgrades -24.7% QDEL - earnings -17.9% ARDX - earnings; worst performer on XBI -9.2% EBS - follow-through; shares (33%) for the week -8.0% XRAY - earnings -7.0% PGNY - earnings -6.2% REPL - follow-through from FDA approval late Thursday; upgraded at Wedbush -5.7% CYTK - earnings -5.3% ANIP - earnings -5.0% RMD - earnings; worst performer on XLV -5.0% RGNX - downgraded at Barclays Week in Review: Earnings scorecard: According to FactSet Scorecard, with 89.76% of companies (149 of 166) having reported, 85.62% of the S&P 1500 Health Care (SP567-SPX) have beaten consensus EPS expectations, vs 81.71% last year (Q2 2025), with an average beat of +19.03% vs +8.67% last year. On the topline, 87.76% have beaten sales expectations, vs 82.32% last year (Q2 2025), with an average beat of +3.11% vs +2.56% last year. Healthcare equities underperformed for the week. The S&P 500 Healthcare Index gained +1.95% vs the S&P 500 Index +3.58%. Outperformers: Biotech Inline: MedTech Underperformers: Pharma, Services, Managed Care Major health groups were all higher for the week on their averages, although only Biotech group outperformed the wider tape. Earnings calendar remained the primary source of newsflow with over half of the scorecard reporting in the first four days this week. Both EPS and Sales metrics remains well ahead of the year ago quarter. Large-cap pharma earnings briefly overshadowed by a mega-merger that would be the largest pharma combination ever. AZN (4.8%) and BMY (0.9%) each declined comment, and Reuters later sourced a senior exec who stated there are "no discussions". Biopharma M&A continued with radiopharma Curium acquiring LNTH for cash + CVR worth up to $8B combined; CNS drugmakers INDV and SUPN will combine in a $7B+ merger of equals. Outside of Pharma, KKR will acquire CRO Integer Holdings in a $5.7B deal. The streak of IPOs continued in Biotech, with three more Nasdaq launches, totaling almost $900M raised. Regulatory sentiment also took a couple steps forward with FDA approving Moderna' seasonal flu vaccine, the first mRNA-based product in the space. The agency also approved Replimune's RP1 less than a week after the successful Adcom. Year-to-date, Healthcare +6.90% vs the S&P 500 +13.32%. Healthcare seventh out of eleven major sectors in CY26. Energy +28.39% and Telecom +2.03% bracket them all. Notable movers for the week: Gainers: BRVE +66.7% - biotech IPO #18 IOVA +55.8% - earnings, guidance; best performer on XBI CAI +45.1% - earnings INSM +33.0% - earnings, guidance TWST +26.3% - earnings; secondary offering, priced HALO +24.9% - earnings; upgraded at Leerink NTRA +20.3% - earnings HNGE +19.6% - earnings TEM +18.6% - sympathy to PSNL earnings (acquisition pending) PRAX +17.2% - earnings RYTM +16.5% - earnings; trial results in AHO CRL +15.0% - earnings; best performer on XLV VEEV +13.1% - stock closed higher 10 of last 11 days, turns green YTD ACAD +12.9% - earnings EHC +12.7% - earnings SRRK +11.9% - earnings CRSP +11.5% - earnings ICUI +9.5% - earnings MDGL +9.1% - upgraded at Wolfe Research; shares down (14%) last week (earnings) IRTC +9.1% - earnings MRNA +7.9% - FDA approves mFlusiva for adults 50 and older WAT +7.8% - earnings CON +7.6% - earnings BDX +6.8% - earnings HUM +5.8% - shares +50% YTD BSX +5.5% - CEO buys $10M in stock (Form 4) LLY +3.2% - earnings Decliners: EBS (33.0%) - earnings; worst performer on XBI BLLN (32.6%) - earnings DVA (23.5%) - earnings; worst performer on XLV ELAN (16.1%) - earnings / sympathy to ZTS BRKR (15.0%) - earnings PODD (14.6%) - earnings; downgrades OSCR (10.6%) - earnings MDLN (10.3%) - earnings ZTS (6.0%) - earnings / sympathy to ELAN AZN (4.8%) - FT report mega-merger; Reuters report "no discussions" Week Ahead (Sat - Sun): Aug 8 - 16 Earnings calendar Mon 10-Aug: before AXSM, RDNT, SGRY after ALC, BBIO, BKD, HIMS Tue 11-Aug: before CAH Corporate calendar "week of 10-Aug" DFTX topline data from phase 3 VOYAGE GAD trial Mon 10-Aug: NRXP hosting investor call to discuss recent FDA feedback on PF-Ketamine ANDA (8:30ET) Wed 12-Aug: BIVI hosting investor call to discuss phase 2 SUNRISE-PD trial (16:15ET) Thu 13-Aug: IDXX hosting Investor Day meeting (8:00ET) Conference calendar Tue 11-Aug: Canaccord Genuity Growth Conference (Aug 11-13) Regulatory calendar Sun 16-Aug: FDA PDUFA for LNTH MK-6240 (F18-florquinitau) NDA, PET-imaging agent targeting Tau in Alzheimer's Disease. Note: Lantheus is pending acquisition by Curium US Peek Ahead to the following week (Aug 17-23) EMA CHMP August monthly meeting replaced by written procedure Mon 17-Aug: FDA PDUFA for BMY iberdomide NDA Sat 22-Aug: FDA PDUFA for CAPR deramiocel BLA Sun 23-Aug: FDA PDUFA for RARE pari-vec BLA Related: ACAD, AGL, ALC, ANIP, ARDX, AXSM, AZN, BBIO, BDX, BIVI, BKD, BLLN, BMRN, BMY, BRKR, BRVE, BSX, CAH, CAI, CAPR, CON, CRL, CRSP, CVRX, CYTK, DFTX, DVA, EBS, EHC, ELAN, GH, GRAL, GRDN, HALO, HIMS, HNGE, HUM, ICUI, IDXX, INSM, IOVA, IRTC, LLY, LNTH, MDGL, MDLN, MRNA, NRXP, NTLA, NTRA, OMDA, OSCR, PGNY, PODD, PRAX, QDEL, RARE, RCEL, RDNT, REPL, RGNX, RMD, RYTM, SGRY, SRRK, STRO, TEM, TNDM, TWST, VEEV, WAT, XRAY, ZTS...(more)	show story hide story
07-Aug-2026 10:38	^ACTIVIST StreetAccount Activist Summary: Week of 3-Aug Summary of notable activist related news for this week: Basic Materials Lithium Ionic (LTH.CN) Notes Waratah (8.9% stake) intends to vote in favour of election of six management nominees at upcoming special meeting Sherritt International (S.CN) Responds to requisition to reconstitute board from Kyma Capital (13.4% stake) Capital Goods Doosan Bobcat (241560.KS) Holder Silchester International Investors LLP discloses 5.05% stake Deceuninck (DECB.BB) Gramo BV (29.4% stake) announces results of initial acceptance period of mandatory public takeover bid Martin Marietta Materials (MLM) FTC grants antitrust clearance for transaction involving Martin Marietta Materials and Stichting Administratiekantoor FGI Consumer Cyclical Ethan Allen Interiors (ETD) Holder Doug Bergeron (5.0% stake) nominates six candidates to the board Energy ReNew Energy Global (RNW) Holder CPPIB (34.4% stake) files amended 13D; discloses 6-Aug confirmatory letter to the board Suncor Energy (SU.CN) Holder Elliott Management (4.5% stake) issues statement supporting leadership transition Financial General Atlantic (+GENATLANTIC) FTC grants antitrust clearance for transaction involving General Atlantic and SambaNova Systems Mobile Infrastructure (BEEP) Confirms receipt of preliminary, non-binding indication of interest from Bombe Asset Management (0.8% stake) Scully Royalty (SRL) Holders MILFAM Group and Kellogg Group report formation of group, representing 48.5% of outstanding shares Healthcare AstraZeneca (AZN.LN) Holders said to express reservations about potential merger with Bristol Myers Squibb Hinge Health, Inc. (HNGE) FTC grants antitrust clearance for transaction involving Gabriel Mecklenburg (~3.1% stake) and Hinge Health Neuronetics (STIM) Establishes framework between board and Jorey Chernett (16% stake) VistaGen Therapeutics (VTGN) SRX Global acquires stake (stake unknown) Services Amazon.com (AMZN) Discloses changes in holdings in 13F filing - 13F Driven Brands Holdings (DRVN) Board rejects unsolicited acquisition proposal from ADW Capital (2.4% stake) Shake Shack (SHAK) Starboard Value said to build stake (stake unknown) True Corp. Public Co. (TRUE.TB) Responds to media reports; confirms China Mobile (7.8% stake) has no intention to exit entire investment Technology DeepSeek (+DEEPSEEK) Resuming second funding round following temporary suspension last month; seeking ~$8B raise at ~$74B valuation - 2CRSI (AL2SI.FP) Sets out the scope and timetable in connection with an independent investigation into the allegations made in the Grizzly Research report Alkami Technology (ALKT) Formally launches sales process amid mounting pressure from holder Jana Partners (6.3% stake) Alphabet (GOOGL) Google discloses material changes in holdings in 13F filing People Incorporated (PPLI) Yakira (0.3% stake) wants People Incorporated to drop pursuit of MGM, prioritize share buybacks instead Sonos (SONO) Holder Coliseum Capital switches filing type from 13G (passive) to 13D (active); reports 15.3% stake Other Greenlight Capital adds new positions in CMCSA, FBIN, PYPL in Q2, exits WFRD -- Seeking Alpha, citing letter Selected activist-related reads: JPMorgan Chase hires Lissauer for activism defense (Reuters) Gore Street Energy Storage will put forward Saba's continuation votes but urges investors to vote against them (AIC) Related: 241560.KS, 941.HK, AL2SI.FP, ALKT, AMZN, AZN.LN, BEEP, BMY, DECB.BB, DRVN, ETD, GOOGL, HNGE, LTH.CN, MLM, PPLI, RNW, S.CN, SHAK, SONO, SRL, SRXH, STIM, SU.CN, TRUE.TB, VTGN, +DEEPSEEK, +GENATLANTIC, +OURA, 002M1L-E, 05HPFF-E, 06FVK7-E, 0DDNFR-E, 0FNHTB-E, 0J76GQ-E, 0NGHZP-E, 0P61SB-E...(more)	show story hide story
06-Aug-2026 00:11	StreetAccount Sector Summary - China Healthcare July Recap July in Review: Hang Seng Innovative Drug 2.01% vs Hang Seng Listed Biotech 4.73% vs Hang Seng Index 12.27% CSI300 Healthcare 5.39% vs CSI300 (4.66%) Trending topics: WuXi AppTec's interim results was released on the evening of 3-Aug. In H1, the company reported NI attributable of CNY11.08B, up 29.43% y/y, surpassing the CNY10B mark in a half-year report for the first time. The company also raised its FY revenue guidance. With such catalyst, by close on the next day, China's A-share innovative drug concept stocks rallied broadly, with the CXO sector leading the gains. WuXi AppTec hit the daily limit-up, closing at CNY141.35, with a total market capitalization of CNY421.8B. Asymchem, Bai hua cun, Luoxin and several others also hit limit-up. Porton Pharma Solutions rose more than 13%, Pharmaron Beijing gained over 10%, while Tigermed, Medicilon, JOINN Laboratories and others also advanced. Hong Kong-listed peers also climbed. WuXi AppTec closed up 11.6%, Pharmaron rose 8%, Asymchem gained 6.6%, and WuXi Biologics added 4.5%. StreetAccount notes that now market attention has shifted beyond the sector's rally itself to whether the CXO industry, after nearly three years of correction, is now seeing a repricing of both fundamentals and valuations. Market argue that easing policy/geopolitical concerns (i.e. US Biosecure Act) and WuXi's strong results drove repricing, while fading pressures from COVID-order normalization and weak biotech funding suggest the recovery is increasingly backed by fundamentals, not just an oversold rebound. On 9-Jul, three China's national authorities including the National Health Commission (NHC) officially released the 2026 edition of the National Essential Drug List, which includes a total of 794 drugs, of which 476 are chemical drugs and biologics. This marks the first revision of the National Essential Drug List in eight years. StreetAccount notes that the Essential Drug List focuses on clinical needs and ensuring a stable supply, and the Reimbursement Drug List focuses on the scope of insurance fund coverage and cost reimbursement. Specifically, the new edition adds 116 new drug varieties, including 68 chemical drugs and biologics, and 48 traditional Chinese medicines (TCM). Among these additions are several standout innovative drugs. For example, the new edition adds 5 diabetes drugs, including GLP-1 drug semaglutide (in diabetes). In oncology, the third-generation EGFR-TKI targeted drug osimertinib, the anti-angiogenic drug bevacizumab, and the PARP inhibitor targeted drug olaparib have also been included. In immunology, telitacicept and adalimumab are among the list. President Trump states tariff on generic drugs will stay at 0% for 2 years then rise to 100% (@realDonaldTrump on truth social). It is well-known that generic drug companies rely on high volume and razor-thin margins. Unlike innovative pharma, they cannot absorb high tariffs through price increases. For Chinese generic drugmakers, the nation's centralized procurement policies have already slashed generic drug profits to fractions of a cent, and imposing 100% to 200% tariffs would be a fatal blow to the industry. StreetAccount notes that in 2025, China's total exports scale of generic drugs reached $5.2B. This includes $1.16B in finished drugs (up 1.01% YoY, making up 13.14% of total finished drug exports) and $4.07B in active pharmaceutical ingredients (APIs) (CCCM-HPIE, Yicai) . While $5.2B is a small fraction of China's overall pharmaceutical market, it may represent the entire annual profit for individual companies. The pharma sector is anxious about this potential penalty, given the fact that Chinese generic exports to the US are primarily high-barrier, high-value products (e.g., injectables, sustained-release drugs), and if lost, the US market would be difficult to replace in the short term. However, the drugmakers are not yet in despair mainly due to a built-in grace period and future variables, giving them time to prepare and adjust their strategies before the tariffs take effect. For example, now Chinese pharmaceutical companies are actively building production facilities in Mexico to bypass the upcoming 2028 tariffs and maintain access to the US market. The pharmaceutical markets in the European Union, Southeast Asia, Central Asia, and Latin America continue to expand in demand, with relatively stable market access regulations. Many companies are adjusting their registration and filing timelines, prioritizing drug approvals in emerging markets to build diversified overseas revenue structures and hedge against potential losses in the U.S. market (NewHealthWorld). According to FiercePharma, a person familiar with the matter says the White House's plan aims to include both finished drugs and API under the initial Section 232 pharmaceutical tariffs on branded drugs and generics makers. So far, Chinese generic drugmakers still remain resilient due to their API pricing power, high technical barriers in finished drug production, and a massive domestic consumer market. However, the greater uncertainty lies in the policy itself (CNBC, Pharmaceutical Executives): Political variables: the 2028 implementation date extends past the next US election. The policy therefore faces significant political variables. The government may be forced to alter the tariffs or issue exemptions to prevent public backlash over soaring healthcare costs. US supply chain vulnerability: The US pharmaceutical industry focuses heavily on high-margin patented drugs, leaving it highly dependent on imports for nearly 80% of its APIs and 69% of its generic drugs (WashU, FDA). API dominant position: China is supplying roughly 40% of the world's APIs (Nikkei Asia), imposing 100% to 200% tariffs would likely trigger catastrophic drug shortages and price spikes within the US, making strict enforcement impractical. US domestic manufacturing capacity: US lacks the domestic manufacturing capacity required for mature, essential medicines. The manufacturing for mature products has been moved overseas. The U.S. is especially dependent on global sources for generics, and supply strains during the pandemic made it clear that innovation alone is not enough. Manufacturing capability is equally critical (Nikkei Asia, 36Kr, Sullivan et al. (2025)) Sector performance: 2026 interim reports of A-share listed pharmas: so far, more than 100 pharmaceutical companies have released their performance results, with over 60% reporting positive results. Six companies posted net profits exceeding CNY1B, while Haisco Pharmaceutical, Huahai Pharmaceutical, Hybio Pharmaceutical, Hansoh Pharmaceutical and others reached record highs. In terms of growth rates, 28 companies, including JOINN Laboratories, Luoxin Pharmaceuticals, and Betta Pharmaceuticals, saw their profits more than double, while 13 companies turned profitable after previous losses. In addition, more than 40 companies reported losses, and 10 companies posted their first losses (company reports, menet). Regulatory actions: On 31-Jul, the proposed winning results of the 12th round of China's national centralized drug procurement were released. All 65 drugs were successfully procured, with 521 products from 327 companies qualifying as proposed winners, marking a record high in scale. StreetAccount notes that dozens of A-share listed companies, including Hengrui Pharmaceuticals, Sichuan Kelun, Huahai Pharmaceutical, Huadong Medicine and Hisun Pharmaceutical had products shortlisted as proposed winners in this batch of centralized procurement. According to NHSA, major market leaders with strong clinical recognition and reliable quality and supply generally secured proposed winning bids. For example, Qilu Pharmaceutical, Sichuan Kelun Pharmaceutical, SSY and Chengdu Brilliant Pharmaceutical each had more than 10 products shortlisted as proposed winners. In addition, 10 reference-listed drugs were proposed winners, including Novartis' valsartan, Bayer's iopromide, Eisai's betahistine and Abbott's dydrogesterone. In July, Shanghai (15-Jul) and Beijing (17-Jul) released commercial health insurance support policies almost simultaneously, each introducing 18 specific measures - a clear signal that commercial health insurance development has entered an acceleration phase. In fact, in March, China's Government Work Report mentioned commercial health insurance twice, explicitly stating for the first time the goal to "accelerate the development of commercial health insurance." The industry widely views this as a formal elevation to national strategic status. However, market seems a bit lukewarm to the policy. Only 61 applications were submitted for the 2026 commercial insurance innovative drug list (NHSA), down more than half from the 141 in 2025. Of the 19 drugs in the first edition, only 223 institutions had stocked them as of Jan-26, with tertiary hospital coverage at just 12.3% (stcn). Looking back at 2025, market expectations for commercial insurance were nearly euphoric. The first commercial insurance innovative drug list was released, covering 19 drugs including blockbuster categories such as CAR-T therapies and rare disease treatments. It was considered as an alternative for innovative drug reimbursement. Yet reality fell short of the expectation. After the first list landed, Huiminbao contributed only CNY1.8B toward innovative drug payments (YiCai). Experts noted that getting included by the list typically requires price concessions, but commercial insurance only covers a limited population and hospital access remains unresolved. In other words, the price-volume trade-off won't pay off in the near term. This market reaction reflects deeper industry concerns: after being included in the commercial insurance list, will the reimbursement/payment volume hold up, and will the drugs be able to secure hospital admission? After piloting in Beijing and Shanghai, verifying the model, and building a replicable playbook, what are the key barriers must be broken through before rolling it out nationally? Little interest from insurance companies: Insurers are reluctant to adopt the commercial health insurance drug list. An insurance company told Health Insight that of the listed drugs, rare diseases and early-stage Alzheimer's are considered uninsurable and unattractive for coverage. Rare diseases are often genetic, meaning the risk exists from birth and is not "accidental." Early Alzheimer's requires costly, long-term treatment, making the risk hard to price or predict. Plus, for the past years, commercial insurance pricing has relied on historical experience, that is to project future rates from past claims. But when a single CAR-T treatment exceeds CNY1M, historical data becomes entirely useless. Medical insurance claims data across different population segments is crucial for commercial insurance actuarial design. However, for the commercial insurance drug list, insurers lack real-world claims data (i.e. incidence and recurrence rates, treatment cost distributions for different pre-existing conditions) from the public medical insurance system, making scientific risk stratification and differentiated pricing impossible. If you price too high then no one buys, yet if the price is too low, the claims would spiral out of control. Beijing's clearing and settlement center has launched and produced the first data-driven product, but a nationwide data-sharing mechanism remains work in progress (Minet); Hospital access: Despite the government's supportive policies, hospital adoption remains extremely low. This is primarily because the commercial insurance catalog is recommendatory rather than mandatory. While the policy removes compliance barriers, it fails to provide financial incentives. Hospitals, burdened by drug cost assessments and management expenses, lack the motivation to stock these drugs unless they can generate reasonable profits and positively impact performance evaluations (SHobserver). High-end medical service may solve the issue, as it falls outside the public health insurance payment system, thus naturally not conflicting with government cost-control efforts, while simultaneously creating market space for commercial health insurance. Multi-lateral cooperation and weak industry infrastructure: Innovative drug payment involves multiple stakeholders and the framework around pricing incentives, risk-sharing, and payment arrangements are still work in progress. Plus, there is a lack of a neutral, regulatable platform for commercial insurance innovative drug information and operations (pharmacube, Sinafinance). Drug development and approvals: Clinical updates: GSK notes licensor Hansoh Pharma's phase III study with Ris-Rez conducted for China met its primary endpoint in relapsed osteosarcoma. HS-20093 demonstrated statistically significant and clinically meaningful improvements in progression-free survival compared with chemotherapy (link); Akeso/Summit Therapeutics announces results of updated OS analysis from Phase III HARMONi clinical trial of Ivonescimab (link); Ascletis Pharma receives U.S. FDA clearance for phase III clinical trial of ASC30 in chronic weight management (link); CSPC Pharmaceutical Group initiates phase II clinical trial of SYH2062 injection for adult essential hypertension (link); Akeso Inc presents Phase II trial results of ligufalimab (AK117) in combination with azacitidine and venetoclax in patients with treatment-naïve AML (link); IND: China's NMPA approves trial of Hengrui Pharmaceuticals' SHR-A2009 with Adebrelimab for NSCLC (link); NMPA approves IND for phase I trial of Henlius Biotech'x HLX37 combined with chemotherapy or HLX43 for solid tumours (link); Shandong Boan Biotech's BA1203 obtains China NMPA's CDE acceptance for IND application in multiple solid tumors (link); Designations: Jiangsu Hengrui Pharmaceuticals receives U.S. FDA orphan drug destination for SHR-4375 injection in pancreatic cancer (link); Sino Biopharmaceutical receives third breakthrough therapy designation for TQB2102 from NMPA for adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have not received any chemotherapy at the relapsed or metastatic stage (link); Jiangsu Hengrui Pharmaceuticals' HRS-7058 capsule included in NMPA's Breakthrough Therapy List for KRAS G12C-mutated locally advanced or metastatic pancreatic cancer that has failed at least one prior line of systemic therapy (link); Sino Biopharmaceutical's TRD205 for treatment of CPSNP receives NMPA Breakthrough Therapy Designation (link); NDA acceptance: Alphamab Oncology obtains NMPA acceptance of new drug application for Anbenitamab (KN026) in combination with docetaxel for injection (HB1801), as neoadjuvant treatment for human EGFR 2 HER2-positive early or locally advanced breast cancer (link); Jiangsu Hengrui Pharmaceuticals' marketing application for SHR-A2009 injection in NSCLC accepted by NMPA (link); Shanghai Junshi Biosciences' new indication application for JS001 accepted by NMPA for perioperative treatment with toripalimab in combination with platinum-based chemotherapy, followed by toripalimab monotherapy as adjuvant treatment, for adult patients with resectable stage II-III NSCLC (link); NDA approvals: NMPA approves marketing of Hengrui Pharmaceuticals's camrelizumab combined with sunitinib malate as first-line therapy for cervical cancer (link); Huahai Pharma's anti-IL-36R antibody HB0034 injection approved to market in generalized pustular psoriasis (link); License-in/out, co-development, M&A Alphamab Oncology enters into license agreement with Pathos AI for rights to JSKN016 outside greater China for upfront $125M (~CNY844M). Jiangsu Alphamab is entitled to receive additional milestone payments, the total aggregate consideration is up to $2.09B and tiered royalties at high-single digit to low-double digit percentage rates. Pathos AI will develop and commercialize JSKN016 in the licensed territory at its own cost and expense. Pathos AI granted the group a warrant to subscribe for shares of Pathos AI's preferred stock with aggregate subscription price of $62.5M CSPC Pharmaceutical Group entering 51:49 joint venture with AstraZeneca to build biologics manufacturing facility in Shijiazhuang, China. The JV's initial business scope will focus on the manufacturing and supply of mutually agreed biologics drug substances (DS) for global markets. China-based IMPACT Therapeutics signed an exclusive licensing agreement worth up to €423.5M ($488M) with UK specialty pharma firm Pharmanovia to develop and commercialize ovarian cancer drug senaparib (IMP4297) across 66 countries outside China. Sino Biopharmaceutical enters into exclusive license agreement with AstraZeneca for TQC3721; to receive upfront payment $200M. Group is eligible to receive the upfront payment with additional development, regulatory and sales milestones, totalling up to $1.9B, as well as tiered royalties ranging up to double-digit percentages based on the annual net sales of TQC3721 products. Group shall grant AstraZeneca an exclusive license to develop, manufacture and commercialize TQC3721 outside China. Sino Biopharmaceutical expands exclusive strategic collaboration with GlaxoSmithKline. Sino-Bio will obtain the commercial rights in mainland China for Trelegy Ellipta and Anoro Ellipta. The company will be responsible for importation, distribution, hospital access, and promotional and non-promotional activities for these products in mainland China. Related: 000538.CH, 000661.CH, 002422.CH, 002653.CH, 002821.CH, 1093.HK, 1177.HK, 1672.HK, 1801.HK, 2196.HK, 2269.HK, 2607.HK, 300199.CH, 300363.CH, 300759.CH, 3347.HK, 3692.HK, 4523.JP, 600276.CH, 603127.CH, 603259.CH, 6160.HK, 7630.HK, 9926.HK, 9966.HK, AZN.LN, GSK, JNJ, LLY, NOVN.SW, ROP.SW...(more)	show story hide story
05-Aug-2026 17:12	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mostly higher on Wednesday. Advancers beat decliners by 2:1 on the XLV. Healthcare +1.34% vs S&P 500 (0.18%). Most major health groups ended higher on the averages. MedTech a laggard, but primarily skewed lower by PODD (20.1%), biggest decliner on XLV, on a slower growth forecast. Devices weighed by Diabetes Tech declines, but offset by CRO strength. CRL +11.4% top gainer on the XLV behind a Q2 beat-and-raise, including the highest organic growth since Q3 of 2023. LST subgroup lightly mixed. Managed Care and Pharma materially outperformed the wider tape. DRG +1.82%. LLY +4.9% and AMGN +4.6% are standouts on their own respective prints, while AZN +3.7% partially climbed back after new media report refuted the Sunday mega-merger media report. DVA (17.2%) on a Q2 beat, but patient care costs expected to drag on H2 operating income. Earnings calendar in full swing with notable reports from large-cap biotech plus almost every corner of the sector. Last night Amgen and Gilead Sciences with Q2 beat-and-raise prints. Eli Lilly reported strong Q2 sales for diabetes and obesity, and mixed results for key oncology franchise. Volume in Mounjaro and Zepbound the key driver of sales growth. CVS Health reported Q2 beat-and-raise print, with MLR 240bps better than StreetAccount consensus. Insulet Corp reported Q2 beat top and bottom lines, but focus on Omnipod sales growth forecast slower than Q3 consensus, and lowered for FY. "No discussions" between AstraZeneca and Bristol Myers, reports Reuters citing a senior level source. Macro Very busy from a headline perspective but no overriding theme for the day. August risk sentiment has been boosted by overall strength in Q2 earnings, cleaner positioning following July momentum unwind, solid macro data and diplomatic offramp hopes surrounding US-Iran conflict. Mixed takeaways from latest barrage of earnings with AI capex scrutiny, elevated expectations, AI adoption/usage/initiatives and resilient travel demand some of the big themes. Middle East headlines continue to revolve around a near-term deal regarding SoH that is seen playing into Iran's outsized focus on leverage over transit. Economic calendar does not seem to be having much impact with some mixed takeaways from ISM services and a softer ADP private payrolls print. Fedspeak has leaned hawkish but no shift in policy expectations with focus on July NFP Friday, CPI next week and continued reaction function uncertainty. Another heavy earnings day with more than 75% of S&P 500 having now reported. Notable Gainers +28.8% ATTO Attovia Therapeutics): day one IPO (biotech #17) +23.6% AMWL (American Well): earnings +23.0% PRGO (Perrigo Co.): earnings +21.6% GERN (Geron): earnings; best performer on XBI +15.7% TWST (Twist Bioscience): secondary offering, priced +13.7% BVS (Bioventus): earnings +13.6% AGL (agilon health): on heavy volume +12.0% TVTX (Travere Therapeutics): earnings +11.3% CRL (Charles River Laboratories): earnings; best performer on XLV +6.1% ACAD (Acadia Pharmaceuticals): earnings +5.9% FTRE (Fortrea Holdings): sympathy to CRL +5.8% PRCT (PROCEPT BioRobotics): earnings; downgrades +5.5% PGEN (Precigen): earnings +4.8% LLY (Eli Lilly): earnings +4.7% RYTM (Rhythm Pharmaceuticals): follow-through, shares +12% WTD +4.6% ALMR (Alamar Biosciences): minority holder ATTO +4.6% AMGN (Amgen): earnings +4.6% CNC (Centene): on above average volume, shares +8% WTD +3.8% AZN (AstraZeneca): Reuters report on M&A story citing senior source +3.6% COR (Cencora): earnings +3.5% ELV (Elevance Health): on light volume, shares +4% WTD +2.5% ZBH (Zimmer Biomet Holdings): earnings +2.4% ELAN (Elanco Animal Health): earnings +1.9% HNGE (Hinge Health, Inc.): earnings +1.8% PACS (PACS Group): earnings +1.4% ONC (BeOne Medicines): earnings Notable Decliners -25.3% LMAT (LeMaitre Vascular): earnings; downgraded at Barrington -21.0% TYRA (Tyra Biosciences): earning; worst performer on XBI -20.1% PODD (Insulet): earnings; downgraded at Opco; worst performer on XLV -17.2% DVA (DaVita): earnings; second-worst on XLV -5.8% CAPR (Capricor Therapeutics): follow-through, shares +2% WTD -5.3% TMDX (TransMedics Group): earnings -5.1% CVS (CVS Health): earnings -4.2% RXRX (Recursion Pharmaceuticals): earnings -3.4% BMY (Bristol Myers Squibb): Reuters report on M&A story citing senior source -2.6% GILD (Gilead Sciences): earnings Eli Lilly higher on strong incretin volumes in Q2, healthy price competition LLY reports Q2 EPS $8.38 ex-items vs FactSet $6.01 on revenue $22.97B vs FactSet $20.69B. Key product topline beats were Mounjaro, Jardiance, Trulicity, and Zebpound. Foundayo reported $98M in launch quarter sales. Lowers top-end of FY EPS outlook by (50c), raises FY revenue guidance by $2.5B at the midpoints. Quick take: Initial analyst takeaways focus heavily on the incretin volumes which drove Q2 outperformance, with Foundayo numbers viewed as roughly inline. Price competition with Novo Nordisk seen as healthy, with volume growth outweighing concessions. Guidance upgrade was well received, plus UBS posits $50/shr EPS in 2027 (FactSet consensus $45.18). On the 10ET call, analysts seek more color around the Foundayo launch trajectory, early indicators from the Medicare Bridge since 1-July, and any incremental thoughts on business development. AstraZeneca recoups week-to-date losses AZN / BMY Reuters reporting "no discussions" between the two large drugmakers, citing a senior source close to the matter. AZN ADRs were down more than (8%) WTD, BMY shares +1% WTD, since Sunday's FT story. Animal Health trades lower following Elanco beat-and-raise ELAN reported Q2 EPS $0.34 ex-items vs FactSet $0.27 on revenue $1.37B vs FS $1.31B, adj EBITDA $288M vs FS $251.4M. Guides Q3 ahead of consensus. Raises FY EPS outlook by 7c, revenue by $67.5M, at the midpoints. Additional guidance in slides. Earnings in Life Science & MedTech ZBH reported Q2 EPS $2.07 ex-items vs FactSet $2.01 on revenue $2.18B vs FS $2.13B. Organic growth +4.0% vs StreetAccount +2.2%. Raises FY EPS by $0.055 at the midpoints, narrowed and raised FY revenue growth outlook by 90bps at the midpoints. PODD reported Q2 EPS $1.66 ex-items vs FactSet $1.45 on revenue $801.7M vs FS $787.4M. Guides Q3 revenue growth slower than consensus. Lowers FY revenue growth by 100bps, now +20-22% vs prior +21-23%. Stock downgraded in reaction CRL reported Q2 EPS $3.02 ex-items vs FactSet $2.74 on revenue $1.00B vs FS $977.2M. Notes organic revenue growth +0.1% highest since Q3 of 2023. Raises FY EPS outlook by 25c at the midpoints. Narrows FY revenue growth (decline). Earnings in Services and Managed Care CVS reported Q2 EPS $2.58 ex-items vs FactSet $1.85 on revenue $106.10B vs FS $100.03B. MLR 87.4% vs StreetAccount 89.8%. Raises FY EPS outlook by 60c at the midpoints, and CFO guidance to at least $11.5B vs prior at least $9.5B. COR reported fiscal Q3 EPS $4.48 ex-items vs FactSet $4.35 on revenue $84.8B vs FS $84.31B. Raises FY EPS outlook by 5c at the midpoints, reaffirms revenue growth guidance. DVA reported Q2 EPS $4.02 ex-items vs FactSet $3.88 on revenue $3.55B vs FS $3.50B. Repeats FY EPS guidance. MDLN reported Q2 EPS $0.50 ex-items vs FactSet $0.32 on revenue $7.69B vs FS $7.51B, adj EBITDA $1.06B vs FS $798.2M. Results and guidance include tariff refunds. Lowers FY adj EBITDA outlook by $200M, reflecting inflationary pressure from the Middle East conflict and other factors. Raises FY organic sales outlook by 50bps. PACS reported Q2 adj EBITDA $166.8M vs FactSet $147.8M on revenue $1.43B vs FS $1.41B. EPS $0.63 ex-items vs FS $0.54. Raises FY adj EBITDA outlook by $35M, revenue by $100M at the midpoints. Earnings in Biotech AMGN reported Q2 EPS $6.29 ex-items vs FactSet $5.62 on revenue $10.05B vs FS $9.43B. Raises FY EPS outlook by 50c and revenue by $1B, at the midpoints. GILD reported Q2 EPS ($6.75) ex-items vs FactSet ($7.26) on revenue $7.80B vs FS $7.40B. Raises FY EPS outlook by $0.375 and product sales by $50M, at the midpoints. Quick take: Sentiment has been generally positive around the update, suggesting results mitigated some concern around IMS data heading into the release. Commonly highlighted was continued outperformance from the HIV franchise (Biktarvy and PrEP) in the quarter, along with raised full year targets - HIV franchise growth now +9-10% (vs +8% prior). Some questioning around Yeztugo growth trajectory (with full year sales reiterated vs raised), however most viewed results and guidance constructively on the durability of the company's HIV portfolio (with no near-term LOE) and potential for ongoing margin expansion. ONC reported Q2 EPS $2.05 vs FactSet $1.66 on revenue $1.71B vs FS $1.62B. Raises FY revenue outlook by $300M, and NG OI by $250M, at the midpoints. UTHR reported Q2 EPS $7.27 vs FactSet $6.86 on revenue $783.3M vs FS $804.6M. Topline light, spread across three biggest products. Management highlights "strong underlying demand" for Tyvaso DPI (MNKD). TVTX reported Q2 EPS ($0.37) vs FactSet ($0.13) on revenue $169.9M vs FS $157.3M. Highlights continued momentum for Fispari including "promising early launch in FSGS" and continued strength in IgAN. Biotech IPO #17 prices 17M shares at $17/shr Now tracking seventeen biotech IPOs ytd in CY2026, with Attovia Therapeutics (ATTO) raising $289M in today's IPO: 17M shares IPO priced at $17/shr. The clinical-stage biotech is focused on therapeutics for immune-mediated diseases. Initial indications include chronic pruritus, atopic dermatitis (AD), and IBDs ulcerative colitis (UC) and Crohn's (CD). Alamar Biosciences (ALMR) holds more than 5% of capital stock, and is eligible for milestones and royalties under their platform license agreement. Note: Alamar was also a 2026 IPO: Shares have traded +59% since pricing at $17/shr on 17-Apr. Notable research in Healthcare today Biotech: OBX initiated overweight at Piper Sandler (Kelsey Goodwin), target is $42 TKNO initiated buy at Roth Capital (Max Masucci), target is $7 or approx. 27% upside. (FactSet average PT $8.50; range $7-12) MedTech: PODD downgraded to perform from outperform at Oppenheimer (Suraj Kalia), notes forward growth outlook. WAT upgraded to buy from hold at TD Cowen (Dan Brennan), target increased to $475 from $408 or approx. 20% upside. (FactSet average PT $434; range $390-475) PRCT downgraded to market perform from outperform at William Blair (Brandon Vazquez), follows Q2 earnings. PRCT downgraded to equal weight from overweight at Wells Fargo Securities (Nathan Treybeck), target cut to $19 from $34 or approx. 4% upside. (FactSet average PT $25; range $16-37) SN.LN (SNN) downgraded to underweight from equal weight at Barclays (Hassan Al-Wakeel), cites Q2 results. Target cut to 1050p from 1290p or approx. 6% downside. (FactSet average PT 1327p; range 1050-1544p) Managed Care: HUM upgraded to equal weight from underweight at Morgan Stanley (Erin Wright), target increased to $370 from $249 or approx. 2% upside. (FactSet average PT $415; range $280-513) Post-close news Insider buying: BSX CEO Michael Mahoney discloses via Form 4 filing a purchase of 208.4K shares, now hold stake of 1.6M shares. Shares trading +2.3% in the after-hours Corporate: SOLV announced plans to separate its HCIT business within the next 12-18 months. Health Information Systems has a run-rate of $1.4B annually, and the market is growing +5-6% annually. Company also reported Q2 EPS $2.55 ex-items vs FactSet $1.90 on revenue $2.21B vs FS $2.15B. Raises FY EPS outlook by 65c at the midpoints. Shares trading +2.9% in the after-hours Research: PODD downgraded to hold from buy at Truist (Richard Newitter), noting diminished confidence in a near-term sustained recovery. Target cut to $153 from $210 or approx. 15% upside. (FactSet average PT $224; range $150-294) Shares trading UNCH in the after-hours Earnings: MCK reports Q1 EPS $9.93 ex-items vs FactSet $9.56 on revenue $105.38B vs FS $103.88B. Raises FY EPS outlook by 40c at the midpoints. Conf. call at 16:30ET Shares trading +2.6% in the after-hours RVMD reports Q2 results including cash & equivalents $3.9B at 30-Jun Conf. call at 16:30ET Shares trading (1.7%) in the after-hours STE reports Q1 EPS $2.59 ex-items vs FactSet $2.49 on revenue $1.49B vs FS $1.49B. Reaffirms FY EPS and revenue growth outlook. Conf. call Thu at 9:00ET Shares trading +1.0% in the after-hours EXEL reports Q2 EPS $0.91 ex-items vs FactSet $0.85 on revenue $628.7M vs FS $636.4M. Lowers FY revenue guidance by $50M at the midpoints. Conf. call at 16:30ET Shares trading (4.4%) in the after-hours EHC reports Q2 adj EBITDA $348M vs FactSet $338.2M on revenue $1.60B vs FS $1.57B, and EPS $1.55 ex-items vs FS $1.48. Raises FY guidance top to bottom. Conf. call Thu at 10:00ET Shares trading +7.8% in the after-hours QGEN reports Q2 EPS $0.62 ex-items vs FactSet $0.60 on revenue $535M vs FS $527.5M. Reaffirms FY guidance top and bottom lines. Conf. call Thu at 9:30ET ADRs trading (2.0%) in the after-hours MIRM reports Q2 EPS ($1.06) vs FactSet ($0.74) on revenue $176.2M vs FS $166.3M. Raises FY revenue outlook by $20M at the midpoints. Conf. call at 16:30ET Shares trading (20.1%) in the after-hours BLLN reports Q2 EPS $0.15 vs FactSet $0.18 on revenue $109.4M vs FS $109.2M, adj EBITDA $16.1M vs FS $18.3M. Reaffirms FY revenue outlook. Conf. call at 16:30ET Shares trading (22.3%) in the after-hours CAI reports Q2 EPS $0.00 vs FactSet $0.01 on revenue $263.7M vs FS $238.1M. Raises FY revenue outlook by $25M at the midpoints. Conf. call at 16:30ET Shares trading +14.8% in the after-hours NVST reports Q2 EPS $0.41 ex-items vs FactSet $0.34 on revenue $731M vs FS $716.1M, adj EBITDA $108M vs FS $98.4M. Raises FY guidance top to bottom. Conf. call at 17:00ET Shares trading +3.9% in the after-hours ARQT reports Q2 EPS $0.11 vs FactSet $0.06 on revenue $129.9M vs FS $118.9M. Raises FY revenue guidance by $45M at the midpoints. Conf. call at 16:30ET Shares trading +10.2% in the after-hours RCUS reports Q2 results including cash & equivalents $775M at 30-Jun. Runway until at least H2 of 2028. Conf. call at 16:30ET Shares trading +1.0% in the after-hours GRAL reports Q2 EPS ($2.56) vs FactSet ($2.66) on revenue $44.7M vs FS $42.4M. Adj EBITDA ($90.3M) vs FS ($70.1M) Conf. call at 16:30ET Shares trading (9.1%) in the after-hours AGL reports Q2 EPS $1.07; unclear if comparable to FactSet $0.14. Reports Q2 revenue $1.50B vs FactSet $1.45B, adj EBITDA $70M vs FS $18.9M. Conf. call at 16:30ET Shares trading +1.1% in the after-hours On Deck: Regulatory FDA PDUFA today for MRNA mFlusiva (mRNA-1010) BLA Earnings tomorrow Thu 6-Aug: before BDX, ZTS, ROIV, INSM, MRK.GR, VTRS, PRAX, OSCR, IMVT, LNTH, TFX, LGND, SRRK, SHC, LFST, HAE, PRVA after NTRA, RMD, GMAB, BMRN, HALO, CYTK, GMED, XENE, DFTX, TXG, CON, RLAY, ICUI, IRTC, DNLI Syndicate / IPO pricing tonight: +BRVE (Braveheart Bio) StreetAccount Healthcare Reads 'No discussions' over AstraZeneca-Bristol Myers deal, senior source says (5-Aug) Reuters The FDA AdComm Reboot: Part 1; Lessons from the Meeting on Capricor's Deramiocel (5-Aug) FDAlawblog How poor countries are dealing with America's AIDS cuts (3-Aug) The Economist Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea (3-Aug) Fierce Pharma (Opinion) AstraZeneca investors balk at prospect of $400 billion Bristol Myers deal (3-Aug) Reuters After Eli Lilly granted one man special access to obesity drug, doctors struggle to get answers (3-Aug) STAT News Kennedy, Oz Contend Fraud Crackdown, Not Skyrocketing Prices, Led Millions To Leave Obamacare (3-Aug) KFF Health News This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ACAD, AGL, ALMR, AMGN, AMWL, ARQT, ATTO, AZN, BDX, BLLN, BMRN, BMY, BSX, BVS, CAI, CAPR, CNC, CON, COR, CRL, CVS, CYTK, DFTX, DNLI, DVA, EHC, ELAN, ELV, EXEL, FTRE, GERN, GILD, GMAB, GMED, GRAL, HAE, HALO, HNGE, HUM, ICUI, IMVT, INSM, IRTC, LFST, LGND, LLY, LMAT, LNTH, MCK, MDLN, MIRM, MNKD, MRK.GR, MRNA, NTRA, NVST, OBX, ONC, OSCR, PACS, PGEN, PODD, PRAX, PRCT, PRGO, PRVA, QGEN, RCUS, RLAY, RMD, ROIV, RVMD, RXRX, RYTM, SHC, SN.LN, SOLV, SRRK, STE, TFX, TKNO, TMDX, TVTX, TWST, TXG, TYRA, UTHR, VTRS, WAT, XENE, ZBH, ZTS, +BRVE...(more)	show story hide story
05-Aug-2026 16:04	FactSet Podcast - Evening Market Recap, 5-Aug Overview: US equities were mixed in Wednesday trading. It was another heavy earnings day with more than 75% of S&P 500 having now reported. There were mixed takeaways with AI capex scrutiny, elevated expectations, AI adoption/usage/initiatives and resilient travel demand some of the big themes. Tickers Mentioned: NVDA, SPCX, LLY, AMD, ANET, DIS, SHOP, BKNG, UBER, CVS, EMR, ZBH, BWA, WYNN, ELAN, OC, FRPT, CDW, LSCC, PINS, DVA, NYT, PODD, SEDG, MTCH, TDC, AZN, BMY, XYZ, DASH, HONA, SNDK, WDC, COP, FOXA, DDOG, PH About This Podcast: The Evening Market Recap Podcast aims to bring listeners up to speed on the trading day as quickly as possible. With a target time of ~5 minutes and a publish time of ~18:00 EDT, this is an ideal listen after the market closes. Find us on Apple and Spotify, or click the link below to listen now. Related: AMD, ANET, AZN, BKNG, BMY, BWA, CDW, COP, CVS, DASH, DDOG, DIS, DVA, ELAN, EMR, FOXA, FRPT, HONA, LLY, LSCC, MTCH, NVDA, NYT, OC, PH, PINS, PODD, SEDG, SHOP, SNDK, SPCX, TDC, UBER, WDC, WYNN, XYZ, ZBH...(more) Reference Link: Market Recap 5-Aug-26	show story hide story
05-Aug-2026 11:45	^OPTIONS StreetAccount Summary - U.S. Unusual Option Volume: VIX (1.0%) to 16.34; S&P 500 +0.2% to 7,748.06 StreetAccount reports options activity showing unusual volume compared to the 30-day average. The list excludes companies that have reported earnings since the prior trading day's close. 8,893% - EYE (National Vision Holdings $23.27, +0.6%) -- 10,110 contracts vs avg 114 - P/C ratio: 0.00 - to report earnings before market Aug-12 2,582% - EWTX (Edgewise Therapeutics $44.93, +0.5%) -- 6,640 contracts vs avg 257 - P/C ratio: 0.00 1,634% - ITT (ITT, Inc. $202.90, -0.9%) -- 13,852 contracts vs avg 848 - P/C ratio: 1.66 - to report earnings before market Aug-06 1,405% - WMS (Advanced Drainage Systems $150.86, +0.7%) -- 1,453 contracts vs avg 103 - P/C ratio: 0.61 - to report earnings before market Aug-06 1,361% - NEOV (NeoVolta $2.85, +12.5%) -- 4,464 contracts vs avg 328 - P/C ratio: 0.00 1,059% - TROX (Tronox Holdings $5.65, -5.0%) -- 10,490 contracts vs avg 991 - P/C ratio: 30.31 - to report earnings after market Aug-05 955% - RL (Ralph Lauren $387.10, +2.4%) -- 1,834 contracts vs avg 192 - P/C ratio: 3.55 - to report earnings before market Aug-06 650% - TPG (TPG, Inc. $47.94, -2.1%) -- 10,615 contracts vs avg 1,634 - P/C ratio: 0.00 - following recent post-earnings move 475% - VTRS (Viatris $17.60, -0.6%) -- 12,630 contracts vs avg 2,660 - P/C ratio: 106.95 - to report earnings before market Aug-06 421% - GFI (Gold Fields $37.76, +10.7%) -- 10,232 contracts vs avg 2,430 - P/C ratio: 0.18 388% - ESTA (Establishment Labs Holdings $93.49, -1.2%) -- 1,565 contracts vs avg 403 - P/C ratio: 1.00 - to report earnings before market Aug-06 385% - CCI (Crown Castle $70.67, -9.0%) -- 6,926 contracts vs avg 1,800 - P/C ratio: 0.23 - SpaceX discuses plan to target the US mobile market 375% - PH (Parker-Hannifin $999.32, +0.7%) -- 1,357 contracts vs avg 361 - P/C ratio: 0.01 - to report earnings before market Aug-06 375% - WT (WisdomTree $22.40, +0.0%) -- 1,202 contracts vs avg 320 - P/C ratio: 0.02 350% - HAWK (HawkEye 360, Inc. $23.78, -2.1%) -- 1,579 contracts vs avg 451 - P/C ratio: 0.00 - to report earnings after market Aug-13 347% - DC (Dakota Gold $5.38, +7.1%) -- 1,728 contracts vs avg 499 - P/C ratio: 0.28 340% - DFTX (Definium Therapeutics $42.92, +1.4%) -- 11,144 contracts vs avg 3,277 - P/C ratio: 0.03 - to report earnings after market Aug-06 339% - TROW (T. Rowe Price Group $115.19, -0.5%) -- 4,438 contracts vs avg 1,309 - P/C ratio: 12.04 339% - SHW (Sherwin-Williams $365.04, +1.0%) -- 4,366 contracts vs avg 1,289 - P/C ratio: 20.33 - follow on from Guggenheim buy initiation 332% - VISN (Vistance Networks $12.46, -0.3%) -- 3,253 contracts vs avg 980 - P/C ratio: 0.00 - to report earnings before market Aug-06 314% - ALK (Alaska Air Group $52.50, -0.1%) -- 13,367 contracts vs avg 4,256 - P/C ratio: 0.01 309% - ENR (Energizer Holdings $22.61, +4.7%) -- 1,290 contracts vs avg 418 - P/C ratio: 0.07 - following recent post-earnings move 302% - TWST (Twist Bioscience $111.50, +12.1%) -- 1,578 contracts vs avg 522 - P/C ratio: 0.52 - upsized $300.0M common stock offering priced at $96/share 301% - AZN (AstraZeneca $162.60, +4.5%) -- 10,560 contracts vs avg 3,512 - P/C ratio: 0.15 - reports that Co is refuting BMY deal speculation 285% - USAS (Americas Gold & Silver $4.86, +10.6%) -- 16,825 contracts vs avg 5,900 - P/C ratio: 0.00 284% - ACA (Arcosa $145.28, +0.0%) -- 347 contracts vs avg 122 - P/C ratio: 187.50 - to report earnings after market Aug-05 281% - PPTA (Perpetua Resources $22.68, +9.7%) -- 3,764 contracts vs avg 1,341 - P/C ratio: 0.06 276% - RIO (Rio Tinto $101.24, +2.3%) -- 9,034 contracts vs avg 3,273 - P/C ratio: 4.43 - sale process for its Infrastructure assets getting closer to launch, expected value A$2-3B Click here to view / receive alerts for Unusual Options Volume Related: ACA, ALK, AZN, CCI, DC, DFTX, ENR, ESTA, EWTX, EYE, GFI, HAWK, ITT, NEOV, PH, PPTA, RIO, RIO.AU, RL, SHW, TPG, TROW, TROX, TWST, USAS, VISN, VTRS, WMS, WT...(more)	show story hide story
05-Aug-2026 09:16	StreetAccount Summary - US Pre-market trading update S&P futures +34.3 to 7799.75, +0.44% vs settlement. 10-year yield +0 bps to 4.62%. Sep WTI +$0.74 or +0.98% to $76.51. Trading Higher: *Market cap >$10B* +22.6% SHOP (Shopify $151.12, +27.82) -- earnings +10.5% DT (Dynatrace $50.50, +4.79) -- earnings +9.9% ANET (Arista Networks $209.40, +18.89) -- earnings +9.7% CRL (Charles River Laboratories $256.89, +22.77) -- earnings +6.7% BKNG (Booking Holdings $207.25, +12.98) -- earnings In sympathy: EXPE +3.3%, ABNB +2.6% +5.8% ELAN (Elanco Animal Health $27.09, +1.49) -- earnings +5.2% AZN (AstraZeneca $163.74, +8.12) -- senior source refutes prior report of M&A talks with BMY +5.0% WYNN (Wynn Resorts $102.50, +4.90) -- earnings +4.9% LLY (Eli Lilly $1,170.32, +54.64) -- earnings +4.4% ZBH (Zimmer Biomet Holdings $100.00, +4.19) -- earnings +4.3% BAM (Brookfield Asset Management $54.18, +2.24) -- earnings +3.6% APP (AppLovin $434.64, +14.94) +3.6% PANW (Palo Alto Networks $379.45, +13.11) +3.5% CMG (Chipotle Mexican Grill $35.02, +1.20) -- comments on public health investigations; says Minnesota Department of Health confirmed no ongoing concerns with company +3.5% DIS (Walt Disney $101.60, +3.42) -- earnings +3.5% U (Unity Software $36.46, +1.24) +3.4% HBM (HudBay Minerals $25.60, +0.83) +3.4% BWA (BorgWarner $65.20, +2.16) -- earnings +3.2% COR (Cencora $316.00, +9.72) -- earnings +3.0% TEAM (Atlassian $113.64, +3.33) +2.9% SCCO (Southern Copper $200.90, +5.74) +2.8% FCX (Freeport-McMoRan $69.20, +1.90) +2.7% DDOG (Datadog $295.89, +7.74) +2.7% CG (Carlyle Group $52.00, +1.36) -- earnings +2.6% FTNT (Fortinet $172.61, +4.32) +2.6% IRM (Iron Mountain $128.75, +3.24) -- earnings +2.4% ALB (Albemarle $123.74, +2.92) +2.4% WDAY (Workday $175.35, +4.07) +2.4% ONC (BeOne Medicines $330.68, +7.67) -- earnings +2.4% MRNA (Moderna $58.33, +1.34) +2.3% HUBS (HubSpot $254.50, +5.61) +2.3% TOST (Toast, Inc. $34.60, +0.79) -- earnings +2.2% META (Meta Platforms $601.00, +13.06) +2.2% KLAR (Klarna Group Plc $21.06, +0.45) +2.1% AA (Alcoa Corp. $47.81, +0.98) +2.1% CRWD (CrowdStrike $215.70, +4.48) +2.1% MDB (MongoDB $388.00, +7.96) +2.0% NTNX (Nutanix $62.74, +1.24) +0.6% GILD (Gilead Sciences $136.06, +0.81) -- earnings +0.3% AMGN (Amgen $391.00, +0.98) -- earnings *Market cap $1B-$10B* +26.1% APPS (Digital Turbine $11.99, +2.48) -- earnings +18.9% KMT (Kennametal $42.87, +6.81) -- earnings +18.4% UPST (Upstart Holdings $35.90, +5.58) -- earnings +17.0% PRGO (Perrigo Co. $12.61, +1.83) -- earnings +15.7% KTOS (Kratos Defense & Security Solutions $60.03, +8.16) -- earnings +15.5% YOU (Clear Secure $64.36, +8.63) -- earnings +15.4% QLYS (Qualys $185.90, +24.84) -- earnings +11.9% TVTX (Travere Therapeutics $62.68, +6.66) -- earnings +11.3% FTK (Flotek Industries $31.39, +3.18) -- earnings +9.5% AMPX (Amprius Technologies $11.83, +1.02) -- earnings +9.4% LRN (Stride $88.00, +7.55) -- earnings +8.5% URGN (UroGen Pharma $43.30, +3.38) -- earnings +8.2% FRPT (Freshpet $67.47, +5.09) -- earnings +7.9% PRMB (Primo Brands $25.14, +1.85) -- earnings +6.6% PGEN (Precigen $6.96, +0.43) -- earnings +6.3% ECO (Okeanis Eco Tankers $62.99, +3.76) -- earnings +6.0% RARE (Ultragenyx Pharmaceutical $27.37, +1.56) -- earnings +5.3% BCRX (BioCryst Pharmaceuticals $9.50, +0.48) -- earnings +5.2% GENI (Genius Sports $8.50, +0.42) -- agreement with Kalshi to provide official data, marketing, media and integrity services +4.8% CXW (CoreCivic $31.61, +1.46) -- sells two additional detention facilities for $734.0M +4.1% RIOT (Riot Platforms $22.45, +0.89) -- earnings +3.9% INOD (Innodata $72.98, +2.77) +3.9% PTRN (Pattern Group $24.60, +0.93) +3.9% TX (Ternium $52.31, +1.97) -- earnings +3.7% SDGR (Schrödinger $16.22, +0.57) -- agreement for Bristol Myers to deploy AI co-scientist Bunsen +3.7% UUUU (Energy Fuels $13.33, +0.47) +3.6% TWST (Twist Bioscience $103.00, +3.56) -- upsized $300.0M common stock offering priced at $96/share +3.6% ENHA (Enhanced Group, Inc. $2.79, +0.10) +3.5% IE (Ivanhoe Electric $10.88, +0.37) -- executive appointments +3.5% MP (MP Materials $49.13, +1.66) +3.4% FLYW (Flywire $17.85, +0.59) -- earnings +3.2% AVAV (AeroVironment $174.47, +5.45) +3.2% NXE (NexGen Energy $10.07, +0.31) -- earnings +3.1% AVT (Avnet $95.40, +2.87) -- earnings +1.4% PSKY (Paramount Skydance $8.50, +0.12) -- earnings *Market cap <$1B* +49.2% GTE (Gran Tierra Energy $10.19, +3.36) -- earnings; to sell its operations in Colombia, Ecuador to Maurel & Prom +31.6% BLMN (Bloomin' Brands $11.74, +2.82) -- earnings +29.8% JLHL (Julong Holding $7.04, +1.62) +24.9% OESX (Orion Energy Systems $12.99, +2.59) -- earnings +23.1% DFNS (T3 Defense $58.31, +10.95) -- purchase order from Israeli defense contractor +17.9% SWIM (Latham Group $6.72, +1.02) -- earnings +16.0% XOS (Xos, Inc. $3.05, +0.42) +15.2% SMRT (SmartRent $1.21, +0.16) -- earnings +15.1% DIBS (1stdibs.com $5.03, +0.66) -- earnings +14.7% KODK (Eastman Kodak $10.24, +1.31) -- earnings +14.4% BEEP (Mobile Infrastructure $2.07, +0.26) +14.3% GSM (Ferroglobe $3.91, +0.49) -- earnings +14.0% TBI (TrueBlue $8.77, +1.08) -- earnings +11.6% TATT (TAT Technologies $46.50, +4.85) -- earnings +8.9% CPSH (CPS Technologies $4.64, +0.38) -- earnings +8.2% METC (Ramaco Resources $10.43, +0.79) -- earnings +7.1% ORN (Orion Group Holdings $10.90, +0.72) +5.9% QNC (Quantum eMotion $2.33, +0.13) +5.8% SOPH (Sophia Genetics $7.24, +0.40) +5.6% NXDR (Nextdoor Holdings $2.44, +0.13) -- earnings +5.0% OGG (Osisko Gold Group Inc. $2.54, +0.12) -- drilling update at Cariboo Gold Project's Regional Property +4.7% SSTK (Shutterstock $6.30, +0.28) -- earnings *Gold/silver related stocks higher -- Gold futures +2.21%* GFI +8.2%, SCZM +7.2%, HMY +7.2%, USAS +7.1%, HL +7.0% (earnings), AU +7.0%, DRD +7.0%, HYMC +7.0%, SA +6.7%, ASM +6.4%, ITRG +6.3%, NG +6.2%, CMCL +6.1%, VZLA +5.9%, KGC +5.7%, ARIS +5.6%, DC +5.6%, EGO +5.6%, AG +5.5%, AGI +5.5%, EQX +5.3%, CGAU +5.2%, MUX +5.2%, WPM +5.2%, EXK +5.2%, WRN +5.0%, AEM +5.0%, SSRM +5.0%, PAAS +4.9%, CDE +4.9%, IAG +4.9%, GOLD +4.9%, BTG +4.9%, SBSW +4.8%, PPTA +4.7%, NEM +4.7%, OR +4.7%, SKE +4.6%, MTA +4.6%, B +4.5%, FSM +4.4%, RGLD +4.4%, SVM +4.2%, FNV +4.2%, CEF +3.5%, AYA +3.4% Trading Lower: *Market cap >$10B* -21.2% PODD (Insulet $131.47, -35.35) -- earnings -15.1% CDW (CDW $130.76, -23.24) -- earnings; CFO Albert Miralles to retire in 2027 -14.4% MDLN (Medline $36.00, -6.04) -- earnings -11.4% SPCX (SpaceX $111.09, -14.24) -- earnings In sympathy: ECHO -6.1%, ASTS -2.9% -10.1% NYT (New York Times $67.99, -7.62) -- earnings -9.1% RRX (Regal Rexnord $200.00, -20.04) -- earnings -8.1% CVS (CVS Health $95.96, -8.46) -- earnings; revamp of its weight management program -7.7% GFS (GlobalFoundries $48.04, -3.98) -- earnings -7.7% VSAT (Viasat $79.50, -6.66) -- earnings -7.6% AMD (Advanced Micro Devices $479.10, -39.48) -- earnings -6.6% DVA (DaVita $213.00, -14.99) -- earnings -6.2% PINS (Pinterest $24.00, -1.58) -- earnings -5.8% FLUT (Flutter Entertainment $98.87, -6.09) -- earnings, CEO transition In sympathy: DKNG -3.2% -5.4% PUK (Prudential $27.92, -1.59) -- Caixin reported Chinese mainland tax ‌authorities levying personal income tax on returns from offshore insurance policies -4.6% CPNG (Coupang $16.00, -0.78) -- earnings -4.0% HSBC (HSBC Holdings $101.78, -4.26) -- Caixin reported Chinese mainland tax ‌authorities levying personal income tax on returns from offshore insurance policies -3.9% FN (Fabrinet $510.52, -20.51) -3.6% TSEM (Tower Semiconductor $230.85, -8.68) -3.5% CRCL (Circle Internet $61.06, -2.19) -- earnings -3.4% LSCC (Lattice Semiconductor $133.34, -4.66) -- earnings -3.4% AAOI (Applied Optoelectronics $127.20, -4.43) -3.2% CBRS (Cerebras Systems $219.89, -7.26) -3.1% MFC (Manulife Financial $43.38, -1.39) -- Caixin reported Chinese mainland tax ‌authorities levying personal income tax on returns from offshore insurance policies -3.0% SN (SharkNinja $163.14, -5.05) -- earnings -2.8% ALAB (Astera Labs $351.51, -10.16) -- earnings -2.7% BBY (Best Buy Co. $84.00, -2.35) -- Jefferies downgrade -2.7% UBER (Uber Technologies $70.08, -1.91) -- earnings -2.5% MRVL (Marvell Technology $213.17, -5.42) -2.5% EMR (Emerson Electric $154.87, -3.97) -- earnings -2.5% GPN (Global Payments $86.01, -2.24) -- earnings -2.4% BMY (Bristol Myers Squibb $64.30, -1.59) -- senior source refutes prior report of M&A talks with AZN -2.4% INTC (Intel $98.43, -2.43) -2.4% NBIS (Nebius Group $220.35, -5.40) -2.2% CRWV (CoreWeave $89.85, -2.05) -- multi-year agreement with Solidigm -2.2% LITE (Lumentum Holdings $830.70, -18.77) -2.2% BE (Bloom Energy $223.00, -5.11) -2.0% T (AT&T $22.91, -0.47) -- SpaceX comments on mobile market -1.9% WSE (Wise Group $12.13, -0.23) -1.9% COHR (Coherent $317.70, -6.03) -1.8% ONTO (Onto Innovation $282.55, -5.05) -1.8% CRDO (Credo Technology $233.60, -4.32) -1.7% MU (Micron Technology $877.14, -15.53) -1.6% VZ (Verizon Communications $46.13, -0.75) -- SpaceX comments on mobile market *Market cap $1B-$10B* -33.7% TBLA (Taboola.com $3.51, -1.78) -- earnings -28.1% CRTO (Criteo $16.10, -6.30) -- earnings -26.7% VPG (Vishay Precision Group $74.00, -27.00) -- earnings -17.2% EOSE (Eos Energy Enterprises $3.60, -0.75) -- earnings -16.9% SEDG (SolarEdge Technologies $40.51, -8.25) -- earnings In sympathy: TE -3.7%, ENPH -3.6%, FSLR -1.9% -16.2% BV (BrightView Holdings $11.00, -2.12) -- earnings -15.5% TDC (Teradata $29.07, -5.32) -- earnings -15.4% LMAT (LeMaitre Vascular $89.51, -16.27) -- earnings -11.2% FUBO (fuboTV $8.48, -1.07) -- earnings -10.3% SNDX (Syndax Pharmaceuticals $17.11, -1.97) -- earnings -10.2% TMDX (TransMedics Group $72.50, -8.25) -- earnings -9.9% EXTR (Extreme Networks $29.14, -3.20) -- earnings -9.9% MBC (MasterBrand $8.54, -0.94) -- earnings -9.4% CC (Chemours $16.24, -1.69) -- earnings -8.2% AROC (Archrock $32.80, -2.94) -- earnings -8.1% LCID (Lucid Group $7.15, -0.63) -- earnings -8.1% TYRA (Tyra Biosciences $29.88, -2.65) -- earnings -7.9% RXRX (Recursion Pharmaceuticals $3.05, -0.26) -- earnings -7.4% PRCT (PROCEPT BioRobotics $16.93, -1.35) -- earnings -7.3% MTCH (Match Group $38.22, -3.02) -- earnings -6.0% LPX (Louisiana-Pacific $72.21, -4.61) -- earnings -6.0% VSH (Vishay Intertechnology $36.50, -2.35) -- earnings -5.9% LIFE (Ethos Technologies $26.03, -1.62) -5.8% OPEN (Opendoor Technologies $3.88, -0.24) -- earnings -5.7% BVS (Bioventus $12.66, -0.76) -- earnings -5.6% GLXY (Galaxy Digital, Inc. $20.90, -1.24) -- earnings -5.1% COHU (Cohu $50.15, -2.69) -4.3% HNGE (Hinge Health, Inc. $76.00, -3.42) -- earnings -4.0% TNDM (Tandem Diabetes Care $19.40, -0.80) -3.9% RUN (SunRun $10.60, -0.43) -- prices $267M securitization of residential solar and storage assets -3.8% OUST (Ouster $46.00, -1.84) -3.6% CIM (Chimera Investment $12.20, -0.46) -- earnings -3.5% WOLF (Wolfspeed $26.12, -0.94) -3.5% CMPS (Compass Pathways $11.39, -0.41) -- earnings -3.1% NVTS (Navitas Semiconductor $12.30, -0.39) -3.0% AEHR (Aehr Test Systems $106.59, -3.30) -2.8% VOYG (Voyager Technologies $32.55, -0.94) -2.7% LIME (Lime $30.23, -0.85) -- earnings -2.5% WK (Workiva $59.70, -1.55) -- earnings *Market cap <$1B* -29.9% TYGO (Tigo Energy $1.43, -0.61) -- earnings -25.1% ANGI (Angi, Inc. $4.65, -1.56) -- earnings -16.8% EVGO (EVgo, Inc. $1.44, -0.29) -- earnings -16.7% SUJA (Suja Life, Inc. $9.50, -1.90) -- earnings -13.8% OSS (One Stop Systems $12.30, -1.97) -- earnings -12.3% FTCI (FTC Solar $2.70, -0.38) -- earnings -11.5% AMOD (Alpha Modus Holdings, Inc. $4.00, -0.52) -10.7% BZFD (BuzzFeed $1.09, -0.13) -- earnings -9.9% BBBY (Bed Bath & Beyond $5.01, -0.55) -- earnings -9.9% EGHT (8x8, Inc $2.02, -0.22) -- earnings -8.8% ATOM (Atomera $5.15, -0.50) -- earnings -6.6% NAGE (Niagen Bioscience $3.24, -0.23) -- earnings -6.1% CHCT (Community Healthcare Trust $16.63, -1.08) -- earnings -4.5% ANGX (Angel Studios $4.26, -0.20) -- earnings Click here to view our Gainers & Decliners page Related: AA, AAOI, ABNB, AEHR, AEM, AG, AGI, ALAB, ALB, AMD, AMGN, AMOD, AMPX, ANET, ANGI, ANGX, APP, APPS, ARIS, AROC, ASM, ASTS, ATOM, AU, AVAV, AVT, AYA, AZN, B, BAM, BBBY, BBY, BCRX, BE, BEEP, BKNG, BLMN, BMY, BTG, BV, BVS, BWA, BZFD, CBRS, CC, CDE, CDW, CEF, CG, CGAU, CHCT, CIM, CMCL, CMG, CMPS, COHR, COHU, COR, CPNG, CPSH, CRCL, CRDO, CRL, CRTO, CRWD, CRWV, CVS, CXW, DC, DDOG, DFNS, DIBS, DIS, DKNG, DRD, DT, DVA, ECHO, ECO, EGHT, EGO, ELAN, EMR, ENHA, ENPH, EOSE, EQX, EVGO, EXK, EXPE, EXTR, FCX, FLUT, FLYW, FN, FNV, FRPT, FSLR, FSM, FTCI, FTK, FTNT, FUBO, GENI, GFI, GFS, GILD, GLXY, GOLD, GPN, GSM, GTE, HBM, HL, HMY, HNGE, HSBC, HUBS, HYMC, IAG, IE, INOD, INTC, IRM, ITRG, JLHL, KGC, KLAR, KMT, KODK, KTOS, LCID, LIFE, LIME, LITE, LLY, LMAT, LPX, LRN, LSCC, MBC, MDB, MDLN, META, METC, MFC, MP, MRNA, MRVL, MTA, MTCH, MU, MUX, NAGE, NBIS, NEM, NG, NTNX, NVTS, NXDR, NXE, NYT, OESX, OGG, ONC, ONTO, OPEN, OR, ORN, OSS, OUST, PAAS, PANW, PGEN, PINS, PODD, PPTA, PRCT, PRGO, PRMB, PSKY, PTRN, PUK, QLYS, QNC, RARE, RGLD, RIOT, RRX, RUN, RXRX, SA, SBSW, SCCO, SCZM, SDGR, SEDG, SHOP, SKE, SMRT, SN, SNDX, SOPH, SPCX, SSRM, SSTK, SUJA, SVM, SWIM, T, TATT, TBI, TBLA, TDC, TE, TEAM, TMDX, TNDM, TOST, TSEM, TVTX, TWST, TX, TYGO, TYRA, U, UBER, UPST, URGN, USAS, UUUU, VOYG, VPG, VSAT, VSH, VZ, VZLA, WDAY, WK, WOLF, WPM, WRN, WSE, WYNN, XOS, YOU, ZBH...(more)	show story hide story
05-Aug-2026 08:52	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis "No discussions" between AstraZeneca and Bristol Myers, reports Reuters citing a senior level source. ADRs for AZN +6%, BMY (1%) in the pre-market. Earnings calendar in full swing with notable reports from large-cap biotech plus almost every corner of the sector. Last night Amgen and Gilead Sciences with Q2 beat-and-raise prints, shares of AMGN and GILD both little changed in the pre-market. Eli Lilly reported strong Q2 sales for diabetes and obesity, and mixed results for key oncology franchise. Volume in Mounjaro and Zepbound the key driver of sales growth. Shares of LLY +5% in the pre-market. CVS Health reported Q2 beat-and-raise print, with MLR 240bps better than StreetAccount consensus. Shares of CVS +3% in the pre-market Insulet Corp reported Q2 beat top and bottom lines, but focus on Omnipod sales growth forecast slower than Q3 consensus, and lowered for FY. Shares of PODD (14%) in the pre-market. Macro S&P futures are up +0.5% on Wednesday morning. Path of least resistance has been higher this week on the back of very strong Q2 earnings, cleaner positioning following July momentum unwind/deleveraging, positive macro surprise momentum and latest bout of diplomatic optimism surrounding the Middle East that has weighed on oil and yields. Busy night of earnings with SPCX hit by capex concerns and AMD under pressure with takeaways focused on very elevated expectations into the print. Middle East the other areas of focus. Headlines continue to suggest an interim deal to open the SoH is imminent, though Houthis said they attacked a Saudi tanker in the Read Sea. Pre-market trading update Trading higher +13.3% TVTX earnings +10.2% PRGO earnings +8.5% CRL earnings +7.5% BCRX earnings +6.9% PGEN earnings +6.4% ELAN earnings +6.0% AZN Reuters report on M&A story citing senior source +5.2% LLY earnings +3.3% CVS earnings +3.3% ZBH earnings +3.2% COR earnings +2.2% ONC earnings +0.4% AMGN earnings +0.2% GILD earnings Trading lower -14.3% PODD earnings -8.4% TMDX earnings -8.2% RXRX earnings -6.9% PRCT earnings; downgraded at Wm Blair and Wells Fargo -5.7% DVA earnings -1.8% HNGE earnings -1.6% BMY Reuters report on M&A story citing senior source Pharma M&A / media report: AZN / BMY Reuters reporting "no discussions" between the two large drugmakers, citing a senior source close to the matter. AZN ADRs were down more than (8%) WTD, BMY shares +1% WTD, since Sunday's FT story. Earnings: LLY reports Q2 EPS $8.38 ex-items vs FactSet $6.01 on revenue $22.97B vs FactSet $20.69B. Key product topline beats were Mounjaro, Jardiance, Trulicity, and Zebpound. Foundayo reported $98M in launch quarter sales. Lowers top-end of FY EPS outlook by (50c), raises FY revenue guidance by $2.5B at the midpoints. Conf. call at 10:00ET Quick take: Initial analyst takeaways focus heavily on the incretin volumes which drove Q2 outperformance, with Foundayo numbers viewed as roughly inline. Price competition with Novo Nordisk seen as healthy, with volume growth outweighing concessions. Guidance upgrade was well received, plus UBS posits $50/shr EPS in 2027 (FactSet consensus $45.18). On the 10ET call, analysts seek more color around the Foundayo launch trajectory, early indicators from the Medicare Bridge since 1-July, and any incremental thoughts on business development. ELAN reports Q2 EPS $0.34 ex-items vs FactSet $0.27 on revenue $1.37B vs FS $1.31B, adj EBITDA $288M vs FS $251.4M. Guides Q3 ahead of consensus. Raises FY EPS outlook by 7c, revenue by $67.5M, at the midpoints. Additional guidance in slides. Conf. call at 8:00ET Biotech Earnings: AMGN reported Q2 EPS $6.29 ex-items vs FactSet $5.62 on revenue $10.05B vs FS $9.43B. Raises FY EPS outlook by 50c and revenue by $1B, at the midpoints. GILD reported Q2 EPS ($6.75) ex-items vs FactSet ($7.26) on revenue $7.80B vs FS $7.40B. Raises FY EPS outlook by $0.375 and product sales by $50M, at the midpoints. Quick take: Sentiment has been generally positive around the update, suggesting results mitigated some concern around IMS data heading into the release. Commonly highlighted was continued outperformance from the HIV franchise (Biktarvy and PrEP) in the quarter, along with raised full year targets - HIV franchise growth now +9-10% (vs +8% prior). Some questioning around Yeztugo growth trajectory (with full year sales reiterated vs raised), however most viewed results and guidance constructively on the durability of the company's HIV portfolio (with no near-term LOE) and potential for ongoing margin expansion. ONC reports Q2 EPS $2.05 vs FactSet $1.66 on revenue $1.71B vs FS $1.62B. Raises FY revenue outlook by $300M, and NG OI by $250M, at the midpoints. Conf. call at 8:00ET UTHR reports Q2 EPS $7.27 vs FactSet $6.86 on revenue $783.3M vs FS $804.6M. Topline light, spread across three biggest products. Management highlights "strong underlying demand" for Tyvaso DPI (MNKD). Conf. call at 9:00ET TVTX reported Q2 EPS ($0.37) vs FactSet ($0.13) on revenue $169.9M vs FS $157.3M. Highlights continued momentum for Fispari including "promising early launch in FSGS" and continued strength in IgAN. Life Science & MedTech Earnings: ZBH reports Q2 EPS $2.07 ex-items vs FactSet $2.01 on revenue $2.18B vs FS $2.13B. Organic growth +4.0% vs StreetAccount +2.2%. Raises FY EPS by $0.055 at the midpoints, narrowed and raised FY revenue growth outlook by 90bps at the midpoints. Conf. call at 8:30ET PODD reports Q2 EPS $1.66 ex-items vs FactSet $1.45 on revenue $801.7M vs FS $787.4M. Guides Q3 revenue growth slower than consensus. Lowers FY revenue growth by 100bps, now +20-22% vs prior +21-23%. Conf. call at 8:00ET CRL reports Q2 EPS $3.02 ex-items vs FactSet $2.74 on revenue $1.00B vs FS $977.2M. Notes organic revenue growth +0.1% highest since Q3 of 2023. Raises FY EPS outlook by 25c at the midpoints. Narrows FY revenue growth (decline). Conf. call at 9:00ET Research: WAT upgraded to buy from hold at TD Cowen (Dan Brennan), target increased to $475 from $408 or approx. 20% upside. (FactSet average PT $434; range $390-475) PRCT downgraded to market perform from outperform at William Blair (Brandon Vazquez), follows Q2 earnings. PRCT downgraded to equal weight from overweight at Wells Fargo Securities (Nathan Treybeck), target cut to $19 from $34 or approx. 4% upside. (FactSet average PT $25; range $16-37) SN.LN (SNN) downgraded to underweight from equal weight at Barclays (Hassan Al-Wakeel), cites Q2 results. Target cut to 1050p from 1290p or approx. 6% downside. (FactSet average PT 1327p; range 1050-1544p) Services & Hospitals and Managed Care Earnings: CVS reports Q2 EPS $2.58 ex-items vs FactSet $1.85 on revenue $106.10B vs FS $100.03B. MLR 87.4% vs StreetAccount 89.8%. Raises FY EPS outlook by 60c at the midpoints, and CFO guidance to at least $11.5B vs prior at least $9.5B. Conf. call at 8:00ET COR reports fiscal Q3 EPS $4.48 ex-items vs FactSet $4.35 on revenue $84.8B vs FS $84.31B. Raises FY EPS outlook by 5c at the midpoints, reaffirms revenue growth guidance. Conf. call at 8:30ET DVA reported Q2 EPS $4.02 ex-items vs FactSet $3.88 on revenue $3.55B vs FS $3.50B. Repeats FY EPS guidance. MDLN reports Q2 EPS $0.50 ex-items vs FactSet $0.32 on revenue $7.69B vs FS $7.51B, adj EBITDA $1.06B vs FS $798.2M. Results and guidance include tariff refunds. Lowers FY adj EBITDA outlook by $200M, reflecting inflationary pressure from the Middle East conflict and other factors. Raises FY organic sales outlook by 50bps. Conf. call at 9:30ET Research: HUM upgraded to equal weight from underweight at Morgan Stanley (Erin Wright), target increased to $370 from $249 or approx. 2% upside. (FactSet average PT $415; range $280-513) On Deck: Regulatory FDA PDUFA for MRNA mFlusiva (mRNA-1010) BLA Corporate NAMS hosting Investor Day meeting (9:00ET) Earnings after the close MCK, RVMD, STE, SOLV, EXEL, EHC, QGEN, MIRM, BLLN, CAI, NVST, ARQT, RCUS, GRAL Earnings tomorrow Thu 6-Aug: before BDX, ZTS, ROIV, INSM, MRK.GR, VTRS, PRAX, OSCR, IMVT, LNTH, TFX, LGND, SRRK, SHC, LFST, HAE, PRVA after NTRA, RMD, GMAB, BMRN, HALO, CYTK, GMED, XENE, DFTX, TXG, CON, RLAY, ICUI, IRTC, DNLI This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AMGN, ARQT, AZN, BCRX, BDX, BLLN, BMRN, BMY, CAI, CON, COR, CRL, CVS, CYTK, DFTX, DNLI, DVA, EHC, ELAN, EXEL, GILD, GMAB, GMED, GRAL, HAE, HALO, HNGE, HUM, ICUI, IMVT, INSM, IRTC, LFST, LGND, LLY, LNTH, MCK, MDLN, MIRM, MNKD, MRK.GR, MRNA, NAMS, NTRA, NVO, NVST, ONC, OSCR, PGEN, PODD, PRAX, PRCT, PRGO, PRVA, QGEN, RCUS, RLAY, RMD, ROIV, RVMD, RXRX, SHC, SN.LN, SOLV, SRRK, STE, TFX, TMDX, TVTX, TXG, UTHR, VTRS, WAT, XENE, ZBH, ZTS...(more)	show story hide story
05-Aug-2026 08:17	StreetAccount Summary - US Pre-market trading S&P futures +34.0 to 7799.5, +0.44% vs settlement. 10-year yield (1) bps to 4.62%. Sep WTI +$0.41 or +0.54% to $76.18. Trading Higher: *Market cap >$10B* +23.2% SHOP (Shopify $151.86, +28.56) -- earnings +10.1% ANET (Arista Networks $209.77, +19.26) -- earnings +10.0% DT (Dynatrace $50.29, +4.58) -- earnings +9.7% BKNG (Booking Holdings $213.21, +18.94) -- earnings In sympathy: ABNB +2.7%, EXPE +2.5% +8.5% CRL (Charles River Laboratories $254.08, +19.96) -- earnings +5.5% ELAN (Elanco Animal Health $27.00, +1.40) -- earnings +5.2% LLY (Eli Lilly $1,173.27, +57.59) -- earnings +5.2% AZN (AstraZeneca $163.71, +8.09) -- senior source refutes prior report of M&A talks with BMY +4.9% WYNN (Wynn Resorts $102.41, +4.81) -- earnings +4.8% APP (AppLovin $439.90, +20.20) +4.7% DY (Dycom Industries $434.75, +19.67) +3.4% DIS (Walt Disney $101.54, +3.36) -- earnings +3.3% ZBH (Zimmer Biomet Holdings $98.96, +3.15) -- earnings +3.2% PANW (Palo Alto Networks $378.01, +11.67) +3.2% COR (Cencora $316.05, +9.77) -- earnings +3.2% IRM (Iron Mountain $129.49, +3.98) -- earnings +2.9% HBM (HudBay Minerals $25.50, +0.73) +2.5% U (Unity Software $36.10, +0.88) +2.5% CVS (CVS Health $107.08, +2.66) -- earnings; revamp of its weight management program In sympathy: CNC +1.4% +2.5% WDAY (Workday $175.49, +4.21) +2.5% ALB (Albemarle $123.89, +3.07) +2.4% AFRM (Affirm Holdings $79.98, +1.86) +2.4% SCCO (Southern Copper $199.90, +4.74) +2.3% TEAM (Atlassian $112.81, +2.50) +2.3% DDOG (Datadog $294.73, +6.58) +2.2% ONC (BeOne Medicines $330.00, +6.99) -- earnings +2.1% HUBS (HubSpot $254.24, +5.35) +2.0% TWLO (Twilio $197.98, +3.93) +1.9% CRWD (CrowdStrike $215.30, +4.08) +1.9% OKTA (Okta, Inc. $150.60, +2.78) +1.9% META (Meta Platforms $598.86, +10.92) +1.9% CMG (Chipotle Mexican Grill $34.45, +0.63) +1.8% ADBE (Adobe $262.24, +4.75) +1.8% FCX (Freeport-McMoRan $68.50, +1.20) +1.8% CCJ (Cameco $94.80, +1.71) +1.8% SNPS (Synopsys $411.00, +7.14) +1.7% CDNS (Cadence Design Systems $346.43, +5.81) +1.7% ITUB (Banco Itau Holding $8.33, +0.14) -- earnings +1.7% MELI (MercadoLibre $1,920.00, +31.50) +1.7% MRNA (Moderna $57.95, +0.96) +1.6% SNOW (Snowflake $321.71, +4.94) +1.6% CRM (Salesforce $194.02, +3.03) +1.6% NVDA (NVIDIA $215.39, +3.45) +1.6% SU (Suncor Energy $65.47, +1.02) +1.6% FIG (Figma $27.55, +0.43) +1.5% NET (Cloudflare $305.79, +4.46) +1.5% PSX (Phillips 66 $208.88, +2.99) -- earnings +1.4% SPOT (Spotify Technology $485.00, +6.83) +1.4% PAYX (Paychex $120.36, +1.70) +1.3% CSCO (Cisco Systems $123.31, +1.57) +1.3% CRCL (Circle Internet $64.10, +0.85) -- earnings +1.2% VST (Vistra $144.92, +1.69) +1.2% ULS (UL Solutions $79.25, +0.91) +1.1% BSP (Bending Spoons $37.85, +0.40) +1.0% TTWO (Take-Two Interactive $242.67, +2.45) +1.0% XYZ (Block, Inc. $85.50, +0.86) +0.8% DVN (Devon Energy $44.40, +0.35) -- earnings +0.4% AMGN (Amgen $391.74, +1.72) -- earnings +0.4% PRU (Prudential Financial $124.03, +0.49) -- earnings +0.3% AES (AES Corp. $14.72, +0.04) -- earnings +0.2% GILD (Gilead Sciences $135.58, +0.33) -- earnings *Market cap $1B-$10B* +25.3% APPS (Digital Turbine $11.92, +2.41) -- earnings +15.6% UPST (Upstart Holdings $35.04, +4.72) -- earnings +14.0% TVTX (Travere Therapeutics $63.84, +7.82) -- earnings +13.7% KMT (Kennametal $41.00, +4.94) -- earnings +12.9% KTOS (Kratos Defense & Security Solutions $58.54, +6.67) -- earnings +11.4% LRN (Stride $89.63, +9.18) -- earnings +11.3% PRGO (Perrigo Co. $12.00, +1.22) -- earnings +10.2% YOU (Clear Secure $61.39, +5.66) -- earnings +8.2% FRPT (Freshpet $67.50, +5.12) -- earnings +7.9% AVT (Avnet $99.83, +7.30) -- earnings +7.4% BCRX (BioCryst Pharmaceuticals $9.69, +0.67) -- earnings +7.4% PRMB (Primo Brands $25.00, +1.71) -- earnings +6.6% PGEN (Precigen $6.96, +0.43) -- earnings +5.9% ECO (Okeanis Eco Tankers $62.70, +3.47) -- earnings +5.5% RIOT (Riot Platforms $22.75, +1.19) -- earnings +5.4% ARIS (Aris Mining $15.51, +0.80) +5.2% AYA (Aya Gold & Silver $24.09, +1.19) +5.1% URGN (UroGen Pharma $41.94, +2.02) -- earnings +4.7% TX (Ternium $52.72, +2.38) -- earnings +4.0% GENI (Genius Sports $8.40, +0.32) -- agreement with Kalshi to provide official data, marketing, media and integrity services +3.8% INOD (Innodata $72.91, +2.70) +3.6% ICL (ICL Group $5.34, +0.19) +3.4% BTDR (Bitdeer Technologies Group $11.77, +0.39) -- Cantor Fitzgerald upgrade +2.9% NXE (NexGen Energy $10.04, +0.28) -- earnings +2.8% FLYW (Flywire $17.75, +0.49) -- earnings +2.8% NEXT (NextDecade $6.70, +0.18) +2.7% SHAK (Shake Shack $68.03, +1.81) -- earnings +2.7% PTRN (Pattern Group $24.32, +0.65) +2.6% PURR (Hyperliquid Strategies $6.99, +0.18) +2.6% FIGR (Figure Technology Solutions $28.35, +0.71) +2.6% MP (MP Materials $48.70, +1.23) +2.5% SGML (Sigma Lithium $11.38, +0.28) +2.4% ESTC (Elastic $72.80, +1.74) +2.3% UUUU (Energy Fuels $13.16, +0.30) +2.2% VRDN (Viridian Therapeutics $21.30, +0.46) +2.2% ENHA (Enhanced Group, Inc. $2.75, +0.06) +2.2% ARCO (Arcos Dorados $8.52, +0.18) +2.1% VYX (NCR Voyix $9.07, +0.19) -- earnings +2.1% DK (Delek US Holdings $67.59, +1.39) -- earnings +2.1% ZIM (Zim Integrated Shipping Services $27.86, +0.57) +2.0% TGB (Trekor Metals Limited $7.99, +0.16) +2.0% VIR (Vir Biotechnology $9.35, +0.18) +1.3% ELF (e.l.f. Beauty $89.02, +1.18) -- Bernstein upgrade *Market cap <$1B* +42.9% GTE (Gran Tierra Energy $9.76, +2.93) -- earnings; to sell its operations in Colombia, Ecuador to Maurel & Prom +32.7% JLHL (Julong Holding $7.19, +1.77) +29.5% DFNS (T3 Defense $61.35, +13.99) -- purchase order from Israeli defense contractor +23.2% BLMN (Bloomin' Brands $10.99, +2.07) -- earnings +15.2% KODK (Eastman Kodak $10.29, +1.36) -- earnings +13.9% XOS (Xos, Inc. $2.99, +0.36) +13.0% SWIM (Latham Group $6.44, +0.74) -- earnings +9.4% TATT (TAT Technologies $45.56, +3.91) -- earnings +9.2% METC (Ramaco Resources $10.53, +0.89) -- earnings +8.4% OFIX (Orthofix Medical $13.22, +1.02) -- earnings +7.4% ORN (Orion Group Holdings $10.93, +0.75) +7.0% GSM (Ferroglobe $3.66, +0.24) -- earnings +6.8% QNC (Quantum eMotion $2.35, +0.15) +6.2% SGHT (Sight Sciences $5.99, +0.35) -- receives FDA 510(k) clearance of the OMNI Ultra Surgical System +6.0% SOPH (Sophia Genetics $7.25, +0.41) +6.0% SSTK (Shutterstock $6.38, +0.36) -- earnings +5.0% IMC (IMC Rare Earths Ltd. $8.63, +0.41) +4.8% SVCO (Silvaco Group $9.20, +0.42) +4.6% GORO (Goldgroup Mining $2.29, +0.10) +4.2% NEOV (NeoVolta $2.64, +0.11) +3.4% AIRJ (AirJoule Technologies $6.04, +0.20) +3.3% OGG (Osisko Gold Group Inc. $2.50, +0.08) +3.2% SLI (Standard Lithium $2.28, +0.07) *Gold/silver related stocks higher; Gold futures +2.36%; Silver +3.3%* GFI +8.1%, SCZM +7.6%, HMY +7.0%, AU +6.8%, DRD +6.6%, USAS +6.6%, HYMC +6.6%, SA +6.2%, SVM +6.2%, PPTA +6.1%, IAG +6.0%, ASM +5.9%, AG +5.9%, SKE +5.9%, NG +5.8%, HL +5.8% (earnings), SBSW +5.8%, GOLD +5.6%, CDE +5.5%, MTA +5.4%, CGAU +5.3%, PAAS +5.2%, AGI +5.2%, KGC +5.2%, EQX +5.1%, TFPM +5.1%, VZLA +5.0%, SSRM +5.0%, EGO +5.0%, FSM +5.0%, OR +4.9%, AEM +4.8%, NEM +4.8%, EXK +4.6%, BTG +4.6%, WPM +4.5%, ITRG +4.4%, B +4.4%, RGLD +4.3%, DC +3.9%, GROY +3.7%, CEF +3.3%, WRN +3.1%, AAUC +2.9% Trading Lower: *Market cap >$10B* -20.8% CDW (CDW $121.96, -32.04) -- earnings; CFO Albert Miralles to retire in 2027 -14.0% PODD (Insulet $143.52, -23.30) -- earnings -10.8% SPCX (SpaceX $111.82, -13.51) -- earnings In sympathy: ECHO -5.7% -9.2% NYT (New York Times $68.65, -6.96) -- earnings -9.2% PINS (Pinterest $23.23, -2.35) -- earnings -8.8% AMD (Advanced Micro Devices $473.00, -45.58) -- earnings -8.3% VSAT (Viasat $79.00, -7.16) -- earnings -8.2% FLUT (Flutter Entertainment $96.40, -8.56) -- earnings -8.1% RRX (Regal Rexnord $202.12, -17.92) -- earnings -7.2% PUK (Prudential $27.38, -2.13) -- Caixin reported Chinese mainland tax ‌authorities levying personal income tax on returns from offshore insurance policies -6.5% CPNG (Coupang $15.69, -1.09) -- earnings -5.7% DVA (DaVita $214.99, -13.00) -- earnings -4.8% GPN (Global Payments $84.05, -4.20) -- earnings -4.6% HSBC (HSBC Holdings $101.20, -4.84) -- Caixin reported Chinese mainland tax ‌authorities levying personal income tax on returns from offshore insurance policies -4.1% UBER (Uber Technologies $69.01, -2.98) -- earnings -4.0% AAOI (Applied Optoelectronics $126.30, -5.33) -3.7% LSCC (Lattice Semiconductor $132.95, -5.05) -- earnings -3.4% GFS (GlobalFoundries $50.26, -1.76) -- earnings -3.4% TSEM (Tower Semiconductor $231.29, -8.24) -3.4% MFC (Manulife Financial $43.27, -1.50) -3.3% INTC (Intel $97.57, -3.29) -3.0% EMR (Emerson Electric $154.00, -4.84) -- earnings -2.8% LITE (Lumentum Holdings $826.09, -23.38) -2.3% FIS (Fidelity National Information Services $43.24, -1.02) -- UBS downgrade -2.2% ALAB (Astera Labs $353.75, -7.92) -- earnings -2.2% CRDO (Credo Technology $232.59, -5.33) -2.2% CBRS (Cerebras Systems $222.18, -4.97) -2.1% ASTS (AST Spacemobile $68.86, -1.45) -2.1% AMKR (Amkor Technology $54.70, -1.17) -2.1% GLW (Corning $156.50, -3.39) -2.1% COHR (Coherent $317.00, -6.73) -2.0% MU (Micron Technology $874.93, -17.74) -1.9% ON (onsemi $79.28, -1.50) -1.9% SNDK (Sandisk $1,399.99, -27.63) -1.9% NBIS (Nebius Group $221.40, -4.34) -1.9% MRVL (Marvell Technology $214.49, -4.10) -1.8% QCOM (Qualcomm $159.80, -2.87) -1.7% BE (Bloom Energy $224.30, -3.81) -1.7% VZ (Verizon Communications $46.09, -0.79) -1.6% T (AT&T $23.00, -0.38) -1.6% KLAC (KLA $192.40, -3.05) -1.6% BBY (Best Buy Co. $84.95, -1.40) -- Jefferies downgrade -1.6% TER (Teradyne $397.00, -6.56) -1.5% WSE (Wise Group $12.17, -0.19) -1.4% DELL (Dell Technologies $460.93, -6.34) -1.4% AMAT (Applied Materials $539.08, -7.54) -1.3% WDC (Western Digital $541.52, -7.04) -1.3% STX (Seagate Technology $834.00, -11.35) -1.2% NI (NiSource $43.98, -0.55) -- earnings -1.0% BMY (Bristol Myers Squibb $65.25, -0.64) -- senior source refutes prior report of M&A talks with AZN -0.3% KHC (Kraft Heinz $26.55, -0.09) -- earnings *Market cap $1B-$10B* -26.7% VPG (Vishay Precision Group $73.99, -27.01) -- earnings -25.4% CRTO (Criteo $16.72, -5.68) -- earnings -22.4% TBLA (Taboola.com $4.10, -1.19) -- earnings -14.0% EOSE (Eos Energy Enterprises $3.74, -0.61) -- earnings -13.3% TDC (Teradata $29.80, -4.59) -- earnings -12.4% SEDG (SolarEdge Technologies $42.70, -6.06) -- earnings In sympathy: TE -3.9%, ENPH -3.3%, FSLR -2.5% -9.3% MBC (MasterBrand $8.60, -0.88) -- earnings -9.3% MTCH (Match Group $37.40, -3.84) -- earnings -8.4% TMDX (TransMedics Group $74.00, -6.75) -- earnings -8.4% RXRX (Recursion Pharmaceuticals $3.03, -0.28) -- earnings -8.3% SNDX (Syndax Pharmaceuticals $17.50, -1.58) -- earnings -8.1% LCID (Lucid Group $7.15, -0.63) -- earnings -7.8% TYRA (Tyra Biosciences $29.99, -2.54) -- earnings -7.5% OPEN (Opendoor Technologies $3.81, -0.31) -- earnings -6.9% CC (Chemours $16.69, -1.24) -- earnings -6.6% PRCT (PROCEPT BioRobotics $17.08, -1.20) -- earnings -5.7% FUBO (fuboTV $9.01, -0.54) -- earnings -5.6% GLXY (Galaxy Digital, Inc. $20.90, -1.24) -- earnings -5.1% VSH (Vishay Intertechnology $36.87, -1.98) -- earnings -5.0% LPX (Louisiana-Pacific $72.97, -3.84) -- earnings -4.8% AROC (Archrock $34.02, -1.72) -- earnings -4.4% RUN (SunRun $10.54, -0.49) -- prices $267M securitization of residential solar and storage assets -4.1% CMPS (Compass Pathways $11.32, -0.48) -- earnings -4.0% NSIT (Insight Enterprises $131.81, -5.45) -3.4% POET (POET Technologies $8.28, -0.29) -3.4% OUST (Ouster $46.21, -1.63) -3.2% WLTH (Wealthfront $9.51, -0.31) -3.1% AEHR (Aehr Test Systems $106.44, -3.45) -3.0% RZLV (Rezolve Ai $2.56, -0.08) -2.8% AXTI (AXT Inc $63.42, -1.85) -2.7% KD (Kyndryl Holdings $14.29, -0.40) -- earnings -2.4% MOS (Mosaic $22.17, -0.54) -- earnings -2.4% PENG (Penguin Solutions $56.47, -1.37) -2.4% NVTS (Navitas Semiconductor $12.38, -0.31) -2.3% MXL (MaxLinear $71.03, -1.69) -2.2% RDW (Redwire $10.40, -0.23) -2.1% CAMT (Camtek $148.44, -3.18) -2.1% WOLF (Wolfspeed $26.49, -0.57) -1.8% CIM (Chimera Investment $12.43, -0.23) -- earnings -1.8% HNGE (Hinge Health, Inc. $77.99, -1.43) -- earnings *Market cap <$1B* -26.5% TYGO (Tigo Energy $1.50, -0.54) -- earnings -20.5% ANGI (Angi, Inc. $4.94, -1.27) -- earnings -18.2% SUJA (Suja Life, Inc. $9.33, -2.07) -- earnings -11.4% BZFD (BuzzFeed $1.08, -0.14) -- earnings -10.8% BBBY (Bed Bath & Beyond $4.96, -0.60) -- earnings -10.7% FTCI (FTC Solar $2.75, -0.33) -- earnings -9.4% ANGX (Angel Studios $4.04, -0.42) -- earnings -8.5% EGHT (8x8, Inc $2.05, -0.19) -- earnings -7.8% OSS (One Stop Systems $13.16, -1.11) -- earnings -5.8% ATOM (Atomera $5.32, -0.33) -- earnings -5.6% IOND (Ionic Digital, Inc. $58.00, -3.44) -4.4% NAGE (Niagen Bioscience $3.32, -0.15) -- earnings -3.4% GILT (Gilat Satellite Networks $11.50, -0.41) -- earnings -3.3% CHCT (Community Healthcare Trust $17.13, -0.58) -- earnings -3.2% NUAI (New Era Energy & Digital $5.11, -0.17) -2.9% WHWK (Whitehawk Therapeutics $4.02, -0.12) -2.9% JBGS (JBG SMITH Properties $11.63, -0.35) -- earnings -2.7% SIDU (Sidus Space $2.17, -0.06) -2.6% HRZN (Horizon Technology Finance $4.43, -0.12) -- earnings Click here to view our Gainers & Decliners page Related: AAOI, AAUC, ABNB, ADBE, AEHR, AEM, AES, AFRM, AG, AGI, AIRJ, ALAB, ALB, AMAT, AMD, AMGN, AMKR, ANET, ANGI, ANGX, APP, APPS, ARCO, ARIS, AROC, ASM, ASTS, ATOM, AU, AVT, AXTI, AYA, AZN, B, BBBY, BBY, BCRX, BE, BKNG, BLMN, BMY, BSP, BTDR, BTG, BZFD, CAMT, CBRS, CC, CCJ, CDE, CDNS, CDW, CEF, CGAU, CHCT, CIM, CMG, CMPS, CNC, COHR, COR, CPNG, CRCL, CRDO, CRL, CRM, CRTO, CRWD, CSCO, CVS, DC, DDOG, DELL, DFNS, DIS, DK, DRD, DT, DVA, DVN, DY, ECHO, ECO, EGHT, EGO, ELAN, ELF, EMR, ENHA, ENPH, EOSE, EQX, ESTC, EXK, EXPE, FCX, FIG, FIGR, FIS, FLUT, FLYW, FRPT, FSLR, FSM, FTCI, FUBO, GENI, GFI, GFS, GILD, GILT, GLW, GLXY, GOLD, GORO, GPN, GROY, GSM, GTE, HBM, HL, HMY, HNGE, HRZN, HSBC, HUBS, HYMC, IAG, ICL, IMC, INOD, INTC, IOND, IRM, ITRG, ITUB, JBGS, JLHL, KD, KGC, KHC, KLAC, KMT, KODK, KTOS, LCID, LITE, LLY, LPX, LRN, LSCC, MBC, MELI, META, METC, MFC, MOS, MP, MRNA, MRVL, MTA, MTCH, MU, MXL, NAGE, NBIS, NEM, NEOV, NET, NEXT, NG, NI, NSIT, NUAI, NVDA, NVTS, NXE, NYT, OFIX, OGG, OKTA, ON, ONC, OPEN, OR, ORN, OSS, OUST, PAAS, PANW, PAYX, PENG, PGEN, PINS, PODD, POET, PPTA, PRCT, PRGO, PRMB, PRU, PSX, PTRN, PUK, PURR, QCOM, QNC, RDW, RGLD, RIOT, RRX, RUN, RXRX, RZLV, SA, SBSW, SCCO, SCZM, SEDG, SGHT, SGML, SHAK, SHOP, SIDU, SKE, SLI, SNDK, SNDX, SNOW, SNPS, SOPH, SPCX, SPOT, SSRM, SSTK, STX, SU, SUJA, SVCO, SVM, SWIM, T, TATT, TBLA, TDC, TE, TEAM, TER, TFPM, TGB, TMDX, TSEM, TTWO, TVTX, TWLO, TX, TYGO, TYRA, U, UBER, ULS, UPST, URGN, USAS, UUUU, VIR, VPG, VRDN, VSAT, VSH, VST, VYX, VZ, VZLA, WDAY, WDC, WHWK, WLTH, WOLF, WPM, WRN, WSE, WYNN, XOS, XYZ, YOU, ZBH, ZIM...(more)	show story hide story
05-Aug-2026 08:08	BMY 'No discussions' happening between Astrazeneca and Bristol Myers Squibb regarding a potential deal -- Reuters, citing senior source close to the situation ($65.89) Article cites the senior source as saying 'never was a deal to be done' StreetAccount notes Semafor reported yesterday that talks between the two remain active Pre-market trading: BMY (1.5%) to $64.89 AZN +5.1% to $163.55 Editor's Note: This comment was revised to include link to the Reuters story. (05-Aug-2026, 09:05 ET) See Related StreetAccount comments: 8/4/2026 12:46:56 PM - AstraZeneca's merger talks with Bristol Myers Squibb remain active - Semafor 8/3/2026 9:18:31 PM - AstraZeneca holders express reservations about potential merger with Bristol Myers Squibb - FT (roughly 17:00 BST/12:00 ET) 8/2/2026 4:46:01 PM - AstraZeneca in talks with Bristol Myers Squibb - media reports Related: AZN.LN Reference Link: Reuters	show story hide story
05-Aug-2026 04:39	1093.HK CSPC Pharmaceutical Group entering 51:49 joint venture with AstraZeneca to build biologics manufacturing facility in Shijiazhuang, China (HK$8.38) The JV's initial business scope will focus on the manufacturing and supply of mutually agreed biologics drug substances (DS) for global markets. Related: AZN.LN Attached Files PDF Document: Press release	show story hide story
04-Aug-2026 13:49	StreetAccount Sector Summary: Healthcare Monthly Recap - July 2026 Month in Review: Healthcare equities outperformed for the month of July 2026. The S&P 500 Healthcare Index added +2.24% vs the S&P 500 Index down (0.13%). Third straight month of gains for Healthcare, and second straight month of outperformance. Outperformers: MedTech, Services Underperformers: Biotech, Managed Care, Pharma Most major health group returns were widely split for the month, either up MSD or down MSD. Pharma group the exception with DRG down (1.11%) including large-cap drugmakers even more widely split in July, between BMY +13%, on earnings, and AZN (11%), on trial results. Q2 earnings were the primary source of newsflow in July, and were off to an ominous beginning with a negative preannouncement by HCA, which pinned volume softness on HIX enrollment declines after the expiry of ACA subsidies. Medical device subgroup traded weaker on this headline, including and through the report by ISRG which echoed concerns around procedure volumes due to the ACA changes. From there forward, sentiment and commentary from peers (both hospitals and device makers) was surprisingly resilient and supported some of the best gains in July. Biopharma M&A continued with several high-premium deals, and the XBI topped $160 for the first time since February 2021, before cooling off in the back half of the month. XBI fell more than (7%) in July, coming after its best month in years during June. Top 5 on the XLV: +23.9% DXCM, +22.7% BAX, +22.3% REGN, +21.6% IQV, +16.5% ABT Bottom 5 on the XLV: -21.7% MRNA, -11.2% ISRG, -8.4% HUM, -6.1% BIIB, -5.0% WST Year-to-date, Healthcare +4.86% vs the S&P 500 +9.41%. Healthcare seventh out of eleven major sectors in CY26. Energy +32.77% and Consumer Discretionary (0.31%) bracket them all. Two IPOs in July, twenty-one YTD 2026: versus three in July 2025 / twenty YTD 2025 cumulatively raised $6.39B YTD vs $2.55B YTD 2025 APMD +56.3% - raised $192M - Biotech SCTX +29.9% - raised $129M - Biotech Notable movers for the month: Gainers: FBRX +260.5% - acquired by ARGX for $2.2B CRNX +123.2% - acquired by VRTX for $10.0B TRAX +118.9% - sympathy to FBRX and TEVA; best performer on XBI AVTR +39.2% - stock higher 11 straight weeks (including earnings 29-Jul) THC +36.2% - earnings CORT +31.7% - earnings DXCM +23.9% - sympathy to ABT (diabetes tech); earnings; best performer on XLV BAX +22.7% - earnings (concluding best one-week gain and third-best month of all time) MMSI +22.6% - earnings; best month since April 2020 REGN +22.3% - earnings; best week in nearly four years IQV +21.6% - earnings MMED +20.7% - sympathy to ABT (diabetes tech) GKOS +19.3% - earnings ILMN +16.6% - earnings; stock higher four straight months ABT +16.5% - earnings; best month since April 2020 TMO +14.5% - earnings; stock higher six straight weeks BMY +13.3% - earnings; 52-week high UHS +13.3% - Medicare proposed rules for HH, OP, ASC; downgrade; earnings Decliners: CAPR (84.0%) - FDA briefing docs / Adcom; worst performer on XBI IONS (34.7%) - trial results in ATTR-CM with AZN; Roche discontinued HD program; Biogen presented CELIA at AAIC; downgraded at Wolfe ALNY (31.7%) - sympathy to AZN trial results in ATTR-CM TEM (24.3%) - acquired PSNL for $1.5B; earnings; fifth double-digit % month in CY2026 MRNA (21.7%) - follows +48% in prior month; worst performer on XLV HIMS (19.9%) - sixth double-digit % month in CY2026; FDA panel recommends peptides for compounding; FTC lawsuit RDY (18.2%) - semaglutide supply issues; downgrades IBRX (18.1%) - shares remain +262% YTD; UAE MAA for Anktiva CELC (17.4%) - FDA approved REVTORPYK; launch readiness questioned CRSP (12.0%) - gene editing weakness with XBI (7.10%) ending six-month win streak ISRG (11.2%) - earnings/procedure growth (comments on HIX/uninsured) AZN (10.5%) - trial results in ATTR-CM w/IONS Related: ABT, ALNY, APMD, ARGX, AVTR, AZN, BAX, BIIB, BMY, CAPR, CELC, CORT, CRNX, CRSP, DXCM, FBRX, GKOS, HIMS, HUM, IBRX, ILMN, IONS, IQV, ISRG, MMED, MMSI, MRNA, PSNL, RDY, REGN, SCTX, TEM, TEVA, THC, TMO, TRAX, UHS, VRTX, WST...(more)	show story hide story
04-Aug-2026 12:46	BMY AstraZeneca's merger talks with Bristol Myers Squibb remain active - Semafor ($65.35 -$0.12) See Related StreetAccount comments: 8/3/2026 8:24:56 AM - Street Takeaways - Bristol Myers Squibb potential merger with AstraZeneca 8/2/2026 4:46:01 PM - AstraZeneca in talks with Bristol Myers Squibb - media reports Related: AZN Reference Link	show story hide story
04-Aug-2026 07:03	LH Labcorp launches FDA-approved PTEN companion diagnostic for prostate cancer ($307.42) LH announced the nationwide availability of Roche's VENTANA PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the FDA to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma. The assay helps identify patients who may be eligible for treatment with AstraZeneca's TRUQAP (capivasertib) in combination with abiraterone acetate and prednisone. Reference Link: Press release Related: AZN.LN, ROP.SW	show story hide story
04-Aug-2026 06:17	SOPH SOPHiA GENETICS announces new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca ($5.69) This multi-year collaboration agreement will advance the development and commercialization of two companion diagnostic programs, bringing SOPHiA GENETICS's decentralized clinical trial assays and companion diagnostic capabilities to AstraZeneca therapies. As part of the collaboration, SOPHiA GENETICS will develop its Solid Tumor application into a decentralized companion diagnostic. In addition, the company will develop and validate its Hematological Oncology application to support a companion diagnostic program for patients with blood cancer. Reference Link: Press release Related: AZN.LN	show story hide story
04-Aug-2026 02:42	Weak London IPO market fuels concerns over UK's equity appeal: CityAM reported that London's IPO market is expected to remain subdued for the rest of the year as domestic and international political uncertainty continues to deter companies from listing. The UK's equity market has seen minimal IPO activity so far this year, with just seven new listings raising a combined £557M. While analysts expect a modest pickup in issuance during the second half, many companies are likely to delay flotations until uncertainty eases. In contrast to the weak IPO backdrop, takeover activity has accelerated as private equity and overseas buyers take advantage of depressed UK valuations. The FT cited LSEG data showing UK-listed companies received £44B of unsolicited takeover bids in the second quarter, the highest level since 2018. Foreign acquirers are increasingly using high-premium public offers to pressure boards into accepting large acquisitions. Concerns over de-listings and companies shifting their focus away from the UK also persist. The Telegraph highlighted speculation over a potential tie-up between AstraZeneca (AZN.LN) and Bristol Myers Squibb. It argued that a tie-up could increase speculation that AstraZeneca may eventually shift primary listing to the US, despite currently retaining London primary listing and UK headquarters. Report warned that other large UK-listed firms could also reconsider their domicile, reinforcing longstanding concerns over the attractiveness of UK equity markets and the persistent valuation discount. For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: AZN.LN	show story hide story
04-Aug-2026 02:23	European macro headlines: Corporate: Continental beats Q2 profit expectations on strong tyre demand (Reuters) AstraZeneca shareholders voice concerns over potential mega-merger with Bristol Myers Squibb (FT) BP's Q2 profit more than doubles from a year ago (Reuters) Lufthansa Q2 profit plunges on higher fuel costs and strikes, lowers full-year guidance (Handelsblatt) Zalando misses Q2 expectations and narrows full-year outlook (Handelsblatt) Evonik benefits from Asian supply bottlenecks, raises profit forecast on "special boom" (Handelsblatt) HSBC beats Q2 estimates, launches $1B buyback and raises cost-saving target (Bloomberg) UBS hit with record $125 million fine for Bank Secrecy Act violations (Investing.com) Aston Martin creditors threaten legal action over branding rights sale in debt financing deal (FT) UK: UK business leaders warm to Conservatives under Kemi Badenoch (FT) Geopolitics: Russia expands shadow fleet of LNG tankers ahead of EU import ban (FT) Europe: Spanish interior minister to open EU emergency meeting on Ceuta migrant crisis (EurActiv) Spanish PM Sánchez faces European backlash after Ceuta migrant crisis (link) EU countries criticizing Spain's migrant amnesty have quietly regularized irregular migrants themselves (FT) EU home affairs ministers expected to show solidarity with Spain at emergency Ceuta meeting (Politico) Europe seeks alternatives to Palantir in push for digital sovereignty (Politico) For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: AML.LN, AZN.LN, BP.LN, CON.GR, EVK.GR, HSBA.LN, LHA.GR, UBSG.SW, ZAL.GR...(more)	show story hide story
03-Aug-2026 21:18	AZN.LN AstraZeneca holders express reservations about potential merger with Bristol Myers Squibb - FT (roughly 17:00 BST/12:00 ET) (11500p) The FT reports that shareholders are concerned about the pending patent cliff and the likelihood of antitrust issues. See Related StreetAccount comments: 8/2/2026 4:46:01 PM - AstraZeneca in talks with Bristol Myers Squibb - media reports Related: BMY Reference Link: Financial Times (subscription required)	show story hide story
03-Aug-2026 16:43	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to slightly lower overall on Monday. Advancers beat decliners by 2:1 on the XLV. Healthcare (0.17%) vs S&P 500 +1.48%. Little changed from the morning, as most major health groups end higher for the session. Pharma was the exception, large drugmakers mostly red (1%) to (2%), however the DRG (1.84%) remained skewed lower by AZN (6.9%) as investors reacted to the mega-merger headlines. BMY +0.2% finished at neither highs nor lows of the day. M&A dominated sector newsflow today, beginning with the potential for the largest pharma merger ever, if the media reports come to fruition. XBI +0.20% or essentially flat. Read-through for biotech cautious, as deal would remove one potential acquirer. BAX +7.4%, picking up where it left off last week, and MCK (3.4%) bracketed the XLV. MRNA +0.6% ahead of an imminent FDA decision on its influenza vaccine. Earnings calendar picks up tonight with VRTX (1.3%), followed by multiple large-cap drugmakers Tuesday morning. M&A Monday: FT reported on Sunday that AstraZeneca has held talks with Bristol Myers Squibb - for a combined company worth around $400B. Actual biopharma M&A on the tape too, with radiopharmaceutical Curium acquiring LNTH +1.6% for cash plus CVR valued at up to $8B combined. CNS drugmakers INDV (6.6%) and Supernus Pharma +3.1% will combine in a merger of equals, the combined company will have revenues approx. $2.2B. Supernus' CEO will lead the combined company. Outside of pharma, ITGR +2.7% confirmed Friday's media report - KKR will acquire the CRO for $127/shr or $5.7B deal. Macro August started up with a risk-on session, helped by several tailwinds. Most Mag 7 names rallied sharply while some cyclical pockets fared well; momentum clawed off an early session selloff in the wake of last week's big rally. Market seemed to largely look past a day of conflicting headlines about the US-Iran conflict (Trump said attacks called off for negotiations, Iran said no negotiations ongoing), though continued escalate/deescalate cycle supportive of market's view that a return to broader kinetic action is unlikely. Today's lower oil also weighed on rates amid a continued flurry of Fed credibility concern/policy uncertainty headlines. Highest ISM manufacturing print in four years supportive of the solid macro narrative. Earnings still a big bullish talking point for stocks with the latest sell-side strategist commentary highlighting the strong Q2 metrics. Also a busy day of M&A headlines. Notable Gainers +12.1% SLS (SELLAS Life Sciences Group, Inc.): best performer on XBI; shares +198% YTD +11.0% HIMS (Hims & Hers Health): shares were down (20%) in July +10.4% TWST (Twist Bioscience): earnings; second-best on XBI +9.5% CDNA (CareDx): upgraded at Craig-Hallum +7.4% BAX (Baxter International): best performer on XLV; shares were +17% last week +7.2% ALNY (Alnylam Pharmaceuticals): upgraded at Raymond James +6.3% REPL (Replimune Group): follow-through, on >2X average volume; PDUFA was Sunday +6.2% ISRG (Intuitive Surgical): FDA 510(k) clearance for DV5 +4.8% SYK (Stryker): Medicare extends CJR-X model +3.6% BSX (Boston Scientific): Medicare extends CJR-X model +3.2% ZBH (Zimmer Biomet Holdings): Medicare extends CJR-X model +3.2% EW (Edwards Lifesciences): Medicare extends CJR-X model +3.1% SUPN (Supernus Pharmaceuticals): to merge with INDV; earnings +2.7% ITGR (Integer Holdings): confirms acquisition by KKR for $127/shr Notable Decliners -11.3% TGTX (TG Therapeutics): earnings; worst performer on XBI -8.4% KRYS (Krystal Biotech): earnings -7.4% SOBI.SS (Swedish Orphan Biovitrum): CEO to step down for outside opportunity -6.9% AZN (AstraZeneca): media report - in talks with BMY; takeaways -6.6% INDV (Indivior Pharmaceuticals): to merge with SUPN; earnings -3.4% MCK (McKesson): worst performer on XLV -2.7% DVA (DaVita): sympathy to FMS; second-worst on XLV -2.4% LLY (Eli Lilly): reports on Wednesday AstraZeneca in talks with Bristol Myers Squibb - media reports On Sunday afternoon, CNBC reported on the potential merger of big pharma companies AstraZeneca (AZN.LN) and Bristol Myers Squibb (BMY), as first reported by FT. Merger would value combined company at roughly $400B. Discussions have taken place over the last few months. According to FactSet data, market cap as of Friday's close: AZN $263B, BMY $133B Takeaways: Analysts highlighted the media reports but view a potential transaction as highly unlikely. While a deal could secure value for BMY investors ahead of key Ph3 readouts, the strategic rationale for AZN is seen as weak. Some pointed to AZN's strong standalone 2030 financial targets, noting that an acquisition would yield limited synergies, while also compounding its exposure to upcoming LOEs. Furthermore, any formal announcement would trigger intense US and UK antitrust and political scrutiny regarding overlapping oncology portfolios and the combined entity's final domicile. Actual M&A in biopharma LNTH and Curium (private) announced announced a definitive agreement under which Curium US will acquire all outstanding shares of LNTH for $102.50 in cash, plus a CVR worth up to $12/shr, for total value of up to $8.0B. Total value represents a 38% premium to the unaffected 60-day VWAP. INDV and SUPN announced a definitive agreement to combine in an all-stock merger of equals, with approx. $2.2B in combined annual revenues. Expect to realize $125M of annual cost synergies. Supernus CEO Jack Khattar will become CEO of the combined company. INDV stockholders will receive a one-time special cash dividend of $1.0 billion in aggregate immediately prior to closing of the merger. Both companies also reported Q2 earnings; both beat-and-raised. According to FactSet data, market cap at Friday's close: INDV $4.8B, SUPN $2.5B KKR takes Integer Holdings private in $5.7B deal ITGR and KKR confirm Friday media report - companies agreed on a definitive agreement for an all-cash transaction at $127/shr or total value of around $5.7B. Medicare extends CJR model as expected, althrough slightly delayed Post-close on Friday, the CMS finalized IPPS and LTCH rule for FY2027, rates +2.3% vs +2.4% proposed. CMS also extended CJR Model nationwide, now called CJR-X, and effective 1-Jan-2028 (vs proposed 1-Oct-2027) Gilead Sciences wins favorable ruling at California Supreme Court CA Supreme Court ruled 6-1 in favor of the HIV drugmaker, the TDF litigation put to rest a multi-decade legal overhang. Federal litigation was settled in 2024, but California went to trial, and lower courts had held Gilead Sciences (GILD) negligent for delaying development of a newer drug with fewer side effects than TDF. Notable research in Healthcare today Pharma: JNJ removed from the US Conviction List at Goldman Sachs. Biotech: ALNY upgraded to strong buy from outperform at Raymond James (Martin Auster), target is $420 or approx. 104% upside. (FactSet average PT $388; range $23-536) ADIL initiated buy at Alliance Global Partners, target is $11 or approx. 229% upside. (FactSet average PT $17; range $6-42) CLYM initiated outperform at RBC Capital Markets (Nevin Varghese), target is $23 or approx. 93% upside. (FactSet average PT $21; range $15-35) PYXS initiated overweight at Wells Fargo Securities (Derek Archila), target is $12 or approx. 353% upside. (FactSet average PT $7; range $5-8) YARW initiated buy at BTIG (Julian Harrison), target is $58 or approx. 66% upside. MedTech: CDNA upgraded to buy at Craig-Hallum Capital (Bill Bonello), notes confidence in near-term and long-term drivers of growth. Target increased to $64 from $35 or approx. 46% upside. (FactSet average PT $44; range $35-50) Managed Care: ALHC downgraded to outperform from strong buy at Raymond James (Parker Snure), target cut to $19 from $22 or approx. 28% upside (FactSet average PT $24; range $16-30) CI downgraded to outperform from strong buy at Raymond James (Parker Snure), target cut to $320 from $350 or approx. 15% upside (FactSet average PT $342; range $297-400) Post-close news Earnings: VRTX reports Q2 EPS $4.73 vs FactSet $4.74 on revenue $3.33B vs FS $3.23B. Raises FY revenue outlook by $125M at the midpoints. Guidance does not incorporate pending acquisition of Crinetics Pharma (CRNX). Conf. call at 16:30ET Shares trading (0.3%) in the after-hours JAZZ reports Q2 EPS $5.71 ex-items vs FactSet $6.18 on revenue $1.21B vs FS $1.11B. Raises FY revenue outlook by $300M at the midpoints. Conf. call at 16:30ET Shares trading+4.4% in the after-hours CRSP reports Q2 results including cash & equivalents $2.36B as of 30-Jun. Casgevy $76M (sales reported by Vertex) +151% y/y growth. Shares trading +2.5% in the after-hours On Deck: Regulatory Sun 2-Aug: FDA PDUFA for REPL TUDRIQEV (vusolimogene oderparepvec-wtpg) BLA on Wed 5-Aug: FDA PDUFA for MRNA mFlusiva (mRNA-1010) BLA Earnings tomorrow before BAYN.GR (call at 8:00ET), MRK (call at 9:00ET), PFE (call at 10:00ET), IDXX (call at 8:30ET), WAT (call at 8:00ET), BNTX, SNN (call at 6:30ET), FMS (call at 8:00ET), RVTY (call at 7:30ET), HSIC (call at 8:00ET), BRKR (call at 9:00ET), RYTM (call at 8:00ET) after AMGN (call at 16:30ET), GILD (call at 16:30ET), DVA (call at 17:00ET), ARWR (call at 16:30ET), BIO (call at 17:00ET), PACS (call Wed at 11:30ET), TVTX (call at 16:30ET), ACAD (call at 16:30ET), HNGE (call at 16:30ET) Earnings on Wed 5-Aug: before LLY, NVO, CVS, COR, ONC, SDZ.SW, MDLN, FRE.GR, RPRX, UTHR, ZBH, ELAN, PODD, CRL, KYMR, LIVN after MCK, RVMD, STE, SOLV, EXEL, EHC, QGEN, MIRM, BLLN, CAI, NVST, ARQT, RCUS, GRAL Corporate on Wed 5-Aug: NAMS hosting Investor Day meeting (9:00ET) StreetAccount Healthcare Reads How poor countries are dealing with America's AIDS cuts (3-Aug) The Economist Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea (3-Aug) Fierce Pharma (Opinion) AstraZeneca investors balk at prospect of $400 billion Bristol Myers deal (3-Aug) Reuters After Eli Lilly granted one man special access to obesity drug, doctors struggle to get answers (3-Aug) STAT News Kennedy, Oz Contend Fraud Crackdown, Not Skyrocketing Prices, Led Millions To Leave Obamacare (3-Aug) KFF Health News This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ACAD, ADIL, ALHC, ALNY, AMGN, ARQT, ARWR, AZN, AZN.LN, BAX, BAYN.GR, BIO, BLLN, BMY, BNTX, BRKR, BSX, CAI, CDNA, CI, CLYM, COR, CRL, CRNX, CRSP, CVS, DVA, EHC, ELAN, EW, EXEL, FMS, FRE.GR, GILD, GRAL, HIMS, HNGE, HSIC, IDXX, INDV, ISRG, ITGR, JAZZ, JNJ, KRYS, KYMR, LIVN, LLY, LNTH, MCK, MDLN, MIRM, MRK, MRNA, NAMS, NVO, NVST, ONC, PACS, PFE, PODD, PYXS, QGEN, RCUS, REPL, RPRX, RVMD, RVTY, RYTM, SDZ.SW, SLS, SNN, SOBI.SS, SOLV, STE, SUPN, SYK, TGTX, TVTX, TWST, UTHR, VRTX, WAT, YARW, ZBH...(more)	show story hide story
03-Aug-2026 16:40	FactSet Podcast - Evening Market Recap, 3-Aug Overview: US equities finished higher in Monday trading, ending near session highs. It was a risk on session to start the month of August with multiple tailwinds in focus. The highest ISM manufacturing print in four years showed support for the solid macro narrative. Tickers Mentioned: AZN, BMY, LNTH, ITGR, KKR, ATKR, PRY, BOW, MAR, TSN, CNH, BABA, BA, TE, FERG, EA, GME, VFC About This Podcast: The Evening Market Recap Podcast aims to bring listeners up to speed on the trading day as quickly as possible. With a target time of ~5 minutes and a publish time of ~18:00 EDT, this is an ideal listen after the market closes. Find us on Apple and Spotify, or click the link below to listen now. Related: ATKR, AZN, BA, BABA, BMY, BOW, CNH, EA, FERG, GME, ITGR, KKR, LNTH, MAR, PRY, TE, TSN, VFC...(more) Reference Link: Market Recap 3-Aug-26	show story hide story
03-Aug-2026 15:01	Afternoon headlines: Iran war: Iran reaffirms no talks with US are planned despite Trump's claim negotiations set to begin today (Reuters) US officials confirm there are no new negotiations with Iran planned (CBS News) Trump calls Iranian leadership duplicitous, says SoH completely controlled by the US (Truth Social) Senior Israeli official says Israel it "will not retreat" from its current position in Gaza (CBS) Corporate: Investors, analysts questioning need for AstraZeneca to make a transformative acquisition of Bristol Myers Squibb (Reuters) Visa acquiring fraud detection startup BioCatch for $2.4B cash amid rise in AI-powered scams (CNBC) FAA certifies Boeing's 737 Max 7, the smallest model in that aircraft family, after a nearly a decade of delays (CNBC) Amazon's market cap tops $3T for first time (Reuters) Economy: US manufacturing activity expanded in July at the fastest pace in more than four years (Bloomberg) June construction spending in the US down 0.1% m/m, missing expectations for a rise (link) JPMorgan says it will deploy over $750B into US housing through 2035 to increase supply and US homeownership (Reuters) US state-level restrictions are increasingly driving Chinese buyers aways from US housing (Nikkei) Energy: Surge in dark tanker transits through Red Sea indicates Saudis are still moving oil despite Houthi threat (Oilprice.com) Trump again demands US oil majors lower retail gasoline prices for US consumers (Reuters) Saudi oil exports declined to 4.19M bpd in July, down 460K bpd from June (Bloomberg) Ukraine struck Russian oil infrastructure at least 30 times in July, the second-highest monthly total of the war (Bloomberg) Washington: Blanche's AG nomination is back on course after he formally rescinded Trump payout fund (Washington Post) White House to meet with AI companies Tuesday to discuss finalized framework for evaluating frontier models (CNBC) For the latest updates on this story and all top news, please visit the US Today's Top News page. Related: AMZN, AZN, BA, BMY, JPM, V...(more)	show story hide story
03-Aug-2026 11:54	^OPTIONS StreetAccount Summary - U.S. Unusual Option Volume: VIX (2.3%) to 15.62; S&P 500 +1.2% to 7,577.02 StreetAccount reports options activity showing unusual volume compared to the 30-day average. The list excludes companies that have reported earnings since the prior trading day's close. 1,851% - TNDM (Tandem Diabetes Care $20.17, +3.4%) -- 7,861 contracts vs avg 425 - P/C ratio: 0.28 - to report earnings before market Aug-06 1,848% - MRCY (Mercury Systems $105.02, +8.2%) -- 4,781 contracts vs avg 259 - P/C ratio: 0.01 - after announcing PLTR partnership today 998% - DOCS (Doximity $21.89, +4.7%) -- 10,335 contracts vs avg 1,035 - P/C ratio: 0.19 - to report earnings after market Aug-06 966% - FERG (Ferguson Enterprises $253.33, +8.1%) -- 1,498 contracts vs avg 155 - P/C ratio: 0.09 - following Friday's announcement of joining the S&P 500, to report earnings before market Aug-10 719% - ARXS (Arxis, Inc. $55.32, +1.9%) -- 1,621 contracts vs avg 225 - P/C ratio: 0.03 576% - NEO (NeoGenomics $16.03, +4.8%) -- 1,152 contracts vs avg 200 - P/C ratio: 0.00 527% - AZN (AstraZeneca $153.60, -9.5%) -- 10,381 contracts vs avg 1,969 - P/C ratio: 0.33 - after Today's news of a potential BMY* merger, and the EU approving AstraZeneca and Daiichi Sankyo Datroway for First-Line Metastatic TNBC patients ineligible for immunotherapy Friday* 517% - GSAT (Globalstar $84.62, +1.5%) -- 4,327 contracts vs avg 837 - P/C ratio: 0.12 441% - ANGI (Angi, Inc. $6.05, +6.7%) -- 507 contracts vs avg 115 - P/C ratio: 4.83 - to report earnings after market Aug-04 433% - WHD (Cactus $64.30, -1.1%) -- 599 contracts vs avg 138 - P/C ratio: 0.01 - follow's Thursday's earnings move 430% - VSAT (Viasat $82.22, +6.9%) -- 22,548 contracts vs avg 5,241 - P/C ratio: 0.42 - after Reaction to Altucher comments, we're told, to report earnings after market Aug-04 391% - TECK (Teck Resources $60.32, +0.1%) -- 7,318 contracts vs avg 1,870 - P/C ratio: 0.04 - following announcing future Anglo Teck Executive Leadership Team Thursday 367% - ACAD (Acadia Pharmaceuticals $25.69, -0.7%) -- 2,004 contracts vs avg 547 - P/C ratio: 1.00 - to report earnings after market Aug-04 362% - IRWD (Ironwood Pharmaceuticals $4.41, +4.1%) -- 974 contracts vs avg 269 - P/C ratio: 2.75 - to report earnings before market Aug-06 355% - AGRO (Adecoagro $9.72, -2.6%) -- 2,621 contracts vs avg 738 - P/C ratio: 0.00 355% - CDNA (CareDx $48.16, +10.2%) -- 1,228 contracts vs avg 346 - P/C ratio: 5.30 - after Craig-Hallum Capital upgrades; notes confidence in NT/LT drivers of growth 326% - RSI (Rush Street Interactive $27.67, +2.8%) -- 12,037 contracts vs avg 3,692 - P/C ratio: 34.30 308% - WGS (GeneDx Holdings $66.86, +2.7%) -- 3,330 contracts vs avg 1,083 - P/C ratio: 19.56 - to report earnings after market Aug-03 305% - ENTG (Entegris $121.96, +2.4%) -- 4,192 contracts vs avg 1,377 - P/C ratio: 0.50 - to report earnings before market Aug-04; scheduled KeyBanc Technology Leadership Forum event Aug-10 299% - BYRN (Byrna Technologies $4.90, +7.7%) -- 1,041 contracts vs avg 349 - P/C ratio: 0.00 290% - UCTT (Ultra Clean Holdings $87.60, +5.1%) -- 2,537 contracts vs avg 876 - P/C ratio: 0.06 - to report earnings after market Aug-03 288% - DQ (Daqo New Energy $13.56, +11.4%) -- 2,076 contracts vs avg 720 - P/C ratio: 1.24 277% - ENLT (Enlight Renewable Energy $82.81, -2.0%) -- 1,048 contracts vs avg 378 - P/C ratio: 0.06 265% - MEOH (Methanex $54.01, -2.8%) -- 1,081 contracts vs avg 408 - P/C ratio: 16.16 259% - KHC (Kraft Heinz $26.30, +1.7%) -- 77,444 contracts vs avg 29,867 - P/C ratio: 0.01 - to report earnings before market Aug-05 255% - UNM (Unum Group $90.48, +5.1%) -- 6,640 contracts vs avg 2,600 - P/C ratio: 0.01 253% - HNGE (Hinge Health, Inc. $77.13, +3.2%) -- 4,137 contracts vs avg 1,632 - P/C ratio: 0.66 - to report earnings after market Aug-04 253% - XE (X-Energy $17.50, +7.3%) -- 11,390 contracts vs avg 4,500 - P/C ratio: 0.66 - follows SGL Carbon and X-energy announcing capacity expansion for nuclear-grade graphite today 243% - ZBRA (Zebra Technologies $291.48, -0.8%) -- 1,763 contracts vs avg 726 - P/C ratio: 0.30 - to report earnings before market Aug-04 241% - AMRZ (Amrize $50.36, +3.0%) -- 2,569 contracts vs avg 1,066 - P/C ratio: 2.82 - to report earnings after market Aug-06 Click here to view / receive alerts for Unusual Options Volume Related: ACAD, AGRO, AMRZ, ANGI, ARXS, AZN, BYRN, CDNA, DOCS, DQ, ENLT, ENTG, FERG, GSAT, HNGE, IRWD, KHC, MEOH, MRCY, NEO, RSI, TECK, TNDM, UCTT, UNM, VSAT, WGS, WHD, XE, ZBRA...(more)	show story hide story
03-Aug-2026 10:27	^MERGERS StreetAccount M&A Summary: Week of 27-Jul Notable M&A activity from this week 27-Jul through 2-Aug): Basic Materials 27-Jul: Luxfer to be acquired by affiliates of Wynnchurch Capital for $17.37 per share in all-cash transaction (LXFR) 28-Jul: A2MP Investments FZCO launches off-market takeover for all remaining Canyon Resources shares at A$0.05/share (CAY.AU, 0PJB8S-E) 29-Jul: Anglo American in talks to sell De Beers for ~ $1B - Bloomberg (AAL.LN, +DEBEERS) 29-Jul: Allied Gold announces termination of arrangement agreement with Zijin Gold, $295M strategic investment in the company by Zijin (AAUC.CN) 31-Jul: Perimeter Solutions acquires Monaco Enterprises (PRM) Capital Goods 27-Jul: Ohmnia Electronics, S.L. (Clerbil, S.L.) offers to acquire Azkoyen for €10/share in cash (AZK.SM, 0G8J6V-E) 27-Jul: TransDigm acquiring Prince & Izant for ~$1.066B in cash (TDG, 0DBG1H-E) 28-Jul: Sanlorenzo submits Interest and offer for the acquisition of the entire business undertaking gf the Italian Sea Group (27-Jul) (TISG.IM, SL.IM) 28-Jul: Germany's Lürssen rumoured to join consortium for The Italian Sea Group;'s acquisition - La Stampa 28-Jul: Azkoyen statement regarding the takeover bid by Ohmnia Electronics, S.L. (AZK.SM, 0G8J6V-E) 28-Jul: Pentair to acquire Taco Group Holdings for ~$1.4B (PNR, 0G8VCP-E) 28-Jul: Leonardo DRS to acquire Raft LLC in all-cash transaction valued at $450M (DRS, 0092V1-E) 29-Jul: I. CO. P. shareholders approve the acquisition of Trevi-Finanziaria Industriale and plan to list on Euronext Milan (ICOP.IM, TFIN.IM) 30-Jul: Hammerson to raise ~ £190M in connection with acquisition of 50% interest in Manchester Arndale for £218M (HMSO.LN, 0D2TQ6-E) 30-Jul: Voluntary Tender Offer by Webuild for 100% of Trevi (TFIN.IM, WBD.IM) 30-Jul: Ingenia Communities in discussions with multiple partners for potential Peet acquisition -- The Australian (INA.AU, PPC.AU) 31-Jul: HEXPOL agrees to acquire leading Italian Wire & Cable compounder Vipa Group for €143.5M on a cash and debt-free basis (HPOL.B.SS, 0V1FF5-E) 31-Jul: Everus Construction Group to acquire Epsilon Industries for $295M in cash (ECG, 09TGBZ-E) 31-Jul: Brookfield Infrastructure Partners exploring potential $5B sale of Northriver Midstream - Reuters (BIP, BIPC, ENB) Consumer Cyclical 27-Jul: Frasers Group and Next both expected to submit bid for Harvey Nichols ahead of tomorrow's deadline for UK bidders - Sky News (FRAS.LN) 30-Jul: Gildan Activewear announces sale of HanesBrands Australia (HAA) for an enterprise valuation of ~A$700M (GIL.CN) Consumer Non-Cyclical 31-Jul: Orkla Snacks acquires The European Candy Group B.V. for €207M (enterprise value) on a cash and debt-free basis (ORK.NO, 0D1G4T-E) 31-Jul: Atlantic Sapphire's Qualified Board unanimously recommends the offer price and the other terms of offer from Coral HoldCo (ASA.NO, 0XYT4P-E) Energy 27-Jul: Boards of Bidco and DCC Energy reach agreement on terms of recommended acquisition by Bidco of entire issued and to be issued share capital of DCC Energy (DCC.LN) 27-Jul: Serica Energy acquires Pharos Energy. Pharos Shareholders to receive 28.6683 pence in cash per Pharos Share; plus 4.0 pence in cash (PHAR.LN, SQZ.LN) 27-Jul: Expand Energy to acquire Twin Eagle (EXE) 28-Jul: SoftVest and Blackbeard sign agreement for $2.2B combination of Permian Basin Royalty Trust and US Land Guild (PBT) 31-Jul: Shell agrees to sell BG Cyprus Limited to MOL Group for up to $720M (SHEL.LN, MOL.HB) Financial 27-Jul: Railpen announces it has no intention to make an offer for IP Group (IPO.LN, 0YJ7YV-E) 27-Jul: Ares Management has held talks to acquire Leonard Green & Partners - FT (ARES, 05H7VP-E) 27-Jul: TPG in exclusive talks to acquire Netrality Data Centers at potential valuation of $2-3B - Bloomberg (TPG, MQG.AU) 27-Jul: Speculation that Tokio Marine is eyeing Insurance Australia Group and Suncorp as acquisition targets - The Australian (8766.JP, IAG.AU, SUN.AU) 27-Jul: SoftBank Corp. is preferred bidder for acquisition of SP.LINKS - Bloomberg (8729.JP, 9434.JP, BX) 27-Jul: SoftBank Group looking to acquire full ownership of SP.Links - Nikkei 29-Jul: Azimut acquires Yapi Kredi Portföy Yönetimi in Turkey; transaction consideration amounts to ~€305M ($349M) (AZM.IM, YKBNK.E.TI) 29-Jul: Tiptree announces aquisition of Universal Shield Insurance Group (TIPT) 29-Jul: Raiffeisen Bank International reports preliminary result of offer to acquire Addiko; exceeds minimum acceptance threshold (ADKO.AV, RBI.AV) 30-Jul: Hongkong Land Holdings to acquire Singapore's Wheelock Place for SG$1.1B ($0.9B) (H78.SP) 30-Jul: Intercontinental Exchange (ICE) to acquire MarketAxess for $167/sh cash (MKTX, ICE) 30-Jul: IG Group Holdings plc discloses the proposed acquisition of Underdog for total consideration of up to ~$1.3B (IGG.LN, 0GR1FD-E) 30-Jul: Banco Santander offers to acquire outstanding shares of Santander Brazil, maximum consideration of €1.91B at a premium of 15% (BSBR, SAN.SM) 30-Jul: HSBC Holdings sells Australian home loan and personal loan portfolio to Blackstone affiliate Virgo BidCo for A$36B ($25B) (HSBA.LN) 30-Jul: TMX Group to combine with MEMX and BOX, TMX Group will have 59% stake in combined business; Implied transaction value ~$2.3B (C$3.2B) (X.CN) 31-Jul: LondonMetric Property, SREIT reach agreement on terms of recommended all-share offer to acquire entire issued and to be issued ordinary share capital of Picton (LMP.LN) 31-Jul: SK to sell its 70.6% stake in SK Siltron to Doosan for KRW2.300T (034730.KS) 31-Jul: Space-Eyes and McKinley Acquisition Corp. announce definitive business combination agreement valuing Space-Eyes at implied EV of $370M (MKLYU) 31-Jul: Banco BPM halts talks regarding the potential merger with Banca Monte dei Paschi di Siena (BAMI.IM, BMPS.IM, ISP.IM, MB.IM) 2-Aug: Banca Monte dei Paschi di Siena considering trying to buy Banco BPM - FT 2-Aug: Pinnacle Investment Management Group considering a bid for Bennelong Funds Management - Australian Financial Review (0J5QFV-E, 0KQMTM-E, PNI.AU) 2-Aug: FleetPartners Group receives indicative acquisition proposal from SG Fleet at A$3.60/share (05NV0X-E, 13NK41-E, FPR.AU) Healthcare 27-Jul: argenx to acquire Forte Biosciences for $77/sh in cash (FBRX, ARGX) 27-Jul: Curium in advanced talks to buy Lantheus for $8B (CVRs included) - Bloomberg (LNTH, 0JCPDC-E) 29-Jul: Synlogic and Caldera Therapeutics (private) announce merger agreement (SYBX) 29-Jul: MIMEDX to acquire Sanara MedTech (SMTI, MDXG) 31-Jul: Integer Holdings in talks to be acquired by KKR for ~$127 per share -- media report (ITGR, KKR) 2-Aug: AstraZeneca in talks with Bristol Myers Squibb - media reports (AZN.LN, BMY) Services 27-Jul: Candle Lake Limited acquires shares in Evolution; triggers a mandatory offer obligation (EVO.SS) 29-Jul: I Squared and InfraVia Capital Partners are preparing a bid to take over Ströer - Manager magazine (SAX.GR) 29-Jul: Clean Harbors acquires ES&H (CLH) 29-Jul: Grant Thornton Advisors to acquire CBIZ for $55/sh, ~$5B in cash (CBZ) 29-Jul: Churchill Downs exploring options to sell certain regional gaming properties (CHDN) 29-Jul: Volue offers A$17/share for Energy One - Australian Financial Review (EOL.AU, 0MWDGK-E) 30-Jul: Group 1 Automotive to acquire dealership assets, real estate of Hennessy Automobile Companies (GPI) 30-Jul: France explores sale of partial stake in telecom operator Orange S.A. in a deal that could be valued at ~ €1.1B - Reuters (ORA.FP) 30-Jul: Service Stream considered frontrunner in Programmed auction, asking price around A$1B (¥112.17B) -- The Australian (05NV0X-E, 2181.JP, 2768.JP, SSM.AU) 31-Jul: Alimentation Couche-Tard to acquire Zabka Group for PLN32/share, or total equity value of PLN32.62B ($8.6B) (ZAB.PW) 31-Jul: System1 Group PLC announces unequivocal rejection of offer from Brave Bison (SYS1.LN, BBSN.LN) 31-Jul: Makino Milling Machine special commitee recommends rejecting Nippon Sangyo Suishin Kiko offer, board accepts recommendation - Nikkei (0FG1V0-E, 6135.JP) 31-Jul: T-Mobile, Deutsche Telekom merger talks hit snag amid concerns of shareholder disapproval -- Semafor (DTE.GR, TMUS) Technology 29-Jul: Bain, LY Corp. to implement tender offer for Kakaku.com at ¥3,520/share (2371.JP) 29-Jul: Amphenol announces acquisitions (APH) 29-Jul: Procore to acquire DroneDeploy for ~$845M cash (PCOR, 0DX8B7-E) 29-Jul: Sony offers to acquire Tamron for ¥200B - Diamond (7740.JP, 6758.JP) 31-Jul: NXP Semiconductors in talks to acquire Ambarella - FT (AMBA) 2-Aug: Prysmian in advanced talks to acquire Atkore; terms unreported - Bloomberg (ATKR, PRY.IM) Transportation 29-Jul: Air France-KLM submits a binding offer for an up to 49.9% stake in TAP Air Portugal (AF.FP) Related: 034730.KS, 2181.JP, 2371.JP, 2768.JP, 6135.JP, 6758.JP, 7740.JP, 8729.JP, 8766.JP, 9434.JP, AAL.LN, AAUC.CN, ADKO.AV, AF.FP, AMBA, APH, ARES, ARGX, ASA.NO, ATKR, AZK.SM, AZM.IM, AZN.LN, BAMI.IM, BBSN.LN, BIP, BIPC, BMPS.IM, BMY, BSBR, BX, CAY.AU, CBZ, CHDN, CLH, DCC.LN, DRS, DTE.GR, ECG, ENB, EOL.AU, EVO.SS, EXE, FBRX, FPR.AU, FRAS.LN, GIL.CN, GPI, H78.SP, HMSO.LN, HPOL.B.SS, HSBA.LN, IAG.AU, ICE, ICOP.IM, IGG.LN, INA.AU, IPO.LN, ISP.IM, ITGR, KKR, LMP.LN, LNTH, LXFR, MB.IM, MDXG, MKLYU, MKTX, MOL.HB, MQG.AU, ORA.FP, ORK.NO, PBT, PCOR, PHAR.LN, PNI.AU, PNR, PPC.AU, PRM, PRY.IM, RBI.AV, SAN.SM, SAX.GR, SHEL.LN, SL.IM, SMTI, SQZ.LN, SSM.AU, SUN.AU, SYBX, SYS1.LN, TDG, TFIN.IM, TIPT, TISG.IM, TMUS, TPG, WBD.IM, X.CN, YKBNK.E.TI, ZAB.PW, +DEBEERS, 0092V1-E, 05H7VP-E, 05NV0X-E, 09TGBZ-E, 0D1G4T-E, 0D2TQ6-E, 0DBG1H-E, 0DX8B7-E, 0FG1V0-E, 0G8J6V-E, 0G8VCP-E, 0GR1FD-E, 0J5QFV-E, 0JCPDC-E, 0KQMTM-E, 0MWDGK-E, 0PJB8S-E, 0V1FF5-E, 0XYT4P-E, 0YJ7YV-E, 13NK41-E...(more)	show story hide story
03-Aug-2026 09:15	StreetAccount Summary - US Pre-market trading update S&P futures +44.8 to 7564, +0.60% vs settlement. 10-year yield (3) bps to 4.68%. Sep WTI ($5.71) or (6.74%) to $78.96. Trading Higher: *Market cap >$10B* +10.0% CNH (CNH Industrial $11.28, +1.03) -- earnings +8.3% FERG (Ferguson Enterprises $253.75, +19.42) -- to join S&P 500 +6.6% WMG (Warner Music Group $27.67, +1.71) -- preliminary FQ3 results; CFO change +4.2% WDAY (Workday $167.00, +6.66) +4.0% HUBS (HubSpot $246.78, +9.42) +3.9% TEAM (Atlassian $105.00, +3.99) +3.9% OKTA (Okta, Inc. $147.44, +5.51) +3.9% BABA (Alibaba Group $126.96, +4.71) -- releases latest Qwen model +3.7% NOW (ServiceNow $115.40, +4.17) -- removed from Goldman Sachs US Conviction List - Directors' Cut +3.7% W (Wayfair $88.00, +3.10) +3.6% FSLR (First Solar $218.61, +7.58) +3.4% CRM (Salesforce $190.30, +6.28) +3.4% FTAI (FTAI Aviation Ltd. $212.98, +6.97) +3.2% IOT (Samsara $38.46, +1.19) +3.2% UAL (United Airlines $125.20, +3.87) -- oil lower +3.1% SHOP (Shopify $120.79, +3.64) +3.1% PANW (Palo Alto Networks $342.08, +10.25) +3.1% BMY (Bristol Myers Squibb $67.34, +2.03) -- AstraZeneca (AZN) reportedly in merger talks with Bristol Myers +3.1% DDOG (Datadog $276.40, +8.43) +3.0% SNOW (Snowflake $302.05, +8.77) +3.0% IBM (IBM $230.29, +6.64) +3.0% CTSH (Cognizant Technology Solutions $57.00, +1.65) +3.0% ADBE (Adobe $257.85, +7.44) +2.9% ACN (Accenture $170.75, +4.83) +2.9% ADSK (Autodesk $241.00, +6.80) -- completed previously announced acquisition of MaintainX Inc. +2.9% PLTR (Palantir Technologies $126.68, +3.62) -- partnership with Mercury Systems +2.8% INTU (Intuit $325.00, +8.93) +2.8% VEEV (Veeva Systems $209.55, +5.77) +2.8% CCL (Carnival $28.58, +0.77) -- oil lower +2.7% QXO (QXO, Inc. $13.66, +0.36) +2.7% FAST (Fastenal $49.00, +1.29) +2.7% LUV (Southwest Airlines $46.18, +1.21) -- oil lower +2.7% MDB (MongoDB $346.50, +9.02) +2.6% DOCU (DocuSign $56.27, +1.44) +2.6% CPRT (Copart $29.87, +0.75) +2.6% U (Unity Software $32.52, +0.81) +2.6% DAL (Delta Air Lines $89.67, +2.23) -- oil lower +2.6% L (Loews $119.00, +2.99) -- earnings +2.5% CRWD (CrowdStrike $195.70, +4.84) +2.5% RKT (Rocket Cos. $13.22, +0.32) +2.5% RBRK (Rubrik $74.15, +1.79) +2.4% BAX (Baxter International $26.80, +0.64) +2.4% VIK (Viking Holdings $106.89, +2.54) -- oil lower; added to Goldman Sachs US Conviction List - Directors' Cut +2.4% CRH (CRH plc $97.30, +2.29) +2.4% AMGN (Amgen $394.25, +9.09) +2.4% RCL (Royal Caribbean Group $325.99, +7.69) -- oil lower +2.3% BA (Boeing $221.08, +4.94) -- BNP Paribas Exane upgrade +2.3% TOST (Toast, Inc. $33.00, +0.73) +2.2% CLX (Clorox $97.63, +2.10) -- increases quarterly dividend by 0.8% to $1.25 from $1.24 +2.2% ORCL (Oracle $132.75, +2.88) +2.2% MCD (McDonald's $276.51, +5.87) +2.1% BNTX (BioNTech $92.50, +1.92) -- designated CEO Ugur Sahin steps down; appoints Guido Oelkers as new CEO from 1-Feb-27 +2.1% CVNA (Carvana $63.68, +1.32) +2.1% BKNG (Booking Holdings $196.95, +4.05) +2.1% GOOGL (Alphabet $363.56, +7.43) +2.1% MSFT (Microsoft $474.33, +9.61) -- added to Goldman Sachs US Conviction List - Directors' Cut +1.8% V (Visa $372.72, +6.59) -- to acquire BioCatch from funds advised by Permira and other shareholders for $2.4B in cash *Market cap $1B-$10B* +27.9% ATKR (Atkore $93.35, +20.39) -- Prysmian (PRY.IM) to acquire Atkore for $95/share in cash, or EV of $3.8B (€3.29B); earnings +14.1% SUPN (Supernus Pharmaceuticals $50.94, +6.31) -- Supernus Pharmaceuticals and Indivior Pharmaceuticals (INDV) announce all-stock merger of equals; earnings +10.3% BOW (Bowhead Specialty Holdings $33.75, +3.16) -- to be acquired by American Family Mutual Insurance Company for $34/sh; earnings +6.3% CDNA (CareDx $46.46, +2.75) -- Craig-Hallum upgrade +6.2% MMYT (MakeMyTrip $60.50, +3.55) -- earnings +5.6% AMC (AMC Entertainment $2.98, +0.16) -- announces record weekend revenue +5.3% TE (T1 Energy $4.39, +0.22) -- T1 and Clearway execute strategic offtake deal +4.1% MNDY (monday.com $90.75, +3.60) +4.1% NCNO (nCino $19.21, +0.75) +4.0% ULCC (Frontier Group $7.02, +0.27) -- oil lower +3.9% VERX (Vertex, Inc. $13.41, +0.50) +3.7% KVYO (Klaviyo $18.50, +0.66) +3.4% VFC (VF Corp $14.81, +0.49) -- insider buy +3.4% IMAX (Imax $49.47, +1.63) -- July global box office gross of $257M +3.3% TENB (Tenable Holdings $33.72, +1.08) +3.2% WIX (Wix.com $56.80, +1.77) +3.2% GTLB (Gitlab $35.60, +1.09) +3.2% AAL (American Airlines Group $15.76, +0.49) -- oil lower +3.1% ZETA (Zeta Global Holdings $22.28, +0.68) +3.1% ASAN (Asana, Inc. $8.58, +0.26) +3.1% CERT (Certara $8.35, +0.25) +3.1% FIVN (Five9 $28.35, +0.84) +3.1% CLBT (Cellebrite DI $15.20, +0.45) +3.0% ESTC (Elastic $67.76, +1.97) +3.0% MBGL (Mobility Global, Inc. $21.00, +0.62) +3.0% ABSI (Absci Corp. $8.01, +0.23) +2.9% LNTH (Lantheus Holdings $102.50, +2.86) -- to be acquired by Curium for $102.50/sh cash plus CVR for up to $12/sh in potential additional cash payments +2.7% ITGR (Integer Holdings $124.52, +3.31) -- confirms agreement to be acquired by KKR for $127/sh cash; earnings *Market cap <$1B* +12.1% AUTL (Autolus Therapeutics $1.67, +0.18) -- earnings; credit facility of up to $250M with Perceptive Advisors +11.7% FTK (Flotek Industries $26.29, +2.75) -- 10-year contract to support 400 MW power project for Puerto Rico electric power authority +9.1% PYXS (Pyxis Oncology $2.89, +0.24) -- Wells Fargo initiated overweight +6.1% CTKB (Cytek Biosciences $4.48, +0.26) +6.0% BIOA (BioAge Labs $9.58, +0.54) +5.2% SCTX (Scribe Therapeutics, Inc. $20.50, +1.02) +5.1% CERS (Cerus $2.26, +0.11) +4.4% ELDN (Eledon Pharmaceuticals $3.53, +0.15) +4.2% ZSQR (Z Squared, Inc. $5.01, +0.20) -- to acquire 100% of Paradox Data and Its Union County campus Trading Lower: *Market cap >$10B* -7.3% AZN (AstraZeneca $157.19, -12.45) -- reportedly in merger talks with Bristol Myers Squibb -6.2% KRYS (Krystal Biotech $320.01, -21.11) -- earnings -5.6% CRCL (Circle Internet $59.08, -3.53) -- Morgan Stanley downgrade -5.5% TSEM (Tower Semiconductor $207.49, -12.18) -4.4% WDC (Western Digital $520.63, -24.21) -4.3% STX (Seagate Technology $819.00, -37.13) -4.1% MU (Micron Technology $788.92, -34.11) -4.1% SMTC (Semtech $112.94, -4.88) -3.9% SNDK (Sandisk $1,167.58, -47.25) -3.7% TER (Teradyne $354.09, -13.60) -3.7% AMKR (Amkor Technology $48.00, -1.87) -- insider sale -3.7% VG (Venture Global $12.89, -0.49) -3.6% ALAB (Astera Labs $300.00, -11.23) -3.4% MRVL (Marvell Technology $181.14, -6.42) -3.3% ONTO (Onto Innovation $250.00, -8.58) -3.3% ANET (Arista Networks $174.45, -5.90) -3.3% KLAC (KLA $176.82, -6.00) -3.3% LITE (Lumentum Holdings $690.50, -23.44) -3.2% CRDO (Credo Technology $200.40, -6.59) -3.2% BE (Bloom Energy $199.24, -6.57) -3.1% TSN (Tyson Foods $56.15, -1.81) -- earnings -3.0% COHR (Coherent $254.96, -7.93) -2.7% EBAY (eBay $110.94, -3.07) -- Wells Fargo downgrade -2.7% LRCX (Lam Research $285.00, -8.02) -2.6% AMD (Advanced Micro Devices $463.85, -12.30) -2.6% RMBS (Rambus $88.68, -2.35) -2.6% ON (onsemi $79.47, -2.14) -2.5% CLS (Celestica $323.02, -8.42) -2.5% GFS (GlobalFoundries $48.75, -1.24) -2.5% AMAT (Applied Materials $495.00, -12.67) -2.5% MPWR (Monolithic Power Systems $1,390.00, -36.03) -2.5% NBIS (Nebius Group $185.58, -4.83) -2.4% MCHP (Microchip Technology $72.54, -1.75) -2.4% INTC (Intel $88.06, -2.14) -2.4% NXPI (NXP Semiconductors $223.67, -5.49) -- UBS downgrade -2.3% TTMI (TTM Technologies $112.75, -2.69) -2.3% NVMI (Nova Measuring Instruments $381.76, -9.11) -2.2% HUT (Hut 8 Corp. $105.31, -2.32) -2.1% DELL (Dell Technologies $397.00, -8.37) -2.1% MGM (MGM Resorts $43.63, -0.94) -2.1% MAR (Marriott International $364.85, -7.98) -- earnings -2.0% CBRS (Cerebras Systems $194.76, -3.95) -2.0% STRL (Sterling Infrastructure $585.00, -11.77) -2.0% LSCC (Lattice Semiconductor $121.75, -2.52) -2.0% CIEN (Ciena $369.59, -7.46) -1.9% ENTG (Entegris $116.74, -2.31) -1.9% BMNR (Bitmine Immersion Technologies $16.95, -0.33) -1.8% GLW (Corning $135.79, -2.46) -- Truist upgrade -1.6% SPCX (SpaceX $106.61, -1.76) *Market cap $1B-$10B* -18.3% SRAD (Sportradar Group $11.88, -2.66) -- earnings -6.4% KLIC (Kulicke & Soffa Industries $83.47, -5.73) -6.0% GME (GameStop $20.42, -1.30) -- private exchange of $1.4B of convertible senior notes for equity -6.0% TWST (Twist Bioscience $86.08, -5.47) -- earnings -5.2% AXTI (AXT Inc $57.28, -3.15) -4.5% GENI (Genius Sports $6.62, -0.31) -4.4% TGTX (TG Therapeutics $49.76, -2.27) -- earnings -4.4% ACMR (ACM Research $75.00, -3.47) -4.2% PLOW (Douglas Dynamics $42.28, -1.85) -- earnings -4.1% MXL (MaxLinear $64.11, -2.71) -4.1% SBH (Sally Beauty Holdings $14.35, -0.62) -- earnings -4.0% FORM (FormFactor $102.00, -4.20) -3.9% AEHR (Aehr Test Systems $76.89, -3.09) -3.7% AAOI (Applied Optoelectronics $90.80, -3.52) -3.6% SARO (StandardAero $28.25, -1.06) -3.4% PCOR (Procore Technologies $52.93, -1.85) -- proposed private placement of $750.0M of convertible senior notes due 2031 -3.4% VSH (Vishay Intertechnology $33.07, -1.15) -3.1% WOLF (Wolfspeed $22.88, -0.74) -3.0% AIP (Arteris $28.99, -0.89) -2.9% RYN (Rayonier $21.15, -0.63) -2.8% OUST (Ouster $37.93, -1.08) -2.6% VICR (Vicor $202.00, -5.37) *Market cap <$1B* -29.5% ZEO (Zeo Energy $0.35, -0.15) -23.1% CIGL (Concorde International Group $0.47, -0.14) -- recent IPO -11.9% HKIT (Hitek Global $2.67, -0.36) -10.3% PN (Skycorp Solar Group $15.49, -1.78) -6.4% SPRY (ARS Pharmaceuticals $4.80, -0.33) -3.8% FBIO (Fortress Biotech $3.01, -0.12) -3.2% MRAM (Everspin Technologies $14.06, -0.47) -3.2% SGMT (Sagimet Biosciences $6.88, -0.23) Oil/energy related lower -- WTI futures (6.6%) after Trump calls off Iran strikes KOS -9.0% (earnings), WTI -5.3%, SOC -3.6%, OBE -3.5%, VET -3.4%, MUR -3.3%, SM -3.2%, PBF -3.2%, BP -2.9%, EQNR -2.6%, WDS -2.5%, APA -2.5%, OXY -2.5%, PARR -2.4%, OVV -2.4%, NOG -2.4%, CRGY -2.4%, RIG -2.3%, PR -2.3%, CVE -2.3%, FANG -2.2%, NEXT -2.2%, DVN -2.1%, PBR -2.0%, CRK -2.0%, BORR -2.0%, COP -2.0%, CNQ -1.9%, SU -1.9%, AR -1.8%, EOG -1.8%, CVX -1.6%, XOM -1.6%, YPF -1.6%, DINO -1.6%, VLO -1.6%, SHEL -1.5%, HAL -1.3%, LNG -1.2%, MPC -1.2%, MTDR -0.8% Click here to view our Gainers & Decliners page Editor's Note: This comment was revised to clarify that NOW was removed from Goldman's US Conviction List, not added (03-Aug-2026, 09:28 ET) Related: AAL, AAOI, ABSI, ACMR, ACN, ADBE, ADSK, AEHR, AIP, ALAB, AMAT, AMC, AMD, AMGN, AMKR, ANET, APA, AR, ASAN, ATKR, AUTL, AXTI, AZN, BA, BABA, BAX, BE, BIOA, BKNG, BMNR, BMY, BNTX, BORR, BOW, BP, CBRS, CCL, CDNA, CERS, CERT, CIEN, CIGL, CLBT, CLS, CLX, CNH, CNQ, COHR, COP, CPRT, CRCL, CRDO, CRGY, CRH, CRK, CRM, CRWD, CTKB, CTSH, CUK, CVE, CVNA, CVX, DAL, DDOG, DELL, DINO, DOCU, DVN, EBAY, ELDN, ENTG, EOG, EQNR, ESTC, FANG, FAST, FBIO, FERG, FIVN, FORM, FSLR, FTAI, FTK, GENI, GFS, GLW, GME, GOOGL, GTLB, HAL, HKIT, HUBS, HUT, IBM, IMAX, INTC, INTU, IOT, ITGR, KLAC, KLIC, KOS, KRYS, KVYO, L, LITE, LNG, LNTH, LRCX, LSCC, LUV, MAR, MBGL, MCD, MCHP, MDB, MGM, MMYT, MNDY, MPC, MPWR, MRAM, MRVL, MSFT, MTDR, MU, MUR, MXL, NBIS, NCNO, NEXT, NOG, NOW, NVMI, NXPI, OBE, OKTA, ON, ONTO, ORCL, OUST, OVV, OXY, PANW, PARR, PBF, PBR, PCOR, PLOW, PLTR, PN, PR, PYXS, QXO, RBRK, RCL, RIG, RKT, RMBS, RYN, SARO, SBH, SCTX, SGMT, SHEL, SHOP, SM, SMTC, SNDK, SNOW, SOC, SPCX, SPRY, SRAD, STRL, STX, SU, SUPN, TE, TEAM, TENB, TER, TGTX, TOST, TSEM, TSN, TTMI, TWST, U, UAL, ULCC, V, VEEV, VERX, VET, VFC, VG, VICR, VIK, VLO, VSH, W, WDAY, WDC, WDS, WIX, WMG, WOLF, WTI, XOM, YPF, ZEO, ZETA, ZSQR...(more)	show story hide story
03-Aug-2026 08:45	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis M&A Monday with the potential for the largest pharma merger ever, if the media reports come to fruition. FT reported on Sunday that AstraZeneca has held talks with Bristol Myers Squibb - for a combined company worth around $400B. Shares of BMY +4% in the pre-market; AZN (6%) in the pre-market. Actual biopharma M&A on the tape too, with radiopharmaceutical Curium acquiring Lantheus for cash plus CVR valued at up to $8.0B combined. Shares of LNTH +3% in the pre-market. CNS drugmakers Indivior ($4.8B) and Supernus Pharma ($2.5B) will combine in a merger of equals, the combined company will have revenues approx. $2.2B. Supernus' CEO will lead the combined company. Shares of INDV +3% and SUPN +15% in the pre-market. Integer Holdings confirms the media report on Friday, KKR will acquire the CRO for $127/shr or $5.7B deal. Shares of ITGR +3% in the pre-market. Macro S&P futures are up +0.5% on Monday morning. Risk sentiment underpinned by renewed traction surrounding escalate to de-escalate narrative as Trump said over the weekend he called off a potential attack on Iran to allow for more talks, which he noted will take place on Monday. Also reports Iran and Oman nearing a deal regarding a new SoH route. Pretty quiet outside of geopolitics. Strength of Q2 earnings season and positive revisions the big theme in recent strategist commentary. Open-weight still the big story in AI with focus on new Qwen3.8-Max model. Fed credibility another high-profile theme with Musalem flagging signaling from bond market. US and Japan confirmed joint intervention to support yen and warned more could be in the pipeline. Big M&A in the weekend headlines with report about potential tie-up in pharma. Pre-market trading update Trading higher +15.4% SUPN to merge with INDV; earnings +4.9% CDNA upgraded at Craig-Hallum +4.1% BMY media report - AZN merger talks; takeaways +3.0% INDV to merge with SUPN; earnings +2.9% LNTH acquired by Curium for cash + CVR +2.7% ITGR confirms acquisition by KKR for $127/shr +2.7% VEEV Wells Fargo comments on impact from AZN-BMY Trading lower -7.9% KRYS earnings -7.2% TWST earnings -6.4% SOBI.SS in European trading; CEO to step down for outside opportunity -6.1% AZN media report - in talks with BMY; takeaways -5.5% TGTX earnings -2.5% REPL follow-through; PDUFA was Sunday -2.3% ABVX sympathy to pharma M&A headlines Pharma M&A: AstraZeneca in talks with Bristol Myers Squibb - media reports On Sunday afternoon, CNBC reported on the potential merger of big pharma companies AstraZeneca (AZN.LN) and Bristol Myers Squibb (BMY), as first reported by FT. Merger would value combined company at roughly $400B. Discussions have taken place over the last few months. According to FactSet data, market cap as of Friday's close: AZN $263B, BMY $133B Takeaways: Analysts highlighted the media reports but view a potential transaction as highly unlikely. While a deal could secure value for BMY investors ahead of key Ph3 readouts, the strategic rationale for AZN is seen as weak. Some pointed to AZN's strong standalone 2030 financial targets, noting that an acquisition would yield limited synergies, while also compounding its exposure to upcoming LOEs. Furthermore, any formal announcement would trigger intense US and UK antitrust and political scrutiny regarding overlapping oncology portfolios and the combined entity's final domicile. Regulatory: NOVN.SW (NVS) FDA approves Pluvicto sNDA for metastatic hormone-sensitive prostate cancer (mHSPC). PDUFA was expected during H2 of 2026. Research: JNJ removed from the US Conviction List at Goldman Sachs. Biotech M&A: LNTH and Curium (private) announced announced a definitive agreement under which Curium US will acquire all outstanding shares of LNTH for $102.50 in cash, plus a CVR worth up to $12/shr, for total value of up to $8.0B. Total value represents a 38% premium to the unaffected 60-day VWAP. INDV and SUPN announced a definitive agreement to combine in an all-stock merger of equals, with approx. $2.2B in combined annual revenues. Expect to realize $125M of annual cost synergies. Supernus CEO Jack Khattar will become CEO of the combined company. INDV stockholders will receive a one-time special cash dividend of $1.0 billion in aggregate immediately prior to closing of the merger. Both companies also reported Q2 earnings; both beat-and-raised. According to FactSet data, market cap at Friday's close: INDV $4.8B, SUPN $2.5B Conf. call at 8:30ET Research: ALNY upgraded to strong buy from outperform at Raymond James (Martin Auster), target is $420 or approx. 104% upside. (FactSet average PT $388; range $23-536) ADIL initiated buy at Alliance Global Partners, target is $11 or approx. 229% upside. (FactSet average PT $17; range $6-42) CLYM initiated outperform at RBC Capital Markets (Nevin Varghese), target is $23 or approx. 93% upside. (FactSet average PT $21; range $15-35) PYXS initiated overweight at Wells Fargo Securities (Derek Archila), target is $12 or approx. 353% upside. (FactSet average PT $7; range $5-8) YARW initiated buy at BTIG (Julian Harrison), target is $58 or approx. 66% upside. Life Science & MedTech M&A: ITGR and KKR confirm Friday media report - companies agreed on a definitive agreement for an all-cash transaction at $127/shr or total value of around $5.7B. Regulatory: Post-close on Friday, the CMS finalized IPPS and LTCH rule for FY2027, rates +2.3% vs +2.4% proposed. CMS also extended CJR Model nationwide, now called CJR-X, and effective 1-Jan-2028. Research: CDNA upgraded to buy at Craig-Hallum Capital (Bill Bonello), notes confidence in near-term and long-term drivers of growth. Target increased to $64 from $35 or approx. 46% upside. (FactSet average PT $44; range $35-50) Services & Hospitals Regulatory: Post-close on Friday, the CMS finalized IPPS and LTCH rule for FY2027, rates +2.3% vs +2.4% proposed. CMS also extended CJR Model nationwide, now called CJR-X, and effective 1-Jan-2028. Managed Care Research: ALHC downgraded to outperform from strong buy at Raymond James (Parker Snure), target cut to $19 from $22 or approx. 28% upside (FactSet average PT $24; range $16-30) CI downgraded to outperform from strong buy at Raymond James (Parker Snure), target cut to $320 from $350 or approx. 15% upside (FactSet average PT $342; range $297-400) On Deck: Regulatory Sun 2-Aug: FDA PDUFA for REPL vuso-vec BLA on Wed 5-Aug: FDA PDUFA for MRNA mFlusiva BLA Corporate JNJ hosting business update call to discuss recent FDA approval of OTTAVA Robotic Surgery System (8:00ET) MRK hosting business update call post-International AIDS Conference (8:00ET) on Wed 5-Aug: NAMS hosting Investor Day meeting (9:00ET) Earnings after the close today: VRTX (call at 16:30ET), JAZZ (call at 16:30ET) Earnings tomorrow Tue 4-Aug: before BAYN.GR, MRK, PFE, IDXX, WAT, BNTX, SNN, FMS, RVTY, HSIC, BRKR, RYTM after AMGN, GILD, DVA, ARWR, BIO, PACS, TVTX, ACAD, HNGE This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABVX, ACAD, ADIL, ALHC, ALNY, AMGN, ARWR, AZN, AZN.LN, BAYN.GR, BIO, BMY, BNTX, BRKR, CDNA, CI, CLYM, DVA, FMS, GILD, HNGE, HSIC, IDXX, INDV, ITGR, JAZZ, JNJ, KRYS, LNTH, MRK, MRNA, NAMS, NOVN.SW, PACS, PFE, PYXS, REPL, RVTY, RYTM, SNN, SOBI.SS, SUPN, TGTX, TVTX, TWST, VRTX, WAT, YARW...(more)	show story hide story
03-Aug-2026 08:24	BMY Street Takeaways - Bristol Myers Squibb potential merger with AstraZeneca ($65.31) Overview: Shares of BMY +4.4% premarket and AZN (4.2%) on media talks of a potential mega merger, which would value the Combined entity at ~$400B. Discussions are said to have taken place over the past few months. Analysts highlighted the media reports but view a potential transaction as highly unlikely. While a deal could secure value for BMY investors ahead of key Ph3 readouts, the strategic rationale for AZN is seen as weak. Some pointed to AZN's strong standalone 2030 financial targets, noting that an acquisition would yield limited synergies, while also compounding its exposure to upcoming LOEs. Furthermore, any formal announcement would trigger intense US and UK antitrust and political scrutiny regarding overlapping oncology portfolios and the combined entity's final domicile. Analyst Commentary: RBC Capital Markets analyst Trung Huynh Notes the unconfirmed reports of a potential deal, with both Co's not commenting on the speculation Sees a potential deal comprising of a ~30% stake for BMY holders based on current market caps, while any formal announcement will likely come tomorrow as UK takeover code rules require AZN to issue a statement Thinks if any deal is announced, intense US and UK regulatory scrutiny will ensue due to their overlapping oncology, immunology, and cardiovascular portfolios Points to the potential deal coming before major Co catalysts, with CVRs highly probable, similar to Celgene precedent Believes it will be difficult to reach value alignment, with AZN focused on its standalone 2030 target, while BMY faces upcoming patent cliffs, viewing a merger as unlikely until there is stronger strategic rationale and more substantive developments Target remains $64; Maintains sector perform Leerink Partners analyst David Risinger Notes reports that BMY/AZN have held preliminary merger talks over the recent months Points to the deal structure likely requiring both cash and shares Sees the portfolios and pipelines for both Co's as very complementary, but the potential deal timing is intriguing given it is happening before major pivotal readouts Mentions key upcoming readouts include milvexian SSP in Q4'26, AF in Q1'27, admilparant IPF in Q4'26, and Cobenfy in ADP and Bipolar; looks for further development on a potential deal Maintains outperform BMO Capital Markets analyst Evan David Seigerman Sees any potential direct buyout deal as unlikely given the large market caps of both Co's Thinks major therapeutic overlaps in indications like MSCLC further lower the likelihood of a deal materializing Notes if a deal were to happen, it would be the largest in pharmaceutical history, eclipsing the Pfizer/Warner-Lambert deal Views the merger report as speculative without official comments from either Co, though it does highlight improving sentiment around M&A in the Pharma space Target remains $60; Maintains market perform Wells Fargo Securities analyst Mohit Bansal Sees a deal beneficial for BMY at the right price, though AZN investors may push back given upcoming LOEs and substantial pipeline risks Thinks AZN would need to essentially price 100% PoS for the BMY's upcoming high risk catalysts to get a deal to work, while synergies are limited given BMY's prior restructurings and >$30B debt load Views the large oncology and immunotherapy portfolio overlaps triggering FTC security, while both firms are 'national champions' with a deal likely facing political headwinds on where the final HQ will be and governance structure Believes the odds of a deal are low given the poor strategic rationale for AZN and heavy regulatory headwinds Target remains $55; Maintains equal weight See Related StreetAccount comments: 8/2/2026 4:46:01 PM - AstraZeneca in talks with Bristol Myers Squibb - media reports Related: AZN.LN	show story hide story
03-Aug-2026 08:21	StreetAccount Summary - US Pre-market trading S&P futures +35.8 to 7555, +0.48% vs settlement. 10-year yield (4) bps to 4.67%. Sep WTI ($5.65) or (6.67%) to $79.02. Trading Higher: *Market cap >$10B* +7.9% FERG (Ferguson Enterprises $252.96, +18.63) -- to join S&P 500 +7.7% CNH (CNH Industrial $11.04, +0.79) -- earnings +4.5% BMY (Bristol Myers Squibb $68.24, +2.93) -- AstraZeneca (AZN) in talks with Bristol Myers Squibb - media reports +4.1% TEAM (Atlassian $105.17, +4.16) +4.0% BABA (Alibaba Group $127.10, +4.85) -- Alibaba releases latest Qwen model +3.6% HUBS (HubSpot $246.00, +8.64) +3.4% OKTA (Okta, Inc. $146.72, +4.79) +3.3% SNOW (Snowflake $303.00, +9.72) +3.2% NOW (ServiceNow $114.81, +3.58) +3.2% DOCU (DocuSign $56.58, +1.75) +3.2% WDAY (Workday $165.44, +5.10) +3.2% FSLR (First Solar $217.75, +6.72) +3.0% ADBE (Adobe $258.00, +7.59) +2.9% CRM (Salesforce $189.34, +5.32) +2.8% PANW (Palo Alto Networks $341.28, +9.45) +2.8% IOT (Samsara $38.30, +1.03) +2.7% ACN (Accenture $170.38, +4.46) +2.7% INTU (Intuit $324.50, +8.43) +2.7% GEN (Gen Digital $28.20, +0.75) +2.6% L (Loews $119.00, +2.99) -- earnings +2.6% SHOP (Shopify $120.17, +3.02) +2.6% ADSK (Autodesk $240.35, +6.15) +2.5% UAL (United Airlines $124.40, +3.07) -- oil lower +2.5% CTSH (Cognizant Technology Solutions $56.74, +1.39) +2.5% W (Wayfair $87.00, +2.10) +2.4% VEEV (Veeva Systems $208.61, +4.83) +2.4% CDNS (Cadence Design Systems $348.34, +8.32) +2.4% DDOG (Datadog $274.46, +6.49) +2.4% PLTR (Palantir Technologies $126.07, +3.01) +2.4% QXO (QXO, Inc. $13.62, +0.32) +2.4% MDB (MongoDB $345.51, +8.03) +2.3% CRWD (CrowdStrike $195.20, +4.34) +2.3% RBRK (Rubrik $74.01, +1.65) +2.3% APP (AppLovin $405.00, +9.10) +2.2% ORCL (Oracle $132.69, +2.82) +2.1% U (Unity Software $32.37, +0.66) +2.1% ZTS (Zoetis $78.91, +1.62) +2.1% AAL (American Airlines Group $15.59, +0.32) -- oil lower +2.1% META (Meta Platforms $568.45, +11.74) +2.1% FIG (Figma $24.82, +0.50) +2.0% IBM (IBM $228.10, +4.45) +2.0% TTWO (Take-Two Interactive $247.76, +4.84) +2.0% ZS (Zscaler $154.20, +3.00) +2.0% APTV (Aptiv Plc $57.59, +1.12) +2.0% CCL (Carnival $28.36, +0.55) +2.0% SNPS (Synopsys $396.50, +7.74) +2.0% LUV (Southwest Airlines $45.85, +0.88) -- oil lower +2.0% TOST (Toast, Inc. $32.90, +0.63) +1.9% BA (Boeing $220.30, +4.16) -- BNP Paribas Exane upgrade +1.9% MSFT (Microsoft $473.44, +8.72) +1.9% MCD (McDonald's $275.71, +5.07) *Market cap $1B-$10B* +28.1% ATKR (Atkore $93.47, +20.51) -- Prysmian (PRY.IM) to acquire Atkore for $95/share in cash, or EV of $3.8B (€3.29B); earnings +15.8% SUPN (Supernus Pharmaceuticals $51.67, +7.04) -- Supernus Pharmaceuticals and Indivior Pharmaceuticals (INDV) announce all-stock merger of equals; earnings +9.2% BOW (Bowhead Specialty Holdings $33.41, +2.82) -- to be acquired by American Family Mutual Insurance Company for $34/sh; earnings +6.7% AMC (AMC Entertainment $3.01, +0.19) -- announces record weekend revenue +6.0% CDNA (CareDx $46.35, +2.64) -- Craig-Hallum upgrade +5.3% TE (T1 Energy $4.39, +0.22) -- T1 and Clearway execute strategic offtake deal +4.5% MMYT (MakeMyTrip $59.50, +2.55) -- earnings +4.1% BILL (Bill Holdings $47.00, +1.87) +4.0% FIVN (Five9 $28.62, +1.11) +3.8% KVYO (Klaviyo $18.51, +0.67) +3.5% ABSI (Absci Corp. $8.05, +0.27) +3.1% ESTC (Elastic $67.85, +2.06) +3.1% SAIL (SailPoint $17.29, +0.52) +3.1% PAYC (Paycom Software $168.97, +5.01) +2.9% GTLB (Gitlab $35.51, +1.00) +2.9% WIX (Wix.com $56.62, +1.59) +2.9% ALM (Almonty Industries $11.38, +0.32) +2.8% SDGR (Schrödinger $15.57, +0.43) +2.8% LNTH (Lantheus Holdings $102.40, +2.76) -- to be acquired by Curium for $102.50/sh cash plus CVR for up to $12/sh in potential additional cash payments +2.7% VERX (Vertex, Inc. $13.26, +0.35) +2.7% QGEN (Qiagen $42.52, +1.12) +2.7% ZETA (Zeta Global Holdings $22.18, +0.58) +2.7% PCT (Purecycle Technologies $6.54, +0.17) +2.6% ASAN (Asana, Inc. $8.54, +0.22) +2.6% PATH (UiPath $13.10, +0.34) +2.6% ITGR (Integer Holdings $124.40, +3.19) -- confirms agreement to be acquired by KKR for $127/sh cash; earnings +2.6% VFC (VF Corp $14.70, +0.38) -- insider buy +2.5% FMC (FMC Corp $10.98, +0.27) +2.5% MNDY (monday.com $89.31, +2.16) +2.5% ALK (Alaska Air Group $48.65, +1.20) +2.4% NOMD (Nomad Foods $12.19, +0.29) +2.4% INDV (Indivior Pharmaceuticals $40.97, +0.96) -- Supernus Pharmaceuticals SUPN) and Indivior Pharmaceuticals announce all-stock merger of equals +2.4% AVPT (AvePoint $13.34, +0.31) +2.4% KD (Kyndryl Holdings $13.87, +0.32) *Market cap <$1B* +32.6% DFNS (T3 Defense $36.71, +9.03) +8.7% PYXS (Pyxis Oncology $2.88, +0.23) -- Wells Fargo initiated overweight +8.6% PUSA (Aureus Greenway Holdings, Inc. $3.28, +0.26) +7.7% FTK (Flotek Industries $25.35, +1.81) -- 10-year contract to support 400 MW power project for Puerto Rico electric power authority +6.9% INTT (inTEST $13.21, +0.86) -- Northland Capital Markets upgrade +6.5% CERS (Cerus $2.29, +0.14) +6.0% BIOA (BioAge Labs $9.58, +0.54) +5.4% GRO (Brazil Potash $2.15, +0.11) +5.3% TSSI (TSS Inc $10.45, +0.53) +5.3% OCS (Oculis Holding $11.91, +0.60) -- FDA provides Oculis Holding feedback on Privosegtor to treat acute MS relapses +5.2% NEOV (NeoVolta $2.22, +0.11) +5.1% TENX (Tenax Therapeutics $14.40, +0.70) +3.7% TLRY (Tilray Brands $4.71, +0.17) +3.6% VYGR (Voyager Therapeutics $3.14, +0.11) +3.6% PD (PagerDuty $10.96, +0.38) Trading Lower: *Market cap >$10B* -8.4% KRYS (Krystal Biotech $312.37, -28.75) -- earnings -6.1% CRCL (Circle Internet $58.80, -3.81) -- Morgan Stanley downgrade -5.3% TSEM (Tower Semiconductor $208.00, -11.67) -5.3% AZN (AstraZeneca $160.63, -9.01) -- AstraZeneca in merger talks with Bristol Myers Squibb - media reports -4.5% SMTC (Semtech $112.50, -5.32) -4.2% AMKR (Amkor Technology $47.80, -2.07) -- insider sale -4.1% SNDK (Sandisk $1,165.43, -49.40) -4.0% ALAB (Astera Labs $298.78, -12.45) -4.0% MU (Micron Technology $790.00, -33.03) -3.7% WDC (Western Digital $524.50, -20.34) -3.7% BE (Bloom Energy $198.20, -7.61) -3.6% MAR (Marriott International $359.45, -13.38) -- earnings -3.5% EBAY (eBay $110.00, -4.01) -- Wells Fargo downgrade -3.4% STX (Seagate Technology $827.00, -29.13) -3.4% VG (Venture Global $12.93, -0.45) -3.0% COHR (Coherent $255.02, -7.87) -3.0% ANET (Arista Networks $175.00, -5.35) -3.0% TSN (Tyson Foods $56.20, -1.76) -- earnings -3.0% ONTO (Onto Innovation $250.82, -7.76) -- awarded $15.0M USAF contract -2.9% MRVL (Marvell Technology $182.20, -5.36) -2.8% NXPI (NXP Semiconductors $222.70, -6.46) -- UBS downgrade -2.8% LRCX (Lam Research $284.89, -8.13) -2.7% CRDO (Credo Technology $201.40, -5.59) -2.7% KLAC (KLA $177.85, -4.97) -2.7% TER (Teradyne $357.77, -9.92) -2.6% AMAT (Applied Materials $494.26, -13.41) -2.5% INTC (Intel $87.97, -2.23) -2.5% ON (onsemi $79.57, -2.04) -2.4% LITE (Lumentum Holdings $696.85, -17.09) -2.4% BMNR (Bitmine Immersion Technologies $16.86, -0.42) -2.4% MGM (MGM Resorts $43.52, -1.05) -2.4% TTMI (TTM Technologies $112.70, -2.74) -2.3% FLEX (Flex $111.17, -2.58) -2.3% MTSI (MACOM Technology $245.64, -5.80) -2.3% WMG (Warner Music Group $25.36, -0.60) -- CFO/COO Armin Zerza steps down for personal reasons, effective 31-Jul -2.3% MPWR (Monolithic Power Systems $1,392.76, -33.27) -2.3% AMD (Advanced Micro Devices $465.00, -11.15) -0.3% ECHO (EchoStar $83.87, -0.22) -- earnings *Market cap $1B-$10B* -18.6% SRAD (Sportradar Group $11.83, -2.71) -- earnings -8.2% GME (GameStop $19.93, -1.79) -- private exchange of $1.4B of convertible senior notes for equity -6.0% TWST (Twist Bioscience $86.10, -5.45) -- earnings -5.4% TGTX (TG Therapeutics $49.20, -2.83) -- earnings -5.1% AXTI (AXT Inc $57.34, -3.09) -5.0% AEHR (Aehr Test Systems $76.01, -3.97) -4.7% ACMR (ACM Research $74.81, -3.66) -4.5% MXL (MaxLinear $63.79, -3.03) -4.1% PLOW (Douglas Dynamics $42.34, -1.79) -- earnings -3.5% SHAZ (SharonAI Holdings $46.55, -1.70) -3.5% VSH (Vishay Intertechnology $33.01, -1.21) -3.4% AAOI (Applied Optoelectronics $91.11, -3.21) -3.4% VECO (Veeco Instruments $48.32, -1.68) -3.4% ALGM (Allegro MicroSystems $40.10, -1.40) -3.3% RMBS (Rambus $88.00, -3.03) -3.2% FORM (FormFactor $102.84, -3.36) -3.2% PENG (Penguin Solutions $50.96, -1.67) -3.2% COHU (Cohu $46.45, -1.54) -3.1% WOLF (Wolfspeed $22.88, -0.74) -3.0% VICR (Vicor $201.17, -6.20) *Market cap <$1B* -29.1% ZEO (Zeo Energy $0.35, -0.15) -19.0% CIGL (Concorde International Group $0.50, -0.12) -- recent IPO -8.6% PN (Skycorp Solar Group $15.78, -1.49) -8.4% SKYQ (Sky Quarry $4.26, -0.39) -4.9% EGG (Enigmatig $3.47, -0.18) -4.7% FBIO (Fortress Biotech $2.98, -0.15) -4.5% SPRY (ARS Pharmaceuticals $4.90, -0.23) -4.1% FNKO (Funko, Inc. $5.59, -0.24) *Oil/energy related lower; WTI futures (6.83%)* KOS -6.3% (earnings), WTI -5.0%, OBE -3.9%, SM -3.0%, MTDR -2.5%, PBF -2.4%, PARR -2.3%, CRGY -2.2%, VET -2.2%, NOG -2.2%, PUMP -2.1%, APA -2.0%, PR -1.9%, NEXT -1.9%, EOG -1.8%, SU -1.8%, CVE -1.7%, OXY -1.7%, COP -1.6%, OVV -1.6%, DVN -1.6%, VLO -1.6%, DINO -1.5%, FANG -1.4%, CNQ -1.4%, HESM +2.4% (earnings) Click here to view our Gainers & Decliners page Related: AAL, AAOI, ABSI, ACMR, ACN, ADBE, ADSK, AEHR, ALAB, ALGM, ALK, ALM, AMAT, AMC, AMD, AMKR, ANET, APA, APP, APTV, ASAN, ATKR, AVPT, AXTI, AZN, BA, BABA, BE, BILL, BIOA, BMNR, BMY, BOW, CCL, CDNA, CDNS, CERS, CIGL, CNH, CNQ, COHR, COHU, COP, CRCL, CRDO, CRGY, CRM, CRWD, CTSH, CUK, CVE, DDOG, DFNS, DINO, DOCU, DVN, EBAY, ECHO, EGG, EOG, ESTC, FANG, FBIO, FERG, FIG, FIVN, FLEX, FMC, FNKO, FORM, FSLR, FTK, GEN, GME, GRO, GTLB, HESM, HUBS, IBM, INDV, INTC, INTT, INTU, IOT, ITGR, KD, KLAC, KOS, KRYS, KVYO, L, LITE, LNTH, LRCX, LUV, MAR, MCD, MDB, META, MGM, MMYT, MNDY, MPWR, MRVL, MSFT, MTDR, MTSI, MU, MXL, NEOV, NEXT, NOG, NOMD, NOW, NXPI, OBE, OCS, OKTA, ON, ONTO, ORCL, OVV, OXY, PANW, PARR, PATH, PAYC, PBF, PCT, PD, PENG, PLOW, PLTR, PN, PR, PUMP, PUSA, PYXS, QGEN, QXO, RBRK, RMBS, SAIL, SDGR, SHAZ, SHOP, SKYQ, SM, SMTC, SNDK, SNOW, SNPS, SPRY, SRAD, STX, SU, SUPN, TE, TEAM, TENX, TER, TGT, TGTX, TLRY, TOST, TSEM, TSN, TSSI, TTMI, TTWO, TWST, U, UAL, VECO, VEEV, VERX, VET, VFC, VG, VICR, VLO, VSH, VYGR, W, WDAY, WDC, WIX, WMG, WOLF, WTI, ZEO, ZETA, ZS, ZTS...(more)	show story hide story
03-Aug-2026 07:30	Autos & Parts, Retail and Travel & Leisure lead; Oil & Gas lags: Autos & Parts the standout outperformer in European trade, underpinned by falling oil prices and easing Middle East tensions, which lifted rate- and fuel-cost-sensitive names across the board. Travel & Leisure also sharply higher, benefiting from the pullback in crude after President Trump held off a fresh strike on Iran. EZJ.LN rose after the UK Takeover Panel extended Castlelake's PUSU deadline to 7-Aug, aligning it with Apollo Global Management's existing timeline in the £5.7B vs £5.5B bidding contest for the airline. Oil & Gas is clear laggard, as Brent crude slid ~5% after Trump's decision to stand down from further military action against Iran eased fears of renewed supply disruption. Move also followed news OPEC+ approved a further output increase from September, completing the unwind of a layer of voluntary production cuts. TTE.FP agreed to acquire a 4GW European renewables portfolio from SHEL.LN while offloading a 50% stake in a separate renewables asset package to KKR for an enterprise value of €1.8B. REP.SM set to launch the next tranche of its €500M buyback. Health Care also softer, weighed down by AZN.LN after reports of preliminary merger talks with Bristol Myers Squibb. Analysts flagged scepticism over deal logic and integration risk given the scale of any combination. Elsewhere, ~PRY.IM~ agreed to buy US electrical infrastructure group Atkore for $95/share (EV ~$3.8B), a deal seen as high-single-digit EPS accretive once synergies are realised. HOLN.SW agreed to sell its loss-making Philippines business to Huaxin. In the UK, rate-sensitive housebuilders Vistry, Bellway and Persimmon jumped 4.8%-6.9% as gilt yields fell alongside the drop in oil prices. For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: AZN.LN, EZJ.LN, HOLN.SW, PRY.IM, REP.SM, SHEL.LN, TTE.FP...(more)	show story hide story
03-Aug-2026 06:04	StreetAccount Macro Headlines: Please see attached for weekend headlines. US-Iran conflict: Iran signals progress in Oman talks on Hormuz as Trump pauses attack and oil falls (Bloomberg, link) Trump says Iran talks begin Monday but sets no deadline after pausing planned attacks (Reuters) AI: Alibaba launches largest AI model Qwen3.8-Max, claiming parity with Anthropic's top system (Bloomberg) Moonshot AI plans to file for Hong Kong IPO this month to raise ~$3.00B (IFR ) AI funding shows signs of strain amid higher borrowing costs and SpaceX's selloff (Nikkei) Markets: Big Tech earnings split market as Fed's Warsh confuses investors and yields climb (link) Bond investors warn of deeper Treasury rout as Fed Chair Warsh's ambiguity erodes credibility (Bloomberg) Yen surges on speculation of fresh Japan-US coordinated intervention (Bloomberg) Bessent says Fed backstop for foreign central banks should be upsized (Reuters ) Morgan Stanley upgrades South Korea to overweight on leverage washout (Bloomberg) Corporate: AstraZeneca and Bristol Myers Squibb hold preliminary merger discussions (FT , Reuters) Prysmian to buy US electrical products maker Atkore for $3.8B in latest North American expansion (link ) CXMT polarizes analysts with extreme price targets as Chinese memory maker challenges Samsung and SK Hynix (Bloomberg) Central banks: ECB says Eurozone household consumption fell sharply after Iran war outbreak as confidence tumbled (Reuters) China's PBOC pledges timely policy tweaks and support for panda bond issuance (Reuters) Economy: Eurozone manufacturing PMI hits nearly 4.5-year high in July, but growth driven by backlog clearance rather than new demand (Reuters) China's private manufacturing PMI slows to 50.9 in July as new orders growth weakens (Reuters) Australian home prices fall at fastest pace since 2022 as rates and tax changes hit demand (Bloomberg) Trade/Tariffs: EU shows restraint and buys time against Trump's renewed tariff threats (Politico) China defends industrial-focused economic model and rejects "overcapacity" critique ahead of US and EU trade talks (Reuters) Geopolitics: Ukrainian drones strike deep into Russia, hitting Wildberries warehouse and killing two in residential attack (CNBC) See Related StreetAccount comments: 8/2/2026 10:49:26 AM - StreetAccount Macro Update: Weekend Headlines Related: 688825.CH, ATKR, AZN.LN, BABA, BMY, PRY.IM, +MOONSHOT.HK...(more)	show story hide story
03-Aug-2026 04:14	StreetAccount Summary - Trading higher/lower: EU mid-morning Trading Higher: +140.6% ALBPS.FP (Biophytis €0.01, +0.01) -- update on HK JV and outlook +11.1% ASPO.FH (Aspo €7.02, +0.70) -- Q2 earnings; plans demerger of demerger of ESL Shipping +9.9% MRN.FP (Mersen €41.20, +3.68) -- Berenberg upgrade +8.9% RWS.LN (RWS Holdings £1.06, +0.09) -- acquisition of Acogroup for an EV of £22.4M +8.1% PNL.NA (PostNL €0.96, +0.07) -- Q2 earnings +7.9% WLN.FP (Worldline €12.94, +0.97) -- sale of Indian payment activities to BillDesk for equity value of ~€60M +7.7% CKN.LN (Clarkson £54.50, +3.65) -- H1 earnings +6.1% NORION.SS (Norion Bank SEK62.30, +3.60) -- sale of NPL portfolio for ~SEK2.6B +5.2% VCP.LN (Victoria £0.68, +0.03) -- "Help to Buy" scheme revival +4.2% TW.LN (Taylor Wimpey £0.81, +0.03) +4.0% BTRW.LN (Barratt Redrow £3.04, +0.12) +2.3% WKP.LN (Workspace Group £3.62, +0.08) +2.1% BAB.LN (Babcock International Group £11.40, +0.24) +2.0% LSL.LN (LSL Property Services £2.47, +0.05) +5.1% LNZ.AV (Lenzing €24.15, +1.20) +4.8% CPI.LN (Capita £2.71, +0.13) -- extension to TfL road user charging contracts; completes private sector contact centre disposal +4.7% SHL.GR (Siemens Healthineers €38.69, +1.74) +4.6% CRBN.NA (Corbion €19.77, +0.88) -- Oddo upgrade +4.6% CLN.SW (Clariant CHF9.55, +0.42) -- Barclays upgrade; Deutsche Bank upgrade +4.2% RNO.FP (Renault €28.38, +1.15) -- France Jul new passenger car registration +3.9% GEST.SM (Gestamp Automoción €3.02, +0.12) -- Q2 earnings +3.9% MRO.LN (Melrose Industries £4.70, +0.18) +3.6% KAP.LN (Kazatomprom £65.10, +2.30) -- Q2 update +3.6% KIN.BB (Kinepolis Group €41.10, +1.45) -- Estimated weekend box office revenues in US, Canada $429.6M, +258.3% y/y - Box Office Mojo +3.2% HLG.GR (Highlight Communications €0.57, +0.02) -- Estimated weekend box office revenues in US, Canada $429.6M, +258.3% y/y - Box Office Mojo +3.2% STAB1L.GR (Stabilus €14.58, +0.46) -- confirms prelim Q3 earnings +2.7% AC.FP (Accor €46.08, +1.23) -- launches second €225M tranche of its €450M buyback programme +2.7% BONEX.SS (BONESUPPORT HOLDING SEK227.20, +6.00) -- enhanced Medicare reimbursement for CERAMENT G +2.7% ELIS.FP (Elis €25.46, +0.66) -- RBC Capital Markets upgrade +2.5% WAF.GR (Siltronic €78.70, +1.90) -- UBS upgrade +2.4% EZJ.LN (EasyJet £6.46, +0.15) -- extends Castlelake PUSU deadline to 7-Aug-26 +2.3% SOI.FP (SOITEC €106.30, +2.40) -- Kepler Cheuvreux upgrade +2.3% PAF.LN (Pan African Resources $0.94, +0.02) -- initiated buy at Jefferies +2.2% HO.FP (Thales €249.50, +5.30) -- Barclays upgrade +2.0% ODL.NO (Odfjell Drilling NOK90.90, +1.80) -- Deepsea Atlantic successfully returns to operations +2.0% UCB.BB (UCB €223.40, +4.40) -- Jefferies upgrade +1.8% AGS.BB (Ageas €73.70, +1.30) -- sale of stake in Maybank Ageas Holdings Berhad to JV partner for €1.1B +1.6% HOC.LN (Hochschild Mining £4.42, +0.07) -- initiated buy at Jefferies Trading Lower: -6.4% AZN.LN (AstraZeneca £117.94, -8.10) -- AstraZeneca in talks with Bristol Myers Squibb (BMY) - media reports -4.3% CHEMM.DC (ChemoMetec DKK410.40, -18.80) -- CFO steps down -4.2% SOBI.SS (Swedish Orphan Biovitrum SEK449.60, -19.80) -- CEO to step down -3.9% FDM.LN (FDM Group (Holdings) £1.19, -0.05) -- H1 earnings -3.8% IPN.FP (Ipsen €161.80, -6.40) -- transferred underperform at Jefferies, prior rating hold -2.6% ABI.BB (Anheuser-Busch InBev €73.68, -1.94) -- holder E.P.S. to sell 10M shares in company -- Reuters -2.0% DR0.GR (Deutsche Rohstoff €79.20, -1.60) -- completes ~€7.5M share buyback program Related: ABI.BB, AC.FP, AGS.BB, ALBPS.FP, ASPO.FH, AZN.LN, BAB.LN, BONEX.SS, BTRW.LN, CHEMM.DC, CKN.LN, CLN.SW, CPI.LN, CRBN.NA, DR0.GR, ELIS.FP, EZJ.LN, FDM.LN, GEST.SM, HLG.GR, HO.FP, HOC.LN, IPN.FP, KAP.LN, KIN.BB, LNZ.AV, LSL.LN, MRN.FP, MRO.LN, NORION.SS, ODL.NO, PAF.LN, PNL.NA, RNO.FP, RWS.LN, SHL.GR, SOBI.SS, SOI.FP, STAB1L.GR, TW.LN, UCB.BB, VCP.LN, WAF.GR, WKP.LN, WLN.FP...(more)	show story hide story
03-Aug-2026 02:49	StreetAccount Summary - European pre-market trading update StreetAccount notes that the pre-market levels mentioned are taken from various market sources Trading Higher +5% CKN.LN (Clarkson) -- H1 earnings +2% to +5% PRY.IM (Prysmian) -- to acquire Atkore for $95/share in cash, or EV of $3.8B (€3.29B) +3% BDT.GR (Bertrandt) -- Q3 earnings +1% DTE.GR (Deutsche Telekom) -- T-Mobile, Deutsche Telekom merger talks hit snag amid concerns of shareholder disapproval -- Semafor, citing sources +1% EZJ.LN (EasyJet) -- extends Castlelake PUSU deadline to 7-Aug +1% BAMI.IM (Banco BPM) -- Banca Monte dei Paschi di Siena considering trying to buy Banco BPM - FT +1% SDZ.SW (Sandoz Group) -- takes further steps to resolve legacy US generic medicine litigation: No impact on full-year 2026 guidance or mid-term outlook +1% STJ.LN (St. James's Place) -- £128.1M buyback programme Mixed -2% to +2% STM.GR (Stabilus) -- final Q3 earnings Trading Lower -5% SOBI.SS (Swedish Orphan Biovitrum) -- CEO to step down -3% AZN.LN (AstraZeneca) -- AstraZeneca in talks with Bristol Myers Squibb - media reports -3% AGS.BB (Ageas) -- to sells its stake in Maybank Ageas Holdings Berhad to its JV partner Maybank for €1.1B -1% PNL.NA (PostNL) -- Q2 earnings Related: AGS.BB, AZN.LN, BAMI.IM, BDT.GR, CKN.LN, DTE.GR, EZJ.LN, PNL.NA, PRY.IM, SDZ.SW, SOBI.SS, STJ.LN, STM.GR...(more)	show story hide story
03-Aug-2026 02:18	European macro headlines: Geopolitics: EU shows restraint and buys time against Trump's renewed tariff threats (Politico) Corporate: AstraZeneca and Bristol Myers Squibb hold preliminary merger discussions (Reuters) Prysmian in advanced talks for all-cash acquisition of Atkore (Bloomberg) Monte dei Paschi explores Banco BPM acquisition as alternative to Intesa takeover (FT) Daimler Truck CEO sees defense push delivering innovation spillovers to civilian business (FT) UK: UK Chancellor Healey sets first Budget for 28-October amid warnings of prolonged tax speculation (Telegraph) Labour overtakes Reform UK in polls for first time in over a year (FT) Farage and Reform UK face growing pressures as poll support slides (Politico) NHS England to adjust key metrics evaluating Palantir federated data platform (FT) UK more than doubles national crime agency officers targeting human smuggling (Bloomberg) Germany: German retail sales fall 1.1% in real terms in June 2026 (DeStatis) German economy posts stronger-than-expected growth, raising hopes of recovery (Bloomberg) BDI warns of China shock 2.0 hitting German industry broadly (Handelsblatt) France: French banks warm to election financing in potential boost for Marine Le Pen (FT) France lowers foreign investment screening threshold to 10% for non-European investors in strategic sectors (Bloomberg, Reuters) Italy: Italy advances nuclear revival amid local opposition to wind projects (FT) Italy plans to sell remaining Monte Paschi stake by end-September (Bloomberg) Europe: 22 EU leaders criticize Spain's migration policies over Ceuta influx (Politico) For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: AZN.LN, BAMI.IM, BMPS.IM, DTG.GR, PRY.IM	show story hide story
02-Aug-2026 16:46	AstraZeneca in talks with Bristol Myers Squibb - media reports CNBC reporting on the potential merger of big pharma companies AstraZeneca (AZN.LN) and Bristol Myers Squibb (BMY), as first reported on Sunday by FT. Merger would value combined company at roughly $400B. Discussions have taken place over the last few months. According to FactSet data, market cap as of Friday's close: AZN $263B, BMY $133B For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: AZN.LN, BMY	show story hide story
31-Jul-2026 02:34	4568.JP EU approves AstraZeneca and Daiichi Sankyo Datroway for First-Line Metastatic TNBC patients ineligible for immunotherapy (¥2567.5) AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the 1st-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02 Phase III trial which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology Reference Link: Press release See Related StreetAccount comments: 6/29/2026 2:05:13 AM - AstraZeneca and Daiichi Sankyo's Datroway recommended for approval in EU for TNBC Related: AZN.LN	show story hide story
30-Jul-2026 23:08	AZN.LN AstraZeneca's Efzimfotase alfa (ALXN1850) injection (subcutaneous) to be included for priority review by China's NMPA in hypophosphatasia (HPP) (12720p) ALXN1850 is a bone-targeted enzyme replacement therapy (ERT) designed to address the underlying cause of hypophosphatasia (HPP) Reference Link: NMPA-CDE	show story hide story
29-Jul-2026 16:06	XNCR Xencor to receive $105M from Alexion to resolve Ultomiris U.S. royalty matter ($19.53) Xencor announced its agreement with AstraZeneca's Alexion Parma to resolve a commercial dispute related to U.S. royalties on Ultomiris (ravulizumab-cwvz). Under the Settlement agreement, Xencor will receive $105M in two equal payments, the first $52.5M payment is anticipated in August 2026 and the second $52.5M payment on the one-year anniversary of the executed Settlement agreement, and Alexion will have no further obligation to pay royalties on U.S. sales of Ultomiris. Xencor expects to continue receiving royalties on ex-U.S. sales of Ultomiris under the existing terms of their license agreement. CEO Bassil Dahiyat stated: "We are pleased to have reached a resolution that provides immediate capital and reflects the value of the U.S. royalty stream that we had previously expected through 2028. We have returned our operating runway estimate to extend through 2028." As previously disclosed, in March 2026, Alexion informed Xencor of its position that no additional royalties were owed on U.S. sales of Ultomiris and that it did not intend to make future payments related to U.S. sales. The Settlement agreement fully resolves the dispute. Financial Guidance: Based on current operating plans, Xencor expects to have sufficient cash resources to fund research and development programs and operations through 2028. Guidance for year-end 2026 cash, cash equivalents and marketable debt securities will be updated with financial results for Q2 of 2026. Reference Link: Press release See Related StreetAccount comments: 3/4/2026 4:06:13 PM - Xencor announces change to Ultomiris royalty revenue forecast Related: AZN.LN	show story hide story
28-Jul-2026 03:53	StreetAccount Summary - Trading higher/lower: EU mid-morning Trading Higher: +19.0% LEHN.SW (LEM Holding CHF444.00, +72.50) -- Q1 earnings +17.1% ESNT.LN (Essentra £1.12, +0.17) -- H1 earnings +16.7% OBD.LN (Oxford BioDynamics £0.00, -0.00) -- signs first commercial agreement for the use of EpiSwitch Orion +12.5% SWTQ.SW (Schweiter Technologies CHF346.00, +37.50) -- Baader Helvea upgrade +11.9% STORY.B.SS (Storytel SEK98.45, +10.65) -- Q2 earnings +7.4% BFIT.NA (Basic-Fit €33.48, +2.38) -- H1 earnings +6.6% SUN.SW (Sulzer CHF151.00, +9.30) -- H1 earnings +6.2% GEMD.LN (Gem Diamonds £0.04, -0.00) -- H1 trading update +6.0% DATA.LN (GlobalData £0.81, +0.05) +6.0% SIKA.SW (Sika Group CHF170.75, +9.60) -- H1 earnings +5.9% SDF.GR (K+S AG €15.23, +0.84) -- BNP Paribas Exane upgrade +5.9% ULVR.LN (Unilever £48.55, +2.75) -- H1 earnings +5.6% EMG.LN (Man Group £3.24, +0.17) -- H1 earnings +5.2% SIGN.SW (SIG Combibloc Group CHF14.84, +0.73) -- Q2 earnings +5.0% HEX.NO (Hexagon Composites NOK10.76, +0.53) -- signs exclusive long-term agreement with IVECO BUS +4.7% FORN.SW (Forbo Holding CHF821.00, +37.00) -- H1 earnings +4.4% COA.LN (Coats Group £0.83, +0.03) -- H1 earnings +4.4% STG.DC (Scandinavian Tobacco Group DKK72.90, +3.10) -- Deutsche Bank upgrade +4.3% MBG.GR (Mercedes-Benz Group €47.55, +1.96) -- Q2 earnings +3.2% PAH3.GR (Porsche Automobil Holding SE €28.18, +0.88) -- +2.9% BMW.GR (Bayerische Motoren Werke €59.12, +1.64) -- +2.7% VOW3.GR (Volkswagen €72.58, +1.88) -- +3.9% NTG.DC (NTG Nordic Transport Group DKK244.00, +9.00) -- price target upgraded at Nordea +3.8% RELAIS.FH (Relais Group €14.85, +0.55) -- acquires 70% of tershine AB from founder and entrepreneur Tobias Ericson +3.5% STX.LN (Shield Therapeutics £0.06, -0.00) -- study results +3.1% ADM.LN (Admiral Group £36.94, +1.10) -- Citi upgrade +3.1% EVPL.LN (Everplay £2.36, +0.07) -- H1 trading update +2.9% LOOMIS.SS (Loomis SEK526.00, +15.00) +2.8% MTX.GR (MTU Aero Engines €358.40, +9.70) +2.7% SAF.FP (Safran €343.80, +9.00) -- H1 earnings +2.6% STAF.LN (Staffline Group £0.48, +0.01) -- H1 earnings Trading Lower: -20.8% ABDP.LN (AB Dynamics £8.21, -2.22) -- FY trading update -9.3% PHIA.NA (Koninklijke Philips €21.42, -2.20) -- Q2 earnings -7.8% SGF.IM (Sogefi €2.05, -0.17) -- H1 earnings -7.2% SPM.IM (Saipem €4.11, -0.32) -- Q2 earnings -6.5% PAL.AV (Palfinger €31.45, -2.15) -- H1 earnings -5.3% NIOX.LN (NIOX Group £0.60, -0.03) -- H1 earnings -5.2% BARC.LN (Barclays £5.06, -0.28) -- Q2 earnings -5.1% WAF.GR (Siltronic €76.00, -4.00) -- sector move -4.1% AIXA.GR (Aixtron €36.81, -1.56) -- -3.2% ASM.NA (ASM International €768.40, -25.20) -- -2.4% NOD.NO (Nordic Semiconductor NOK157.50, -3.90) -- -4.9% SUBC.NO (Subsea 7 NOK299.40, -16.00) -3.5% VSVS.LN (Vesuvius £3.83, -0.14) -- BNP Paribas Exane downgrade -3.5% MAIRE.IM (MAIRE €13.14, -0.48) -- initiated market perform at Bernstein -3.1% BSL.GR (Basler €25.10, -0.80) -2.8% UTG.LN (UNITE Group £5.39, -0.16) -- H1 earnings -2.7% GAW.LN (Games Workshop Group £191.10, -5.40) -- FY earnings -2.4% AI.FP (Air Liquide €173.54, -4.20) -- H1 earnings -2.4% LUCE.LN (Luceco £2.50, -0.06) -- H1 trading update -2.3% MC.FP (LVMH Moet Hennessy Louis Vuitton €469.45, -10.85) -- H1 earnings -2.3% ML.FP (Cie Generale des Etablissements Michelin SA €34.43, -0.80) -- H1 earnings -2.1% SESG.FP (SES €6.98, -0.15) -1.8% TGS.NO (TGS-NOPEC Geophysical Co. NOK128.70, -2.40) -1.8% NWF.LN (NWF Group £1.39, -0.02) -- FY earnings -1.7% AZN.LN (AstraZeneca £127.18, -2.24) -1.7% SQZ.LN (Serica Energy £2.34, -0.04) -1.6% FORT.LN (Forterra Plc £1.35, -0.02) -- H1 earnings; appoints new CFO Related: ABDP.LN, ADM.LN, AI.FP, AIXA.GR, ASM.NA, AZN.LN, BARC.LN, BFIT.NA, BMW.GR, BSL.GR, COA.LN, DATA.LN, EMG.LN, ESNT.LN, EVPL.LN, EVPL.LN, FORN.SW, FORT.LN, GAW.LN, GEMD.LN, HEX.NO, LEHN.SW, LOOMIS.SS, LUCE.LN, MAIRE.IM, MBG.GR, MC.FP, ML.FP, MTX.GR, NIOX.LN, NOD.NO, NTG.DC, NWF.LN, OBD.LN, PAH3.GR, PAL.AV, PHIA.NA, RELAIS.FH, SAF.FP, SDF.GR, SESG.FP, SGF.IM, SIGN.SW, SIKA.SW, SPM.IM, SQZ.LN, STAF.LN, STG.DC, STORY.B.SS, STX.LN, SUBC.NO, SUN.SW, SWTQ.SW, TGS.NO, ULVR.LN, UTG.LN, VOW3.GR, VSVS.LN, WAF.GR...(more)	show story hide story
28-Jul-2026 00:11	2162.HK Keymed Biosciences' CLARITY-Gastric01 global Phase III trial of CMG901 achieves positive topline results Demonstrated that, compared to the investigator-choice regimen, CMG901 (sonesitatug vedotin, AZD0901) displayed a statistically significant and highly clinically meaningful improvement in overall survival (OS) in patients with second or later-line Claudin 18.2 (CLDN18.2)-positive advanced gastric cancer. The trial enrolled patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer or esophageal adenocarcinoma (EAC), with an enrollment criterion of CLDN18.2 expression in at least 25% of tumor cells at any staining intensity. The trial featured dual primary endpoints, namely OS for the third or later-line treatment population and progression-free survival (PFS) for the overall trial population. The trial met not only the dual primary endpoint of OS for third or later-line treatments, but also the key secondary endpoint of OS in the overall trial population for second or later-line treatments. Results demonstrated an improving trend in the PFS of patients receiving second or later-line treatments, but did not achieve statistical significance. Demonstrated good tolerability. See Related StreetAccount comments: 3/10/2026 5:23:31 AM - AstraZeneca doses first patient in phase III clinical trial of sonesitatug vedotin (AZD0901) in combination with capecitabine 6/2/2024 3:17:09 PM - Keymed Biosciences announces latest results from a Phase I clinical study of CMG901 (AZD0901) at the ASCO annual meeting 2024 Related: 2157.HK, AZN.LN Attached Files PDF Document: Press release	show story hide story
27-Jul-2026 17:02	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished moderately higher overall on Monday. Advancers beat decliners by nearly 4:1 on the XLV. Healthcare +0.52% vs S&P 500 +0.02%. Moderate gains for almost all major health groups for the session. Managed Care dispatched some early morning softness to finish flat and just inline. ISRG +5.7%, shares remain lower (10%) MTD, and RVTY (2.2%) bracketed the XLV. MedTech the relative outperformer, with Medical devices catching a bid amidst today's risk-on trade. LST names unable to gain much traction, traded more mixed. Biotech ended essentially flat on a choppy session marked by high-premium M&A and fresh FDA insight into a hotly debated drug application. CAPR (64.5%) after FDA briefing documents. FBRX +39.6% acquired by ARGX (%) for around $2.2B. Positive read-across for TRAX +18.3%, shares now +121% YTD. AZN +0.2% the key earnings report on the tape this morning; muted response to a roughly inline print and guidance just maintained. A late-stage clinical failure for AstraZeneca's Ultomiris seen as benefitting OMER +15.8%. Relatively quiet weekend for sector newsflow, with Monday morning M&A returning to Biotech group. Argenx paying $2.2B to acquire Forte Biosciences. Earnings calendar this week ramps significantly, but slowly with only AstraZeneca on the tape Monday morning. Q2 results were mixed, with oncology drug sales light, and company just reaffirmed FY guidance. Regulatory calendar this week highlighted by back to back FDA Adcoms in Biotech. Briefing materials were published Monday morning for Capricor Therapeutics. FDA tone remains negative on efficacy, benefit-risk assessment. Macro Risk sentiment bolstered by pause in kinetic hostilities in the Middle East. Followed some of the dampened traction/hope last week surrounding the escalate to de-escalate narrative. However, still a lot skepticism when it comes to sustainable diplomatic offramps. Oil selloff and lower yield backdrop supportive of the broadening out trade, with select consumer groups, pockets of cyclicals among best performers. Semis under pressure again despite continued support for the AI compute/capex narrative. However, latest headlines \also played into some concerns surrounding circular financing and China competition. Former followed another ramp in scrutiny surrounding elevated hyperscaler capex sustainability. Pretty quiet elsewhere ahead of a big macro and micro week. FOMC the macro highlight on Wednesday with latest flurry of previews highlighting expectations for a hawkish hold. Roughly 35% of S&P market cap reports this week, including four of the Mag 7 names. Notable Gainers +46.6% GOSS (Gossamer Bio): strategic and regulatory updates in PAH +39.6% FBRX (Forte Biosciences): acquired by ARGX for $2.2B in cash +18.3% TRAX (First Tracks Biotherapeutics Inc): sympathy to FBRX; best performer on XBI +15.8% OMER (Omeros): sympathy to AZN trial results +8.0% ZBIO (Zenas BioPharma): second-best performer on XBI +7.7% HIMS (Hims & Hers Health): follow-through, shares down (15%) last week +5.7% ISRG (Intuitive Surgical): risk-on trade, Medical devices rebound; best performer on XLV +5.0% MMED (MiniMed Group): risk-on trade, Medical devices rebound +4.4% VEEV (Veeva Systems): risk-on trade; second-best on XLV +4.4% THC (Tenet Healthcare): on average volume; shares up +20% last week +4.2% BAX (Baxter International): risk-on trade, Medical equipment rebound +4.0% RMD (ResMed): risk-on trade, Medical devices rebound; smpathy to PHG +3.9% RYTM (Rhythm Pharmaceuticals): initiation +2.8% BSX (Boston Scientific): risk-on trade, Medical devices rebound +2.6% DXCM (Dexcom): risk-on trade, Medical devices rebound Notable Decliners -72.9% MPLT (MapLight Therapeutics): trial results in schizophrenia; worst performer on XBI -64.5% CAPR (Capricor Therapeutics): FDA publishes briefing documents ahead of Wed Adcom -24.2% OTLK (Outlook Therapeutics): follow-through; upgraded at BTIG -13.3% LEGN (Legend Biotech): CEO steps dowped down effective 24-Jul -12.4% SCTX (Scribe Therapeutics, Inc.): day two biotech IPO -11.0% REPL (Replimune Group): sympathy to CAPR; ahead of briefing docs tomorrow / Adcom Thursday -5.8% ACHC (Acadia Healthcare): on above average volume -5.3% ASTH (Astrana Health): on below average volume -4.4% CORT (Corcept Therapeutics): downgraded at Wolfe Research -4.4% PHG (Koninklijke Philips): earnings (early release) -4.1% TWST (Twist Bioscience): on below average volume -2.2% RVTY (Revvity): worst performer on XLV -2.1% HUM (Humana): rotation, MCO unwind AstraZeneca slightly higher following Q2 print AZN reports Q2 core EPS $2.63 vs consensus $2.48 on revenue $15.38B vs consensus $15.39B. Maintains FY26 financial guidance. Quick take: A few analysts point out that while there were no updates on key H2 catalysts (namely AVANZAR and SERENA-4) it was confirmed that there should be no delays there. DNB Carnegie says pipeline momentum in the coming 18 months looks strong, including those two key oncology read-outs - both having a sales potential >$5B. Overall, the Q2 results and guidance reiteration mean limited changes to consensus forecasts at this stage. Koninklijke Philips lower on Q2 print; focus on tariff refund PHIA.NA (PHG) results were scheduled for Tuesday morning, but were released early on Monday afternoon. Q2 EPS €0.49 ex-items vs consensus €0.33 on revenue €4.36B vs €4.31B. Raises FY26 EBITDA marginby 100bps to reflect tariff refund benefit. ADRs subsequently halted lower on the NYSE, and resumed lower. Guardant Health lower following Freenome's FDA clearance FRNM FDA approved PMA for SimpleScreen CRC. Decision date 24-Jul-2026. Freenome announces it will received $100M milestone payment from Abbott (ABT) under their existing commercial agreement. (GH) SMID-cap Biotech headlines FBRX acquired by ARGX.BB (ARGX) for $77/shr in cash, or total equity value of $2.2B. CAPR FDA publishes briefing materials ahead of Wednesday's Adcom for deramiocel for CM in DMD Reviewers reiterate the negative stance from the prior CRL - the benefit-risk assessment appears unfavorable in the absence of evidence of effectiveness. Panel to vote on the evidence from Study HOPE-3. LEGN disclosed that CEO Ying Huang stepped down effective 24-July. Aan Bash named interim CEO and the company has begun a comprehensive search process for a permanent successor. SRPT announced that Michael Severino has been appointed CEO effective 28-Jul. Previous CEO at Tessera Therapeutics, and a former exec at AbbVie. The retirement of Doug Ingram was announced in February 2026. FDA approved first NDSRI for treatment of ADHD in adults and children 4578.JP FDA approved first NDSRI, Otsuka's SIMTRIYO (centanafadine), for the treatment of ADHD in adults and pediatric patients. Otsuka expects SIMTRIYO will be available later this year following scheduling by the U.S. DEA. (SUPN) Notable research in Healthcare today Biotech: CAPR downgraded to neutral from buy at B Riley Securities (Madison El-Saadi), target cut to $10 from $63 or approx. 56% upside. CORT downgraded to underperform from peer perform at Wolfe Research (Kalpit Patel) OTLK upgraded to buy from neutral at BTIG (Julian Harrison) notes positive labeling outcome with today's FDA approval of Lytenava, target is $4 or approx. 184% upside. CMPS initiated equal weight at Wells Fargo Securities (Benjamin Burnett), target is $13 or approx. % upside. DFTX initiated overweight at Wells Fargo Securities (Benjamin Burnett), target is $68 or approx. 58% upside. GHRS initiated overweight at Wells Fargo Securities (Benjamin Burnett), target is $44 or approx. 61% upside. HELP initiated overweight at Wells Fargo Securities (Benjamin Burnett), target is $16 or approx. 110% upside. MDGL initiated overweight at Wells Fargo Securities (Sadia Rahman), target is $685 or approx. 26% upside. PLYX initiated buy at Lucid Capital Markets (Dev Prasad), target is $7 or approx. 241% upside. PMN initiated buy at Chardan Capital (Keay Nakae), target is $20 or approx. 64% upside. RYTM initiated overweight at JPMorgan (Priyanka Grover), target is $145 or approx. 42% upside. SMMT transferred buy at Clear Street, rating and $31 PT unchanged. Analyst is Mara Goldstein. MedTech: PROF upgraded to strong buy from outperform at Raymond James (Michael Freeman), target remains $11 or approx. 41% upside. COCH initiated buy at Lucid Capital Markets (Alex Nowak), target is $2 or approx. 203% upside. Post-close news Corporate: BSX discloses via 8-K a new global restructuring plan, to initiate in 2026 and complete by the end of 2029. Company expects a substantial amount of the savings to be reinvested in strategic growth initiatives. Shares trading (0.7%) in the after-hours Earnings: UHS reports Q2 adj EBITDA $677.9M vs StreetAccount $681.2M, EPS $5.98, on revenue $4.64B vs FS $4.58B. Lowers FY26 adj EBITDA outlook by $51.5M, raises revenue by $28.5M, and lowers EPS by $0.615 - all at the midpoints Conference call tomorrow at 9:00ET Shares trading (3.5%) in the after-hours On Deck: Earnings tomorrow: before GSK (call at 9:00ET), IQV (call at 9:00ET), CNC (call at 8:30ET), INCY (call at 8:00ET), ALKS (call at 8:00ET), RGEN (call at 8:00ET) after CHE (call Wed at 10:00ET), ACHC (call Wed at 9:00ET) Earnings on Wed 29-Jul: before BSX (call at 8:00ET), HUM (call at 8:00ET), TEVA (call at 8:00ET), BIIB (call at 8:30ET), GEHC (call at 8:30ET), IONS (call at 8:30ET), AVTR (call at 8:00ET), BLCO (call at 8:00ET), OPCH (call at 8:30ET) after ICLR (call Thu at 8:00ET), ALGN (call at 16:30ET), CORT (call at 17:00ET), GKOS (call at 16:30ET), VKTX (call at 16:30ET), WAY (call at 16:30ET), ADPT (call at 16:30ET) Conference BTIG Biotechnology Conference (Jul 28-29) Regulatory FDA briefing documents ahead of Thu Adcom (REPL) on Wed 29-Jul: FDA Adcom: CTGTAC to review CAPR deramiocel BLA for CM in DMD on Thu 30-Jul: FDA Adcom: CTGTAC to review REPL vusolimogene oderparepvec (RP1) for advanced melanoma This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4578.JP, ABT, ACHC, ADPT, ALGN, ALKS, ARGX.BB, ASTH, AVTR, AZN, BAX, BIIB, BLCO, BSX, CAPR, CHE, CMPS, CNC, COCH, CORT, DFTX, DXCM, FBRX, FRNM, GEHC, GH, GHRS, GKOS, GOSS, GSK, HELP, HIMS, HUM, ICLR, INCY, IONS, IQV, ISRG, LEGN, MDGL, MMED, MPLT, OMER, OPCH, OTLK, PHG, PHIA.NA, PLYX, PMN, PROF, REPL, RGEN, RMD, RVTY, RYTM, SCTX, SMMT, SRPT, SUPN, TEVA, THC, TRAX, TWST, UHS, VEEV, VKTX, WAY, ZBIO...(more)	show story hide story
27-Jul-2026 16:24	FactSet Podcast - Evening Market Recap, 27-Jul Overview: US equities were mostly higher in Monday trading. Today's risk sentiment was bolstered by a pause in kinetic hostilities in the Middle East. In macro news, June headline durable goods missed, though core capital goods orders and shipments both beat. Tickers Mentioned: MSFT, GOOGL, NVDA, AAPL, MU, SPCX, ASML, AZN, BKR, MPLT, RKLB, UAL, DAL, BF.B, QBTS, ARGX, FBRX, CBRL, T About This Podcast: The Evening Market Recap Podcast aims to bring listeners up to speed on the trading day as quickly as possible. With a target time of ~5 minutes and a publish time of ~18:00 EDT, this is an ideal listen after the market closes. Find us on Apple and Spotify, or click the link below to listen now. Related: AAPL, ARGX, ASML, AZN, BF.B, BKR, CBRL, DAL, FBRX, GOOGL, MPLT, MSFT, MU, NVDA, QBTS, RKLB, SPCX, T, UAL...(more) Reference Link: Market Recap 27-Jul-26	show story hide story
27-Jul-2026 14:01	^PVTSUMM StreetAccount Summary - Private Company Weekly Recap - Week of 20-Jul Summary This past week's funding activity was led by Ant International raising $1.2B in Series A funding from Ant Group and Alibaba, Atoms securing $1.7B in Series B from a16z and Bain Capital, and Meshy raising $400M in Series B from Monolith Management and IDG Capital Partners. Major M&A transactions included Magnolia Oil & Gas acquiring WildFire Energy for ~$4.06B including debt, Dassault Systemes acquiring ArisGlobal for ~$1.8B with up to $200M in additional consideration, and Iberdrola acquiring an 80% stake in Caruna for €2.1B. Strategic partnerships included AMD and Anthropic confirming a partnership to deploy up to 2 gigawatts of AMD Instinct MI450 Series GPUs, Microsoft signing a multi-billion dollar agreement to use Mistral AI's data centers, and Databricks and Microsoft expanding their enterprise AI partnership. Regulatory approvals included multiple FTC antitrust clearances including TMX Group's RAFI Indices purchase and Standard BioTools' Treeline Biosciences merger, EU approval of PIF consortium's Electronic Arts acquisition, and FDA approval of Rezzayo's sNDA adding pediatric indication for ages 12-18. IPO activity included Scribe Therapeutics opening at $25.00 on the Nasdaq, Reformation expecting its IPO to price $15-17 per share, and AlphaSense exploring a potential IPO in the coming months. Top Funding News Commercial Services Ant International (Singapore) (11VSD8-E) - raises $1.2B in Series A funding Investors: Ant Group Co., Ltd. (+ANT); Alibaba Group Holding Ltd. (BABA) Sila Nanotechnologies, Inc. (0DVHNN-E) - raises $300M in Later Stage Rounds funding Investors: Eight Enterprises LLC; Atreides Management LP; Matrix Management Corp.; Sutter Hill Ventures LLC; Deer Management Co. LLC; T. Rowe Price Associates, Inc. (Private Equity) Cathedral (United States) (13XCMX-E) - raises $160M in Series A funding Investors: a16z Capital Management LLC; Sequoia Capital Glow Security, Inc. (11WQG7-E) - raises $100M in Series B funding Investors: Index Ventures SA; Sequoia Capital; Swish Venture; Lux Capital Group LLC; Cyberstarts Venture Fund Ltd.; Redpoint Ventures; Holly Ventures; Operator Collective Management LLC; Greenoaks Capital Management LLC Electronic Technology Etched.ai, Inc. (0WJQQR-E) - raises $300M in Later Stage Rounds funding Investors: Jane Street Group LLC; SK hynix, Inc. (000660.KS); Sequoia Capital; Diffusion Capital Partners BV; a16z Capital Management LLC Finance Atoms (California) (0JXLDC-E) - raises $1.7B in Series B funding Investors: SV Angel LLC; Abstract Ventures LLC; a16z Capital Management LLC; Chemistry Ventures Management LLC; Alpha Square Group; Bain Capital Ventures LP; Uber Technologies, Inc.; A-Star Partners LLC; Fifth Wall Ventures Management LLC; K5 Global LP IVY GmbH (0RW8DR-E) - raises $180M in Series B funding Investors: Tiger Global Management LLC (Private Equity); Unofficial Management Inc; Hummingbird Ventures Management NV; Brevan Howard Digital; Farooq Malik; Jamie Cox; Victor Cardenas; Gavin Uberti; Jan Oberhauser; Balaji Srinivasan; Karim Atiyeh; Soma Capital Management LLC; Alexander Rinke; Sean Neville; QED Investors LLC; Alan Chang; CMT Digital Management LLC /Venture Capital; Alexandre Bouaziz; Road Capital Management LP; Victor Riparbelli; David Millán Vélez Health Technology Crystalys Therapeutics, Inc. (115S5R-E) - raises $130M in Series B funding Investors: An Venture Partners; HBM Partners AG; Perceptive Advisors (Private Equity); LSV Capital Management LLC; Trails Edge Capital Partners LP; KB Investment Co., Ltd.; Catalys Pacific LLC; Novo Ventures 1 A/S; Cormorant Asset Management LP/Private Equity/; Wellington Management Co. LLP (Private Equity); Frazier Life Sciences Management LP; SR One Capital Management LP; Alexandria Venture Investments LLC; Longwood Fund Management LLC; Soleus Capital Management LP; KCap Biotechnology Fund LP; Pontifax Management Co. Ltd.; Wedbush Family Partners LLC; Pivotal Bioventure Partners Investment Advisor LLC Producer Manufacturing SKL Robotics Ltd. (10GQXZ-E) - raises $152M in Series A funding Investors: Robert Bosch Stiftung GmbH; Fubon Financial Venture Capital Co. Ltd.; Prime Movers Lab LLC; Schaeffler AG; Aglaé Management SAS Technology Services Meshy LLC (13X458-E) - raises $400M in Series B funding Investors: Granite Asia Capital Pte. Ltd.; Bertelsmann Asia Investments; Matrix Partners (Beijing) Investment Management Co. Ltd.; Beijing Source Code Capital Co. Ltd.; Monolith Management Ltd (China); IDG Capital Partners Co., Ltd. Candid Group, Inc. (0M6Z44-E) - raises $120M in Later Stage Rounds funding Investors: Sixth Street Advisers LLC (Private Equity); Oak HC/FT Management Co. LLC; Eight Enterprises LLC; Y Combinator LLC Notable M&A Basic Materials OCS to acquire entire issued and to be issued share capital of Mitie at 221.6pence in cash (0NWWSK-E,MTO.LN) NovaGold Resources to acquire 100% of Donlin Gold (0D05P4-E,NG.CN) Capital Goods Ohmnia Electronics, S.L. (Clerbil, S.L.) offers to acquire Azkoyen for €10/share in cash (0G8J6V-E,AZK.SM) Consumer Non-Cyclical Intersnack Group to acquire all outstanding shares of Utz Brands for $14.25 per share in cash (0DPNZP-E,UTZ) The Vita Coco announces the acquisition of Copra, Inc. (0HHVW8-E,COCO) Copra, Inc. engages in producing and supplying coconut water. Nestle agrees to sell 50% of its waters and premium beverages business to Platinum Equity (0XYN7W-E,NESN.SW) Brown-Forman receives an unsolicited takeoiver proposal from Sazerac, concludes the proposal is not actionable (0F72KP-E,BF.B) Energy Magnolia Oil & Gas announces acquisition of WildFire Energy for ~$4.06B, inclusive of debt (0MBNDN-E,MGY) boards of Bidco and DCC Energy reach agreement on terms of recommended acquisition by Bidco of entire issued and to be issued share capital of DCC Energy (0VQVVM-E,DCC.LN,KKR) Financial Mavis confirms agreement to acquire Pep Boys from Icahn Enterprises for $700M in cash (+MAVISTIRE,1284S0-E,IEP) Mavis Tire Supply LLC is an online dealer of discount tires, which engages in the provision of snow-winter and special all season tires. Equals Group enters into transaction process deed to acquire OFX Group for A$1.00/sh (0B1BK5-E,OFX.AU) Equals Group Plc engages in the provision of international payment services. Perpetual receives further revised proposal from EQT-backed Windflower at A$22.50/share (0NQ36L-E,EQT.SS,PPT.AU) DNB Bank enters agreement to divest its shareholding in Luminor Holding to OTP Bank (0LGG3P-E,BX,DNB.NO,OTP.HB) Healthcare Royalty Pharma acquires royalty interest in AstraZeneca's (AZN.LN) cliramitug for up to $425M from Neurimmune (0H2PMP-E,4592.JP,AZN.LN,RPRX) Cardinal Health will acquire the Diabetes Health business of AdaptHealth Corp., and, in its entirety, Strive Medical for ~$360M. (0NSX8G-E,AHCO,CAH) Surgery Partners announces entry into agreement to sell ownership interests in Idaho Falls facilities to Intermountain Health (0L7X83-E,SGRY) Services Pepkor proposes to acquire 57.1% stake in combined Flash-Shop2Shop fintech platform valued at ZAR21.3B (0W56H3-E,PPH.SJ) Accor signs definitive binding agreement on the sale of its c.30.7% stake in Essendi (formerly AccorInvest) (0JG2YG-E,AC.FP,BX) AccorInvest Group SA owns and operates a portfolio of owned and leased hotels. Pinewood Technologies Group announces Ridgeview Partners makes non-binding acquisition offer of £4.48 in cash per share (0CPMTM-E,PINE.LN) Technology Dassault Systemes to acquire ArisGlobal for ~$1.8B in cash at closing and up to $200M in additional consideration (09L4PJ-E,DSY.FP) ArisGlobal LLC provides software solutions for the life sciences industry. TE Connectivity Plc to acquire Astrodyne TDI for $1.4B (0XG27F-E,TEL) Bullish announces Siris to acquire non-core Equiniti business lines (082CG8-E,0BRVV5-E,BLSH) Equiniti Group Ltd. is a holding company, which engages in the provision of technology and solutions for complex and regulated administrations, serving blue-chip enterprises, and public sector organizations. SIRIS Capital Group LLC (SIRIS Capital Group) is a private equity firm founded in 2011 by Frank Baker, Peter Berger and Jeffrey Hendren. Utilities Iberdrola to acquire 80% stake in Caruna for €2.1B (0DYGLS-E,IBE.SM) Caruna Oy provides electricity distribution services. Strategic Partnerships/Contracts Capital Goods RTX's Collins Aerospace and Etihad Engineering create nacelle MRO joint venture (0G8FMT-E,RTX) Joby, Virgin Atlantic formalize partnership to bring Joby's air taxi service to UK (+VA.LN,JOBY) VC Properties, Vertical Aerospace sign MOU to explore eVTOL air mobility at Pinheirinho; terms undisclosed (0JY8LF-E,EVTL) Consumer Non-Cyclical Cadiz Inc and RIC Energy sign MOU to advance solar / hydrogen development at Cadiz Ranch (0MH9G6-E,CDZI) Energy Kuwait Oil Company to form 51-49 JV with PE consortium (BAM, BN, BX, KKR, 0BDHZ4-E) Liberty Energy, PowerBridge LLC form JV to develop powered data center campuses (09W8SK-E,LBRT) PowerBridge LLC develops and manages electric transmission lines and other energy infrastructure projects. Healthcare Tempest announces development collaboration with Senlang Biotechnology for TPST-4003 (0NY5M3-E,TPST) PolyPid announces exclusive partnership with Azurity Pharmaceuticals, to potentially receive over $320M in upfront and milestone payments (0L499Z-E,PYPD) Azurity Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. HBM Holdings subsidiary Nona Biosciences enters research collaboration with Medical University of Vienna for infectious diseases (101VKP-E,2142.HK) Zorronet Ltd. enters strategic collaboration with Samura s.r.o. (0Z73Q7-E,PHGE) Services Shinsegae, OKO form JV to develop hospitality projects (004170.KS,0N2NMK-E) Technology AMD and Anthropic confirm strategic partnership to deploy up to 2 gigawatts of AMD Instinct MI450 Series GPUs (+ANTHROPIC,AMD,AMZN,GOOGL,NVDA) Microsoft signs a 'multi-billion' dollar agreement to use Mistral AI's data centers; Samsung in talks to invest in Mistral at €20bn valuation (+MISTRAL, 005930.KS, MSFT) Databricks and Microsoft expand partnership for enterprise AI (+DATABRICKS, MSFT) Harvey expands collaboration with Microsoft on legal AI (MSFT, 0V79BJ-E) Rezolve Ai announces partnership with Zilch (+ZILCH,RZLV) Zilch Technology Ltd. provides buy-now-pay-later card for shoppers that can use to buy from major retailers with no additional fees. zerohash and Marqeta announce partnership to enable stablecoin spending across global card networks (132ZBY-E,MQ) Transportation Indigo and CFM International sign MoU for 1,000+ LEAP-1A engines (05MQWM-E,539448.IN,GE,SAF.FP) CFM combines the resources, engineering expertise and product support of two major aircraft engine manufacturers: Snecma (SAFRAN Group) of France, and GE of the U.S. Regulatory/Leadership Antitrust FTC grants antitrust clearance for TMX Group's purchase of RAFI Indices (0DHX7H-E,X.CN) FTC grants antitrust clearance for Standard BioTools' merger with Treeline Biosciences (0NSH8V-E,LAB) FTC grants antitrust clearance for ExlService's acquisition of iMerit Inc. (0XWDCP-E,EXLS) FTC grants antitrust clearance of TDK's acquisition of Frabric8Labs (0JJ9H6-E,6762.JP) FTC grants antitrust clearance for Figure Technology's purchase of Kiavi (00FTQR-E,FIGR) Hancock Whitney receives regulatory and shareholder approvals to acquire One Florida Bank (0LWW6P-E,HWC) EU clears PIF consortium's acquisition of Electronic Arts (0C29W1-E,0MDTT5-E,10J49M-E,EA) EU clears Taifu Kechuang Special Steel's acquisition of Prosperity Kingsfield (000708.CH,0H1XGG-E) EU clears Ares Management Corp's acquisition of a stake in Eni's Plenitude (+PLEN.IM,ARES,ENI.IM) EU clears Asterion Industrial Partners' acquisition of a stake in Southern Water (MQG.AU, 0KD5YS-E) EU clears Saica's acquisition of Thimm Group (0LP8LW-E) EU sets a provisional deadline of 25-Aug to rule on Bain Capital's acquisition of a 51% stake in Everllence (05G8Z3-E,VOW.GR) EU sets a provisional deadline of 25-Aug to rule on Verdane's acquisition of a stakes in Telenor Connexion, BLDNG.ai and Whereby (05W6RG-E,TEL.NO) EU sets a provisional deadline of 28-Aug to rule on GBL portfolio company Sanoptis's acquisition of a majority stake in Oftalvist from HLA Vistahermosa (0L8K90-E,GBLB.BB) EU sets a provisional deadline of 28-Aug to rule on Centerbridge Partners' acquisition of a stake in Ebury (SAN.SM, +EBURY, 06KFSS-E) Iris receives regulatory approvals for takeover bid for Reef Casino Trust, removes minimum acceptance condition (11ZFC0-E,RCT.AU) Germany expected to impose unspecified conditions on Energy Fuels purchase of VAC (05S207-E,13QDVD-E,ASM.AU,UUUU) -- Bloomberg (paywalled link) Drugs FDA investigating Cyclospora outbreak (0H1V5D-E) FDA issues CRL to Apiject Systems NDA for glycopyrrolate solution (0N7MMW-E) FDA approves sNDA for Rezzayo, adds pediatric indication ages 12-18 years old (08F12G-E,0DKD2V-E,CRMD) Par Health launches first generic in the US of Janumet XR (MRK, 12XBBS-E) Aptar Pharma announces GMP certification at Nanopharm (0CDHQL-E,ATR) Adienne S.r.l. withdrew its application for a marketing authorization of Azacitidine Adienne for the treatment of MDS, CMML and AML (0FY2YL-E) EU's CHMP adopted a positive opinion recommending the granting of a marketing authorization for Tafamidis Accord (063D6L-E, 0FDQR4-E) EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation for Riociguat Accord (BAYN.GR, MRK, 063D6L-E, 0FDQR4-E) EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation under exceptional circumstances for the medicinal product Nezglyal (0F0YSR-E) EU's CHMP adopted positive opinion recommending granting of marketing authorisation for medicinal product Lyrokaul (0GKFFS-E) European Medicines Agency has recommended refusal of marketing authorisation for KemSu (0YFM7C-E) European Medicines Agency has recommended refusal of marketing authorisation for Meplyffa (0YY57X-E,ZVRA) Litigation Anthropic sues AI security firm Abnormal over logo (0LMVPH-E, +ANTHROPIC) AEM Holdings notes Advantest Test Solutions filed amended complaint alleging US patent infringement (0TW4Y5-E,AWX.SP) Avis Budget Group and Pentwater Capital Management release joint statement noting Avis' filing of court motion seeking approval of previously announced settlement (06ZD2V-E,CAR) Polymarket issues statement on ANJ ruling that blocks its website in France (+POLYMKT) ICC Arbitration Tribunal rules that Hanol Biopharma's notice of contract termination in regards to HL161 is invalid (009420.KS,0VKZT6-E,1093.HK) Other Kalshi files for CFTC approval of perpetual precious-metals futures (+KALSHI) -- Bloomberg (paywalled link) Regulatory European Commission preliminary finds TikTok in breach of Digital Services Act for failing to ensure safe accounts for minors (+TIKTOK, +DOUYIN) DOE approves Xcimer's laser fusion design (0TP97D-E) IPO Filings and Developments Capital Goods Lyntris, Inc. files for NYSE IPO of indeterminate size (+LYNX) Healthcare Scribe Therapeutics, Inc. IPO opens at $25.00 on the Nasdaq; priced at $15/sh; IPO filed on 2-Jul-26 (+SCTX, SCTX) Services Reformation, Inc. expects to offer ~14.1M shares (incl. ~4.6M for holders) priced in the range of $15-17/sh; IPO filed on 25-Jun-26 (+REF) Technology AlphaSense working with advisors to explore potential IPO in "coming months" (+ALPHASENSE,0BY6CY-E) -- The Information, citing sources (paywalled link) Brooks Automation evaluates initial public offering (+BROOKS,0NZSW0-E) -- Bloomberg (paywalled link) Private Company Reads OpenAI says Hugging Face breach was caused by one of its models -- Axios (paywalled link) OpenAI President Greg Brockman acknowledges Moonshot AI's Kimi K3 as good model, too early to determine if the Chinese firm piggybacked OpenAI tech -- Bloomberg (paywalled link) NVIDIA in talks to provide ~$250B backstop for OpenAI as part of Ohio data center project developed by SoftBank Energy -- Reuters (paywalled link) Waymo exploring a split from Uber as tensions over Robotaxi deepen -- FT (paywalled link) President Trump to host a group of private company Nuclear Energy CEOs after reactors reached criticality -- Bloomberg (paywalled link) Click here to view / receive alerts for Private Company Recap Related: 000660.KS, 000708.CH, 004170.KS, 005930.KS, 009420.KS, 1093.HK, 2142.HK, 4592.JP, 539448.IN, 6762.JP, AC.FP, AHCO, AMD, AMZN, ARES, ASM.AU, ATR, AWX.SP, AZK.SM, AZN.LN, BABA, BAM, BAYN.GR, BF.B, BLSH, BN, BX, CAH, CAR, CDZI, COCO, CRMD, DCC.LN, DNB.NO, DSY.FP, EA, ENI.IM, EQT.SS, EVTL, EXLS, FIGR, GBLB.BB, GE, GOOGL, HWC, IBE.SM, IEP, JOBY, KKR, LAB, LBRT, MGY, MQ, MQG.AU, MRK, MSFT, MTO.LN, NESN.SW, NG.CN, NVDA, OFX.AU, OTP.HB, PHGE, PINE.LN, PPH.SJ, PPT.AU, PYPD, RCT.AU, RPRX, RTX, RZLV, SAF.FP, SAN.SM, SCTX, SGRY, TEL, TEL.NO, TPST, UTZ, UUUU, VOW.GR, X.CN, ZVRA, +ALPHASENSE, +ANT, +ANTHROPIC, +BROOKS, +DATABRICKS, +DOUYIN, +EBURY, +KALSHI, +LYNX, +MAVISTIRE, +MISTRAL, +OPENAI, +PLEN.IM, +POLYMKT, +REF, +SCTX, +TIKTOK, +VA.LN, +ZILCH, 00FTQR-E, 05G8Z3-E, 05MQWM-E, 05S207-E, 05W6RG-E, 063D6L-E, 06KFSS-E, 06ZD2V-E, 082CG8-E, 08F12G-E, 09L4PJ-E, 09W8SK-E, 0B1BK5-E, 0BDHZ4-E, 0BRVV5-E, 0BY6CY-E, 0C29W1-E, 0CDHQL-E, 0CPMTM-E, 0D05P4-E, 0DHX7H-E, 0DKD2V-E, 0DPNZP-E, 0DYGLS-E, 0F0YSR-E, 0F72KP-E, 0FDQR4-E, 0FY2YL-E, 0G8FMT-E, 0G8J6V-E, 0GKFFS-E, 0H1V5D-E, 0H1XGG-E, 0H2PMP-E, 0HHVW8-E, 0JG2YG-E, 0JJ9H6-E, 0JY8LF-E, 0KD5YS-E, 0L499Z-E, 0L7X83-E, 0L8K90-E, 0LGG3P-E, 0LMVPH-E, 0LP8LW-E, 0LWW6P-E, 0MBNDN-E, 0MDTT5-E, 0MH9G6-E, 0N2NMK-E, 0N7MMW-E, 0NQ36L-E, 0NSH8V-E, 0NSX8G-E, 0NWWSK-E, 0NY5M3-E, 0NZSW0-E, 0TP97D-E, 0TW4Y5-E, 0V79BJ-E, 0VKZT6-E, 0VQVVM-E, 0W56H3-E, 0XG27F-E, 0XWDCP-E, 0XYN7W-E, 0YFM7C-E, 0YY57X-E, 0Z73Q7-E, 101VKP-E, 10J49M-E, 11ZFC0-E, 1284S0-E, 12XBBS-E, 132ZBY-E, 13QDVD-E...(more)	show story hide story
27-Jul-2026 13:38	500087.IN Cipla receives U.S. FDA approval for generic Advair Diskus (Fluticasone Propionate and Salmeterol Inhalation Powder), across all three strengths (INR 1409.85) Cipla announced that Cipla USA has received FDA approval for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in all three strengths-100/50 mcg, 250/50 mcg, and 500/50 mcg. The product is a therapeutically equivalent version of Advair Diskus, a widely prescribed combination therapy indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The product is expected to be launched in Q2 of FY 2026-27 in the United States of America. Related: AZN.LN, GSK.LN, MRK, NOVN.SW Attached Files PDF Document: Press release	show story hide story
27-Jul-2026 08:50	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Relatively quiet weekend for sector newsflow, with Monday morning M&A returning to Biotech group. Argenx paying $2.2B to acquire Forte Biosciences. Shares of FBRX +40% in the pre-market. Earnings calendar this week ramps significantly, but slowly with only AstraZeneca on the tape Monday morning. Q2 results were mixed, with oncology drug sales light, and company just reaffirmed FY guidance. ADRs for AZN up +1% in the pre-market. Regulatory calendar this week highlighted by back to back FDA Adcoms in Biotech. Briefing materials were published Monday morning for Capricor Therapeutics. Shares of CAPR down (60%) as FDA tone remains negative on efficacy, benefit-risk assessment. Macro S&P futures are up +0.9% on Monday morning. Oil down, yields down, stocks up. Market supported by recent pause in hostilities in the Middle East. Headlines have highlighted some semblance of traction behind Omani-led diplomacy efforts, along with US concerns about the effectiveness of additional bombing around the SoH and dwindling munitions. AI also in the headlines with reports about a NVDA backstop for an OpenAI data center lease supportive of both the compute/capex demand and circularity scrutiny narratives. Also more discussion about corporate push to rein in AI costs, including via increased use of open-source models. Memory another big story amid the 466% surge in China's CXMT following its IPO and the push by AAPL (and pushback by MU) for White House approval to utilize China chips. Weekend headlines also continued to focus on the heightened uncertainty surrounding the Fed into this week's policy decision. Pre-market trading update Trading higher +39.6% FBRX acquired by ARGX for $2.2B in cash +26.1% GOSS microcap biotech; strategic and regulatory updates in PAH +13.4% OMER +7.6% FRNM FDA approves PMA for SimpleScreen CRC +7.0% SRPT appoints new CEO +5.7% LQDA shares were +8% last week +2.5% KURA trial results in ccRCC +2.0% GH read-across from FRNM (low volume) +1.8% OTLK follow-through; upgraded at BTIG +1.1% AZN earnings +0.9% ABT commerical partner with FRNM Trading lower -60.9% CAPR FDA publishes briefing documents ahead of Wed Adcom -6.6% LEGN CEO steps dowped down effective 24-Jul -4.2% CORT downgraded at Wolfe Research Pharma Earnings: AZN reports Q2 core EPS $2.63 vs consensus $2.48 on revenue $15.38B vs consensus $15.39B. Maintains FY26 financial guidance. Conf. call at 6:45ET Quick take: A few analysts point out that while there were no updates on key H2 catalysts (namely AVANZAR and SERENA-4) it was confirmed that there should be no delays there. DNB Carnegie says pipeline momentum in the coming 18 months looks strong, including those two key oncology read-outs - both having a sales potential >$5B. Overall, the Q2 results and guidance reiteration mean limited changes to consensus forecasts at this stage. Regulatory: 4578.JP FDA approved first NDSRI, Otsuka's SIMTRIYO (centanafadine), for the treatment of ADHD in adults and pediatric patients. Otsuka expects SIMTRIYO will be available later this year following scheduling by the U.S. DEA. (SUPN) Biotech M&A: FBRX acquired by ARGX.BB (ARGX) for $77/shr in cash, or total equity value of $2.2B. Conf. call at 8:00ET Regulatory: CAPR FDA publishes briefing materials ahead of Wednesday's Adcom for deramiocel for CM in DMD Reviewers reiterate the negative stance from the prior CRL - the benefit-risk assessment appears unfavorable in the absence of evidence of effectiveness. Panel to vote on the evidence from Study HOPE-3. Corporate: LEGN disclosed that CEO Ying Huang stepped down effective 24-July. Aan Bash named interim CEO and the company has begun a comprehensive search process for a permanent successor. SRPT announced that Michael Severino has been appointed CEO effective 28-Jul. Previous CEO at Tessera Therapeutics, and a former exec at AbbVie. The retirement of Doug Ingram was announced in February 2026. Research: OTLK upgraded to buy from neutral at BTIG (Julian Harrison) notes positive labeling outcome with today's FDA approval of Lytenava, target is $4 or approx. 184% upside. CORT downgraded to underperform from peer perform at Wolfe Research (Kalpit Patel) CMPS initiated equal weight at Wells Fargo Securities (Benjamin Burnett), target is $13 or approx. % upside. DFTX initiated overweight at Wells Fargo Securities (Benjamin Burnett), target is $68 or approx. 58% upside. GHRS initiated overweight at Wells Fargo Securities (Benjamin Burnett), target is $44 or approx. 61% upside. HELP initiated overweight at Wells Fargo Securities (Benjamin Burnett), target is $16 or approx. 110% upside. MDGL initiated overweight at Wells Fargo Securities (Sadia Rahman), target is $685 or approx. 26% upside. PLYX initiated buy at Lucid Capital Markets (Dev Prasad), target is $7 or approx. 241% upside. PMN initiated buy at Chardan Capital (Keay Nakae), target is $20 or approx. 64% upside. RYTM initiated overweight at JPMorgan (Priyanka Grover), target is $145 or approx. 42% upside. SMMT transferred buy at Clear Street, rating and $31 PT unchanged. Analyst is Mara Goldstein. Life Science & MedTech Regulatory: FRNM FDA approved PMA for SimpleScreen CRC. Decision date 24-Jul-2026. Freenome announces it will received $100M milestone payment from Abbott (ABT) under their existing commercial agreement. (GH) Research: COCH initiated buy at Lucid Capital Markets (Alex Nowak), target is $2 or approx. 203% upside. On Deck: Earnings after the close today UHS (call on Tue at 9:00ET) Earnings on Tue 28-Jul: before GSK, IQV, CNC, INCY, ALKS,RGEN after CHE, ACHC Regulatory on Tue 28-Jul: FDA briefing documents ahead of Wed Adcom (REPL) on Wed 29-Jul: FDA Adcom: CTGTAC to review CAPR deramiocel BLA for CM in DMD Conference on Tue 28-Jul: BTIG Biotechnology Conference (Jul 28-29) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4578.JP, ABT, ACHC, ALKS, ARGX.BB, AZN, CAPR, CHE, CMPS, CNC, COCH, CORT, DFTX, FBRX, FRNM, GH, GHRS, GOSS, GSK, HELP, INCY, IQV, KURA, LEGN, LQDA, MDGL, OMER, OTLK, PLYX, PMN, REPL, RGEN, RYTM, SMMT, SRPT, SUPN, UHS...(more)	show story hide story
27-Jul-2026 08:49	AZN.LN Transcript Intelligence: AstraZeneca Q2 Earnings Guidance Guidance Summary (Call Time: 27-Jul-26 06:45 ET): Nearer-term: Total revenue mid-to-high single digits in full-year 2026. Core EPS low double digits in full-year 2026. Core gross margin stable or slightly higher versus 2025 in 2026. R&D expenses upper end of low-20s percentage range of revenue in full-year 2026. Capital expenditure increase around one-third in 2026. Milestone payments ~$2.5B in 2026. Other operating income broadly similar H2 versus H1 in 2026. Core finance costs higher in H2 versus H1 in 2026. AMPLYIFY positioned as significant growth driver through remainder of 2026. Commercial access for Baxfendy in US to broaden over next few quarters ahead of Medicare Part D in 2028. Pre-launch investments for tozorakimab ongoing with launch preparations underway following positive Phase 3 data. Datroway launches in triple-negative breast cancer and additional markets in H2 of 2026. Tagrisso franchise to maintain strong growth through new combinations and lifecycle management in 2026. Multiple key Phase 3 trial readouts scheduled over next 18 months. First subject in for EMBOLD and ELUMINATE Phase 3 programs for elecoglipron; readouts in coming quarters. Phase 3 data for tozorakimab in COPD to be presented at European Respiratory Society Congress in September 2026. Regulatory filings for Ultomiris in IgA nephropathy progressing in US and Japan with decisions expected soon. Filing for efzimfotase alfa in hypophosphatasia covers patients above two years of age; regulatory decisions in near term. Primary aldosteronism trial for Baxfendy accruing rapidly with data expected next year. Longer-term: Revenue ambition $80B in 2030. Peak-year revenue for Datroway over $5B. Peak-year revenue for Etcamah over $5B. Peak-year revenue for Baxfendy over $5B. Peak-year sales for tozorakimab over $5B. Sone-Ve peak-year revenue $3B - $5B globally. First Phase 3 data for oral PCSK9 inhibitor laroprovstat in H1 of 2027. Fixed-dose combination of laroprovstat with rosuvastatin advancing into Phase 3 targeting dyslipidemia. Combination of oral PCSK9 and elecoglipron in development for cardiovascular risk management. Phase 3 data for puxi-sam expected in 2027. Five Phase 3 trials for elecoglipron underway targeting obesity and type 2 diabetes with broad patient populations. ELEVATE outcomes program for elecoglipron to assess value in heart failure and chronic kidney disease. Initiation of Phase 3 monotherapy trial for amylin receptor agonist AZD6234 planned following positive Phase 2 data. Six pivotal data readouts for new molecular entities expected in 2027. Next-generation IO bispecifics have 16 Phase 3 trials across eight tumor types including five in combination with ADCs. Cell therapy and T-cell engager portfolios advancing with multiple Phase 3 trials in hematology and autoimmune diseases. Off-the-shelf and in vivo cell therapy programs progressing supporting long-term growth beyond 2030. Ultomiris and other C5 franchise assets to expand into new indications including rare renal diseases. CAMBRIA-1 trial for camizestrant in adjuvant breast cancer to read out in 2027 targeting intermediate/high-risk patients. Multiple fixed-dose combinations with dapagliflozin in Phase 3 with This summary was created with GenAI, optimized by StreetAccount. See Related StreetAccount comments: 7/27/2026 08:49:11 AM - Transcript Intelligence: AstraZeneca Q2 Earnings Themes 7/27/2026 08:49:10 AM - Transcript Intelligence: AstraZeneca Q2 Earnings Q&A 7/27/2026 02:17:25 AM - StreetAccount Metrics Recap - AstraZeneca Q2 Earnings 7/27/2026 02:07:57 AM - AstraZeneca reports Q2 Core EPS $2.63 vs consensus $2.48 Reference Link: Transcript	show story hide story
27-Jul-2026 08:49	AZN.LN Transcript Intelligence: AstraZeneca Q2 Earnings Themes Themes Summary (Call Time: 27-Jul-26 06:45 ET): Themes: Advance pipeline innovation: Drive growth through late-stage assets, new molecular entities, and transformative technology platforms. Diversify portfolio: Offset loss of exclusivity with strong performance in oncology, rare disease, and respiratory segments. Expand global reach: Leverage broad geographic footprint and emerging market launches to sustain momentum. Invest in manufacturing & R&D: Commit to long-term growth via increased CapEx and robust clinical development programs. Navigate competitive landscape: Defend key franchises through lifecycle management, combinations, and strategic partnerships. Risks: Pace of innovation setbacks: Inherent pipeline risk as not all late-stage programs succeed; competition and regulatory changes add uncertainty. Opportunities: Unlock multi-blockbuster launches: New approvals (e.g., Sone-Ve, Baxfendy) and upcoming readouts offer significant revenue potential globally. Strategic Adjustments: Pursue post-2030 growth platforms: Accelerate investment in ADCs, cell therapies, oral small molecules, and global BD collaborations. This summary was created with GenAI, optimized by StreetAccount. See Related StreetAccount comments: 7/27/2026 08:49:10 AM - Transcript Intelligence: AstraZeneca Q2 Earnings Q&A 7/27/2026 02:17:25 AM - StreetAccount Metrics Recap - AstraZeneca Q2 Earnings 7/27/2026 02:07:57 AM - AstraZeneca reports Q2 Core EPS $2.63 vs consensus $2.48 Reference Link: Transcript	show story hide story
27-Jul-2026 08:49	AZN.LN Transcript Intelligence: AstraZeneca Q2 Earnings Q&A Q&A Summary (Call Time: 27-Jul-26 06:45 ET): Initial data for oral PCSK9 anticipated in H1 2027; competitive positioning hinges on clinical outcomes and broad portfolio synergies. Sone-ve’s blockbuster potential underpinned by strong survival data, global market access plans, and expanded Claudin18.2 patient targeting. Camizestrant’s SERENA-4 trial designed to enrich for endocrine-sensitive patients; tolerability profile remains favorable ahead of H2 readout. Zegfrovy demonstrates high, durable response in exon20-mutant lung cancer; first-line filing based on robust ASCO-presented data. AVANZAR study structured to enable regulatory success via ITT or biomarker-positive groups; TROP2 ADC design supports best-in-class claims. Cliramitug positioned as an add-on depleter therapy with promising cross-indication mechanistic rationale; efzimfotase alfa expected to expand coverage due to superior tolerability and dosing convenience versus Strensiq. Saruparib opportunity in prostate cancer seen as significant ($5B+), leveraging improved design over prior PARP studies for broader efficacy and tolerability benefits. This summary was created with GenAI, optimized by StreetAccount. See Related StreetAccount comments: 7/27/2026 02:17:25 AM - StreetAccount Metrics Recap - AstraZeneca Q2 Earnings 7/27/2026 02:07:57 AM - AstraZeneca reports Q2 Core EPS $2.63 vs consensus $2.48 Reference Link: Transcript	show story hide story
27-Jul-2026 06:09	StreetAccount Macro Headlines: Please see attached for weekend headlines. US-Iran: US and Iran pause strikes as Oman negotiates a SoH transit deal (FT, Bloomberg, CBS, Reuters ) Ambassador Waltz says Trump paused Iran attacks to create room for diplomacy (Washington Post ) Top US military generals raise concerns over escalation, diminishing air defense stockpiles (CNN, Axios) Energy: Bab el-Mandeb ship traffic falls after Houthi attacks, SoH crossings stay low over weekend (Reuters ) Asia-bound Saudi oil supertanker clears Red Sea via the longer Suez route (Bloomberg ) AI: Nvidia reportedly talks to backstop OpenAI with about $250B in financing guarantees for Ohio data-center project (link , Bloomberg ) Nvidia to invest $1B in Naver's AI project to help finance AI data center (link , Reuters ) Nvidia launches Open Secure AI Alliance to safeguard open-source models as US debates potential restrictions (Semafor ) Tech firms rally behind open-weight AI models in fresh push over the weekend (Axios ) AI companies setting records for Washington lobbying spending in bid to influence US policy (FT ) SoftBank adds 21 lenders to expand the syndicate for its $40B bridge loan backing its OpenAI investment (Bloomberg ) Moonshot AI plans to release its Kimi K3 model for public download (Bloomberg ) Chinese state media suggests tiered release system for future AI, restricting access to most powerful features (Bloomberg ) Samsung, SK Hynix and Nvidia join a $700B US-Korea AI push (Nikkei ) Dealmakers turning to creative public and private funding for AI data-center buildouts (The Information ) Corporate: CXMT surges more than 470% in its Shanghai debut, becoming China's top onshore-listed memory chipmaker (Nikkei ) Qualcomm plans double-digit chip price increase from September amid smartphone and memory shortage (Digitimes ) Apple is said to focus on privacy to ease smart glasses concerns (Bloomberg, TechCrunch ) Brown-Forman rebuffs Sazerac's $15B bid, saying it doesn't fit its vision for the company's future (Semafor, link ) United's CEO Kirby explored merging with profitable rival Delta last year, but talks didn't advance (link ) Argenx agrees to buy Forte Biosciences for $2.2B to expand immunology pipeline (Reuters ) AstraZeneca beats Q2 profit expectations and reaffirms 2026 guidance (Reuters) Vodafone raises profit guidance as Q1 service revenue growth beats estimates (FT) Economy: Big US companies resume hiring after pausing for a year, as AI drives renewed staffing needs (link ) US businesses concerned about labor shortages as immigrants lose protected status following SCOTUS ruling (NY Times ) China industrial profits record slowest gain this year with subdued consumer demand weighing (Bloomberg, FT ) German IFO business morale rose more than expected in July, driven by sharply improved expectations (Reuters ) Markets: Uneasy market mood builds as stocks face tests from tech earnings and Fed rate decision this week (link ) Crypto exchanges launch perpetual futures on CXMT to let investors trade Chinese AI stocks despite access controls (FT ) Central banks: BOJ rate-hike bets increase as yen hits multidecade lows (Nikkei ) Economists expect BoE to talk tough but keep rates on hold (FT ) See Related StreetAccount comments: 7/26/2026 12:41:58 PM - StreetAccount Macro Update: Weekend Headlines Related: 000660.KS, 005930.KS, 035420.KS, 688825.CH, 9984.JP, AAPL, AEP, ARGX, AZN.LN, BF.B, DAL, FBRX, GOOG, MSFT, NVDA, QCOM, UAL, VOD.LN, +ANTHROPIC, +MOONSHOT.HK, +OPENAI...(more)	show story hide story
27-Jul-2026 03:08	AZN.LN Quick Take - AstraZeneca Q2 viewed as being broadly in-line; focus remains on key catalysts AVANZAR and SERENA-4 still expected in H226 (12774p +104p) Key metrics (revenues, core operating profit) broadly in-line and Core EPS beat was driven by lower/favourable tax. AstraZeneca reconfirmed Total Revenue and Core EPS guidance for FY 2026 at CER. On track to deliver ambition of $80B in total revenue in 2030 (even despite the CARDIO-TTRansform Wainua P3 failure). A few analysts point out that while there were no updates on key H2 catalysts (namely AVANZAR and SERENA-4) it was confirmed that there should be no delays there. DNB Carnegie says pipeline momentum in the coming 18 months looks strong, including those two key oncology read-outs - both having a sales potential >$5B. Overall, the Q2 results and guidance reiteration mean limited changes to consensus forecasts at this stage. Note that webcast for investors and analysts will take place at 11:45 BST See Related StreetAccount comments: 7/27/2026 2:17:25 AM - StreetAccount Metrics Recap - AstraZeneca Q2 Earnings 7/27/2026 2:07:57 AM - AstraZeneca reports Q2 Core EPS $2.63 vs consensus $2.48	show story hide story
27-Jul-2026 02:49	StreetAccount Summary - European pre-market trading update StreetAccount notes that the pre-market levels mentioned are taken from various market sources Trading Higher +2% to +7% DCC.LN (DCC Energy) -- Boards of Bidco and DCC Energy reach agreement on terms of recommended acquisition by Bidco of entire issued and to be issued share capital of DCC Energy +2% SPM.IM (Saipem) -- awarded two new contracts, one offshore in Ivory Coast and one onshore in Italy, for a total value of ~€800M +2% SGO.FP (Compagnie de Saint-Gobain) -- Saint-Gobain seeking to more than double North American business through capex and acquisitions, despite US housing slump - FT, citing CEO +1.3% SAP.GR (SAP) -- to commence second tranche of share buyback program +0.5% to +1% DKSH.SW (DKSH Holding) -- to acquire the Meliane oral contraceptive brand from Bayer across +0.5% to +1% ANA.SM (Acciona) -- Galp Energia SGPS acquires 361 MW fully operational onshore wind portfolio in Spain from Acciona Energía; transaction reflects enterprise value of €420M +0.5% to +1% AZN.LN (AstraZeneca) -- Q2 earnings notes high-level results from the CLARITY-Gastric01 global Phase III trial showed that Sone-Ve improved survival in gastric cancer Ultomiris fails primary endpoint in adult/adolescent HSCT-TMA trial, but shows promise in paediatric patient +1% EVO.SS (Evolution) -- Candle Lake Limited acquires shares in Evolution; triggers a mandatory offer obligation +0.75% ARGX.BB (argenx) -- to acquire Forte Biosciences for $77/sh in cash +0.5% TFI.FP (TF1) -- Q2 earnings Mixed -1% to +4% GALP.PL (Galp Energia SGPS) -- Q2 earnings -0.7% to +3% VOD.LN (Vodafone Group) -- Q1 earnings -2% to +2% VSVS.LN (Vesuvius) -- H1 Trading Update: trading profit £74M vs year-ago £77.0M; now expects FY trading profit to be slightly ahead of FY25 trading profit Related: ANA.SM, ARGX.BB, AZN.LN, DCC.LN, DKSH.SW, EVO.SS, GALP.PL, SAP.GR, SGO.FP, SPM.IM, TFI.FP, VOD.LN, VSVS.LN...(more)	show story hide story
27-Jul-2026 02:27	European macro headlines: Corporate: AstraZeneca beats Q2 profit expectations and reaffirms 2026 guidance (Reuters) Vodafone service revenue growth beats forecasts; full-year guidance raised (Bloomberg) UniCredit's Orcel sees path to agreement on Commerzbank takeover (Bloomberg) EQT raises offer for Australia's Perpetual to A$2.55B (Reuters) TeamSystem's private equity owners look at stake sale at €8B valuation (FT) Exploration Company in talks to raise $300M, pushing valuation above $2B (Bloomberg) Central Banks: ECB's Lane says September policy decision will be fully data-dependent (Bloomberg) ECB's Zigman says Middle East shock's inflation impact will take months to emerge (Bloomberg) BoE expected to hold rates despite jump in oil prices (FT, Bloomberg) UK lenders accuse BoE of ignoring Wall Street's capital edge (FT) Geopolitics: Trump threatens substantial new tariffs on EU over Google fines (Politico, Reuters) Iran warns Britain would be 'legitimate target' if it backs US in conflict (Reuters) France raises questions over UK participation in EU's €5B tech start-up fund (FT) Markets: Narrow AI rally leaves Stoxx 600 heavily dependent on handful of stocks (Bloomberg) Economy: Eurozone data set to show resilient growth and faster inflation ahead of ECB meeting (Bloomberg) UK: Burnham signals tougher welfare rules to tackle soaring benefits bill (Bloomberg) UK pension giants back £1B Scale-Up Fund for domestic science and tech firms (Bloomberg) Germany: Merz names Steffen Bilger Germany's new transport minister after initial setback (Bloomberg) Italy: Meloni government weighs €14bn energy security and defence spending plan (Bloomberg) For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: AZN.LN, CBK.GR, EQT.SS, UCG.IM, VOD.LN	show story hide story
27-Jul-2026 02:17	AZN.LN StreetAccount Metrics Recap - AstraZeneca Q2 Earnings (12670p) Key operating metrics: Product sales: Oncology Tagrisso $1.94B vs consensus $1.97B, +7.2% y/y Imfinzi $1.85B vs consensus $1.94B, +27.4% y/y Lynparza $829M vs consensus $869M, (1.1%) y/y Calquence $1022M vs consensus $986M, +17.2% y/y Enhertu $888M, +33.3% y/y Zoladex $316M vs consensus $292M, +7.5% y/y CVRM Farxiga $1.80B vs consensus $1.78B, (16.1%) y/y Brilinta $80M vs consensus $92M, (62.8%) y/y Lokelma $221M vs consensus $206M, +26.3% y/y Roxadustat $14M vs consensus $51.0M, (80.8%) y/y Crestor $332M vs consensus $335M, +3.8% y/y Respiratory/Inflammation Symbicort $671M vs consensus $696M, (6.2%) y/y Fasenra $570M vs consensus $554M Breztri $346M vs consensus $334M, (31.1%) y/y Saphnelo $209M vs consensus $207M, +25.1% y/y Tezspire $390M vs consensus $159M, +151.6% y/y Pulmicort $120M vs consensus $100M, +13.2% y/y BioPharma: V&I Beyfortus $79M vs consensus $87M, (37.3%) y/y FluMist $18M vs consensus $9M, +80% y/y Rare Disease Soliris $389M vs consensus $390M, (26.6%) y/y Ultomiris $1314M vs consensus $1334M, +11.6% y/y Strensiq $536M vs consensus $473M, +35.7% y/y Koselugo $177M vs consensus $166M, +29.2% y/y Alliance revenue $874M vs consensus $857M Enhertu $550M vs year-ago $436M Tezspire $218M vs consensus $159M and year-ago $155M Beyfortus $32M vs year-ago $27M See Related StreetAccount comments: 7/27/2026 2:11:51 AM - AstraZeneca notes high-level results from the CLARITY-Gastric01 global Phase III trial showed that Sone-Ve improved survival in gastric cancers 7/27/2026 2:07:57 AM - AstraZeneca reports Q2 Core EPS $2.63 vs consensus $2.48	show story hide story
27-Jul-2026 02:15	AZN.LN AstraZeneca's Ultomiris fails primary endpoint in adult/adolescent HSCT-TMA trial, but shows promise in paediatric patients (12670p) High-level results from the ALXN1210-TMA-313 Phase III clinical trial showed that Ultomiris (ravulizumab) did not achieve statistical significance for the primary endpoint of event-free survival through 26 weeks compared to placebo in adults and adolescents (aged 12 years or older) with thrombotic microangiopathy after haematopoietic stem cell transplant (HSCT-TMA). The primary endpoint was defined as the time from randomisation until TMA-related clinical worsening or death, whichever occurred first. In paediatric patients with HSCT-TMA, the ALXN1210-TMA-314 open-label Phase III trial of Ultomiris demonstrated clinically meaningful overall survival of 87.2% at 26 weeks and 73.4% at 52 weeks, as previously disclosed. Alexion, AstraZeneca Rare Disease is advancing regulatory filings for Ultomiris in paediatric patients with HSCT-TMA, based on these results and data from ALX-TMA-502, an external control study, which further supports clinically meaningful benefit on overall survival.1-3 Ultomiris showed a trend toward treatment benefit in adults and adolescents with HSCT-TMA at 26 weeks compared to placebo. Discussions with health authorities are ongoing regarding the interpretation of these data, including in the context of real-world evidence. Editor's Note: This comment was resent for ticker OMER, which is +15% in US pre-market trading in reaction (Ultomiris pot. competitor to OMER's Yartemlea) (27-Jul-2026, 09:22 ET) Reference Link: Press release Related: OMER	show story hide story
27-Jul-2026 02:11	AZN.LN AstraZeneca notes high-level results from the CLARITY-Gastric01 global Phase III trial showed that Sone-Ve improved survival in gastric cancers (12670p) Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers Results provide opportunity to expand CLDN18.2 positivity to ≥25% expression, representing ~60% of patients in this setting CLARITY-Gastric01 is the first Phase III trial to show overall survival benefit with an anti-CLDN18.2 ADC in this setting First pivotal readout from AstraZeneca's wholly owned ADC portfolio Sone-Ve has received Orphan Drug Designation from the FDA and the European Commission for the treatment of gastric and GEJ cancers. It has also received Breakthrough Designation in China for the 2nd-line treatment of gastric cancer. Reference Link: Press release	show story hide story
27-Jul-2026 02:07	AZN.LN AstraZeneca reports Q2 Core EPS $2.63 vs consensus $2.48 (12670p) Reports Q2: Revenue $15.38B vs consensus $15.39B Core Operating profit $5.16B vs consensus $5.13B Interim dividend increased 3 cents to $1.06 per share (79.5 pence, 10.32 SEK) Management commentary "In H1 we saw strong performance and continued pipeline delivery, including six key positive Phase III programmes and eight first approvals in major markets, including in the US for Baxfendy, our first-in-class medicine for hypertension.While we are disappointed by the CARDIO-TTRansform outcome, we are on track to deliver our $80B Total Revenue ambition, which assumes successes and setbacks. We remain confident in the strength of our pipeline and have more than twenty high-value readouts due over the next 18 months.We continue to invest at pace in our transformative technologies, and in our commercial execution to bring our innovative medicines to patients around the globe and drive growth beyond 2030." FY 2026 Guidance AstraZeneca reconfirms Total Revenue and Core EPS guidance for FY 2026 at CER, based on the average foreign exchange rates through 2025. Total Revenue is expected to increase by a mid-to-high single-digit percentage Core EPS is expected to increase by a low double-digit percentage The Core Tax rate is expected to be between 18-22% If foreign exchange rates for July 2026 to December 2026 were to remain at the average rates seen in June 2026, it is anticipated that Total Revenue in FY 2026 would benefit from a low single-digit percentage positive impact (unchanged) compared to the performance at CER, and Core EPS growth would be broadly similar (unchanged) to the growth at CER. Reference Link: Press release	show story hide story
24-Jul-2026 14:28	StreetAccount Summary: Notable Drug Events expected for the week of 26-Jul Mon 27-Jul Trial results: KURA Ph1 data for darlifarnib + cabozantinib in ccRCC (call 8:00ET) Corporate update: AZN.LN (AZN) earnings call (3:00ET) FDA briefing materials: CAPR CTGTAC to publish materials ahead of the 29-Jul meeting for deramiocel BLA Tue 28-Jul FDA briefing materials: REPL CTGTAC to publish materials ahead of the 30-Jul meeting for vusolimogene oderparepvec BLA Wed 29-Jul Regulatory decisions: NRXP FDA GDUFA for KETAFREE ANDA in suicidal ideation in depression, including bipolar depression Regulatory meeting: CAPR FDA Adcom (CTGTAC) to review deramiocel BLA Thu 30-Jul Regulatory decision: VTRS FDA PDUFA for MR-100A-01 NDA for contraception Regulatory meeting: REPL FDA Adcom (CTGTAC) review vusolimogene oderparepvec BLA Fri 31-Jul Corporate update: ABBV earnings call (9:00ET) also expected July 2026 Trial results: NTHI (Ph2 IDH-mutant glioma), EVMN (Ph 2 AD) Related: ABBV, AZN.LN, CAPR, EVMN, KURA, NRXP, NTHI, REPL, VTRS...(more)	show story hide story
24-Jul-2026 08:44	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings calendar building with strong prints from Edwards Lifesciences and Tenet Healthcare overnight. Shares of EW +7% and THC +16% in the pre-market. HCA reports full Q2 results pre-open; shares are down around (4%) since the preannounce ten days ago. EMA CHMP recommended twelve (12) medicines for approval at the July 2026 meeting ( including one biosimilar and three generics). FDA PCAC continues into Day 2. Yesterday, the panel recommended the first four peptides for inclusion on the compounding list. Three more peptides scheduled for today. Macro S&P futures are up +0.2% on Friday morning. Market trying to bounce on a fairly quiet headline day. Mag 7 outperforming after falling nearly 5% in prior session in what was biggest one-day decline since "Liberation Day". Oil on the defensive despite report that Iran rejected a recent ceasefire proposal from the US, while US conducted a 13th consecutive wave of strikes on Iran on Friday. Oil pullback seems to be helping yields stabilize. Recent bond yield backup and accompanying pickup in Fed tightening expectations has been another overhang on risk sentiment. Not much from the earnings calendar as the focus shifts to next week's peak week that features four of the Mag 7 names. Trump's new tariffs have received a lot of headlines but were widely telegraphed and don't seem to be much of an issue for markets at this point. Pre-market trading update Trading higher +17.1% THC earnings; call at 1130ET +6.8% EW earnings; upgraded at Leerink +6.4% NKTR sympathy to SAN.FP discontinuation +5.9% MNKD FDA approves Furoscix sNDA; private placement $50M; call at 9ET +2.2% NAMS EMA CHMP positive opinion +1.5% HCA earnings; call at 10ET +1.3% STTK initiation +0.9% GEHC preannounce; CFO departure Trading lower -5.2% SMMT earnings; stock sales agreement -1.6% SNY update on amlitelimab program (discontinuation of OX40 for AD) -0.4% LEGN downgraded at UBS EMA CHMP publishes summary of opinions for July 2026 meeting Summary here. EMA recommends twelve (12) new medicines for approval (including one biosimilar and three generics), and extension of therapeutic indication for another eight (8). CHMP issued three (3) negative opinions for MAA. Positive opinions for MAA include: LIB Therapeutics (private) / Everest (1952.HK) Lyrokaul (lerodalcibep) Menarini (private) / NewAmsterdam (NAMS) Evlarco (obicetrapib / ezetimibe) Menarini (private) / NewAmsterdam (NAMS) Ubeslo (obicetrapib) Roche (ROP.SW) Susvimo (rabinizumab) Janssen (JNJ) / Protagonist (PTGX) Icotyde (icotrokinra) Glaxosmithkline (GSK) Lynavoy (linerixibat) Minoryx (private) Nezglyal (leriglitazone) Shionogi (4507.JP) Zokovea (ensitrelvir) Plus one biosimilar and three generics Also gave positive opinion to update the composition of COVID-19 vaccines Bimervax (HIPRA), Comirnaty (PFE / BNTX), Nuvaxovid (NVAX) and Spikevax (MRNA). Extensions of indication were recommended for: Enhertu (4568.JP / AZN), Jivi (BAYN.GR), Piqray (NOVN.SW), Repatha (AMGN), Riltrava Aerosphere (AZN), Rinvoq (ABBV), Trixeo Aerosphere (AZN), and Trodelvy (GILD) Negative opinions for MAA include: Proveca (private) KemSu (sufentanil / ketamine) ZVRA Meplyffa (arimoclomol citrate) CATS Consultants' (private) Qezzaqar (catequentinib) Re-examination of application: OMER Yartemlea (narsoplimab) MAAT.FP Xervyteg (allogeneic faecal microbiota, pooled) Withdrawal of application: Adienne (private) Azacitidine Adienne (azacitidine) SAN.FP / REGN Dupixent (dupilumab) AZN Imfinzi (durvalumab) Pharma Trial results: SAN.FP announced the discontinuation of further development of OX40 mAb amlitelimab in atopic dermatitis (AD). Decides not to submit regulatory applications, citing totality of the efficacy and safety data to date. (APGE, KYMR, NKTR, REGN) Biotech Regulatory: MNKD announced that FDA approved Furoscix ReadyFlow sNDA, an at-home treatment option designed to help adults with heart failure or chronic kidney disease address edema earlier. Company also announced a private placement ($50M) - plans to use to fund the $45M CVR payment triggered by approval. Conf. call at 9:00ET Earnings: SMMT reported Q2 results including cash & equivalents $690.7M at 30-Jun. Expects HARMONi-3 events for final PFS in squamous NSCLC to be reached in H2 of 2026; interim analysis of OS planned. Filed a common stock sales agreement for up to $380M Research: LEGN downgraded to neutral from buy at UBS (Ashwani Verma), citing competition for Carvykti. Target cut to $28 from $49 or approx. 19% upside. (FactSet average PT $54; range $27-86) STTK initiated overweight at JPMorgan (Brian Cheng), target is $10 or approx. 41% upside. (FactSet average PT $16; range $11-18) IPO priced: SCTX Scribe Therapeutics Inc 8.6M share IPO priced at $15/shr, or $129M raise before the shoe. Lead candidate is a CRISPR-based gene editing agent for lowering LDL-C Twentieth healthcare IPO we've tracked in 2026, and the fifteenth biotech IPO. Average YTD return for Biotech IPOs +64%, skewed by MANE. Median YTD return +9%. Scheduled to begin trading on Nasdaq at 10:20ET Life Science & MedTech Earnings: EW reported Q2 EPS $0.78 vs FactSet $0.74 on revenue $1.74B vs FS $1.70B. Raises FY26 sales growth guidance to +10-11% from +9-11%; Reaffirms FY26 EPS guidance Stock upgraded in reaction Corporate / management change / preannounce: GEHC announced that CFO Jay Saccaro will step down for an opportunity outside of the medtech industry. Companny also announces preliminary Q2 revenue $5.30B vs FactSet $5.26B, guides Q2 EPS ahead of prior expectation, and reaffirms FY26 financial guidance. Research: EW upgraded to outperform from market perform at Leerink Partners (Mike Kratky), target increased to $101 from $87 or approx. 20% upside. (FactSet average PT $101; range $85-110) RBC Capital Markets transfers coverage on seventeen stocks in large-cap medical device space. Analyst is Kendall Au. Outperform ratings on 13; sector perform on 4. Services & Hospitals Earnings: HCA reports Q2 adj EBITDA $4.03B, inline with 14-Jul preannouncement. Repeats FY26 financial guidance (lowered on 14-Jul). Conf. call at 10:00ET THC reported Q2 adj EBITDA $1.30B vs FactSet $1.14B on revenue $5.63B vs FS $5.43B. Raises FY26 guidance from top to bottom lines Quick Take: Commentary on the Q2 print is broadly positive, with the beat attributed to improved pricing and strong hospital expense management. EBITDA exceeded expectations even excluding the benefit from the out-of-period prior-year Medicaid DPP, while HIX headwinds came in better than feared following unfavorable peer reports. Guidance commentary is also constructive, with the magnitude of the guidance raise seen as signaling continued underlying momentum. On the call, focus will be on the DPP benefit, utilization trends, payer mix, and the durability of recent expense performance. Conf. call at 11:30ET On Deck: Regulatory (cont.): FDA advisory committee (Day 2 of 2): Compounding Drugs to discuss peptides (Jul 24 8:00-16:15ET) FDA PDUFA today for Otsuka (4578.JP) in ADHD Peek Ahead to next week (Jul 27 - Aug 2) Overview: FDA advisory committee meetings for CAPR and REPL; FDA PDUFA goal dates for MNKD and OTLK. Earnings volume ramps significantly in the third week of the Q2 season, including: AZN, UHS, CNC, GSK, BSX, HUM, BIIB, GEHC, TEVA, ALGN, BMY, CI, REGN, SNY, SYK, MTD, DXCM, ILMN, GH, ABBV, MRNA This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 1952.HK, 4507.JP, 4568.JP, 4578.JP, ABBV, ALGN, AMGN, APGE, AZN, BAYN.GR, BIIB, BMY, BNTX, BSX, CI, CNC, DXCM, EW, GEHC, GH, GILD, GSK, HCA, HUM, ILMN, JNJ, KYMR, LEGN, MAAT.FP, MNKD, MRNA, MTD, NAMS, NKTR, NOVN.SW, NVAX, OMER, OTLK, PFE, PTGX, REGN, ROP.SW, SAN.FP, SCTX, SMMT, SNY, STTK, SYK, TEVA, THC, UHS, ZVRA...(more)	show story hide story
24-Jul-2026 07:55	EMA CHMP publishes summary of opinions for July 2026 meeting Summary here. EMA recommends twelve (12) new medicines for approval (including one biosimilar and three generics), and extension of therapeutic indication for another eight (8). CHMP issued three (3) negative opinions for MAA. Positive opinions for MAA include: LIB Therapeutics (private) / Everest (1952.HK) Lyrokaul (lerodalcibep) Menarini (private) / NewAmsterdam (NAMS) Evlarco (obicetrapib / ezetimibe) Menarini (private) / NewAmsterdam (NAMS) Ubeslo (obicetrapib) Roche (ROP.SW) Susvimo (rabinizumab) Janssen (JNJ) / Protagonist (PTGX) Icotyde (icotrokinra) Glaxosmithkline (GSK) Lynavoy (linerixibat) Minoryx (private) Nezglyal (leriglitazone) Shionogi (4507.JP) Zokovea (ensitrelvir) Plus one biosimilar and three generics Also gave positive opinion to update the composition of COVID-19 vaccines Bimervax (HIPRA), Comirnaty (PFE / BNTX), Nuvaxovid (NVAX) and Spikevax (MRNA). Extensions of indication were recommended for: Enhertu (4568.JP / AZN), Jivi (BAYN.GR), Piqray (NOVN.SW), Repatha (AMGN), Riltrava Aerosphere (AZN), Rinvoq (ABBV), Trixeo Aerosphere (AZN), and Trodelvy (GILD) Negative opinions for MAA include: Proveca (private) KemSu (sufentanil / ketamine) ZVRA Meplyffa (arimoclomol citrate) CATS Consultants' (private) Qezzaqar (catequentinib) Re-examination of application: OMER Yartemlea (narsoplimab) MAAT.FP Xervyteg (allogeneic faecal microbiota, pooled) Withdrawal of application: Adienne (private) Azacitidine Adienne (azacitidine) SAN.FP / REGN Dupixent (dupilumab) AZN Imfinzi (durvalumab) For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: 1952.HK, 4507.JP, 4568.JP, ABBV, AMGN, AZN, BAYN.GR, BNTX, GILD, GSK, JNJ, MAAT.FP, MRNA, NAMS, NOVN.SW, NVAX, OMER, PFE, PTGX, REGN, ROP.SW, SAN.FP, ZVRA...(more)	show story hide story
24-Jul-2026 06:31	AZN.LN EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Trixeo Aerosphere (12624p -64p) The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Trixeo Aerosphere . The marketing authorisation holder for this medicinal product is AstraZeneca AB. The CHMP adopted a new strength of the pressurised inhalation suspension (5 micrograms of formoterol fumarate dihydrate, glycopyrronium bromide 18 micrograms, equivalent to 14.4 micrograms of glycopyrronium, and budesonide 160 micrograms) associated with a new indication as follows: Trixeo Aerosphere is indicated as a maintenance treatment of asthma in patients 12 years of age and older who are not adequately controlled by a combination of a medium dose inhaled corticosteroid and a long-acting beta2-agonist. Reference Link	show story hide story
24-Jul-2026 06:27	AZN.LN EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for Riltrava Aerosphere (12610p -78p) The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for AstraZeneca AB's Riltrava Aerosphere CHMP adopted a new strength of the pressurised inhalation suspension (5 micrograms of formoterol fumarate dihydrate, glycopyrronium bromide 18 micrograms, equivalent to 14.4 micrograms of glycopyrronium, and budesonide 160 micrograms) associated with a new indication The full indications for Riltrava Aerosphere will be as follows: Riltrava Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long‑acting beta2‑agonist or combination of a long-acting beta2‑agonist and a long‑acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1). Riltrava Aerosphere is indicated as a maintenance treatment of asthma in patients 12 years of age and older who are not adequately controlled by a combination of a medium dose inhaled corticosteroid and a long-acting beta2-agonist. New text in bold Reference Link	show story hide story
24-Jul-2026 06:22	4568.JP EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for Enhertu (¥2799.5) The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Daiichi Sankyo Europe GmbH's Enhertu The CHMP adopted a new indication as follows: HER2-positive breast cancer Enhertu in combination with pertuzumab is indicated for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer (for biomarker-based patient selection, see section 4.2). The full indications for Enhertu will be as follows: Breast cancer HER2-positive breast cancer Enhertu in combination with pertuzumab is indicated for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer (for biomarker-based patient selection, see section 4.2). Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. HER2-low and HER2-ultralow breast cancer Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment (see sections 4.2 and 5.1). HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4.2). Non-small cell lung cancer (NSCLC) Enhertu as monotherapy is indicated for the treatment of adult patients with advanced NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. Gastric cancer Enhertu as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Other unresectable or metastatic solid tumours Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumours who have received prior treatment and who have no satisfactory treatment options (see sections 4.4 and 5.1; for biomarker-based patient selection, see section 4.2). New text in bold Related: AZN.LN Reference Link	show story hide story
24-Jul-2026 05:45	AZN.LN StreetAccount Consensus Metrics Preview - AstraZeneca Q2 Earnings (12654p -34p) Scheduled to report Q2 earnings on 27-Jul at 07:00 UKT, with a call to follow at 11:45 UKT Provided by the Company: Total Revenues $15.39B Product Sales $15.37B Core Operating Profit $5.13B Core EPS $2.48 Product sales: Oncology Tagrisso $1.97B Imfinzi $1.94B Lynparza $869M Calquence $986M Enhertu $338M Zoladex $292M CVRM Farxiga $1.78B Brilinta $92M Lokelma $206M Roxadustat $51M Crestor $335M Toprol-XL $150M Respiratory/Inflammation Symbicort $696M Fasenra $554M Breztri $334M Saphnelo $207M Tezspire $159M Pulmicort $100M BioPharma: V&I Beyfortus $87M Synagis $41M FluMist $9M Rare Disease Soliris $390M Ultomiris $1.33B Strensiq $473M Koselugo $166M Alliance revenue $857M Enhertu $338M Tezspire $159M Price history for Q2 (Since 28-Apr close): AZN-GB (9.1%) STOXX Europe 600 +5.9% Last four quarter % moves: (1%), +2%, +3%, +3% Revenue has beaten consensus 15 of the past 20 quarters EPS has beaten consensus 17 of the past 20 quarters, 1 in-line	show story hide story
23-Jul-2026 02:05	AZN.LN AstraZeneca announces Etcamah in combination with CDK4/6 inhibitor approved in EU for 1st-line advanced ER-positive breast cancer (12702p) AstraZeneca's Etcamah (camizestrant ) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) has been approved in the European Union for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer upon detection of ESR1 mutation and without disease progression during 1st-line endocrine therapy in combination with a CDK4/6 inhibitor. The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use and was based on the positive results from the pivotal SERENA-6 Phase III trial published in The New England Journal of Medicine. In a planned interim analysis, the Etcamah combination reduced the risk of disease progression or death by 56% versus standard-of-care treatment with an aromatase inhibitor (AI) (anastrozole or letrozole) in combination with a CDK4/6 inhibitor (based on a hazard ratio [HR] of 0.44; 95% confidence interval [CI]:0.31-0.60; p<0.00001; median progression-free survival (PFS) 16.0 versus 9.2 months). Data for the key secondary endpoints of time to second disease progression (PFS2) and overall survival (OS) were immature at the time of the interim analysis of the SERENA-6 trial, however, a subsequent pre-planned analysis demonstrated a statistically significant and clinically meaningful PFS2 benefit of 25.7 months versus 19.1 months in favour of the Etcamah combination (HR: 0.63; 95% CI: 0.46-0.86; p=0.00373) and OS continued to mature in favour of the Etcamah combination (HR: 0.87; 95% CI: 0.57-1.30). The trial will continue to assess OS as a key secondary endpoint. Reference Link: Press release See Related StreetAccount comments: 5/22/2026 8:02:28 AM - EU's CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for AstraZeneca's Etcamah	show story hide story
22-Jul-2026 07:08	RPRX Royalty Pharma acquires royalty interest in AstraZeneca's (AZN.LN) cliramitug for up to $425M from Neurimmune ($58.42) RPRX announced that it has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug (AZD0171 ) for up to $425M, including $125M upfront. Cliramitug is a Phase 3 first-in-class TTR-fibril-depleting antibody designed to remove amyloid deposits in patients with TTR amyloidosis with cardiomyopathy (ATTR-CM), a progressive, degenerative and fatal disease caused by misfolded proteins that accumulate in the heart. Currently approved therapies for ATTR-CM slow disease progression by preventing ATTR accumulation but do not target amyloid already accumulated in the heart. Cliramitug is currently in the Phase 3 DepleTTR-CM trial with results expected in 2028. AstraZeneca provided a peak sales target of between $3B and $5B for cliramitug at its May 2024 Investor Day. Transaction terms Under the terms of the agreement, Royalty Pharma will provide Neurimmune up to $425M, including $125M upfront, in exchange for a 3% to 4% royalty on worldwide net sales of cliramitug. In Q1 of 2027, Royalty Pharma will provide another $125M in cash to Neurimmune, with the remaining $175M payable based on the achievement of certain clinical and regulatory milestones. Reference Link: Press release Related: 4592.JP, AZN.LN, 0H2PMP-E	show story hide story
22-Jul-2026 06:06	European pharma faces US trade pressure amid sector underperformance: EU Healthcare sector remains structural laggard versus broader Stoxx 600, based on FD data, and even more recent tactical outperformance faded. EU pharmaceutical companies in particular confronting intensifying US trade pressure. US President Trump yesterday said generic drug manufacturers must move production to US or face 100% import duty from Aug 2028 (Bloomberg, CNBC, Handelsblatt). Recent research commissioned by Northern Ireland estimates US tariffs could reduce region's pharmaceutical exports to US by 18%, contributing to 15% decline in overall Northern Irish goods exports to the US (BBC). At the same time, Trump administration has launched Section 301 investigation into Germany following healthcare reforms aimed at reducing spending on innovative medicines (Handelsblatt). Washington views Europe's lower drug prices as contributing to higher costs in the US. President Trump already imposed 100% tariffs on certain imported drugs from companies unwilling to lower US prices or expand domestic manufacturing (Reuters). Other EU nations in talks to avoid similar probe (Politico). With Europe's share of global pharmaceutical R&D spending having declined sharply, companies face growing incentives to either raise European prices or accelerate investment in US manufacturing to mitigate tariff risks. For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: AZN.LN, MRK.GR, NOVN.SW, SDZ.SW	show story hide story
21-Jul-2026 19:08	President Trump states tariff on generic drugs will stay at 0% for 2 years then rise to 100% - Truth Social From Donald J. Trump @realDonaldTrump on truth social: Effective August 1st, 2026, all Generic Drugs being brought into the United States will continue to have a TARIFF of ZERO PERCENT for a two year period of time, after which the TARIFF will be raised to 100% for a one year period of time, and 200% thereafter. This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them. The objective of this Policy is to protect the people of the United States. The Policy on Patented, Branded, or Innovative Drugs, which has been so successful, will remain as is. Pharmaceutical Facilities are being built, at a level never seen before, all over the United States of America. Thank you for your attention to this matter! President DONALD J. TRUMP See Related StreetAccount comments: 9/25/2025 8:15:14 PM - Trump says pharmaceutical products imported into US will be hit with 100% tariff starting 1-Oct - Truth Social post 4/8/2025 10:02:33 PM - Follow-up: US President Donald Trump says the US will unveil "major" tariff on imports of pharmaceutical goods - NBC News Related: 000100.KS, 068270.KS, 1099.HK, 1177.HK, 196170.KS, 2269.HK, 3692.HK, 4151.JP, 4502.JP, 4503.JP, 4506.JP, 4507.JP, 4519.JP, 4523.JP, 4528.JP, 4568.JP, 4578.JP, 500257.IN, 500420.IN, 500488.IN, 524715.IN, 524804.IN, 532321.IN, 539523.IN, 543904.IN, 600276.CH, 603259.CH, 9926.HK, ABBV, ALNY, AMGN, ARGX, ASND, AZN.LN, BAYN.GR, BBIO, BIIB, BMRN, BMY, BNTX, CORT, CSL.AU, EXEL, GALD.SW, GILD, GMAB, GRFS, GSK.LN, HALO, HIK.LN, INCY, INSM, IPN.FP, JAZZ, JNJ, LEGN, LLY, LONN.SW, MDGL, MRK, MRK.GR, MRNA, NBIX, NOVN.SW, NOVO.B.DC, ORNBV.FH, PFE, RDY, REC.IM, REGN, ROIV, RPRX, RVMD, SAN.FP, SDZ.SW, SMMT, SOBI.SS, TECH, TEVA, TGTX, UCB.BB, UTHR, VRTX, VTRS, ZTS...(more) Reference Link: truth social	show story hide story
20-Jul-2026 08:08	^EUPMREADS StreetAccount European Reads Markets: An odyssey through Metlen's interconnected solar empire (AV) Company mentioned: MTLN.LN AstraZeneca highlights rare diseases in $80bn revenue push (FT) Company mentioned: AZN.LN How Ferrari lost its sex appeal. Sports cars have been enshittified (UnHerd) Company mentioned: RACE China's mysterious new billionaires are conquering the world (Economist) Coffee drinkers turning to whole beans as prices soar, says Lavazza (FT) News/Politics: Closing Europe's dangerous missile gap (Economist) Putin Likes His Worst Option in Ukraine (Project Syndicate) Argentina and Spain serve up worst World Cup final contender but justice prevails for La Roja (F365) Culture, Entertainment, Misc: Why Am I Left-Handed? (Quanta) Ozempic culture: The obsession with beauty and youth shapes film, TV and books (El Pais) How to sell a kettle. Brand positioning reaches boiling point (Economist) China Is Building A System To Track Asteroids That Could Potentially Smash Into Earth (ZH) While Vienna's coffeehouses bred modernism, in Belgrade's kafanas grew conspiracy and rage (Aeon) Related: AZN.LN, MTLN.LN, RACE	show story hide story
20-Jul-2026 06:11	StreetAccount Macro Headlines: Please see attached for weekend headlines. US-Iran: US completes ninth night of strikes on Iran as casualties rise, escalating wider war fears (Axios, Bloomberg , Washington Post) Iran says two tankers in Strait of Hormuz exploded and were immobilized as US launched fresh strikes (Reuters, CNN ) Peace talks could continue as Rubio cites Iran's desire to negotiate, while Iran says mediators' proposals received (NY Times) Energy: Hormuz traffic near standstill Monday as Iran targeted vessels over weekend, with ships turning off transponders (Bloomberg ) US gasoline prices top $4 Monday as renewed US-Iran hostilities disrupt Hormuz energy flows (Reuters, NBC ) Markets: Everyday investors moving on from Mag 7s in favor of AI build-out beneficiaries for growth (link, Bloomberg ) Citi says Mag 7 "no longer relevant," recommending a broader AI "growth cluster" strategy (Bloomberg ) AI-driven memory spending raises fears of another boom-bust glut in cyclical memory chips (FT ) Alphabet and SpaceX drive record US equity sales, with more coming and an Anthropic IPO likely by September (The Information ) South Korean retail investors face steep losses after leveraged AI bets reverse (CNBC, Reuters ) Beijing deploys state-backed "national team" funds buying up to CNY60B to steady markets (FT , SCMP ) Speculated mega pension fund JGB buying swings yields and yen, prompting fears of market distortion (Nikkei ) Corporate: TSMC CFO says Arizona capacity will accelerate on a multi-year demand trend; won't rule out issuing bonds (CNBC, Reuters) SpaceX's Musk calls reports of a ~$52B Foxconn server order "fake news" (Digitimes , Economic Daily) SpaceX targets 23-Jul for its next Starship launch after 16-Jul last-second abort (Reuters) Tesla ramps up production at its German Gruenheide plant, expecting higher demand and capacity use in 2026 (Bloomberg ) Prologis says Segro rejected its sweetened third bid worth £18.2B, a 33.8% premium (FT ) AstraZeneca targets rare diseases to drive an $80B revenue push, saying the area is largely untapped (FT ) American Airlines CEO targets closing a $3B+ profit gap via reliability, premium cabins and planned wide-body orders (CNBC ) Lockheed Martin plans a cheaper Patriot missile design to rapidly replenish low stockpiles (FT ) Boeing boosts PAC-3 seeker production 30% last year and plans a similar increase to replenish US stocks (Bloomberg ) Boeing expects to fund a 737 Max successor program by decade-end, warns on demand constraints (FT ) FDA says a cyclospora-positive Taylor Farms lettuce sample was a false positive (CBS ) Truelink is nearing a near-$1B deal to buy coffee syrup maker Lyons Magnus (link ) Samsung Biologics to buy PolyPeptide in $1.8B deal (Reuters, FT ) AI: Moonshot AI temporarily pauses new sign-ups (Reuters) Moonshot AI's Kimi K3's efficiency may demand more high-bandwidth memory than compute (Bloomberg ) Alibaba shares rally in Asia Monday after previewing Qwen3.8 Max, a 2.4T-parameter heavyweight model (Bloomberg, link ) Morgan Stanley cashes in on the AI boom, leading debt deals financing data-center buildouts (FT ) Trump administration officials criticize OpenAI's Dean Ball on regulation, casting doubt on ties (Axios ) Koch-owned Molex agreed to a $6.29B data-center cable deal with Prysmian, doubling US fiber capacity (link ) CXMT's $8.6B IPO was over 500x oversubscribed, but demand cools amid global chip-stock selloff (Reuters ) See Related StreetAccount comments: 7/19/2026 12:13:48 PM - StreetAccount Macro Update: Weekend Headlines Related: 207940.KS, 2317.TT, 2330.TT, AAL, AZN.LN, BA, BABA, GOOGL, LMT, MS, NVDA, PLD, PPGN.SW, PRY.IM, SGRO.LN, SPCX, TSLA, TSM, YUM, +ANTHROPIC, +MOONSHOT.HK, +OPENAI...(more)	show story hide story
19-Jul-2026 18:47	1167.HK Jacobio Pharmaceuticals Group doses first patient for Phase Ib/III trial of JAB-23E73 with nab-paclitaxel and gemcitabine for KRAS-mutant pancreatic cancer (HK$4.65) JAB-23E73 is an orally available pan-KRAS inhibitor independently developed by the company. See Related StreetAccount comments: 12/21/2025 7:32:37 AM - Jacobio Pharmaceuticals Group, AstraZeneca enter license and collaboration agreement for Pan-KRAS inhibitor JAB23E73. Related: AZN.LN Attached Files PDF Document: Press release	show story hide story
17-Jul-2026 14:19	ABVX Abivax re-engages Centerview to hold discussions with large-cap pharma companies -- La Lettre ($135.77 -$2.00) Article notes ABVX had suspended discussions with pharma companies such as AstraZeneca (AZN.LN) and Eli Lilly (LLY) late last month, in order to complete its fundraising, and note that there is no urgency or pressure regarding a potential acquisition based on its new financial resources. See Related StreetAccount comments: 7/1/2026 8:42:48 AM - Follow-up: Abivax places 6.4M ADSs at $125.00/each to raise $800M from previously announced $600M 6/30/2026 5:06:34 PM - Abivax announces launch of public offering of ~$600M ADSs Related: AZN.LN, LLY, 06K51G-E Reference Link	show story hide story
14-Jul-2026 17:38	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mostly lower on Tuesday. Decliners beat advancers by 3:1 on the XLV, although breadth narrowed as LST stocks bid higher. Healthcare (1.91%) vs S&P 500 +0.38%. Most major health groups ended lower for the session, led by Services following today's profit warning by HCA (7.0%) and Q2 commentary on lower surgery volumes, and a payer mix shift observed - primarily patients who lost insurance coverage on the Exchanges. Negative read-across to MedTech, where Device stocks fell low to mid-single digits. ISRG (6.8%) to fresh lows, SYK (6.2%), GEHC (5.6%) were notable decliners. HSIC +1.3% and BIIB (8.2%) bracketed the XLV movers. Payers were early beneficiaries of the HCA update, but gains moderated as investors wait for MCO bellwethers to report this week. LST stocks caught a bid in afternoon trading. Alzheimer's data underpinned the XBI +0.07%, lone advancer in Heatlhcare. Biogen lower on detailed Tau data presentation at AAIC; recall topline results were announced in May. Inverse dose response raising new questions about the program. Preannouncements on the tape, including today's reset by HCA Healthcare - the hospital calling out payer mix and specifically a rise in the uninsured. Another preannouncement, a material profit warning from Evotec. Company points primarily to timing, only small sliver operational underperformance. Q2 earnings season officially begins tomorrow with ELV and JNJ, followed by UNH and ABT the next day. Macro Busy day with a lot of moving pieces. Rate rally on cooler June CPI a positive for risk sentiment, offering some pushback for recent hawkish lean in Fed narrative. Momentum bounce another tailwind following latest unwind pressure that continued to be largely chalked up to technical dynamics. Bank reporters mixed as widespread beats also up against elevated expectations and some company-specific pockets of scrutiny. Scattered pressure on software following negative preannouncement from IBM that highlighted AI-driven capex shift to hardware. HCA the other big disappointment following its negative preannouncement, weighing heavily on healthcare sector. Oil off earlier highs amid still-unsettled US-Iran situation (Trump backing off 20% toll proposal for call for trade/investment deals). Also thoughts spillover will be fairly contained by the escalate to de-escalate narrative. Notable Gainers +201.8% NXTC (NextCure): microcap biotech; reverse merger with Avere Therapeutics +14.1% ATAI (AtaiBeckley): follow-through, shares +10% WTD +10.7% DMRA (Damora Therapeutics): best performer on XBI +9.6% TXG (10X Genomics): follow-through, shares +181% YTD; 52-week high +8.9% ERAS (Erasca): secondary offering, priced; clinical update; second-best on XBI +8.5% SGMT (Sagimet Biosciences): on below average volume; shares +5% WTD +7.0% CELC (Celcuity): FDA approves Revtorpyk (gedatolisib) ahead of Friday's PDUFA +5.6% SYRE (Spyre Therapeutics): on 2X average volume; shares +2% WTD +1.3% HSIC (Henry Schein): best performer on XLV; on average volume +1.2% MTD (Mettler-Toledo International): LST relative performers +1.1% TMO (Thermo Fisher Scientific): LST relative performers +0.9% A (Agilent Technologies): LST relative performers +0.8% WAT (Waters): LST relative performers +0.6% CNC (Centene): payers read-across from HCA; 52-week high +0.4% ELV (Elevance Health): payers read-across from HCA; 52-week high +0.3% CVS (CVS Health): PBM Caremark reaches settlement with FTC; 52-week high Notable Decliners -14.5% DNLI (Denali Therapeutics): sympathy to BIIB; worst performer on XBI -13.7% QTTB (Q32 Bio): follow-through, secondary offering -11.9% EVO (Evotec): preannounced H1 revenue and cut FY guidance -10.5% ANAB (AnaptysBio): follow-through, shares were +5% yesterday -9.0% PRCT (PROCEPT BioRobotics): robotics weak in sympathy to HCA -8.3% CYH (Community Health Systems): providers in sympathy to HCA -8.2% BIIB (Biogen): worst performer on XLV; presented detailed Tau data at AAIC -7.9% ATEC (Alphatec Holdings): medical devices weak in sympathy to HCA -6.9% HCA (HCA Healthcare): preannounced Q2 results and revised FY guidance -6.8% ISRG (Intuitive Surgical): robotics weak in sympathy to HCA; 52-week low -6.6% KRYS (Krystal Biotech): on above average volume -6.1% SYK (Stryker): medical devices weak in sympathy to HCA -5.7% MBX (MBX Biosciences, Inc.): CEO transition -5.7% THC (Tenet Healthcare): providers in sympathy to HCA -5.6% UHS (Universal Health Services): providers in sympathy to HCA -5.6% GEHC (GE HealthCare Technologies): MedTech read-across from HCA -5.4% SGRY (Surgery Partners): providers in sympathy to HCA -5.1% MDT (Medtronic): medical devices weak on read-across from HCA -4.9% GMED (Globus Medical): medical devices weak on read-across from HCA -4.7% PHG (Koninklijke Philips): sympathy to HCA; sympathy to Apnimed -4.0% SNN (Smith & Nephew): medical devices weak on read-across from HCA -3.4% BAX (Baxter International): read-across from HCA -3.2% ZBH (Zimmer Biomet Holdings): medical devices weak on read-across from HCA -3.2% IONS (Ionis Pharmaceuticals): sympathy to partner BIIB -2.7% ARDT (Ardent Health): providers in sympathy to HCA Hospitals trading lower after following HCA update on uninsured volume Pre-market trading update: HCA (9.2%), ARDT (8.5%), CYH (5.2%), UHS (5.1%), THC (4.6%) HCA announced preliminary financial and operating results for Q2, ahead of FactSet consensus from the top to bottom lines. Focus however is on management's commentary, specifically on the disclosure of a payer mix shift observed - primarily patients who lost insurance coverage on the Exchanges. The company also described some positive factors, and revised FY26 financial guidance downward from top to bottom. Company will report on 24-Jul and hold earnings call that morning. MedTech weak on HCA profit warning, surgery volumes, uninsured trends Sector flash: XLV down (1.56%) vs S&P 500 +0.36% on Tuesday morning. Moderate advancers only on the XLV, mostly Payers (eg. HUM +1.0%), after today's HCA profit warning and Q2 commentary on lower surgery volumes, primarily driven by Exchange headwinds. Beyond the direct read-across for Hospitals, many large-cap medical device makers trading lower by mid-single-digits in reaction. SYK (5.5%), ZBH (4.4%), MDT (4.2%), ISRG (3.8%), BSX (3.3%) Sleep Apnea stocks trade with medical devices and with novel drug treatment filed by FDA +APMD, IPO pending biotech, announced that FDA has accepted its NDA for AD109, a treatment for adults with obstructive sleep apnea. PDUFA goal date is 28-Feb-2027. (INSP, PHG, RMD) AstraZeneca gains global rights to EGFR inhibitor approved in lung cancer AZN in-licensed global rights to FDA-approved lung cancer drug Zegfrovy (sunvozertib) from Dizal (688192.CH), paying up to $1.5B. Terms include an upfront payment of $600M, and milestones of up to $900M. Notable research in Healthcare today Biotech: ZEAL.DC downgraded to hold from buy at Jefferies (Benjamin Jackson), target cut to DKK320 from DKK505, or approx. 14% upside. (FactSet average PT DKK402; range DKK300-540) ARWR initiated buy at Stifel (James Condulis), target is $98 or approx. 32% upside. (FactSet average PT $91; range $46-110) MedTech: QGEN downgraded to hold from buy at Berenberg (Harry Gillis), target cut o $45.50 from $59 or approx. 10% upside. (FactSet average PT $43; range $36-49) BEAT initiated buy at Maxim Group (Anthony Vendetti), target is $2 or approx. 245% upside. Post-close news Regulatory: CMS proposes Physician Fee Schedule for CY2027 Press Release; Fact Sheet; Proposed Rule (1592pp) Corporate: CELC issues press release on FDA approval of Revtorpyk (gedatolisib) (PFE) in mBC. StreetAccount reported the approval earlier from the FDA. Commercial launch in late Q3 2026. Label Conference call at 17:30ET Shares trading (6.0%) in the after-hours On Deck: Conference (cont.): AAIC 2026 meeting (Jul 12-15) Earnings tomorrow before the open: JNJ (call at 8:30ET), ELV (call at 8:30ET) Earnings on Thu 16-Jul morning: UNH (call at 8:00ET), ABT (call at 9:00ET) Regulatory on Wed 15-Jul: Senate HELP Committee hearing (10:00ET) "Nominations of Sean Kaufman to be Assistant Secretary for Preparedness and Response for the Department of Health and Human Services and Erica Schwartz to be Director of the Centers for Disease Control and Prevention" This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 688192.CH, A, ABT, ANAB, ARDT, ARWR, ATAI, ATEC, AZN, BAX, BEAT, BIIB, BSX, CELC, CNC, CVS, CYH, DMRA, DNLI, ELV, ERAS, EVO, GEHC, GMED, HCA, HSIC, HUM, INSP, IONS, ISRG, JNJ, KRYS, MBX, MDT, MTD, NXTC, PFE, PHG, PRCT, QGEN, QTTB, RMD, SGMT, SGRY, SNN, SYK, SYRE, THC, TMO, TXG, UHS, UNH, WAT, ZBH, ZEAL.DC...(more)	show story hide story
14-Jul-2026 06:21	StreetAccount Macro Headlines: US-Iran: US launched a third straight night of strikes on Iran after Trump announced a multiday attack wave (link , Bloomberg , NY Times) Iran says ballistic missiles hit US base in Jordan (Reuters ); UAE says Iranian missiles struck oil tankers in SoH (Reuters, Bloomberg) Trump open to hitting Iran's Pickaxe Mountain, the fortified nuclear site yet to be targeted during conflict (Reuters) Iran-backed Houthis hit Saudi Arabia with ballistic missiles and drones, risking wider Tehran-Washington conflict (Bloomberg , Axios ) Energy: Trump reinstates Hormuz naval blockade with plans to charge 20% fee, notifies Congress of war resumption (Bloomberg, Axios, Reuters) Sanctioned Iranian oil supertankers successfully transited Strait of Hormuz before Trump announced reinstatement of blockade (Bloomberg) Trump's Hormuz toll threat spur Gulf moves to bypass chokepoint via new routes and UAE ports (CNBC ) Analysts warn Trump's proposed Hormuz toll fee would add ~$16 per barrel to crude shipped the strait (CNBC ) Outlook for oil prices hinges on China's decision on when to meaningfully resume crude purchases (NY Times) Asian refiners turn to buying more US crude as US-Iran hostilities worsen and Hormuz traffic stalls (Bloomberg ) Markets: Russell 2000 tracking for biggest annual gain since 2003 as investors look for AI opportunities beyond big tech (FT) BofA FMS warns overly bullish global stock positioning, suggests reducing exposure (Bloomberg , Reuters ) SK Hynix rebounds more than 3% in Seoul after early losses, highlighting AI-driven stock volatility (Bloomberg ) Rout in leveraged single stock ETFs magnifying pain for South Korea's retail investors (Bloomberg) Japan FinMin Katayama floats bond inclusion in tax-free investment program, revision of GPIF portfolio (Bloomberg, Reuters) Corporate: TSMC expected to report 59% y/y in Q2 net profit after strong chip demand drove better-than-forecast 36% rise in revenue (Reuters) AI-driven memory price spikes raise consumer electronics costs, causing record shipment declines (Nikkei ) Counterpoint data shows smartphone shipments hit a 13-year Q2 low as memory chip costs push prices up, hurt demand (Reuters) Apple and Huawei avoided China's Q2 smartphone decline as IDC reported falling overall shipments (Reuters) Samsung denies report it is exploring potential US ADR offering (Reuters , Bloomberg ) Google backs a major US solar project, signaling ongoing renewable demand despite Trump's tax-credit rollbacks (FT ) Retailers redesigning packaging and cutting marketing to defend the $9.99 price threshold (link ) Authorities are investigating Taco Bell and lettuce in a multistate cyclosporiasis outbreak affecting 80+ people (Washington Post ) BP said it expects lower Q2 upstream output from Middle East conflict, but highlights improved oil trading (Reuters ) AstraZeneca signs an exclusive license for lung cancer drug Zegfrovy, deal worth up to $1.5B (link ) Saudi's Riyadh Air plans more Airbus and Boeing aircraft deals after finally starting operations (Bloomberg) Taiwan's UMC mass-produces silicon photonics wafers in Singapore, targeting AI-driven optical interconnect demand (CNBC ) AI: Nvidia more than halves number of Asian ‌customers authorized to buy AI chips, part of efforts to curb Chinese access (FT) Google pushes TPU adoption by courting "neocloud" providers to challenge Nvidia's AI infrastructure dominance (Digitimes ) Tech executives fear the Trump administration's AI scrutiny could extend to demands for private AI ownership stakes (NY Times ) US data-center developers plan to sell majority equity stakes as AI infrastructure demand accelerates (link ) New York first state to impose one-year moratorium on large new data-center construction (Washington Post ) Samsung Foundry has secured Anthropic as a customer to manufacture its custom AI chips (X , Newsworks Korea ) Google Deepmind's Hassabis urges the US to create an AI watchdog that can screen top models and coordinate slowdowns (Axios ) Central banks: Strategists believe Fed Chair Warsh and his taskforce will struggle to shrink balance sheet without upsetting funding markets (Bloomberg) Fed to buy $10B of Treasury bills this period, unchanged vs previous two periods as policymakers look at strengthening reserves (Bloomberg) Japan will add a footnote to its economic blueprint to protect BOJ independence in monetary policy (Reuters ) China's central bank increases longer-term liquidity via reverse repos to support tax payments and debt demand (Bloomberg ) RBNZ Chief Economist Conway said central bank will respond if Middle East inflation pressures prove persistent (Bloomberg) BOK expected to increase interest rates on Thursday with inflation at 2.5-year high (Reuters) Economy: June US consumer inflation likely rose slowly as gasoline prices fell, but unlikely to offer comfort to households (Reuters ) Without AI, US workers' productivity keeps rising due to tight labor markets, digitization, and remote work (NY Times ) China export growth accelerates in June, maintaining strong pace underpinned by AI infrastructure demand (SCMP , Nikkei ) China Q2 GDP growth forecast to have slowed amid weakness in consumer spending, investment (Bloomberg) South Korean government upgrades 2026 economic growth forecast, underpinned by AI semiconductor boom (Reuters) UK retail spending in June boosted by heatwave and World Cup, but high rates and energy bills keep recovery fragile (Bloomberg) Australian business and consumer confidence lifts as fuel prices eased (Bloomberg) Washington: Business groups oppose defense-bill provision requiring Pentagon approval for contractors' buybacks and dividends (CNBC ) Private credit: Higher-for-longer rates from Middle East-driven inflation are straining private credit, exposing weak borrowers (CNBC ) Related: 000660.KS, 005930.KS, 2330.TT, AAPL, AIR.FP, AMZN, AZN.LN, BA, BP.LN, GOOGL, META, MSFT, NVDA, PSKY, TGT, WBD, WMT, YUM, +ANTHROPIC, +HUAWEI...(more)	show story hide story
14-Jul-2026 02:02	AZN.LN AstraZeneca enters into exclusive license agreement with Dizal Pharmaceutical Co Ltd for Zegfrovy (sunvozertinib); AstraZeneca will make upfront payment to Dizal of $600M and additional payments of up to $900M (12610p) AstraZeneca has entered into an exclusive license agreement with Dizal Pharmaceutical Co Ltd (688192.CH) for ZEGFROVY (sunvozertinib) a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. AstraZeneca will acquire worldwide rights to develop and commercialise Zegfrovy. Zegfrovy is approved in the US and China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. ~80-85% of lung cancer patients globally have NSCLC. ~10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia, have EGFR-mutated (EGFRm) NSCLC. Roughly one in four patients with EGFRm NSCLC has a tumour with an exon 20 insertion mutation or other atypical mutation for which targeted treatment options are limited. Financial considerations AstraZeneca will make an upfront payment to Dizal of $600M and additional payments of up to $900M upon achievement of specific development, regulatory and sales-related milestones. Additionally, Dizal will receive tiered royalties on the global sales of Zegfrovy. The transaction is expected to close in H2 of 2026, subject to customary closing conditions and regulatory clearances. The transaction does not impact AstraZeneca's financial guidance for 2026. Reference Link: Press release Related: 688192.CH	show story hide story
13-Jul-2026 16:59	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed yet slightly higher overall on Monday. Advancers outnumbered decliners on the XLV. Healthcare +0.25% vs S&P 500 (0.79%). Most major health groups end little changed on their averages. Two outliers were Managed Care with payers up +1% to +4% each, inveestors positionining into Q2 earnings season. Biggest drag remained Biotech for a second-straight day, the XBI fell another (2.32%) after closing lower (3.20%) on Friday. No M&A Monday, and no significant catalyst in either direction. MRNA (1.9%) firmed early, but finished around session lows. SMID-caps came under pressured again, again with limited upside from the large-caps. BIIB +5.0% (upgrade, FDA approval) and ONC +1.8% (upgrade) offered some support to large-caps. BIIB edging out CI +3.8% atop the XLV gainers list; HUM +3.5% subject of a bullish upgrade. Earnings season kicks off this week with two large payers, ELV +2.2% and UNH +1.1%. HCA (3.9%) and RMD (2.6%) led all XLV decliners, former amid Payer bid into earnings, latter downgraded and amid sleep apnea drug headlines. AAIC 2026 meeting underway, and shares of Biogen caught an upgrade ahead of tomorrow's Tau presentation. Sector newsflor fairly quiet over the weekend, but a handful of rating changes hit the tape Monday morning in all major groups. Humana upgraded at Wells Fargo, with a new street-high target price. Q2 earnings season begins Wednesday with ELV and JNJ, followed by UNH and ABT the following day. Macro Another big momentum selloff the focus Monday following a weak Asia session overnight. Similar to the momentum unwind that preceded last week's stabilization, no notable fundamental catalyst for the move (though talk about earnings risk in memory revolving around DRAM ASPs and HBM mix). Technical talk has continued to revolve around seasonality, leveraged ETF impact and passive flow dynamics. Continued ramp in US-Iran kinetic tensions (and US reimposing SoH blockade) the other big story, driving a rally in oil and backup in rates. When it comes to latter, also some hawkish takeaways from comments out of Fed's Waller (who kicks off a busy week of Fedspeak). Rotation providing some semblance of a cushion, though cyclicals somewhat of a mixed bag. Busy week ahead at both the macro and micro level. This includes CPI, PPI, retail sales, Warsh testimony, bank earnings and a couple of high-profile semi results. Notable Gainers +90.7% QTTB (Q32 Bio): trial results in alopecia ariata; upgraded at Wells Fargo +82.7% AGEN (Agenus): private placement ($340M) and development updates +10.2% CNMD (CONMED): media report, exploring sale +6.3% TMDX (TransMedics Group): shares remain (38%) YTD +5.2% ANAB (AnaptysBio): trial results in rectal cancer with GSK; best performer on XBI +5.1% MESO (Mesoblast): upgraded at Bell Potter +5.0% BIIB (Biogen): upgraded at Truist; best performer on XLV, second-best XBI +3.8% CI (Cigna Group): second-best on XLV; sympathy to HUM; shares higher for fifth straight day +3.5% VEEV (Veeva Systems): shares remain (12%) YTD +3.5% HUM (Humana): upgraded at Wells Fargo +3.1% BMY (Bristol Myers Squibb): FDA files NDA for mezigdomide in RRMM +3.0% ZBH (Zimmer Biomet Holdings): shares +4% last week +2.7% WAY (Waystar Holding): shares down (4%) last week Notable Decliners -15.1% TSHA (Taysha Gene Therapies): shares were down (4%) on Friday; worst performer on XBI -9.6% REPL (Replimune Group): second-worst on XBI; shares +2% YTD -8.6% LQDA (Liquidia): shares were down (4%) on Friday -8.4% NTLA (Intellia Therapeutics): shares (8%) on Friday, stock lower last five days -8.3% AKTS (Aktis Oncology): sympathy to GSK/ANAB -7.5% KYMR (Kymera Therapeutics): downgraded at RBC Capital Markets -7.3% DFTX (Definium Therapeutics): FDA finalizes guidance on psychedelic trials, schedules public hearing -6.4% RLAY (Relay Therapeutics): shares were down (4%) on Friday -4.6% GLUE (Monte Rosa Therapeutics): shares (6%) on Friday -3.9% HCA (HCA Healthcare): worst performer on XLV; shares (16%) YTD -3.9% ATAI (AtaiBeckley): FDA finalizes guidance on psychedelic trials, schedules public hearing -3.6% ALNY (Alnylam Pharmaceuticals): shares were down (4%) on Friday -3.3% CMPS (Compass Pathways): FDA finalizes guidance on psychedelic trials, schedules public hearing -2.9% NKTR (Nektar Therapeutics): shares were down (4%) on Friday -2.6% RMD (ResMed): downgraded at Citi; second-worst on XLV Biogen trades higher following FDA approval of Leqembi IQLIK BIIB +5.0% now leading gainer on the XLV, and extending Monday gains after FDA announced the approval of the subcutaneous injection formulation for Alzheimer's drug Leqembi, branded Leqembi IQLIK. Stock was up +3% earlier after the bullish upgrade by Truist, ahead of Tuesday presentation of its Tau program (BIIB080) (IONS) at AAIC 2026. Sleep apnea drug developer Apnimed files for Nasdaq IPO +APMD Apnimed Inc files to list on the Nasdaq. S-1. Sole product candidate in the clinic: AD109 (Oxnimbi) for obstructive sleep apnea (OSA). (INSP, PHIA.NA RMD) Small-cap biotech Q32 Bio higher on alopecia ariata data; bullish upgrade QTTB announced 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating anti-IL7RA bempikibart in patients with severe or very severe alopecia ariata (AA). Clinically meaningful efficacy data on the primary endpoint was observed, supporting phase 3 development to begin in H1 of 2027. Stock upgraded in reaction. Wells Fargo puts $66 price target on the shares. StreetAccount notes that rights once held by AMGN were regained in 2023 following Amgen's acquistion of Horizon. Amgen retains certain milestone payment opportunities. Small-cap biotech Agenus higher on consortium investment, refocus on colon cancer AGEN announced a consortium private placement for $340M to support development of BOT+BAL in MSS colon cancer. Bristol Myers higher on FDA filing NDA in RRMM BMY announced that FDA has accepted its NDA for mezigdomide combo in patients with r/r Multiple Myeloma. PDUFA goal date is 13-May-2027. GSK lower despite hitting registrational trial in rectal cancer GSK annouced that the registrational phase 2 study of Jemperli (ANAB) in dMMR/MSI-H rectal cancer met its primary endpoint, showing a meaningful CR rate at 12 months. Company to share data with regulatory authorities and seek AA in the US. Notable research in Healthcare today Pharma: AZN downgraded to hold from buy at HSBC (Rajesh Kumar), following WAINUA trial results (last week). Target cut to 13,750p from 16,500p or approx. 7% upside. (FactSet average PT 16,296p; range 11484-18474p) Biotech: BIIB upgraded to buy from hold at Truist (Danielle Brill), ahead of 14-Jul data presentation at AAIC. Target increased to $235 from $190 or approx. 18% upside. (FactSet average PT $222; range $157-300) KYMR downgraded to sector perform from outperform at RBC Capital Markets (Brian Abrahams), cites valuation. Target increased however to $115 from $106 or approx. 4% downside. (FactSet average PT $124; range $97-155) MESO upgraded to buy from speculative buy at Bell Potter (John Hester), target remains A$4.45 or approx. 99% upside. (FactSet average PT A$3-5) ONC upgraded to buy from hold at Jefferies (Faisal Khurshid), cites factors including belief that Brukinsa could outperform expectations. Target increased to $380 from $333 or approx. 27% upside. (FactSet average PT $416; range $340-501) QTTB upgraded to overweight from equal weight at Wells Fargo (Derek Archila), notes increased confidence in AA following part B data. Target increased to $66 from $10 or approx. 243% upside. (FactSet average PT $14; range $10-20) KARD seeing initial sell-side coverage following IPO on 18-Jun. Shares have traded +54% since pricing at $16/shr. All buy-equivalent rating so far (Jefferies, JPMorgan, Leerink, TD Cowen) with an average PT $44 or approx. 77% upside (range $37-51) MedTech: RMD downgraded to neutral from buy at Citi (Laura Sutcliffe), target cut to $235 from $270 or approx. 15% upside. (FactSet average PT $269; range $180-327) WST initiated outperform at BNP Paribas Exane (Curtis Moiles), target is $447 or approx. 26% upside. (FactSet average PT $379; range $340-410) Services: BTSG initiated buy at Guggenheim Securities (Jason Cassorla), target is $81 or approx. 13% upside. (FactSet average PT $74; range $58-90) Managed Care: HUM upgraded to overweight at Wells Fargo (Stephen Baxter), cites moderating MA cost trend. Target increased to $502 or approx. 28% upside. (FactSet average PT $315; range $195-468) Post-close news Corporate: MBX announced CEO transition, Kent Hawryluk steps down effective immediately, Board appoints current Executive Chairman Steve Hoerter as next CEO and Chairman. Company also removed interim tag from CFO John Smither. Shares trading (10.1%) in the after-hours Trial results: ERAS announced updated interim clinical data from phase 1 study of '0015 in RAS-mutant solid tumors, plans for potential registration-enabling studies in lung and pancreatic cancers. Company also announced $500M secondary offering. Shares trading (0.6%) in the after-hours Secondary offerings: QTTB announced $200M secondary offering Shares trading (5.2%) in the after-hours Research: ARWR initiated buy at Stifel (James Condulis), target is $98 or approx. 32% upside. (FactSet average PT $91; range $46-110) Shares trading +0.9% in the after-hours On Deck: Jul 11 - 19 Overview: Earnings season kicks off with ELV and JNJ pre-open on 15-Jul, then UNH and ABT the following day. FDA PDUFA for CELC gedatolisib NDA in 2L breast cancer. Conference calendar (cont.): AAIC 2026 meeting (Jul 12-15) Corporate calendar Tue 14-Jul: SNDX R&D Day (8:30ET) BIIB Investor Event at AAIC (12:00ET) Earnings calendar Wed 15-Jul: before JNJ (call at 8:30ET), ELV (call at 8:30ET) Thu 16-Jul: before UNH (call at 8:00ET), ABT (call at 9:00ET) Regulatory calendar Wed 15-Jul: Senate HELP Committee hearing (10:00ET) "Nominations of Sean Kaufman to be Assistant Secretary for Preparedness and Response for the Department of Health and Human Services and Erica Schwartz to be Director of the Centers for Disease Control and Prevention" Fri 17-Jul: FDA PDUFA for CELC gedatolisib NDA in 2L breast cancer (PFE) Peek Ahead to the following week (Jul 20-26) Overview: Earnings season ramps with a variety of large-cap names, plus an FDA advisory committee on peptides, and PDUFA goal date for Otsuka's (4578.JP) investigational NDSRI for ADHD in children, adolescents, and adults. Earnings calendar Tues: DHR, NVS Wed: MOH, MEDP, CYH Thu: ROP.SW, SRT3.GR, DGX, TMO, WST Fri: THC StreetAccount Healthcare Reads American Aid Worker With Ebola 'Stable' in German Hospital (13-Jul) Bloomberg German hospital treats US Ebola patient infected in Congo (13-Jul) Reuters HHS presses ahead with effort to curb antidepressant use (13-Jul) STAT News Top emerging biotech hubs in 2026 (13-Jul) Fierce Biotech This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AGEN, AKTS, ALNY, AMGN, ANAB, ARWR, ATAI, AZN, BIIB, BMY, BTSG, CI, CMPS, CNMD, DFTX, ERAS, GLUE, GSK, HCA, HUM, INSP, IONS, KARD, KYMR, LQDA, MBX, MESO, NKTR, NTLA, ONC, PHIA.NA, QTTB, REPL, RLAY, RMD, SNDX, TMDX, TSHA, VEEV, WAY, WST, ZBH...(more)	show story hide story
13-Jul-2026 08:57	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis AAIC 2026 meeting underway, and shares of Biogen caught an upgrade ahead of tomorrow's Tau presentation. Shares of BIIB +1% in the pre-market. Sector newsflor fairly quiet over the weekend, but a handful of rating changes hit the tape Monday morning in all major groups. Humana upgraded at Wells Fargo, with a new street-high target price. Shares of HUM +2% in the pre-market. Q2 earnings season begins Wednesday with ELV and JNJ, followed by UNH and ABT the following day. Macro S&P futures are down (0.4%) on Monday morning. Ramp in Middle East tensions continued over the weekend with Strait of Hormuz still the big sticking point. However, oil/yields off highs with the likely focus on the escalate to de-escalate dynamic, which has been a feature of both the conflict and ceasefire/MOU. Momentum weakness the bother big story with an overnight selloff that did not seem to be accompanied by any fundamental catalysts. However, this weekend did bring more discussion about competition (both within the frontier model universe and from open-source models) and the overhang from AI debt issuance. Very busy week on tap at both the macro and micro level with CPI/PPI/retail sales, Warsh testimony/busy Fedspeak calendar and start of Q2 earnings season with five big banks reporting on Tuesday morning. Pre-market trading update Trading higher +72.5% QTTB trial results in alopecia ariata; call at 8ET +57.3% AGEN private placement ($340M) and development updates; call 830ET +5.0% MESO upgraded at Bell Potter +3.4% CNMD media report, exploring sale +3.0% ONC upgraded at Jefferies +2.2% WAY +1.5% HUM upgraded at Wells Fargo +1.1% BIIB upgraded at Truist Trading lower -2.9% KYMR downgraded at RBC Capital Markets (low volume) -2.4% RMD downgraded at Citi (low volume) -1.9% NKTR -1.3% MRNA follow-through -1.1% AZN downgraded at HSBC Pharma Trial results: GSK annouced that the registrational phase 2 study of Jemperli (ANAB) in dMMR/MSI-H rectal cancer met its primary endpoint, showing a meaningful CR rate at 12 months. Company to share data with regulatory authorities and seek AA in the US. Regulatory: BMY announced that FDA has accepted its NDA for mezigdomide combo in patients with r/r Multiple Myeloma. PDUFA goal date is 13-May-2027. Research: AZN downgraded to hold from buy at HSBC (Rajesh Kumar), following WAINUA trial results (last week). Target cut to 13,750p from 16,500p or approx. 7% upside. (FactSet average PT 16,296p; range 11484-18474p) Biotech Trial results: QTTB announced 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating anti-IL7RA bempikibart in patients with severe or very severe alopecia ariata (AA). Clinically meaningful efficacy data on the primary endpoint was observed, supporting phase 3 development to begin in H1 of 2027. StreetAccount notes that rights once held by AMGN were regained in 2023 following Amgen's acquistion of Horizon. Amgen retains certain milestone payment opportunities. Conf. call at 8:00ET Corporate: AGEN announced a consortium private placement for $340M to support development of BOT+BAL in MSS colon cancer. IPO filing: +APMD Apnimed Inc files to list on the Nasdaq. S-1. Sole product candidate in the clinic: AD109 (Oxnimbi) for obstructive sleep apnea (OSA). Research: BIIB upgraded to buy from hold at Truist (Danielle Brill), ahead of 14-Jul data presentation at AAIC. Target increased to $235 from $190 or approx. 18% upside. (FactSet average PT $222; range $157-300) KYMR downgraded to sector perform from outperform at RBC Capital Markets (Brian Abrahams), cites valuation. Target increased however to $115 from $106 or approx. 4% downside. (FactSet average PT $124; range $97-155) MESO upgraded to buy from speculative buy at Bell Potter (John Hester), target remains A$4.45 or approx. 99% upside. (FactSet average PT A$3-5) ONC upgraded to buy from hold at Jefferies (Faisal Khurshid), cites factors including belief that Brukinsa could outperform expectations. Target increased to $380 from $333 or approx. 27% upside. (FactSet average PT $416; range $340-501) KARD seeing initial sell-side coverage following IPO on 18-Jun. Shares have traded +54% since pricing at $16/shr. All buy-equivalent rating so far (Jefferies, JPMorgan, Leerink, TD Cowen) with an average PT $44 or approx. 77% upside (range $37-51) Life Science & MedTech Preannounce: INMD guides Q2 revenue $95.2-95.4M vs FactSet $92.6M, and FY26 revenue $365-375M vs FactSet $370.0M. Recall that the company received an unsolicited offer last week. Media report: CNMD reportedly exploring sale amid takeover interest - Bloomberg Research: RMD downgraded to neutral from buy at Citi (Laura Sutcliffe), target cut to $235 from $270 or approx. 15% upside. (FactSet average PT $269; range $180-327) WST initiated outperform at BNP Paribas Exane (Curtis Moiles), target is $447 or approx. 26% upside. (FactSet average PT $379; range $340-410) Services & Hospitals Research: BTSG initiated buy at Guggenheim Securities (Jason Cassorla), target is $81 or approx. 13% upside. (FactSet average PT $74; range $58-90) Managed Care Research: HUM upgraded to overweight at Wells Fargo (Stephen Baxter), cites moderating MA cost trend. Target increased to $502 or approx. 28% upside. (FactSet average PT $315; range $195-468) On Deck: Conference (cont.): AAIC 2026 meeting (Jul 12-15) Corporate on Tue 14-Jul: SNDX R&D Day (8:30ET); BIIB Investor Event at AAIC (12:00ET) Earnings on Wed 15-Jul: before JNJ (call at 8:30ET), ELV (call at 8:30ET) Regulatory on Wed 15-Jul: Senate HELP Committee hearing (10:00ET) "Nominations of Sean Kaufman to be Assistant Secretary for Preparedness and Response for the Department of Health and Human Services and Erica Schwartz to be Director of the Centers for Disease Control and Prevention" This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AGEN, AMGN, ANAB, AZN, BIIB, BMY, BTSG, CNMD, ELV, GSK, HUM, INMD, JNJ, KARD, KYMR, MESO, MRNA, NKTR, ONC, QTTB, RMD, SNDX, WAY, WST...(more)	show story hide story
13-Jul-2026 06:53	Telecom, energy, media and chemicals the top gainers; construction, tech, industrials and airlines the big laggards: Telecom outperforms, supported by continued strength in Vodafone (VOD.LN) after last week's announcement that Emirates Telecommunications (e&) agreed to sell its 16.2% stake to Xavier Niel's investment vehicle Vega at a 13% premium. Reuters cited Berenberg saying Niel's involvement could accelerate cost-cutting and free cash flow growth. Elsewhere, Smartoptics Group (SMOP.NO) surges following a strong Q2 earnings update. Oil & Gas gains as oil prices climb after renewed US-Iran hostilities and Iran's move to close the Strait of Hormuz fuels supply concerns. The geopolitical backdrop lifts the sector broadly, while Equinor (EQNR.NO), Var Energi (VAR.NO), Harbour Energy (HBR.LN), Aker BP (AKRBP.NO) and DNO (DNO.NO) advance after partners secure new Norwegian drilling permits. Media also benefits from the broader rotation into defensive sectors. Chemicals outperforms, with Akzo Nobel (AKZA.NA) extending gains after Nippon Paint (4612.JP) confirms a €7.5B indicative offer for its decorative paints business, although the company reiterates support for its planned merger with Axalta (AXTA). The spotlight is also on EMS-Chemie (EMSN.SW) following an upgrade to Hold from Kepler Cheuvreux after better-than-expected H1 results and improving global sales momentum. Technology declines as semiconductor names track a sharp sell-off in Asian chipmakers overnight following SK Hynix's (000660.KS) US listing on Friday. Investors also remain cautious ahead of ASML's (ASML.NA) earnings later this week. Offsetting some weakness, Computacenter (CCC.LN) and IONOS Group (IOS.GR) higher on bullish broker calls, while Gofore (GOFORE.FH) trades higher following strong June sales data. Industrial Goods & Services lags after Kongsberg Gruppen (KOG.NO) slumps despite solid Q2 results, with investors disappointed by weaker-than-expected order intake and cash flow. Construction & Materials underperforms despite gains in Rexel (RXL.FP) after an upgrade from BNP Paribas, as broader cyclical sentiment remains weak. Financial Services also underperform as Plus500 (PLUS.LN) tumbles after keeping annual forecasts unchanged despite strong H1 results. Travel & Leisure falls as higher oil prices weigh on airlines, with Lufthansa (LHA.GR) and Ryanair (RYA.ID) declining on concerns over higher fuel costs, highlighted in latest Reuters report. Fraport (FRA.GR) outperforms after a BNP Paribas Exane rating upgrade despite weaker June traffic. Health Care weaker as AstraZeneca (AZN.LN) falls following an HSBC downgrade, outweighing GSK (GSK.LN) news of positive Phase II trial data for Jemperli. For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: AKRBP.NO, AKZA.NA, ASML.NA, AZN.LN, CCC.LN, DNO.NO, EMSN.SW, EQNR.NO, FRA.GR, GOFORE.FH, GSK.LN, HBR.LN, IOS.GR, KOG.NO, LHA.GR, PLUS.LN, RXL.FP, RYA.ID, SMOP.NO, VAR.NO, VOD.LN...(more)	show story hide story
13-Jul-2026 00:41	AZN.LN AstraZeneca downgraded to hold from buy at HSBC (12834p) Downgrade follows results from WAINUA Phase 3 trial, which failed to meet primary endpoint Target cut to 13,750p from 16,500p, 7% upside (FactSet average target 16286.12p; range 11484.14-18474.48p) Analyst is Rajesh Kumar	show story hide story
10-Jul-2026 22:26	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities finished broadly lower on Friday. Worst performing sector and lone decliner on the green tape. Decliners narrowly outnumbered advancers on the XLV. Healthcare (0.81%) vs S&P 500 +0.42%. All major health groups ended lower on their averages on Friday. Nearly all remaining weekly gains were wiped away, most notably in Biotech with the XBI (3.20%) today. SMID-cap biotech dragged, and no help from large-cap names either. MRNA (10.8%) sell-off we're told is commentary out JPMorgan, longtime bear in the name, naming it a top short idea. Overall sector newsflow remained very quiet, ahead of Q2 earnings season kickoff next week. One small biotech IPO was postponed again. DXCM +2.7% and MRNA bracketed the XLV. Pharma and Services groups down more than 1% on the averages. MedTech today's relative performer, supported by a few moderate gains in the medical devices field, LST subgroup was more mixed. Macro: A fairly quiet Friday session capped off an up week for both S&P 500 and Nasdaq. Very few shifts in broader narrative with market in waiting mode ahead of some key catalysts next week (CPI, retail sales, Warsh testimony, and Q2 earnings kickoff, notably moneycenter banks, IBs). Momentum trade stabilizing again (semis, memory mixed), though broadening trade in play with select cyclicals (homebuilders, machinery, pockets of retail, banks, PE, materials) outperforming. Iran tensions remain in focus, with Trump saying Friday Iran wants to continue talks, though told Tehran ceasefire is over, while Iranian sources denied talks would take place next week, parliamentary speaker Ghalibaf said Iran would prepare comprehensive defense if US breaches MOU. Other areas of focus include more hawkish Fed rate outlook (markets pricing 34 bp of hikes through year-end, up 6 bp w/w), more concerns around AI-related tech debt, equity supply following today's (well-received) $26.5B SK Hynix offering, Friday's fairly sizable opex, and high bar into Q2 earnings (reaction to this week's Samsung Electronics update, growing concerns around an earnings bubble). Notable Gainers on Friday: +11.9% TRAX - best performer on XBI; follow-through, shares +88% for the week +11.4% XFOR - initiation +2.7% DXCM - best performer on XLV; shares +5% for the week Notable Decliners on Friday: -10.9% RGNX - worst performer on XBI; shares end +5% for the week -10.8% MRNA - JPMorgan top short idea; worst performer on XLV; second-worst on XBI; shares down (14%) for the week and +132% YTD -10.6% PRME - gene editing stocks weak with XBI (3%); shares turn red (2%) for the week -9.4% IONS - follow-through, reaffirms FY26 guidance -8.8% BEAM - gene editing stocks weak with XBI (3%); shares turn red (6%) for the week -7.9% NTLA - gene editing stocks weak with XBI (3%) -5.7% BKD - reported June occupancy results -5.3% CRSP - gene editing stocks weak with XBI (3%) -5.0% RDY - follow-through, downgraded at Elara; ADRs down (8%) for the week -3.9% AZN - follow-through, ADRs are (12%) for the week Week in Review: Healthcare equities underperformed for the week. The S&P 500 Healthcare Index declined (1.85%) vs the S&P 500 Index +1.23%. Outperformers: none Underperformers: Pharma, Services, Biotech, MedTech, Managed Care Major health groups were mostly lower for the week - only MCOs a hair higher on average. High-premium biopharma M&A deal was the primary story once again. Vertex Pharma bought an endocrinology pipeline in Crinetics Pharma, for an enterprise value of $10B. Through Thursday's market close, the XBI was +35% since 1-Jun. The XBI weekly winning streak ended however at four weeks after a pivot on Friday as investors questioned whether biotech had run too far too fast. A midweek clinical surprise by AstraZeneca (12%) also renewed the idea of clinical risk in drug development. Earnings season kicks off next week with JNJ and ELV, then UNH and ABT. Year-to-date, Healthcare +3.92% vs the S&P 500 +10.66%. Healthcare ninth out of eleven major sectors in CY26. Energy +22.15% and Consumer Discretionary (0.71%) bracket them all. Notable movers for the week: Gainers: FBRX +109.9% - trial results in vitiligo with IL15/CD122 CRNX +97.9% - acquired by VRTX for $10.0B TRAX +87.8% - read-across from FBRX (and from TEVA); best performer on XBI EWTX +14.8% - 52-week high; shares +83% YTD XENE +13.1% - 52-week high; shares +54% YTD SYRE +12.8% - 52-week high; shares +198% YTD BBIO +11.3% - read-across from AZN TXG +9.5% - 52-week high; shares +162% YTD DXCM +5.2% - best performer on XLV; shares +11% MTD Decliners: IONS (28.8%) - sympathy to AZN; reaffirms FY26 financial guidance; worst performer on XBI ALHC (16.7%) - media report on whistleblower suit MRNA (14.4%) - JPMorgan top short idea; worst performer on XLV IBRX (12.9%) - shares remain +315% YTD AZN (12.1%) - trial results in ATTR-CM TWST (8.7%) - shares remain +186% YTD VRTX (8.1%) - acquired CRNX for $10.0B ($8.8B net cash) BIIB (7.9%) - ahead of Tau data at AAIC Week Ahead (Sat - Sun): Jul 11 - 19 Overview: Earnings season kicks off with ELV and JNJ pre-open on 15-Jul, then UNH and ABT the following day. FDA PDUFA for CELC gedatolisib NDA in 2L breast cancer. Conference calendar Sun 12-Jul: AAIC 2026 meeting (Jul 12-15) Corporate calendar Tue 14-Jul: R&D Day SNDX (8:30ET); Investor Event at AAIC BIIB (12:00ET) Earnings calendar Wed 15-Jul: before JNJ (call at 8:30ET), ELV (call at 8:30ET) Thu 16-Jul: before UNH (call at 8:00ET), ABT (call at 9:00ET) Regulatory calendar Wed 15-Jul: Senate HELP Committee hearing (10:00ET) "Nominations of Sean Kaufman to be Assistant Secretary for Preparedness and Response for the Department of Health and Human Services and Erica Schwartz to be Director of the Centers for Disease Control and Prevention" Fri 17-Jul: FDA PDUFA for CELC gedatolisib NDA in 2L breast cancer (PFE) Peek Ahead to the following week (Jul 20-26) Overview: Earnings season ramps with a variety of large-cap names, plus an FDA advisory committee on peptides, and PDUFA goal date for Otsuka's (4578.JP) investigational NDSRI for ADHD in children, adolescents, and adults. Related: 4578.JP, ABT, ALHC, AZN, BBIO, BEAM, BIIB, BKD, CELC, CRNX, CRSP, DXCM, ELV, EWTX, FBRX, IBRX, IONS, JNJ, MRNA, NTLA, PFE, PRME, RDY, RGNX, SNDX, SYRE, TEVA, TRAX, TWST, TXG, UNH, VRTX, XENE, XFOR...(more)	show story hide story
10-Jul-2026 10:42	1093.HK CSPC Pharmaceutical Group discloses receipt of $25M research & development milestone payment under strategic collaboration & license agreement with ASTRAZENECA (HK$8.11) Reference is made to the announcement of CSPC Pharmaceutical Group, dated 30-Jan-26 (attached), in relation to the entering into of the strategic collaboration and license agreement between the group and AstraZeneca; as disclosed in the Announcement, the group entered into the agreement with AstraZeneca to develop innovative long-acting peptide medicines, utilising the group's proprietary sustained-release delivery technology platform and AI-driven peptide drug discovery platform. The board is pleased to announce that, following the receipt of the upfront payment under the agreement on 29-May-26 (attached), the group has received a research and development milestone payment of $25M from AstraZeneca on 10-Jul-26. The achievement of this milestone indicates that the relevant research and development work under the agreement is progressing steadily as planned See Related StreetAccount comments: 5/29/2026 8:22:36 AM - CSPC Pharmaceutical Group receives $1.2B upfront from AstraZeneca under agreement announced 30-Jan 1/30/2026 2:10:02 AM - AstraZeneca to pay $1.2B upfront in multi-billion-dollar CSPC Pharmaceuticals obesity collaboration Related: AZN.LN Attached Files PDF Document: Press release	show story hide story
10-Jul-2026 08:41	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Healthcare sector newsflow very quiet overnight. Small biotech IPO postponed again. Sanofi's subcutaneous version of Sarclisa approved by FDA. Development was supported by Blackstone Life Sciences. Bausch + Lomb's recently acquired candidate fails mid-stage trial for glaucoma, but clears pathway for study in geographic atrophy. Looking ahead, AAIC 2026 meeting begins on Sunday, and earnings season begins next Wednesday, 15-Jul, with Elevance Health and JNJ reporting before the open, followed by UnitedHealth and Abbott the next day. Macro S&P futures are down (0.1%) on Friday morning. Quiet from a headline perspective heading into a very busy week ahead on both the macro and micro fronts. Highlights for next week include inflation data and start of a Q2 earnings season expected to deliver a second straight Q of 20%+ growth. When it comes to earnings, focus will be on the big banks (JPM, BAC, C, WFC and GS on Tuesday and MS on Wednesday) and a couple of overseas semi names (ASML on Wednesday and TSMC on Thursday). Momentum a laggard this morning following yesterday's rally. Supply in the headlines with widely anticipated $26.5B+ listing from SKHY. Dampened Middle East tensions also in focus with no new US strikes, talks between the two sides continuing and US reiteration of preference for a diplomatic solution. Pre-market trading update Trading higher +6.7% ACOG initiation (low volume) +2.5% XFOR initiation (low volume) +2.5% CMPS +2.2% MRNA shares are (4%) WTD +1.6% BTSG initiation at Raymond James; positive mention at Jefferies (low volume) +1.4% ALNY follow-through, shares were (3%) yesterday +0.2% IONS follow-through, reaffirms FY26 guidance Trading lower -5.2% BKD reported June occupancy results -2.1% RDY follow-through, ADRs are (3%) WTD; downgraded at Elara -1.3% AZN follow-through, ADRs are (9%) WTD -0.5% OCUL on 33K shares Pharma Regulatory: SAN.FP (SNY) FDA announced the approval of Sarclisa Escena, the subcutaneous injection formulation of Sanofi's multiple myeloma drug Sarclisa. The PDUFA goal date was 23-Jul following the three month extension reported in April. Blackstone Life Sciences (BX) invested in the development of the subcutaneous formulation, and is eligible to receive royalties on sales. AbbVie (ABBV) via its acquistion of ImmunoGen is entitled to milestones and royalties on Sarclisa. Research: RDY downgraded to reduce from accumulate at Elara Capital (Bino Pathiparampi), target cut to INR 1283 from INR 1444 or approx 3% upside. (FactSet average PT INR 1356; range INR 1040-1750) Biotech Regulatory: Elevar Therapeutics (private, majority owned by HLB Co Ltd 028300.KS) announced that FDA issued another CRL for its oral VEGF-TKI rivoceranib in combo with anti-PD-1 antibody camrelizumab as 1L treatment for uHCC. Resubmission followed a CRL in March 2025, and the PDUFA was 23-Jul-2026. Glenmark Pharma (532296.IN) FDA published the approval letter for the Ryaltris sNDA reported 8-Jul, which confirmed the label expansion of the pediatric indication for ages 6-11 years. Previously the approval was for seasonal allergic rhinitis in patients 12 and older. (HIK.LN) Trial results: BLCO announced that phase 2 study evaluating BL1107 (formerly WB007) in patients with glaucoma did not achieve its primary endpoint. Bausch + Lomb acquired Whitecap Biosciences in 2025 based on promise of the candidate for geographic atrophy (GA), and will now refocus on that plan. Corporate: IONS reaffirms previous FY26 financial guidance from 29-Apr. Update follows disappointing trial results by partner AstraZeneca yesterday, and shares of IONS down (21%) week-to-date. Syndicate / IPO: +TARX the expected IPO pricing for Tarsier Pharma was postponed again, we're told. Per the recent F-1A , Tarsier is a clinical-stage biotech with a focus on treating ocular diseases; lead product ph3 TRS01. Research: ACOG initiated outperform at Raymond James (Ryan Deschner), target is $20 or approx. 135% upside. LKFT resumed equal weight at Morgan Stanley (Judah Frommer), target is $30 or approx. 2% downside. (FactSet average PT $32; range $22-44) XFOR initiated overweight at Wells Fargo (Derek Archila), target is $11 or approx. 178% upside. (FactSet average PT $12; range $10-13) Services & Hospitals Corporate: BKD reported June 2026 (and Q2) occupancy results. Research: BTSG initiated outperform at Raymond James (Parker Snure), target is $80 or approx. 12% upside. (FactSet average PT $70; range $58-90) BTSG Jefferies identified as a Top Pick heading into Q2 earnings, along with RDNT, ACHC, and CVS. On Deck: Conference on Sun 12-Jul: AAIC 2026 meeting (Jul 12-15) Corporate early Q3 readouts: DFTX (ph3 GAD); PMN (ph1 AD) Regulatory early Q3: CMS proposal of Physician Fee Schedule (PFS) for CY2027 Peek Ahead to next week Jul 13-19 Overview: Earnings season kicks off with ELV and JNJ pre-open on 15-Jul, then UNH and ABT the following day. FDA PDUFA for CELC gedatolisib NDA in 2L breast cancer. And Further Ahead Jul 20-26 Overview: Earnings season ramps with a variety of large-cap names, plus an FDA advisory committee on peptides, and PDUFA goal date for Otsuka's (4578.JP) investigational NDSRI for ADHD in children, adolescents, and adults. This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 028300.KS, 532296.IN, ABBV, ACOG, ALNY, AZN, BKD, BLCO, BTSG, BX, CMPS, HIK.LN, IONS, LKFT, MRNA, OCUL, RDY, SAN.FP, XFOR...(more)	show story hide story
10-Jul-2026 01:50	European macro headlines: Central Banks: ECB's Lagarde says she is not a candidate in French presidential race but will advocate for pro-European values (Reuters) BoE chief economist Huw Pill signals interest rate hikes needed to control inflation (BBC) Geopolitics: Von der Leyen presents EU options for restricting or banning trade with Israeli settlements (EurActiv) UK: Andy Burnham secures overwhelming Labour MP backing, set to become next UK prime minister (Bloomberg, Euronews) Markets: Energy profits surge to mask weaker momentum as Stoxx 600 Q2 earnings growth forecast at 15.3% (Reuters) Germany: German chancellor Merz promotes 'Reformkanzler' image amid record-low approval and AfD rise (Politico) France: Bank of France upgrades Q2 growth outlook as French economy rebounds in June (Reuters) Corporate: Airbus workers in Spain launch strike over pay and working conditions until end of July (Reuters) Volkswagen to halve model lineup, slash production capacity and cut up to 100,000 jobs in major overhaul (Independent) US appeals court upholds ruling invalidating Pfizer patents in AstraZeneca Tagrisso lawsuit (Reuters) Vinci Airports expects slower air traffic growth due to higher fuel prices and geopolitical tensions (Reuters) For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: AIR.FP, AZN.LN, DG.FP, VOW3.GR	show story hide story
09-Jul-2026 17:27	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities traded below (0.09%) the S&P500 +0.81% with Managed care and MedTech as outperformers. XBI +0.80% led by TRAX +56.0% in reaction to strong Phase IB placebo-controlled vitiligo data. DRG (0.79%) traded lower weighed by AZN (5.7%) trial results in ATTR-CM. BMO Capital initiates coverage on sixteen names in Medical Supplies and Devices. Top story in healthcare today is AZN and IONS trading lower after the CARDIO-TTRansform Phase 3 trial for WAINUA in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to Week 140 compared with placebo. Earnings season begins on 15-Jul with Elevance Health and JNJ reporting before the open, followed by UnitedHealth and Abbott the next day. Macro US equities finished higher in Thursday trading, ending a bit off best levels. S&P 500 and Nasdaq now on pace for weekly gains. Momentum was again the big driver in a continuation of Wednesday's rebound (though SOX still more than 11% below its 22-Jun ATH). AZNcame under pressure after trial for its Wainua drug on a rare type of heart disease failed to meet its primary objective. Initial claims came in at 215K for the latest week; below 218K consensus and prior 217K (revised up from 215K). Continuing claims printed at 1814K vs 1820K forecast, above previous 1806K (revised down from 1814K). June existing home sales down 2.4% m/m to a 4090K SAAR (below 4200K consensus and prior 4170K); release noted buyers sensitive to affordability issues. On Fedspeak, Fed's Williams said policymakers studying inflation scenarios; suggested it is unclear how much smaller Fed's balance sheet can get. Nothing policy-related from Dallas's Logan. Fed today released leadership information and objectives for Warsh's task force program. Notable Gainers +78.3% FBRX (Forte Biosciences): reacting to Phase IB vitiligo data meeting primary endpoint of mean FVASI improvement from baseline at week 24. +56.0% TRAX (First Tracks Biotherapeutics Inc): surging on strong Phase IB placebo-controlled vitiligo data; best performer on XBI. +15.1% BBIO (BridgeBio Pharma): sympathy to AZN, second best performer on XBI. +9.2% CNMD (CONMED): initiated market perform at BMO Capital Markets +5.1% GH (Guardant Health): reacting to competitor data in CRC blood test, Leerink positive comments +4.4% EWTX (Edgewise Therapeutics): initiated outperform at Oppenheimer +4.3% CRL (Charles River Laboratories): best performer on XLV. +3.4% NEO (NeoGenomics): launches PTEN IHC companion diagnostic for prostate cancer +3.3% ATEC (Alphatec Holdings): initiated outperform at BMO Capital Markets +2.7% NTRA (Natera): receives certification as a Class C device under the European Union's In Vitro Diagnostic Regulation (IVDR) +2.4% WAT (Waters): initiated outperform at RBC Capital Markets +1.5% SRPT (Sarepta Therapeutics): upgraded to outperform from peer perform at Wolfe Research +0.6% GMED (Globus Medical): initiated outperform at BMO Capital Markets +0.5% MOH (Molina Healthcare): UBS previewed MCO earnings Notable Decliners -23.9% IONS (Ionis Pharmaceuticals): trial results in ATTR-CM, partner with AZN; worst performer on XBI. -5.7% AZN (AstraZeneca): trial results in ATTR-CM -5.3% TARS (Tarsus Pharmaceuticals): to acquire iRenix Medical in upfront consideration of ~$75M -3.2% MCK (McKesson): worst performer on XLV -1.6% RDY (Dr. Reddy's Laboratories): discloses manufacturing issue with API in semaglutide -0.8% ABT (Abbott Labs): reacting to competitor data in CRC blood test. AstraZeneca trading lower on trial results AZN.LN CARDIO-TTRansform Phase 3 trial of AstraZeneca's eplontersen does not meet primary endpoint. The CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to Week 140 compared with placebo. Ionis and AstraZeneca will continue to analyze the full data set, and results will be shared with the scientific community at the European Society of Cardiology (ESC) Congress in August 2026. QuickTake: Analysts across the board view the result as a negative surprise, with consensus peak sales for Wainua expected to fall sharply from ~$2.6B to below $0.5B, implying a 2-3% hit to AstraZeneca's share price, though near-term sentiment may be more negative. Despite the disappointment, a number of firms maintain their Outperform/Buy ratings on the stock, noting that the pipeline miss represents only a ~3% NPV downside to base case valuations, and that AZN's broader pipeline of clinical projects remains underappreciated. A key silver lining highlighted from today's news is the nominally significant HR of 0.71 observed in treatment-naïve patients, which could support a new Phase 3 trial in this subgroup. Analysts also flag a positive read-across to Sanofi given its royalty exposure to a competing product ( Alnylam's Amvuttra, which is already approved). It was noted Wainua would have been a significant competitor to Amvuttra had CARDIO-TTransform been positive. Looking ahead, attention now turns to the next wave of ATTR innovation via "depleters," with AZN's own Phase 3 cliramitug (DepleTTR) data expected in 2027, which analysts believe could synergistically combine with Wainua to offer improved long-term outcomes in ATTR-CM FBRX and TRAX trading higher on trial results FBRX Forte Biosciences announces results from the FB102 double-blind placebo-controlled phase 1B study in vitiligo TRAX First Tracks Biotherapeutics also trades higher; UBS comments on IL15/CD122 mechanism after competitor data ) UBS analyst Michael Yee notes that strong data from competitor Forte Biosciences today further validates the IL15/CD122 drug class and its potential in a broader range of indications. Teva reported IL15 data in Vitiligo earlier this week. Firm maintains buy rating on TRAX. Freenome announces that updated SimpleScreen CRC blood test met all endpoints Freenome (0G9YV9-E) announced favorable results from its pivotal clinical validation study assessing the performance of assay and algorithm improvements for its updated version of the SimpleScreen CRC blood-based colorectal cancer (CRC) screening test. In August 2025, Freenome and Abbott (ABT) entered into a commercial collaboration agreement to bring SimpleScreen CRC to market. Leerink analyst Puneet Souda (outperform rating GH), notes that these V2 results provide an overhang lift for Guardant's Shield, expects to build on its early lead. Shares of GH and ABT reacting to the news. Tarsus Pharmaceuticals shares edge lower on iRenix Medical acquisition news TARS to acquire iRenix Medical in upfront consideration of ~$75M, consisting of $37.5M in cash and $37.5M in Tarsus common stock. Potential approval and commercial milestone payments of up to $490M. Based on data from the completed Phase 2B/3 RELIEF trial, and in alignment with feedback from the FDA, Tarsus plans to initiate a Phase 3 study designed to evaluate the tolerability and safety of IRX-101 compared to povidone-iodine. The study is expected to begin enrolling in H1 of 2027 with results anticipated in 2028 Notable research in Healthcare today Pharma: **ROP.SW upgraded to buy from hold at Vontobel Biotech: SRPTSarepta Therapeutics upgraded to outperform from peer perform at Wolfe Research EWTX Edgewise Therapeutics initiated outperform at Oppenheimer, Target is $51, 10% upside (FactSet average target $49.15; range $30-66) 1SXP.GR upgraded to outperform from sector perform at RBC Capital Markets Life Science & MedTech: WAT initiated outperform at RBC Capital Markets with $435 target, 18% upside (FactSet average target $407.82; range $350-460) A resumed hold at Jefferies ALGN initiated outperform at BMO Capital Markets with $209 target, 20% upside (FactSet average target $208.23; range $175-240) ATEC initiated outperform at BMO Capital Markets with $11 target, 19% upside (FactSet average target $16.45; range $11-24) CNMD initiated market perform at BMO Capital Markets with $36 target, 7% upside (FactSet average target $39.60; range $39-40) ENOV initiated outperform at BMO Capital Markets with $29 target, 23% upside (FactSet average target $41.90; range $32-55) GEHCinitiated market perform at BMO Capital markets with $70 target, 8% upside (FactSet average target $78.94; range $65-98) GMED initiated outperform at BMO Capital Markets with $94 target, 23% upside (FactSet average target $107.27; range $80-122) IART initiated market perform at BMO Capital Markets with $19 target, 10% upside (FactSet average target $17.86; range $11-27) ISRG initiated outperform at BMO Capital Markets with $518 target, 25% upside (FactSet average target $571.59; range $366-750) NVST initiated market perform at BMO Capital Markets with $27 target, 5% upside (FactSet average target $29.62; range $21-35) SOLV initiated market perform at BMO Capital Markets with $81 target, 8% upside (FactSet average target $83.08; range $60-100) STMN.SW initiated outperform at BMO Capital Markets with CHF121 target, 18% upside (FactSet average target CHF112.47; range CHF83-130) SYK initiated outperform at BMO Capital Markets with $369 target, 13% upside (FactSet average target $389.54; range $315-465) TFX initiated outperform at BMO Capital Markets with $159 target, 22% upside (FactSet average target $145.89; range $135-160) ZBH initiated market perform at BMO Capital Markets with $95 target, 8% upside (FactSet average target $95.50; range $83-110) Services & Hospitals: HSICinitiated market perform at BMO Capital markets with $85 target, 2% upside (FactSet average target $88.73; range $64-100) XRAY initiated market perform at BMO Capital markets with $12 target, 2% upside (FactSet average target $13.43; range $9-17) Post Close News SOBI.SS Swedish Orphan Biovitrum announces CDA issues positive reimbursement recommendation for EMPAVELI (pegcetacoplan) for the treatment of C3G and primary IC-MPGN BLCO Bausch + Lomb Phase 2 study for Glaucoma Neuroprotective Candidate does not meet primary endpoint IVA.FP Inventiva announces completion of EIB warrant restructuring with issuance of new EIB warrants DNLI Denali Therapeutics to give opening plenary address at AAIC 2026; to highlight breakthroughs in delivering biologic therapies across blood-brain barrier NRIX Nurix Therapeutics reports Q2 EPS ($0.81) vs FactSet ($0.72) [15 est, ($0.86)-(0.45)] BTSG BrightSpring Health Services initiated outperform at Raymond James, Target is $80, 12% upside (FactSet average target $69.67; range $58-90) On Deck Jul 6-12 Corporate calendar early Q3 readouts: DFTX (ph3 GAD); PMN (ph1 AD) Regulatory calendar early Q3: CMS proposal of Physician Fee Schedule (PFS) for CY2027 Conference calendar Sun 12-Jul: AAIC 2026 meeting (Jul 12-15) Syndicate calendar / potential IPO pricing Wed 8-Jul (post-close) +TARX (Tarsier Pharma) - F-1A - clinical-stage biotech with focus on treating ocular diseases; lead product ph3 TRS01 Peek Ahead to next week Jul 13-19 Overview: Earnings season kicks off with ELV and JNJ pre-open on 15-Jul, then UNH and ABT the following day. FDA PDUFA for CELC gedatolisib NDA in 2L breast cancer. Further Ahead Jul 20-26 Overview: Earnings season ramps with a variety of large-cap names, plus an FDA advisory committee on peptides, and PDUFA goal dates for: SNY/BX, 4578.JP, and Elevar Therapeutics. StreetAccount Healthcare Reads** AstraZeneca's Wainua fails key heart disease trial, shares tumble (9-Jul) Reuters. ARPA-H launches $160 million effort to develop custom gene editing drugs (9-Jul) STAT News. Outbreak of diarrhea-causing parasite grows to more than 1,000 cases (9-Jul) STAT News, Bloomberg. Qiagen Draws Early Takeover Interest From EQT, Advent (9-Jul) Bloomberg. White House reviewing top contenders to lead FDA (8-Jul) STAT News Alignment faces whistleblower lawsuit over accounting claims (8-Jul) Modern HC Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics (8-Jul) STAT News How much and why ACA Marketplace premiums are going up in 2027 (8-Jul) Peterson-KFF 5 takeaways from STAT's series on the soaring cost of health insurance (7-Jul) STAT News Experimental Ebola Trial Begins in Congo as Death Toll Tops 500 (6-Jul) Bloomberg Congo says confirmed Ebola cases rise to 1,561, including 506 deaths (6-Jul) Reuters This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 1SXP.GR, A, ABT, ALGN, ATEC, AZN, AZN.LN, BBIO, BLCO, BTSG, CNMD, CRL, DNLI, ENOV, EWTX, FBRX, GEHC, GH, GMED, HSIC, IART, IONS, ISRG, IVA.FP, MCK, MOH, NEO, NRIX, NTRA, NVST, RDY, ROP.SW, SOBI.SS, SOLV, SRPT, STMN.SW, SYK, TARS, TFX, TRAX, WAT, XRAY, ZBH...(more)	show story hide story
09-Jul-2026 11:46	^OPTIONS StreetAccount Summary - U.S. Unusual Option Volume: VIX (3.6%) to 16.29; S&P 500 +0.5% to 7,522.76 StreetAccount reports options activity showing unusual volume compared to the 30-day average. The list excludes companies that have reported earnings since the prior trading day's close. 6,338% - BCE (BCE $21.34, -0.5%) -- 31,352 contracts vs avg 495 - P/C ratio: 276.47 796% - ACI (Albertsons Cos. $14.32, +2.4%) -- 23,119 contracts vs avg 2,905 - P/C ratio: 0.03 608% - YUM (YUM! Brands $162.90, -1.4%) -- 2,944 contracts vs avg 484 - P/C ratio: 11.41 - reports Taco Bell has pulled certain menu items amid nationwide parasite outbreak 520% - IONS (Ionis Pharmaceuticals $66.01, -21.8%) -- 13,269 contracts vs avg 2,551 - P/C ratio: 2.81 - CARDIO-TTRansform Phase 3 trial of AstraZeneca's eplontersen does not meet primary endpoint 497% - MRSH (Marsh $178.79, -0.1%) -- 1,848 contracts vs avg 372 - P/C ratio: 32.60 468% - BBIO (BridgeBio Pharma $89.17, +13.8%) -- 8,223 contracts vs avg 1,757 - P/C ratio: 0.13 - AZN P3 CARDIO-TTRansform of Wainua in ATTR-CM data read through 464% - IESC (IES Holdings $641.34, +3.6%) -- 1,016 contracts vs avg 219 - P/C ratio: 0.01 460% - SHOO (Steven Madden $40.54, +3.9%) -- 6,808 contracts vs avg 1,480 - P/C ratio: 0.00 446% - SAR (Saratoga Investment $17.83, -0.8%) -- 1,217 contracts vs avg 273 - P/C ratio: 34.79 - following recent post earnings move 427% - PSNL (Personalis $14.60, +3.5%) -- 7,057 contracts vs avg 1,654 - P/C ratio: 0.02 408% - ALNY (Alnylam Pharmaceuticals $337.23, +4.2%) -- 3,222 contracts vs avg 790 - P/C ratio: 0.78 - AZN P3 CARDIO-TTRansform of Wainua in ATTR-CM data read through 366% - ANGX (Angel Studios $4.00, +3.0%) -- 1,442 contracts vs avg 393 - P/C ratio: 0.00 366% - CRNX (Crinetics Pharmaceuticals $83.52, +0.0%) -- 3,012 contracts vs avg 823 - P/C ratio: 0.09 332% - VIK (Viking Holdings $101.37, +3.5%) -- 4,743 contracts vs avg 1,429 - P/C ratio: 12.41 330% - LASR (nLight $75.95, +29.4%) -- 4,583 contracts vs avg 1,388 - P/C ratio: 0.52 - Awarded combined $86M contract with LMT under the Joint Laser Weapons System (JLWS) program 330% - FE (FirstEnergy $47.79, -0.6%) -- 3,155 contracts vs avg 957 - P/C ratio: 0.02 329% - LESL (Leslie's $6.82, -4.5%) -- 1,170 contracts vs avg 356 - P/C ratio: 42.33 325% - BFH (Bread Financial $95.66, +2.0%) -- 530 contracts vs avg 163 - P/C ratio: 264.00 303% - AZN (AstraZeneca $177.45, -6.3%) -- 4,460 contracts vs avg 1,470 - P/C ratio: 0.40 - CARDIO-TTRansform Phase 3 trial of eplontersen does not meet primary endpoint 303% - FRMM (Forum Market $6.13, +2.8%) -- 3,003 contracts vs avg 991 - P/C ratio: 0.02 300% - SNY (Sanofi $43.67, +2.1%) -- 5,748 contracts vs avg 1,914 - P/C ratio: 0.02 - AZN P3 CARDIO-TTRansform of Wainua in ATTR-CM data read through 274% - TOYO (TOYO Co. $6.36, -2.7%) -- 2,181 contracts vs avg 797 - P/C ratio: 0.02 272% - AMRZ (Amrize $49.59, +0.3%) -- 2,738 contracts vs avg 1,005 - P/C ratio: 52.69 252% - KHC (Kraft Heinz $24.93, +0.0%) -- 70,463 contracts vs avg 27,999 - P/C ratio: 0.02 233% - MDA (MDA Space $35.76, -7.5%) -- 459 contracts vs avg 197 - P/C ratio: 2.04 - increases previously announced bought deal offering to 23.0M common shares 212% - NFGC (New Found Gold $1.54, +2.7%) -- 970 contracts vs avg 457 - P/C ratio: 31.33 205% - ABEO (Abeona Therapeutics $7.07, +4.0%) -- 1,339 contracts vs avg 654 - P/C ratio: 0.00 Click here to view / receive alerts for Unusual Options Volume Related: ABEO, ACI, ALNY, AMRZ, ANGX, AZN, BBIO, BCE, BFH, CRNX, FE, FRMM, IESC, IONS, KHC, LASR, LESL, MDA, MRSH, NFGC, PSNL, SAR, SHOO, SNY, TOYO, VIK, YUM...(more)	show story hide story
09-Jul-2026 11:03	PBYI US Appeals Court affirms district court decision finding certain claims of Pfizer's '314 and '162 patents invalid in patent litigation against AstraZeneca -- court filing ($7.93 -$0.21) As background, Wyeth (Pfizer; PFE) appealed from a final decision of the United States District Court for the District of Delaware granting judgment as a matter of law of invalidity of asserted claims 1, 3, and 9 of U.S. Patent 10,603,314 and asserted claim 1 of U.S. Patent 10,596,162 in litigation brought against AstraZeneca alleging that its Tagrisso infringed the two patents The district court granted JMOL of invalidity for lack of enablement of the asserted claims determining that no reasonable jury could have found the asserted claims not invalid. Wyeth appealed, seeking to reinstate the jury verdict on the ground that the district court erred in granting JMOL of invalidity for lack of enablement of the asserted claims of the '314 and '162 patents See linked comments for reference On appeal, the Federal Circuit today affirmed the district court decision, concluding that the district court did not err in granting JMOL of invalidity of the asserted claims of the '314 and '162 patents due to a lack of enablement. Puma Biotechnology is exclusive licensee of the the '314 and '162 patents, and under Puma's worldwide exclusive license agreement with Pfizer the company maintains contractual rights to recover monetary damages in the AstraZeneca litigation Case is Wyeth LLC v. AstraZeneca Pharmaceuticals LP; #24-2325 in US Court of Appeals for the Federal Circuit. Decision linked below See Related StreetAccount comments: 9/16/2024 9:07:23 AM - Puma Biotechnology discloses Wyeth files notice appealing District Court's judgment - 8-K 8/14/2024 1:49:13 PM - Puma Biotechnology trading lower after judge issues ruling in Wyeth vs. Astrazeneca Pharmaceuticals (case 21 C 1338) 8/7/2024 9:05:28 AM - Puma Biotechnology discloses bench trial ruling finds for Wyeth and against AstraZeneca - 8-K Related: AZN.LN, PFE Reference Link	show story hide story
09-Jul-2026 09:22	StreetAccount Summary - US Pre-market trading update S&P futures +16.0 to 7544.75, +0.21% vs settlement. 10-year yield +0 bps to 4.57%. Aug WTI +$0.41 or +0.56% to $73.93. Trading Higher: *Market cap >$10B* +16.8% ALNY (Alnylam Pharmaceuticals $378.00, +54.50) -- sympathy to ATTR-CM competitor AstraZeneca's Phase 3 trial of eplontersen missing primary endpoint +8.5% BBIO (BridgeBio Pharma $85.02, +6.69) -- sympathy to ATTR-CM competitor AstraZeneca's Phase 3 trial of eplontersen missing primary endpoint +8.4% ASX (ASE Technology Holding $43.30, +3.37) -- June consolidated net revenue; Cathay Financial initiates buy +7.7% GLW (Corning $198.24, +14.21) +7.1% BE (Bloom Energy $272.22, +17.93) -- responds to report published yesterday by Hunterbrook Media +6.6% MU (Micron Technology $1,011.41, +62.61) -- up to $3B strategic investment to strengthen U.S. semiconductor ecosystem +5.8% COHR (Coherent $335.50, +18.45) +5.6% LITE (Lumentum Holdings $747.00, +39.90) +5.3% NBIS (Nebius Group $228.02, +11.54) +5.3% CRDO (Credo Technology $272.28, +13.59) +5.2% WULF (TeraWulf $24.02, +1.19) +5.2% ALAB (Astera Labs $413.64, +20.48) +5.1% CBRS (Cerebras Systems $191.02, +9.30) -- expansion of European infrastructure footprint; plans 200 MW of capacity by end of 2027 +4.2% IREN (IREN $44.80, +1.79) +4.1% VRT (Vertiv Holdings $330.90, +13.09) +3.8% ANET (Arista Networks $187.87, +6.82) +3.7% GEV (GE Vernova $1,110.11, +39.12) +3.6% CLS (Celestica $373.80, +13.06) +3.4% FPS (Forgent Power Solutions $46.84, +1.55) +3.3% CDE (Coeur Mining $15.74, +0.50) +3.2% CIEN (Ciena $455.01, +14.04) +3.1% CRWV (CoreWeave $92.79, +2.79) +3.0% HUT (Hut 8 Corp. $109.32, +3.21) +3.0% CAT (Caterpillar $976.72, +28.64) +2.9% RKLB (Rocket Lab $85.80, +2.45) +2.9% P (Everpure $80.00, +2.27) +2.7% EME (EMCOR Group $790.00, +21.02) +2.7% APH (Amphenol $162.50, +4.28) +2.6% FSLR (First Solar $230.19, +5.89) +2.5% QNT (Quantinuum $77.52, +1.91) +2.5% ETN (Eaton Corp. $409.35, +9.79) +2.5% FCX (Freeport-McMoRan $58.95, +1.45) *Market cap $1B-$10B* +18.5% SMPL (Simply Good Foods $15.22, +2.38) -- earnings +11.4% ENVX (Enovix $5.71, +0.59) -- appoints Michael Vyvoda (fomerly with Apple) as COO +9.9% FCEL (FuelCell Energy $24.78, +2.24) -- collaboration with Siemens (SIE.GR) +8.0% CECO (CECO Environmental $85.90, +6.37) -- JPMorgan initiates overweight +7.1% COHU (Cohu $55.80, +3.68) -- Baird initiates outperform +7.0% SHAZ (SharonAI Holdings $81.50, +5.33) -- B Riley Securities initiates buy +6.1% FLNC (Fluence Energy $16.27, +0.93) +5.8% PRM (Perimeter Solutions $35.76, +1.97) -- JPMorgan initiates overweight +5.7% AAOI (Applied Optoelectronics $121.00, +6.56) +5.6% VSH (Vishay Intertechnology $44.56, +2.37) +5.6% VPG (Vishay Precision Group $114.00, +6.05) +5.6% CELC (Celcuity $115.00, +6.10) +5.4% AMPX (Amprius Technologies $12.20, +0.62) +5.1% OUST (Ouster $45.61, +2.20) +4.9% ENHA (Enhanced Group, Inc. $2.76, +0.13) +4.8% KEEL (Keel Infrastructure $4.78, +0.22) +4.7% WYFI (WhiteFiber, Inc. $38.48, +1.74) +4.7% POET (POET Technologies $8.91, +0.40) +4.4% AIP (Arteris $35.96, +1.50) +4.2% APLD (Applied Digital $32.76, +1.32) +4.2% MARA (MARA Holdings $12.53, +0.51) -- agreement with HIF to acquire strategic powered land site in Texas +4.2% RIOT (Riot Platforms $21.97, +0.88) +4.0% CLSK (Cleanspark $12.90, +0.50) +3.9% ENPH (Enphase Energy $44.68, +1.66) +3.8% PENG (Penguin Solutions $81.47, +3.00) +3.8% CIFR (Cipher Mining $22.69, +0.84) +3.7% BRUN (Boost Run $30.95, +1.12) +3.7% EOSE (Eos Energy Enterprises $4.67, +0.17) +3.6% CORZ (Core Scientific $24.35, +0.85) +3.5% VOYG (Voyager Technologies $35.27, +1.18) -- multi-million-dollar contract to deliver agentic-AI spectrum operations platform for undisclosed program +3.4% AMSC (American Superconductor $37.24, +1.24) +3.4% LWLG (Lightwave Logic $7.07, +0.23) +3.3% BTDR (Bitdeer Technologies Group $12.97, +0.41) -- to open $36M manufacturing facility in Sparks, NV +3.2% INOD (Innodata $71.25, +2.23) +3.1% AEVA (Aeva, Inc. $22.16, +0.66) +2.9% NESR (National Energy Services Reunited $27.99, +0.79) +2.8% TGB (Trekor Metals Limited $6.65, +0.18) +2.8% RGC (Regencell Bioscience Holdings $6.67, +0.18) +2.7% FRMI (Fermi $7.56, +0.20) +2.7% TE (T1 Energy $7.55, +0.20) +2.7% EXK (Endeavour Silver $7.93, +0.21) +2.6% AG (First Majestic Silver $16.21, +0.41) -- Q2 production +2.6% GLXY (Galaxy Digital, Inc. $25.50, +0.64) +2.6% SOLS (Solstice Advanced Materials $62.57, +1.56) -- Truist upgrade *Market cap <$1B* +16.3% JLHL (Julong Holding $3.56, +0.50) +11.6% AP (Ampco-Pittsburgh $8.00, +0.83) -- customer order activity during 1H26 totaled ~$268M +10.7% WRAP (Wrap Technologies $1.76, +0.17) +9.7% RTB (RTB Digital Inc $21.15, +1.87) +6.9% CNTN (Canton Strategic Holdings, Inc. $2.48, +0.16) +6.7% PLYX (Polaryx Therapeutics $2.72, +0.17) -- HC Wainwright initiates buy +6.7% CCXI (Churchill Capital Corp. XI $16.28, +1.02) +6.5% ZSQR (Z Squared, Inc. $7.50, +0.46) +6.5% INMD (InMode $15.40, +0.94) -- Steel Partners offers to acquire for $16.75 per share in cash +6.3% MRLN (Merlin $4.56, +0.27) -- Cantor Fitzgerald initiates overweight +6.0% TRT (Trio-Tech International $11.50, +0.65) +5.4% VELO (Velo3D $14.50, +0.75) -- Cantor Fitzgerald initiates overweight +5.4% SWMR (Swarmer, Inc. $43.71, +2.22) +5.3% BNC (CEA Industries $2.78, +0.14) +5.1% GLSI (Greenwich LifeSciences $19.84, +0.97) -- EMA approval for use of commercially manufactured GP2 in FLAMINGO-01 +4.9% OCC (Optical Cable $16.67, +0.78) +4.9% NUAI (New Era Energy & Digital $4.56, +0.21) +4.2% CEPL (Capstone Energy+ $12.38, +0.50) +4.2% SHMD (Schmid Group $5.20, +0.21) +4.0% MRAM (Everspin Technologies $18.09, +0.70) +4.0% BKSY (Blacksky Technology $26.92, +1.04) +3.7% ASM (Avino Silver & Gold Mines $5.94, +0.21) +3.7% IRD (Opus Genetics $4.25, +0.15) -- BEST1 program update with timeline for OPGx-BEST1 results +3.5% KULR (KULR Technology Group $3.27, +0.11) +3.4% FATE (Fate Therapeutics $3.03, +0.10) -- FDA clearance of Investigational New Drug Application for FT839 *Semis broadly higher -- iShares Semi ETF (SOXX) +4.76%* AEHR +15.9% (follow-on production order), AMAT +8.6%, AXTI +8.4%, UCTT +7.8% (appoints Michael Keogh as CFO), WDC +7.4%, STX +7.2%, AMKR +7.0%, LRCX +6.9%, KLAC +6.9%, TER +6.7%, ACMR +6.7%, ENTG +6.6%, ALGM +6.5%, ONTO +6.4%, AOSL +6.4%, ICHR +6.4%, MXL +6.4%, NVTS +6.4%, MRVL +6.3%, WOLF +5.9%, SNDK +5.8%, ACLS +5.7%, RMBS +5.6%, VECO +5.5%, TTMI +5.4%, ARM +5.3%, INTC +4.7%, AMBA +4.7%, MPWR +4.5%, SITM +4.4%, ALMU +4.3%, CEVA +4.3%, FORM +4.2%, MCHP +4.2%, GFS +4.2%, CAMT +4.1%, NVMI +4.0%, AMD +3.8% (William Blair initiates market perform), MX +3.8%, ON +3.8%, AVGO +3.7% (in reaction to report Meta Platforms (META) to begin Iris chip production in September), QCOM +3.5%, TXN +3.5%, NXPI +3.5%, SWKS +3.3%, TSEM +3.3%, ADI +3.2%, INDI +3.0%, PLAB +2.9%, ASML +2.9%, LSCC +2.7%, SMCI +2.6%, TSM +2.1% Trading Lower: *Market cap >$10B* -7.9% AZN (AstraZeneca $174.40, -14.88) -- trial for Wainua heart disease drug failed to meet its primary objective In sympathy: IONS -18.9% -5.2% IBM (IBM $286.20, -15.85) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software; Tata Consultancy (532540.IN) earnings sympathy -4.5% FIG (Figma $20.70, -0.97) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -4.5% CRM (Salesforce $159.15, -7.43) -- KeyBanc downgrade; Bloomberg report Starbucks (SBUX) using AI to develop internal tools to reduce reliance on software -4.5% NOW (ServiceNow $102.90, -4.88) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -3.9% WDAY (Workday $132.44, -5.44) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -3.6% META (Meta Platforms $581.21, -21.91) -- Reuters reports to begin production of new AI chip (Iris) as part of plans to scale to 14GW of compute next year -3.5% ADBE (Adobe $213.19, -7.75) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -3.5% HUBS (HubSpot $190.96, -6.86) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -3.3% TEAM (Atlassian $82.65, -2.82) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -3.3% PEP (PepsiCo $137.74, -4.77) -- earnings -3.0% RDY (Dr. Reddy's Laboratories $13.70, -0.42) -- issue with the active pharmaceutical ingredient (API) used in certain batches of semaglutide product -3.0% OKTA (Okta, Inc. $142.31, -4.46) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -3.0% PLTR (Palantir Technologies $128.27, -3.96) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -3.0% RBRK (Rubrik $81.83, -2.57) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -3.0% INTU (Intuit $262.65, -8.25) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.9% VEEV (Veeva Systems $182.78, -5.39) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.8% PSKY (Paramount Skydance $9.48, -0.27) -- Reuters reports US states may sue to block PSKY/WBD deal next week; Arete Research downgrade -2.7% FTNT (Fortinet $152.42, -4.29) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.6% ZS (Zscaler $139.79, -3.76) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.6% MDB (MongoDB $349.94, -9.46) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.5% U (Unity Software $28.71, -0.75) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.3% PINS (Pinterest $22.02, -0.51) -2.3% SHOP (Shopify $116.49, -2.73) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.2% SNOW (Snowflake $255.60, -5.71) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.2% NTNX (Nutanix $52.75, -1.18) -2.2% DDOG (Datadog $255.37, -5.72) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.2% ADSK (Autodesk $201.41, -4.63) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.1% MSFT (Microsoft $375.30, -8.04) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.1% APP (AppLovin $511.00, -11.18) -2.1% SPOT (Spotify Technology $474.89, -10.33) -2.0% CRWD (CrowdStrike $187.37, -3.75) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.0% PDD (PDD Holdings $83.05, -1.69) -2.0% GH (Guardant Health $153.00, -3.17) -1.9% PANW (Palo Alto Networks $314.65, -5.94) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -1.9% ZM (Zoom Video $85.75, -1.65) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -1.9% DT (Dynatrace $43.00, -0.84) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -1.9% NET (Cloudflare $268.09, -5.31) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software; Tata Consultancy (532540.IN) earnings sympathy -1.8% AMZN (Amazon.com $239.28, -4.34) -1.8% PAYX (Paychex $104.61, -1.97) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -1.7% GOOGL (Alphabet $355.77, -6.16) -1.7% COST (Costco Wholesale $937.08, -16.05) -- June net sales -1.7% RDDT (Reddit $192.00, -3.31) -1.7% MOH (Molina Healthcare $227.00, -3.94) -1.7% FROG (JFrog $91.12, -1.61) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -1.7% ACN (Accenture $133.20, -2.36) -- Tata Consultancy (532540.IN) earnings sympathy; Bloomberg report Starbucks (SBUX) using AI to develop internal tools to reduce reliance on software *Market cap $1B-$10B* -7.8% MDA (MDA Space $35.67, -3.00) -- to acquire Collecte Localisation Satellites for €567M (C$920M) in cash; upsized offering of 23M shares at C$35.60/sh -4.2% GLUE (Monte Rosa Therapeutics $23.05, -1.01) -3.8% RXT (Rackspace Technology $6.33, -0.25) -- preliminary Q2 results, PLTR agreement, $250M ATM -3.6% KVYO (Klaviyo $16.01, -0.59) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -3.1% APPN (Appian $23.51, -0.76) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.9% MNDY (monday.com $78.70, -2.32) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.9% AVPT (AvePoint $12.12, -0.36) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.7% PATH (UiPath $11.11, -0.31) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.7% LEVI (Levi Strauss $23.70, -0.67) -- earnings, raises dividend -2.6% SAIL (SailPoint $14.72, -0.39) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.5% ESTC (Elastic $58.60, -1.48) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.4% ZETA (Zeta Global Holdings $21.13, -0.53) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.4% PCTY (Paylocity Holding $112.50, -2.71) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.4% MAT (Mattel $12.86, -0.31) -- Goldman Sachs downgrade -2.4% LION (Lionsgate Studios Corp. $13.25, -0.33) -2.4% GVA (Granite Construction $140.01, -3.51) -- Goldman Sachs downgrade -2.3% S (SentinelOne $17.40, -0.41) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.1% ASAN (Asana, Inc. $6.93, -0.15) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.0% GTLB (Gitlab $31.10, -0.64) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software -2.0% WIX (Wix.com $46.79, -0.97) -- SBUX reportedly using AI to develop internal tools to reduce reliance on software *Market cap <$1B* -25.3% BYRN (Byrna Technologies $4.44, -1.50) -- earnings; definitive agreement to acquire Hero Defense Systems assets -18.6% GLOO (Gloo Holdings $3.24, -0.74) -- 7.0M-share secondary priced at $3.25/share -2.9% FBRX (Forte Biosciences $19.99, -0.59) -- results from the FB102 double-blind placebo-controlled phase 1B study in vitiligo Click here to view our Gainers & Decliners page Related: AAOI, ACLS, ACMR, ACN, ADBE, ADI, ADSK, AEHR, AEVA, AG, AI, AIP, ALAB, ALGM, ALMU, ALNY, AMAT, AMBA, AMD, AMKR, AMPX, AMSC, AMZN, ANET, AOSL, AP, APH, APLD, APP, APPN, ARM, ASAN, ASM, ASML, ASX, AVGO, AVPT, AXTI, AZN, BBIO, BE, BKSY, BNC, BRUN, BTDR, BYRN, CAMT, CAT, CBRS, CCXI, CDE, CECO, CELC, CEPL, CEVA, CIEN, CIFR, CLS, CLSK, CNTN, COHR, COHU, CORZ, COST, CRDO, CRM, CRWD, CRWV, DDOG, DT, EME, ENHA, ENPH, ENTG, ENVX, EOSE, ESTC, ETN, EXK, FATE, FBRX, FCEL, FCX, FIG, FLNC, FORM, FPS, FRMI, FROG, FSLR, FTNT, GEV, GFS, GH, GLOO, GLSI, GLUE, GLW, GLXY, GOOGL, GTLB, GVA, HL, HUBS, HUT, IBM, ICHR, INDI, INMD, INOD, INTC, INTU, IONS, IRD, IREN, JLHL, KEEL, KLAC, KULR, KVYO, LEVI, LION, LITE, LRCX, LSCC, LWLG, MARA, MAT, MCHP, MDA, MDB, META, MNDY, MOH, MPWR, MRAM, MRLN, MRVL, MSFT, MU, MX, MXL, NBIS, NESR, NET, NOW, NTNX, NUAI, NVMI, NVTS, NXPI, OCC, OKTA, ON, ONTO, OUST, P, PANW, PATH, PAYX, PCTY, PDD, PENG, PEP, PINS, PLAB, PLTR, PLYX, POET, PRM, PSKY, Q, QCOM, QNT, RBRK, RDDT, RDY, RGC, RIOT, RKLB, RMBS, RTB, RXT, S, SAIL, SHAZ, SHMD, SHOP, SITM, SMCI, SMPL, SNDK, SNOW, SOLS, SPOT, STX, SWKS, SWMR, TE, TEAM, TER, TGB, TRT, TSEM, TSM, TTMI, TXN, U, UCTT, VECO, VEEV, VELO, VG, VOYG, VPG, VRT, VSH, WDAY, WDC, WIX, WOLF, WRAP, WULF, WYFI, ZETA, ZM, ZS, ZSQR...(more)	show story hide story
09-Jul-2026 08:56	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis AZN.LN and IONS trading lower in pre-market after the CARDIO-TTRansform Phase 3 trial for WAINUA in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to Week 140 compared with placebo. Yesterday, major health groups ended mostly lower by 1-2% on the averages, led by MedTech, Services, and Pharma. Managed Care was the lone advancer, led by CNC +1.5% and CI +1.1%. COR +1.7% and MRNA (7.5%) bracketed the XLV. Sector specific newsflow remained very light and took a backseat to geopolitics and market rotations. Hospital stocks pressured after multiple downgrades hit the tape, although risk-off trade hit more healthcare names. Earnings season begins on 15-Jul with Elevance Health and JNJ reporting before the open, followed by UnitedHealth and Abbott the next day. Macro S&P futures up 0.3% in Thursday morning trading. Comes after US equities finished mostly lower on Wednesday despite a rebound in momentum/semis/memory. Market seemingly helped by stabilization in oil and rates. Fits with expectations this week's flare-up in Middle East tensions will not lead to a meaningful reescalation of kinetic activity (Trump said yesterday Iran called and wants to make a deal). However, short positioning in oil and Iran's heightened focus on SoH control still flagged as areas of concern. Wednesday's momentum bounce another positive for risk sentiment. Fits with thoughts recent unwind was much more about technical dynamics than any real shift in the AI capex demand narrative. Not much on tap over next couple of days but next week brings some high-profile macro events and the start of Q2 earnings season featuring the banks. AZN under pressure after trial for its Wainua drug on a rare type of heart disease failed to meet its primary objective. Initial claims and June existing home sales highlight the economic calendar this morning. Fed's Williams and Logan also set to speak today. Pre-market trading update: Trading higher +17.9% ALNY sympathy to AZN +10.4% BBIO sympathy to AZN Trading lower -20.6% IONS trial results in ATTR-CM, partner with AZN -7.7% AZN trial results in ATTR-CM -3.6% RDY discloses manufacturing issue with API in semaglutide -1.9% MOH UBS previewed MCO earnings Pharma Trial Results: AZN.LN CARDIO-TTRansform Phase 3 trial of AstraZeneca's eplontersen does not meet primary endpoint. The CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to Week 140 compared with placebo. Ionis and AstraZeneca will continue to analyze the full data set, and results will be shared with the scientific community at the European Society of Cardiology (ESC) Congress in August 2026. QuickTake: Analysts across the board view the result as a negative surprise, with consensus peak sales for Wainua expected to fall sharply from ~$2.6B to below $0.5B, implying a 2-3% hit to AstraZeneca's share price, though near-term sentiment may be more negative. Despite the disappointment, a number of firms maintain their Outperform/Buy ratings on the stock, noting that the pipeline miss represents only a ~3% NPV downside to base case valuations, and that AZN's broader pipeline of clinical projects remains underappreciated. A key silver lining highlighted from today's news is the nominally significant HR of 0.71 observed in treatment-naïve patients, which could support a new Phase 3 trial in this subgroup. Analysts also flag a positive read-across to Sanofi given its royalty exposure to a competing product ( Alnylam's Amvuttra, which is already approved). It was noted Wainua would have been a significant competitor to Amvuttra had CARDIO-TTransform been positive. Looking ahead, attention now turns to the next wave of ATTR innovation via "depleters," with AZN's own Phase 3 cliramitug (DepleTTR) data expected in 2027, which analysts believe could synergistically combine with Wainua to offer improved long-term outcomes in ATTR-CM patients. Research: ROP.SW upgraded to buy from hold at Vontobel Biotech M&A: TARS to acquire iRenix Medical in upfront consideration of ~$75M, consisting of $37.5M in cash and $37.5M in Tarsus common stock. Potential approval and commercial milestone payments of up to $490M. Based on data from the completed Phase 2B/3 RELIEF trial, and in alignment with feedback from the FDA, Tarsus plans to initiate a Phase 3 study designed to evaluate the tolerability and safety of IRX-101 compared to povidone-iodine. The study is expected to begin enrolling in H1 of 2027 with results anticipated in 2028 Trial Results: RYTM discloses NEJM Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity Regulatory: MRNA EU Commission signs joint procurement contract for mRESVIA vaccine REGN NICE recommends Regeneron's Libtayo to treat recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy Research: SRPT Sarepta Therapeutics upgraded to outperform from peer perform at Wolfe Research EWTX Edgewise Therapeutics initiated outperform at Oppenheimer, Target is $51, 10% upside (FactSet average target $49.15; range $30-66) 1SXP.GR upgraded to outperform from sector perform at RBC Capital Markets Life Science & MedTech Regulatory: NTRA Natera's Signatera receives certification as a Class C device under the European Union's In Vitro Diagnostic Regulation (IVDR) ROP.SW Roche receives CE Mark for blood test to identify tuberculosis infection Corporate: NEO NeoGenomics launches PTEN IHC companion diagnostic for prostate cancer Research: WAT initiated outperform at RBC Capital Markets with $435 target, 18% upside (FactSet average target $407.82; range $350-460) A resumed hold at Jefferies BMO Capital Markets analyst Vik Chopra initiates coverage on sixteen names in Medical Supplies and Devices. Eight stocks with outperform ratings, eight with market perform ratings. ALGN initiated outperform at BMO Capital Markets with $209 target, 20% upside (FactSet average target $208.23; range $175-240) ATEC initiated outperform at BMO Capital Markets with $11 target, 19% upside (FactSet average target $16.45; range $11-24) CNMD initiated market perform at BMO Capital Markets with $36 target, 7% upside (FactSet average target $39.60; range $39-40) ENOV initiated outperform at BMO Capital Markets with $29 target, 23% upside (FactSet average target $41.90; range $32-55) GEHC initiated market perform at BMO Capital markets with $70 target, 8% upside (FactSet average target $78.94; range $65-98) GMED initiated outperform at BMO Capital Markets with $94 target, 23% upside (FactSet average target $107.27; range $80-122) IART initiated market perform at BMO Capital Markets with $19 target, 10% upside (FactSet average target $17.86; range $11-27) ISRG initiated outperform at BMO Capital Markets with $518 target, 25% upside (FactSet average target $571.59; range $366-750) NVST initiated market perform at BMO Capital Markets with $27 target, 5% upside (FactSet average target $29.62; range $21-35) SOLV initiated market perform at BMO Capital Markets with $81 target, 8% upside (FactSet average target $83.08; range $60-100) STMN.SW initiated outperform at BMO Capital Markets with CHF121 target, 18% upside (FactSet average target CHF112.47; range CHF83-130) SYK initiated outperform at BMO Capital Markets with $369 target, 13% upside (FactSet average target $389.54; range $315-465) TFX initiated outperform at BMO Capital Markets with $159 target, 22% upside (FactSet average target $145.89; range $135-160) ZBH initiated market perform at BMO Capital Markets with $95 target, 8% upside (FactSet average target $95.50; range $83-110) Services & Hospitals Research: HSIC initiated market perform at BMO Capital markets with $85 target, 2% upside (FactSet average target $88.73; range $64-100) XRAY initiated market perform at BMO Capital markets with $12 target, 2% upside (FactSet average target $13.43; range $9-17) Managed Care Corporate: CNC Centene's Meridian Health Plan of Illinois awarded Illinois Medicaid contract Press Release Research: UBS analyst AJ Rice previews MCO earnings for Q2 - firm is most positive on diversified MCOs and Medicare Advantage, over the Medicaid focus names. (UNH, ELV, CI, MOH, CNC) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 1SXP.GR, A, ALGN, ALNY, ATEC, AZN, AZN.LN, BBIO, CI, CNC, CNMD, ELV, ENOV, EWTX, GEHC, GMED, HSIC, IART, IONS, ISRG, MOH, MRNA, NEO, NTRA, NVST, RDY, REGN, ROP.SW, RYTM, SOLV, SRPT, STMN.SW, SYK, TARS, TFX, UNH, WAT, XRAY, ZBH...(more)	show story hide story
09-Jul-2026 08:21	StreetAccount Summary - US Pre-market trading S&P futures +14.3 to 7543, +0.19% vs settlement. 10-year yield +0 bps to 4.57%. Aug WTI +$0.56 or +0.76% to $74.08. Trading Higher: *Market cap >$10B* +18.1% ALNY (Alnylam Pharmaceuticals $382.05, +58.55) -- sympathy to TTR-CM competitor AstraZeneca's Phase 3 trial of eplontersen missing primary endpoint +9.0% BBIO (BridgeBio Pharma $85.35, +7.02) -- sympathy to TTR-CM competitor AstraZeneca's Phase 3 trial of eplontersen missing primary endpoint +6.7% TER (Teradyne $374.95, +23.38) +6.2% CBRS (Cerebras Systems $193.05, +11.33) -- expansion of European infrastructure footprint; plans 200 MW of capacity by end of 2027 +6.2% GLW (Corning $195.49, +11.46) +6.0% AMKR (Amkor Technology $70.91, +4.00) +5.9% MU (Micron Technology $1,005.10, +56.30) +5.8% WDC (Western Digital $582.10, +31.80) +5.8% ONTO (Onto Innovation $308.30, +16.85) +5.8% AMAT (Applied Materials $603.50, +33.00) +5.7% MRVL (Marvell Technology $244.99, +13.28) +5.6% KLAC (KLA $233.50, +12.32) +5.6% RMBS (Rambus $115.74, +6.10) +5.6% LRCX (Lam Research $351.86, +18.71) +5.5% CRDO (Credo Technology $273.00, +14.31) +5.4% SNDK (Sandisk $1,820.50, +93.32) +5.3% VICR (Vicor $277.00, +13.84) +5.3% STX (Seagate Technology $905.95, +45.93) +5.1% ENTG (Entegris $145.76, +7.04) +5.0% ALAB (Astera Labs $413.00, +19.84) +5.0% WULF (TeraWulf $23.97, +1.14) +5.0% INTC (Intel $115.77, +5.53) +4.9% COHR (Coherent $332.57, +15.52) +4.8% MTSI (MACOM Technology $319.99, +14.76) +4.6% MPWR (Monolithic Power Systems $1,375.55, +60.04) +4.4% LITE (Lumentum Holdings $738.45, +31.35) +4.3% TTMI (TTM Technologies $151.50, +6.21) +4.2% IREN (IREN $44.81, +1.81) +4.2% BE (Bloom Energy $264.94, +10.65) +4.1% ON (onsemi $97.67, +3.88) +4.1% SITM (SiTime $637.53, +25.40) +4.1% Q (Qnity Electronics $147.95, +5.78) +4.0% SMTC (Semtech $133.93, +5.09) +3.9% NBIS (Nebius Group $224.98, +8.50) +3.8% AVGO (Broadcom $403.39, +14.70) -- in reaction to report Meta Platforms (META) to begin Iris chip production in September +3.7% GFS (GlobalFoundries $70.50, +2.53) +3.6% ANET (Arista Networks $187.50, +6.45) +3.6% FLEX (Flex $138.23, +4.86) +3.6% LSCC (Lattice Semiconductor $137.22, +4.74) +2.4% TOST (Toast, Inc. $29.25, +0.68) -- Goldman Sachs upgrade +1.4% MRNA (Moderna $74.84, +1.04) -- EU Commission signs joint procurement contract for mRESVIA vaccine +1.4% VALE (Vale $14.25, +0.20) -- update regarding resignation of Chairman Daniel André Stieler *Market cap $1B-$10B* +18.7% AEHR (Aehr Test Systems $80.60, +12.71) -- follow-on production order +18.2% ENVX (Enovix $6.06, +0.94) -- appoints Michael Vyvoda (fomerly with Apple) as COO +17.4% SMPL (Simply Good Foods $15.07, +2.23) -- earnings +11.6% FCEL (FuelCell Energy $25.16, +2.62) -- collaboration with Siemens (SIE.GR) +7.6% AXTI (AXT Inc $64.66, +4.54) +6.7% ICHR (Ichor Holdings $94.75, +5.94) +6.4% ACMR (ACM Research $104.39, +6.32) +6.3% SHAZ (SharonAI Holdings $80.95, +4.78) -- B Riley Securities initiates buy +6.0% AAOI (Applied Optoelectronics $121.32, +6.88) +5.9% MXL (MaxLinear $91.11, +5.06) +5.9% NVTS (Navitas Semiconductor $14.15, +0.79) +5.7% CECO (CECO Environmental $84.04, +4.51) -- JPMorgan initiates overweight +5.4% COHU (Cohu $54.92, +2.80) -- Baird initiates outperform +5.3% FORM (FormFactor $117.50, +5.91) +5.2% UCTT (Ultra Clean Holdings $106.19, +5.28) -- appoints Michael Keogh as CFO +5.2% WYFI (WhiteFiber, Inc. $38.65, +1.91) +5.2% OUST (Ouster $45.65, +2.24) +5.1% VPG (Vishay Precision Group $113.50, +5.55) +5.0% KEEL (Keel Infrastructure $4.79, +0.23) +4.8% RGC (Regencell Bioscience Holdings $6.80, +0.31) +4.8% POET (POET Technologies $8.91, +0.40) +4.6% VSH (Vishay Intertechnology $44.14, +1.95) +4.6% ENHA (Enhanced Group, Inc. $2.75, +0.12) +4.6% VECO (Veeco Instruments $56.95, +2.48) +4.5% PENG (Penguin Solutions $82.02, +3.55) +4.5% MARA (MARA Holdings $12.56, +0.54) -- agreement with HIF to acquire strategic powered land site in Texas +4.4% AMBA (Ambarella $78.00, +3.26) +4.2% WOLF (Wolfspeed $37.36, +1.50) +4.1% PRM (Perimeter Solutions $35.17, +1.38) -- JPMorgan initiates overweight +2.7% SOLS (Solstice Advanced Materials $62.67, +1.66) -- Truist upgrade +2.3% AG (First Majestic Silver $16.16, +0.36) -- Q2 production *Market cap <$1B* +11.7% AP (Ampco-Pittsburgh $8.01, +0.84) -- customer order activity during 1H26 totaled ~$268M +11.0% BGDE (Mawson Infrastructure Group $7.95, +0.79) +9.3% FBRX (Forte Biosciences $22.50, +1.92) -- results from the FB102 double-blind placebo-controlled phase 1B study in vitiligo +7.1% CCXI (Churchill Capital Corp. XI $16.35, +1.09) +7.0% GLSI (Greenwich LifeSciences $20.19, +1.32) -- EMA approval for use of commercially manufactured GP2 in FLAMINGO-01 +6.1% ALMU (Aeluma $18.83, +1.09) +5.6% VELO (Velo3D $14.52, +0.77) -- Cantor Fitzgerald initiates overweight +5.1% TENX (Tenax Therapeutics $18.63, +0.90) +5.1% CNTN (Canton Strategic Holdings, Inc. $2.44, +0.12) +4.7% SWMR (Swarmer, Inc. $43.43, +1.94) +4.4% KULR (KULR Technology Group $3.30, +0.14) +4.2% BNC (CEA Industries $2.75, +0.11) +3.8% MRLN (Merlin $4.45, +0.16) -- Cantor Fitzgerald initiates overweight +3.1% PLYX (Polaryx Therapeutics $2.63, +0.08) -- HC Wainwright initiates buy Trading Lower: *Market cap >$10B* -7.6% AZN (AstraZeneca $174.85, -14.43) -- PIII CARDIO-TTRansform of Wainua in ATTR-CM did not meet primary endpoint In sympathy: IONS -21.0% -4.8% CRM (Salesforce $158.63, -7.95) -- KeyBanc downgrade; Bloomberg report Starbucks (SBUX) using AI to develop internal tools to reduce reliance on software -4.4% NOW (ServiceNow $103.06, -4.72) -- Starbucks (SBUX) using AI to develop internal tools to reduce reliance on software -- Bloomberg -4.0% IBM (IBM $289.97, -12.08) -- Tata Consultancy (532540.IN) earnings sympathy; Bloomberg report Starbucks (SBUX) using AI to develop internal tools to reduce reliance on software -3.7% RDY (Dr. Reddy's Laboratories $13.60, -0.52) -- issue with the active pharmaceutical ingredient (API) used in certain batches of semaglutide product -3.7% META (Meta Platforms $580.77, -22.35) -- Reuters reports to begin production of new AI chip (Iris) as part of plans to scale to 14GW of compute next year -3.6% PSKY (Paramount Skydance $9.40, -0.35) -- Reuters reports US states may sue to block PSKY/WBD deal next week; Arete Research downgrade -3.6% WDAY (Workday $132.90, -4.98) -- Starbucks (SBUX) using AI to develop internal tools to reduce reliance on software -- Bloomberg -3.2% ADBE (Adobe $213.80, -7.14) -3.1% FIG (Figma $21.00, -0.67) -2.9% HUBS (HubSpot $192.00, -5.82) -2.8% PLTR (Palantir Technologies $128.54, -3.68) -2.6% MDB (MongoDB $350.00, -9.40) -2.6% ACN (Accenture $131.99, -3.57) -- Tata Consultancy (532540.IN) earnings sympathy; Bloomberg report Starbucks (SBUX) using AI to develop internal tools to reduce reliance on software -2.5% INTU (Intuit $264.25, -6.65) -2.2% SHOP (Shopify $116.65, -2.57) -2.2% PDD (PDD Holdings $82.90, -1.84) -2.1% MSFT (Microsoft $375.46, -7.88) -2.1% ZS (Zscaler $140.55, -3.00) -2.0% PINS (Pinterest $22.09, -0.44) -2.0% U (Unity Software $28.88, -0.58) -1.9% NET (Cloudflare $268.25, -5.15) -1.9% PEP (PepsiCo $139.75, -2.76) -- earnings -1.8% OKTA (Okta, Inc. $144.10, -2.67) -1.8% RYAN (Ryan Specialty Holdings $40.53, -0.76) -- Wolfe Research downgrade -1.7% NTNX (Nutanix $53.04, -0.89) -1.7% VEEV (Veeva Systems $185.00, -3.17) -1.7% ADSK (Autodesk $202.55, -3.49) -1.7% COST (Costco Wholesale $937.16, -15.98) -- June net sales -1.7% PNR (Pentair $72.00, -1.26) -- Wolfe Research downgrade *Market cap $1B-$10B* -8.5% MDA (MDA Space $35.40, -3.27) -- to acquire Collecte Localisation Satellites for €567M (C$920M) in cash; offering of 20.0M common shares at C$35.60/sh -4.0% LEVI (Levi Strauss $23.40, -0.97) -- earnings; Q3 & FY26 guide; increases quarterly dividend -2.7% FIGS (FIGS, Inc. $9.99, -0.28) -2.7% MAT (Mattel $12.81, -0.36) -- Goldman Sachs downgrade -2.4% DOCU (DocuSign $46.10, -1.12) -2.4% ICL (ICL Group $4.95, -0.12) -2.4% ZETA (Zeta Global Holdings $21.13, -0.53) -2.3% FIVN (Five9 $23.64, -0.56) -2.1% S (SentinelOne $17.44, -0.37) -2.1% GVA (Granite Construction $140.53, -2.99) -- Goldman Sachs downgrade -2.0% GSBD (Goldman Sachs BDC $8.75, -0.18) -- BofA downgrade -1.9% PATH (UiPath $11.20, -0.22) -1.9% SNAP (Snap $4.54, -0.09) -1.8% KALU (Kaiser Aluminum $165.89, -3.00) -- Wells Fargo downgrade *Market cap <$1B* -31.8% AFJK (Aimei Health Technology Co. $18.20, -8.49) -- terminates business combination agreement with United Hydrogen Group -19.0% BYRN (Byrna Technologies $4.81, -1.13) -- definitive agreement to acquire Hero Defense Systems assets -15.8% GLOO (Gloo Holdings $3.35, -0.63) -- 7.0M-share secondary priced at $3.25/share -8.4% TVRD (Tvardi Therapeutics $4.58, -0.42) -6.2% PHR (Phreesia $10.00, -0.66) Click here to view our Gainers & Decliners page Related: AAOI, ACMR, ACN, ADBE, ADSK, AEHR, AFJK, AG, ALAB, ALMU, ALNY, AMAT, AMBA, AMKR, ANET, ASOLS, AVGO, AXTI, AZN, B, BBIO, BE, BGDE, BNC, BYRN, CBRS, CCXI, CECO, CNTN, COHR, COHU, COST, CRDO, CRM, DOCU, ENHA, ENTG, ENVX, FBRX, FCEL, FIG, FIGS, FIVN, FLEX, FORM, GFS, GLOO, GLSI, GLW, GSBD, GVA, HUBS, IBM, ICHR, ICL, INTC, INTU, IONS, IREN, JLAP, KALU, KEEL, KLAC, KULR, LEVI, LITE, LRCX, LSCC, MARA, MAT, MDA, MDB, META, MPWR, MRLN, MRNA, MRVL, MSFT, MTSI, MU, MX, MXL, NBIS, NET, NOW, NTNX, NVTS, OKTA, ON, ONTO, OUST, P, PATH, PD, PDD, PENG, PEP, PHR, PINS, PL, PLTR, PLYX, PNR, POET, PRM, PSKY, PWR, Q, RDY, RGC, RMBS, RYAN, S, SHAZ, SHOP, SITM, SMPL, SMTC, SNAP, SNDK, STX, SWMR, TE, TENX, TER, TOST, TTMI, TVRD, U, UCTT, VALE, VECO, VEEV, VELO, VICR, VPG, VSH, WDAY, WDC, WOLF, WULF, WYFI, ZETA, ZS...(more)	show story hide story
09-Jul-2026 06:48	AZN.LN Street Takeaways - AstraZeneca ~(9%) lower as PIII CARDIO-TTRansform of Wainua in ATTR-CM did not meet primary endpoint (12840p -1400p) Overview AZN.LN ~(9%) lower (and IONS down (20%) premarket) after the CARDIO-TTRansform Phase 3 trial for WAINUA (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to Week 140 compared with placebo. In this contemporary patient population treated with standard of care, including a majority on a stabilizer, adding eplontersen did not provide a statistically significant benefit. In a prespecified subgroup analysis of patients treated with eplontersen monotherapy compared to placebo, a nominally significant hazard ratio of 0.71 was observed on the composite outcome of CV mortality and recurrent CV events. In patients who were on stabilizer therapy at baseline, no treatment effect was observed. Note that Eplontersen is a once-monthly RNA-targeted silencer that can be self-administered via an autoinjector or as a pre-filled syringe by healthcare professional administration in the U.S. It reduces production of TTR protein at its source in the liver. WAINUA (eplontersen) has now been approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN in over 20 countries, including in the EU as Wainzua. Below we look at some analyst commentary on the CARDIO-TTRansform trial failure. Analysts across the board view the result as a negative surprise, with consensus peak sales for Wainua expected to fall sharply from ~$2.6B to below $0.5B, implying a 2-3% hit to AstraZeneca's share price, though near-term sentiment may be more negative. Despite the disappointment, a number of firms maintain their Outperform/Buy ratings on the stock, noting that the pipeline miss represents only a ~3% NPV downside to base case valuations, and that AZN's broader pipeline of clinical projects remains underappreciated. A key silver lining highlighted from today's news is the nominally significant HR of 0.71 observed in treatment-naïve patients, which could support a new Phase 3 trial in this subgroup. Analysts also flag a positive read-across to Sanofi given its royalty exposure to a competing product ( Alnylam's Amvuttra, which is already approved). It was noted Wainua would have been a significant competitor to Amvuttra had CARDIO-TTransform been positive. Looking ahead, attention now turns to the next wave of ATTR innovation via "depleters," with AZN's own Phase 3 cliramitug (DepleTTR) data expected in 2027, which analysts believe could synergistically combine with Wainua to offer improved long-term outcomes in ATTR-CM patients. Analyst Commentary: BNP Paribas Exane analyst Peter Verdult Notes AZN had been guiding to Wainua being a >$5B peak sales opportunity versus consensus peak at $2.6B, and BNPP at $2.9B. Firm sees consensus falling to <$0.5B with an implied share price hit for AZN of 2-3%, though expects the initial reaction to be more negative, in light of perceived risks into AVANZAR and SERENA-4 Ph III datasets. Firm sees some positive read across to Sanofi, given their chunky 30% royalty exposure to Amvuttra; firm notes Wainua would have been a significant competitor to Amvuttra had CARDIO-TTransform been positive. Notes Wainua is currently approved in ATTR-PN and generates $0.2bn of sales. The ATTR-PN market is 10x smaller than the ATTR-CM market (~6k vs. ~60k diagnosed US patients respectively), with prevalence rates thought to be as high as ~240k in the US. Sees the next wave of innovation to come in the form of depleters by the end of the decade, which although they compromise on the convenience angle is the only type of ATTR drug that has the potential to resolve the disease post-amyloid formation; thus theoretically positioned to be the most effective out of the three types of ATTR assets (stabilisers, silencers and depleters). In this space, next looks forward to Ph III cliramitug DepleTTR data due in 2027. Notes that while AZN remains a consensual OW across the buyside and sellside continues to see an attractive risk reward and argues the pipeline constructed by the current management team remains underappreciated; 300 clinical projects with 100 Ph III trials ongoing across oncology, respiratory, rare, and CV/metabolism. Also view AZN's position in China (12% of sales) as a competitive advantage. Believes the 2030 revenue target of $80B can be comfortably exceeded and sees margin concerns as overdone. Target remains £170; Maintains outperform Bernstein analyst Justin Smith Firm has spoken to AZN who are extremely and disappointed surprised by this news. Firm says it is too because AZN recently doubled the size of cardioTTRansform to 1,400 patients (at great expense) to increase chances of positive, statistically rigorous results on the primary endpoint in the total population (Vyndamax pre-treated and treatment naive patients). Notes the high volume US physicians it has spoken too over the last 12months were also confident in the design and rationale of cardioTTRansform. Nonetheless, believes that the consensus peak sales estimate for Wainua (in all diseases) of $2B is low as the corresponding forecast for the key competing product Amvuttra (ALNY) is $9B. Also understands from AZN that, considering the strong effectiveness of Wainua in the prespecified subgroup of treatment naïve patients (which is important as the US treatment rate in ATTR-CM is 25%) firm understands that AZN might contemplate running a new phase 3 trial in this population. Furthermore, believes that the nominally significant result for Wainua in cardioTTRansform in treatment naive patients support to its bull-thesis in which AZN's first in class novel depleter cliramitug, which will likely report phase 3 data in 2027 (AZN peak sale guide $3-5B) might synergistically combine with Wainua to offer significantly improved effects in the long term in ATTR-CM patients. Target remains £189; Maintains outperform Citi analyst Graham Parry Notes that although a benefit (HR=0.71) was seen in the monotherapy-subgroup firm notes this was only nominally significant and no treatment effect was seen in combination with stabiliser therapy. Sees it as unlikely that results are filable given primary endpoint miss and Alnylam's Amvuttra is already approved. Thinks results are a negative surprise, however, NPV downside from removing $3.6B peak (cons $3.3B) Wainua from firm's model would be only 3% off a base case DCF of £180 (i.e. still >20% above current share price) and firm says this is just one of many PIII products in the AZN pipeline. Sees expectations into remaining 2H data (camizestrant SERENA-4 and Datroway AVANZAR) as already very cautious and little focus on upside from detailed data for tozorakimab (IL33) COPD (likely at ERS Sept) and efzimfotase alfa in adults (HICKORY, likely ASBMR Oct). Notes AZN's next opportunity to access the ATTR -cardiomyopathy may come via its TTR depleter cliramitug (ALXN2220) is currently being evaluated in the pivotal PIII DepleTTR-CM trial in ATTR-CM, with topline data expected >2027 according to AZN Target remains £180; Maintains buy/top pick Related: ALNY, BBIO, IONS, SAN.FP	show story hide story
09-Jul-2026 06:40	Basic resources, banks, tech, industrials and retail the top gainers; healthcare, food/beverage, autos and energy the main laggards: Basic Resources the strongest-performing sector, supported by rebounding metal prices, with copper snapping a two-day losing streak as it shrugs off a fresh round of US strikes on Iran to track broader gains in risk assets. Banks also outperform as investors rotate into financials amid improving market sentiment. UniCredit (UCG.IM) remains in focus after nearing majority control of Commerzbank (CBK.GR) in its proposed €45B hostile takeover, while UBS (UBSG.SW) attracts attention after the SEC clears the path for debt-to-equity conversion under a Swiss bail-in scenario. Technology rebounds after recent weakness, helped by renewed optimism around AI infrastructure demand following reports China could allow limited access to Nvidia's (NVDA) H200 chips. Semiconductor names lead the advance, with Siltronic (WAF.GR) surging after a BNP Paribas upgrade citing stronger AI-driven wafer demand. IT services firm Computacenter (CCC.LN) rallies after raising full-year guidance on strong AI infrastructure demand, while information services group Wolters Kluwer (WKL.NA) advances following a JPMorgan upgrade highlighting its AI positioning. Retail moves higher, boosted by positive US earnings from Costco (COST) and Levi Strauss (LEVI), both highlighting strong consumer demand despite inflationary pressures. Hugo Boss (BOSS.GR) also in focus after urging shareholders to reject Frasers Group's (FRAS.LN) €2.7B takeover proposal. Industrial Goods & Services gain with spotlight on news the Trump administration has secured more than $3B in defence deals and joint ventures at the 2026 NATO summit. Airbus (AIR.FP) also reports H1 aircraft deliveries rising 15% y/y, keeping it on track to meet FY guidance. Health Care the weakest sector after AstraZeneca (AZN.LN) slumps following disappointing Phase III trial results for its ATTR-CM treatment, outweighing separate reports it is nearing a UK reimbursement agreement with Daiichi Sankyo for Enhertu. Press also notes GSK (GSK.LN) has terminated its neuroscience collaboration with Alector (ALEC) after dual clinical failures. Elsewhere, SCHOTT Pharma (1SXP.GR) bucks the sector trend after raising guidance on strong quarterly performance, while Ipsen (IPN.FP) gains after positive Phase III migraine trial results. Autos & Parts underperforms as Stellantis (STLAM.IM) falls following a JPMorgan downgrade on concerns a rapid earnings recovery will require deeper restructuring. Porsche (P911.GR) under pressure after reporting weaker H1 deliveries, while Volkswagen (VOW3.GR) remains in focus ahead of a key supervisory board meeting on proposed job cuts and factory closures. Food & Beverage lags despite Barry Callebaut (BARN.SW) narrowing its volume guidance after reporting resilient shipment volumes, with investors continuing to rotate away from defensive sectors. Oil & Gas edges lower amid continued disruption around the Strait of Hormuz, with press noting White House is preparing for a prolonged conflict, while Goldman Sachs warns renewed tensions could delay recovery in Middle East oil supplies. OMV (OMV.AV) reports lower hydrocarbon production and Middle East-related operational impacts in its trading update. Utilities also underperform even as Centrica (CNA.LN) confirms a 20-year regulated agreement to extend the life of the UK's Sizewell B nuclear plant. Severn Trent (SVT.LN) reports trading in line with expectations. For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: 1SXP.GR, AIR.FP, AZN.LN, BARN.SW, BOSS.GR, CBK.GR, CCC.LN, CNA.LN, FRAS.LN, GSK.LN, IPN.FP, OMV.AV, P911.GR, STLAM.IM, SVT.LN, UBSG.SW, UCG.IM, VOW3.GR, WAF.GR, WKL.NA...(more)	show story hide story
09-Jul-2026 06:11	StreetAccount Macro Headlines: US-Iran: US launches another round of strikes on Iran, prompting retaliation by IRGC against targets in Kuwait, Bahrain (link, Bloomberg) White House preparing for a prolonged Iran confrontation over the Strait of Hormuz (Axios) Energy: Ship traffic through the Strait of Hormuz nearly halted after US strikes on Iran for a second straight day (Bloomberg ) Goldman Sachs says renewed tensions could delay recovery in Middle East oil supplies by disrupting Hormuz shipping (Bloomberg) Unprecedented foreign demand for US diesel and propane straining Gulf-to-East Coast fuel reserves (Bloomberg ) US oil majors poised to announce record profits from Iran war, setting up conflict with Trump (FT) AI: Meta to invest ~$10B on first Canadian data center, largest outside of US (Bloomberg) China weighing limits on AI models popular with American companies (link ) China's vulnerability database says Anthropic's Claude Code contains backdoor flaws that could send sensitive data (link ) Corporate: SK Hynix's US listing more than 7x oversubscribed, long only and sovereign wealth funds among participants (Bloomberg) Costco reports higher Q3 sales as it draws inflation-weary consumers, including to fuel pumps (link ) Levi Strauss raises FY guidance, projecting 7%-7.5% revenue growth on expanded offerings and direct-to-consumer shift (CNBC ) US states may sue next week to block Paramount's Warner Bros. Discovery acquisition over competition concerns (Reuters ) A $80B debt load looms over David Ellison's Warner Bros. deal (link ) Kalshi plans to expand beyond event prediction into derivatives covering metals, FX and energy (Reuters ) Michael Burry buys Flutter and DraftKings shares, betting regulation will rein in prediction markets (Reuters) AstraZeneca shares fall after its Wainua heart treatment trial fails to reduce cardiovascular deaths (CNBC ) Prologis pushes for talks on a $16.9B Segro bid; it has until 22-Jul to offer or walk away (link ) Porsche deliveries fell 16% in the first half, including a 13% drop in North America (link ) China memory giant CXMT launches book build for next week's IPO, seeks to raise $4.3B (Bloomberg, Reuters ) Apple iPhone and AirPod assembler Luxshare Precision slides in Hong Kong trading debut (Bloomberg) Markets: South Korea's leveraged ETF retail frenzy now drives over 70% of trading value (Bloomberg) South Korea's developed-market push is tempered by 1997 crisis scars as FX market openings proceed cautiously (FT) Economy: US back-to-school spending expected to decline 6% y/y (Reuters ) China factory-gate inflation rises to highest since July 2022, driven by surge in raw material prices (Reuters, FT ) South Korea's AI chip boom is widening wealth gap, with huge semiconductor bonuses leaving other workers feeling worse off (FT) Germany's exports rose in May as manufacturers stayed resilient despite Iran-war uncertainty (Reuters ) Central banks: BOJ says Iran war may push more firms to raise prices later this year, reinforcing caution on inflation (Reuters ) BOK Governor Shin reiterates need to raise interest rates amid inflation risks (Yonhap, Bloomberg ) PBOC reaffirms accommodative monetary policy amid weak domestic demand, external shocks (Reuters) Trade/Tariffs: Chinese manufacturers leverage rare earths export restrictions to seize market share and move up industrial value chain (FT) Geopolitics: White House says Trump secured over $3B in defense deals and joint ventures at the 2026 NATO summit (Fact Sheet) Trump grants Ukraine a license to produce Patriot missiles and PAC-3 interceptors (FT ) Trump says decision on US troop levels in Europe will depend on agreements on Greenland, Iran (Bloomberg) Trump softens tone on Spain after claiming Madrid honored unspecified payment requests (Bloomberg) Related: 000660.KS, AAPL, AZN.LN, COST, DKNG, FLUT, HON, LEVI, META, P911.GR, PLD, PSKY, SGRO.LN, WBD, +ANTHROPIC, +KALSHI, +OPENAI...(more)	show story hide story
09-Jul-2026 04:36	StreetAccount Summary - Trading higher/lower: EU mid-morning Trading Higher: +43.6% OMASP.FH (Oma Savings Bank €16.84, +5.10) -- S-Bank Plc cash tender offer at €17.20/sh +17.2% PTEC.LN (Playtech £3.80, +0.55) -- trading update +14.8% MAS.NO (Måsøval NOK37.80, +4.90) -- Salmar to acquire 70% of shares in Måsøval +14.1% 1SXP.GR (SCHOTT Pharma $20.45, +2.48) -- prelim earnings; RBC Capital Markets upgrade +11.3% BGO.LN (Bango £0.64, +0.07) -- trading update +11.2% CCC.LN (Computacenter £45.74, +4.64) -- trading update +10.9% WAF.GR (Siltronic €88.30, +8.75) -- BNP Paribas Exane upgrade +9.6% COTN.SW (COMET Holding CHF386.00, +33.60) -- BofA ugprade +7.2% BNOR.NO (BlueNord NOK537.00, +36.00) -- earnings +6.7% RVRC.SS (RVRC Holding SEK59.95, +3.80) -- acquisition +6.2% ADMCM.FH (Admicom €25.45, +1.55) +6.0% SENS.SW (Sensirion Holding CHF80.00, +4.50) -- SEK-SGP4x Evaluation Kit availability; semis +6.0% BRK.LN (Brooks MacDonald Group £14.05, +0.80) -- trading update +5.4% SIVE.SS (Sivers Semiconductors SEK40.62, +2.12) +5.2% M12.GR (M1 Kliniken €17.50, +0.90) +5.1% TIMA.GR (ZEAL Network €45.50, +2.20) -- acquisition +4.7% BONEX.SS (BONESUPPORT HOLDING SEK239.40, +10.60) +4.6% NDX1.GR (Nordex €42.38, +1.86) -- trading update +4.5% NOKIA.FH (Nokia €10.66, +0.46) -- partnership for AI-enabled defense operations +4.3% ELM.LN (Elementis £1.55, +0.06) -- initiated buy at Kepler Cheuvreux +4.3% PTP.GR (Pentixapharm Holding AG €2.18, +0.09) -- FDA Fast Track Designation +4.2% JEN.GR (Jenoptik €40.00, +1.62) -- target up at Jefferies +4.1% SAGA.LN (Saga Plc £6.11, +0.24) -- initiated buy at Berenberg +4.1% WKL.NA (Wolters Kluwer €61.90, +2.40) -- JPMorgan upgrade +4.0% HEIJM.NA (Heijmans €105.40, +4.00) -- renews credit facility +3.9% STMPA.FP (STMicroelectronics €60.76, +2.26) -- semis +3.9% INDT.SS (Indutrade SEK209.00, +7.80) -- ABG Sundal Collier upgrade +3.8% PCO.PW (Pepco Group PLN38.03, +1.40) -- trading update +3.7% MELE.BB (Melexis €76.95, +2.75) -- semis +3.6% BIOMAR.DC (BioMar DKK116.20, +4.00) -- initiated buy at DNB Carnegie +3.6% GLEN.LN (Glencore £5.08, +0.18) -- Goldman Sachs upgrade +3.4% VEI.NO (Veidekke NOK191.80, +6.40) -- ABG Sundal Collier upgrade +3.4% EBS.AV (Erste Group Bank €116.20, +3.80) -- reinstated buy at Goldman Sachs +3.3% DEZ.GR (Deutz AG €9.16, +0.29) -- acquisition +3.1% VTY.LN (Vistry Group £2.40, +0.07) +2.7% ITM.LN (ITM Power £1.18, +0.03) -- grant award +2.6% YPSN.SW (Ypsomed Holding CHF362.60, +9.20) -- trading update +2.2% GXI.GR (Gerresheimer €30.42, +0.64) -- in sentiment with SCHOTT Pharma (1SXP.GR) sector: +5.5% NIVI.B.SS (Nivika Fastigheter SEK37.40, +2.00), +5.2% SMHN.GR (SÜSS MicroTec €80.40, +3.95) , +3.5% BCHN.SW (Burckhardt Compression Holding CHF453.00, +15.50), +3.0% VACN.SW (VAT Group CHF670.80, +19.60) sector: +4.1% HOC.LN (Hochschild Mining £4.53, +0.18), +4.1% ANTO.LN (Antofagasta £36.61, +1.46), +3.6% AAL.LN (Anglo American £34.87, +1.23), +2.4% FRES.LN (Fresnillo £26.08, +0.62) Trading Lower: -17.1% CPI.LN (Capita £2.30, -0.48) -- trading update -8.6% AZN.LN (AstraZeneca £128.34, -12.24) -- CARDIO-TTRansform Phase 3 trial of eplontersen does not meet primary endpoint -8.6% PLEJD.SS (Plejd AB SEK954.50, -91.00) -- earnings -5.7% ALSTW.FP (StreamWIDE €72.40, -4.40) -5.2% F85.GR (Contango Silver & Gold, Inc. €13.12, -0.72) -5.2% HAG.GR (HENSOLDT €76.40, -4.06) -- mwb research downgrade -5.0% EPR.NO (Europris NOK82.70, -4.30) -- earnings -4.8% ZIG.LN (Zigup Plc £4.52, -0.23) -4.3% RHM.GR (Rheinmetall €1,026.40, -45.60) -- mwb research downgrade -4.2% R3NK.GR (Renk Group €45.22, -1.93) -- mwb research downgrade -3.7% 4C.SS (4C Group SEK9.73, -0.36) -- earnings -3.7% AVIO.IM (Avio €31.41, -1.21) -- approves issuance of 3.3M shares on connection with Advent International's previously disclosed acquisition of ~7% stake at €33.40/sh -3.6% HSW.LN (Hostelworld Group £1.06, -0.04) -- trading update -3.2% HO.FP (Thales €228.50, -7.50) -2.8% POLR.LN (Polar Capital Holdings £8.73, -0.25) -- AuM update -2.7% DATA.LN (GlobalData £0.74, -0.02) -- trading update; Peel Hunt downgrade -2.6% AOF.GR (ATOSS Software €71.90, -1.90) -2.6% CAP.FP (Capgemini €88.74, -2.34) -2.6% HFG.GR (HelloFresh €3.72, -0.10) -- target down at Stifel -2.4% KINV.B.SS (Kinnevik SEK51.38, -1.24) -- transferred hold at Kepler Cheuvreux; prior rating was buy -2.3% TKMS.GR (TKMS AG & Co. KGaA €87.90, -2.00) -2.0% INTRUM.SS (Intrum SEK3.31, -0.07) -- direct issue -1.9% P911.GR (Porsche €45.38, -0.86) -- worldwide deliveries Related: 1SXP.GR, 4C.SS, AAL.LN, ADMCM.FH, ALSTW.FP, ANTO.LN, AOF.GR, AVIO.IM, AZN.LN, BCHN.SW, BGO.LN, BIOMAR.DC, BNOR.NO, BONEX.SS, BRK.LN, CAP.FP, CCC.LN, COTN.SW, CPI.LN, DATA.LN, DEZ.GR, EBS.AV, ELM.LN, EPR.NO, F85.GR, FRES.LN, GLEN.LN, GXI.GR, HAG.GR, HEIJM.NA, HFG.GR, HO.FP, HOC.LN, HSW.LN, INDT.SS, INTRUM.SS, ITM.LN, JEN.GR, KINV.B.SS, M12.GR, MAS.NO, MELE.BB, NDX1.GR, NIVI.B.SS, NOKIA.FH, OMASP.FH, P911.GR, PCO.PW, PLEJD.SS, POLR.LN, PTEC.LN, PTP.GR, R3NK.GR, RHM.GR, RVRC.SS, SAGA.LN, SENS.SW, SIVE.SS, SMHN.GR, STMPA.FP, TIMA.GR, TKMS.GR, VACN.SW, VEI.NO, VTY.LN, WAF.GR, WKL.NA, YPSN.SW, ZIG.LN...(more)	show story hide story
09-Jul-2026 04:26	European momentum unwinds as markets question AI infrastructure returns: European tech's outperformance versus broader Stoxx 600 has narrowed toward neutral, according to FDS data, as investors begin questioning returns on massive AI infrastructure spending. BNP Paribas in recent note framed this as broader "melting momentum" moment rather than fundamental break in AI trade. Bank's global momentum factor has fallen ~10% from highs, with equal-weighted indices outperforming cap-weighted peers in both Europe and the US, driven by falling energy prices, cooling inflation, and delayed Fed hike expectations. AI Enablers specifically are down ~9% from highs despite still being up 45% YTD, with concerns centered on cheaper open-source models, hyperscaler capex discipline, and rising semiconductor costs. Still, BNP argues bulk of selloff behind us and remains medium-term optimistic, noting AI adoption remains early-stage. Bank sees any further Jul weakness, seasonally a weak month for momentum, as buying opportunity. Instead, Citi in recent note said European software stocks heading into earnings with investors still cautious and waiting for a catalyst, as macro uncertainty and AI competition weigh on sentiment. Broker expects decent but mostly unspectacular results from SAP.GR, DSY.FP, SAGE.LN and possibly a cautious upgrade from CAP.FP. Kairos Partners, in separate note, said markets starting to distinguish between companies who build infrastructure and companies who will be able to extract economic value. Broker favors software, cybersecurity, cloud platforms and businesses with proprietary data over commoditising AI hardware. HSBC sees European healthcare as beneficiary of rotation away from tech given cheap valuations, favoring AZN.LN, BAYN.GR and SAN.FP. For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: AZN.LN, BAYN.GR, CAP.FP, DSY.FP, SAGE.LN, SAN.FP, SAP.GR...(more)	show story hide story
09-Jul-2026 02:57	StreetAccount Summary - European pre-market trading update StreetAccount notes that the pre-market levels mentioned are taken from various market sources Trading Higher +4% to +5% PTEC.LN (Playtech) -- trading update +5% 1SXP.GR (SCHOTT Pharma) -- prelim. earnings; RBC Capital Markets upgrade +3% to +4% CCC.LN (Computacenter) -- trading update +5% DEZ.GR (Deutz AG) -- acquisition of FFG for €1.6B +1% to +5% NDX1.GR (Nordex) -- order intake +2% AC.FP (Accor) -- Accor prepares potential US IPO of Ennismore -- Bloomberg +2% SZU.GR (Suedzucker) -- earnings +2% OMV.AV (OMV) -- production update +1% IPN.FP (Ipsen) -- positive Phase III Dysport data +1% CNA.LN (Centrica) -- 20-year CfD deal for Sizewell B extension +1% SVT.LN (Severn Trent) -- trading update +1% KOF.FP (Kaufman & Broad) -- earnings +0.5% AIR.FP (Airbus SE) -- June orders and deliveries update +0.5% ROP.SW (Roche Holding) -- CE Mark for tuberculosis blood test; Vontobel upgrade Mixed -2% to +3.5% BARN.SW (Barry Callebaut) -- revenue Trading Lower -5% AZN.LN (AstraZeneca) -- Eplontersen Phase 3 trial misses primary endpoint -1% FIE.GR (Fielmann Group) -- prelim. earnings Related: 1SXP.GR, AC.FP, AIR.FP, AZN.LN, BARN.SW, CCC.LN, CNA.LN, DEZ.GR, FIE.GR, IPN.FP, KOF.FP, NDX1.GR, OMV.AV, PTEC.LN, ROP.SW, SVT.LN, SZU.GR...(more)	show story hide story
09-Jul-2026 02:13	European macro headlines: Geopolitics: Trump links US troop levels in Europe to allies' stance on Greenland and Iran war (Bloomberg, FT) Trump disrupts NATO summit with trade cut-off threat to Spain and renewed Greenland claims (Reuters) Trump claims Spain agreed to higher payments after he threatened trade embargo (Bloomberg) NATO reaffirms collective defence commitment despite Trump's disruptions over Spain and Greenland (Politico) Erdogan urges EU to end exclusion of Turkey from European defence plans (EurActiv) UK: UK housing market downturn eases slightly, but sentiment remains fragile (Reuters) Andy Burnham plans "Number 10 North" in Manchester with possible deputy PM based there (FT) Burnham signals pragmatic, low-profile approach to US relations as next UK PM (Politico) France: Le Pen campaigns with protégé Jordan Bardella in tow to broaden National Rally appeal (Politico) Italy: Italy leads push to water down environmental rules in next EU €2T budget (Politico) Switzerland: Switzerland optimistic it can keep favourable 15% US tariff rate under Trump deal (Reuters) Corporate: UniCredit nears majority control of Commerzbank in €45B hostile takeover (Reuters) Volkswagen faces key supervisory board test over plans for 100,000 job cuts and factory closures (Reuters) Airbus deliveries rise 15% in first half to 351 planes, on track for 870 target (Reuters) Accor lines up banks for potential US IPO of Ennismore Lifestyle Group (Bloomberg) Nordex Q2 wind project orders jump year-on-year, boosted by major US deals (Reuters) AstraZeneca and Daiichi Sankyo near UK reimbursement deal for Enhertu breast cancer drug (Reuters) SEC clears path for UBS debt-to-equity conversion in Swiss bail-in scenario (Reuters) GSK terminates neuroscience collaboration with Alector after dual clinical failures (Reuters) For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: AIR.FP, AZN.LN, CBK.GR, GSK.LN, NDX1.GR, UBSG.SW, UCG.IM, VOW3.GR...(more)	show story hide story
09-Jul-2026 02:05	AZN.LN CARDIO-TTRansform Phase 3 trial of AstraZeneca's eplontersen does not meet primary endpoint (14240p) The CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to Week 140 compared with placebo. In this contemporary patient population treated with standard of care, including a majority on a stabilizer, adding eplontersen did not provide a statistically significant benefit. In a prespecified subgroup analysis of patients treated with eplontersen monotherapy compared to placebo, a nominally significant hazard ratio of 0.71 was observed on the composite outcome of CV mortality and recurrent CV events. In patients who were on stabilizer therapy at baseline, no treatment effect was observed. In the overall population, multiple secondary, imaging and biomarker analyses favored eplontersen versus placebo.Large and sustained reductions in transthyretin (TTR) were observed, consistent with the silencer class for ATTR. Eplontersenwas well tolerated, with a favorable safety profile consistent with previous results. CARDIO-TTRansform is a Phase 3, multicenter, randomized, double-blinded, placebo-controlled study to evaluate the safety and efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care: 57% of patients in each arm received a stabilizer treatment at baseline, and a further 24% in each arm initiated a stabilizer during the trial. Ionis and AstraZeneca will continue to analyze the full data set, and results will be shared with the scientific community at the European Society of Cardiology (ESC) Congress in August 2026. Reference Link: Press release Related: IONS	show story hide story
08-Jul-2026 16:02	AZN.LN US FDA grants orphan drug designation to AstraZeneca drug for the treatment of ADPKD (14240p) According to the FDA's Orphan Drug product website, AstraZeneca has been granted Orphan drug designation for a drug identified as "human IgG1kappa monoclonal antibody that specifically binds to pappalysin-1, a protease that cleaves insulin-like growth factor binding protein-4 releasing insulin-like growth factor-1" for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Designation date 8-Jul-26 StreetAccount notes that the drug referenced could be AZD1613, which the company is currently studying as a treatment for ADPKD in the phase 1 PIONER-PKD trial FDA orphan drug designation is primarily a function of the disease not the drug - drugs that target diseases with fewer than 200,000 US patients will be granted orphan designation, and in some cases drugs targeting more than 200,000 patients can be granted the designation when the FDA judges that costs could not otherwise be recovered. Reference Link	show story hide story
08-Jul-2026 07:42	4568.JP UK is close to agreement with Daiichi Sankyo and AstraZeneca for Enhertu - Bloomberg (¥2717) The article notes if the parties reach a deal, the NHS is expected to obtain a lower price for Enhertu compared to many other European countries. The two companies' spokespeople say the firms are continuing talks with the NHS and NICE for Enhertu for breast cancer patients with low HER2 protein levels. Related: AZN.LN Reference Link: Bloomberg	show story hide story
08-Jul-2026 07:28	Construction, autos, miners and retail the biggest laggards; energy and defensive sectors outperform: Construction & Materials one of the weakest sectors. Housebuilder Vistry Group (VTY.LN) slumps after reporting an H1 loss driven by restructuring costs and heavier sales incentives, while steelmakers Acerinox (ACX.SM) and Aperam (APAM.NA) fall after BNP Paribas downgrades both on weaker stainless steel market fundamentals. Autos & Parts also come under pressure, with Mercedes-Benz (MBG.GR) reporting slide in global Q2 car sales, including a sharp decline in China amid ongoing demand weakness. Pirelli (PIRC.IM) declines after Citi downgrades the shares to neutral. Basic Resources lags as miners weaken on softer commodity sentiment and broker downgrades. Rio Tinto (RIO.LN) falls after Morgan Stanley cuts the stock to underweight, while BHP Group (BHP.LN) declines following news of planned industrial action at Port Hedland. Retail underperforms, with Jeronimo Martins (JMT.PL) falling despite Kepler Cheuvreux upgrading the stock to buy. Tesco (TSCO.LN) reportedly exploring the sale of its central eastern European business. In Luxury, L'Oréal (OR.FP) in focus after announcing a long-term Gucci beauty licensing agreement. Banks also among the day's weakest performers. Spanish lenders Banco Sabadell (SAB.SM) falls after Goldman Sachs initiates coverage with a sell rating, while Banco Santander (SAN.SM) declines amid reports of a restructuring of its Asia-Pacific investment banking operations and voluntary redundancy discussions in Spain. Of note, UniCredit (UCG.IM) says it has secured a 47.6% holding in Commerzbank (CBK.GR), bringing it closer to taking control of Germany's second-largest lender. AIB Group (AIBG.LN) also weakens following an RBC downgrade to underperform. Oil & Gas the best-performing sector thanks to a sharp rebound in crude prices after renewed US-Iran tensions. Integrated energy names lead gains, with Repsol (REP.SM) advancing after reporting stable Q2 upstream production alongside a sharp improvement in refining and chemicals margins, while Equinor (EQNR.NO) rises following its Q2 trading update. TGS (TGS.NO) rallies on a strong Q2 operational update driven by robust multi-client activity, while Vallourec (VK.FP) gains after completing its share buyback programme and reaffirming significant shareholder returns. Utilities outperforms vs broader market, helped by defensive positioning. E.ON (EOAN.GR) rises after the UK's CMA seeks feedback on its proposed acquisition of OVO Energy, while Severn Trent (SVT.LN) gains despite Ofwat finding the company in breach of wastewater obligations after deciding against a financial penalty. Food, Beverage & Tobacco also supported by flight to safety, with fertiliser producer Yara International (YAR.NO) gaining after Danske Bank upgrades the shares to buy, while salmon producer SalMar (SALM.NO) is in the spotlight following its Q2 harvest volume update. Defensive inflows also helping Telecom, with focus on Bahnhof (BAHN.B.SS) after Telenor (TEL.NO) agrees to acquire a controlling stake in the Swedish broadband provider. Also focus on media reports of Nokia (NOKIA.FH) pivoting towards AI data centre infrastructure, riding the boom in optical networking and switches. Health Care also helped by defensive tilt, with deal activity attracting attention as GSK (GSK.LN) and AstraZeneca (AZN.LN) both announce separate strategic licensing agreements with Sino Biopharmaceutical covering respiratory therapies. For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: ACX.SM, AIBG.LN, APAM.NA, AZN.LN, BAHN.B.SS, BHP.LN, CBK.GR, EOAN.GR, EQNR.NO, GSK.LN, JMT.PL, MBG.GR, NOKIA.FH, OR.FP, PIRC.IM, REP.SM, RIO.LN, SAB.SM, SALM.NO, SAN.SM, SVT.LN, TEL.NO, TGS.NO, TSCO.LN, UCG.IM, VK.FP, VTY.LN, YAR.NO...(more)	show story hide story
08-Jul-2026 02:22	European macro headlines: Geopolitics: Trump revives NATO grievances and Greenland claim at Ankara summit, casting shadow over proceedings (Politico) NATO European leaders push to secure Trump's recommitment at Ankara summit amid disputes (Reuters) NATO hails transatlantic defense deals as EU prioritizes 'Buy European' arms industry (Politico) Trump voices disappointment with NATO allies and renews demand for US control of Greenland (EurActiv) Europe and Canada defense spending growth expected to slow to 11% in 2026, NATO says (EurActiv) UK: UK jobs market downturn eases slightly as temporary hiring and salaries rise (Reuters) Nigel Farage by-election gambit undercut by rivals' refusal to participate (FT ) France: Le Pen launches fourth French presidential bid after court clears path despite conviction (Reuters, Politico, EurActiv) Germany: Germany could gain market share from US fees on Chinese-built ships, DIW study finds (Reuters) Europe: EU plans to close maritime carbon loophole, raising fees for ships stopping at non-EU ports (FT) EU eyes taxes on flight tickets and sugar to bolster long-term budget (EurActiv) Corporate: Nokia pivots to AI data center infrastructure, riding boom in optical networking and switches (link) Airbus and MTU Aero Engines launch joint venture for hydrogen fuel-cell aviation powertrains (AeroXplorer) Santander overhauls Asia-Pacific business, removes Beijing chief and tightens oversight (Reuters) AstraZeneca licenses Sino Biopharm's experimental COPD drug TQC3721 for $200M upfront (Reuters) Vitol prepares to open Caracas office as trading houses deepen Venezuela oil presence (Reuters) BHP Port Hedland workers announce eight-hour strike, raising iron ore supply concerns (Bloomberg) Coty returns Gucci Beauty license to Kering for about $400 million to cut debt (Reuters) For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: AIR.FP, AZN.LN, BHP.LN, GSK.LN, KER.FP, MTX.GR, NOKIA.FH...(more)	show story hide story
07-Jul-2026 18:15	1177.HK Sino Biopharmaceutical enters into exclusive license agreement with AstraZeneca for TQC3721; to receive upfront payment $200M (HK$4.82) Group is eligible to receive the upfront payment with additional development, regulatory and sales milestones, totalling up to $1.9B, as well as tiered royalties ranging up to double-digit percentages based on the annual net sales of TQC3721 products. Group shall grant AstraZeneca an exclusive license to develop, manufacture and commercialize TQC3721 outside China. See Related StreetAccount comments: 8/25/2025 6:53:35 AM - Sino Biopharmaceutical to present results of studies of TQC3721, TQC2731, TQC3403 at ERS 2025 6/9/2025 7:43:35 AM - Sino Biopharmaceutical receives NMPA approval for phase III registrational clinical study of TQC3721 on maintenance treatment for chronic obstructive pulmonary disease Related: AZN.LN Attached Files PDF Document: Press release	show story hide story
06-Jul-2026 16:32	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equites ended mostly lower overall on Monday. Decliners outnumbered advancers 2:1 on the XLV. Healthcare (1.17%) vs the S&P +0.72%. Major health groups ended mixed overall but all underperformed the tape. Pharma among the worst performers; DRG (1.58%). Few sector-specific catalysts aside from a few rating changes, as HSBC downgraded Merck KGaA, Pfizer, and Roche, while upgrading GSK. Elsewhere, Novartis announced an agreement to acquire Myricx Bio for $1.1B upfront, plus up to $400M in milestones. The stock was simultaneously downgraded by Vontobel on valuation, NVS (2.8%). RMD +4.2% and BIIB (3.5%) bracketed the XLV. Earnings season begins on 15-Jul with JNJ reporting before the open, followed by UnitedHealth and Abbott the next day. Macro Today's big story was the momentum rebound, coming after a two-day slump that saw the SOX drop more than 11%. No specific catalyst but some analyst discussion about extent of drawdown and some attribution to positioning and seasonality. Some help today from continued AI capex optimism with boost from latest AI infrastructure/capacity agreements (WULF, IREN); AVGO also extended its tech collaboration with AAPL. Broadening-out trade took a breather though a lot of recent commentary on more stocks trading above their 50-day moving averages and wider sector participation (Financials the top sector MTD). Not much else in the headlines. Notable Gainers +15.2% ENOV (Enovis): follow-through; positive comments from BTIG +11.7% RGNX (REGENXBIO): best performer on XBI +4.2% RMD (ResMed): best performer on XLV +2.6% MRNA (Moderna): shares were +19% last week; best performer on XLV +0.7% TWST (Twist Bioscience): despite downgrade at Evercore ISI Notable Decliners -6.9% SLS (SELLAS Life Sciences Group, Inc.): worst performer on XBI -3.5% BIIB (Biogen): worst performer on XLV -2.9% PODD (Insulet): follow-through; launches Omnipod 5/Discover in Spain -2.8% NVS (Novartis): acquires Myricx Bio for up to $1.5B; downgraded at Vontobel -2.6% VERA (Vera Therapeutics): ahead of PDUFA on Tuesday -2.6% ROP.SW (Roche Holding): in European trading; downgraded at HSBC -2.6% AZN (AstraZeneca): shares traded down (1%) on Friday -2.4% PFE (Pfizer): downgraded at HSBC -2.3% NVO (Novo Nordisk): shares traded down (2%) on Friday -2.0% MRK.GR (Merck KGaA): in European trading; downgraded at HSBC -1.3% GILD (Gilead Sciences): despite upgrade at HSBC -1.0% GSK (GSK Plc): despite upgrade at HSBC Novartis lower with an early-stage acquisition and a downgrade NVS agrees to acquire Myricx Bio for $1.1B upfront, with up to $400M in potential milestone payments. Stock also downgraded today at Vontobel. Firm was somewhat cautious on the deal, but action seemed more focused on valuation after shares reached price target CHF128. Pharvaris NV lower after confirming standard review of NDA submission PHVS announces FDA acceptance of NDA for deucrictibant IR for on-demand treatment of hereditary angioedema attacks. PDUFA date is 23-Apr-2027. Quick take: Leerink analyst Joseph Schwartz notes that standard review was the base case assumption, investor focus remains on the upcoming phase 3 readout in prophylaxis of HAE. Notable research in Healthcare today Pharma: GSK.LN (GSK) upgraded to hold from reduce at HSBC (Rajesh Kumar), notes management change and pipeline to drive growth. Target increased to 1,860p from 1,500p or approx. 8% downside. (FactSet average target 2140p; range 1700-2825p) NOVN.SW (NVS) downgraded to hold from buy at Vontobel (Stefan Schneider), target remains CHF128. (FactSet average target CHF124; range CHF94-139) MRK.GR downgraded to hold from buy at HSBC (Rajesh Kumar), notes high valuation. Target increased however to €170 from €160 or approx. 30% upside. (FactSet average target €146; range €121-179) ROP.SW downgraded to hold from buy at HSBC (Rajesh Kumar), target remains CHF365 or approx. 5% upside. (FactSet average target CHF357; range CHF230-428) PFE downgraded to hold from buy at HSBC (Rajesh Kumar), notes recent management changes and a lack of short-term catalysts. Target cut to $28 from $32 or approx. 15% upside. (FactSet average PT $29; range $24-36) APTX.CN seeing initial sell-side coverage following TSX IPO last month. All buy-equivalent ratings so far (BMO, CIBC, Jefferies, Scotiabank, Stifel, TD Cowen) with an average PT C$41 or approx. 20% upside; range C$39-43. Biotech: GILD upgraded to buy from hold at HSBC (Rajesh Kumar), notes optimism around HIV market and attractive valuation. Target increased to $155 from $133 or approx. 18% upside. (FactSet average target $161; range $122-180) AVTX initiated outperform at Leerink Partners (Thomas Smith), target is $38 or approx. 102% upside. (FactSet average target $45; range $34-60) PBLS seeing initial sell-side coverage following IPO on 18-Jun. Shares have traded +48% since pricing at $16/shr - the largest HC IPO of the year raised $670M before the shoe. All buy-equivalent ratings so far today (BofA, Evercore ISI, Guggenheim, Leerink, LifeSci Capital) with an average PT $42 or approx. 41% upside; range $40-45. MedTech: TWST downgraded to in line from outperform at Evercore ISI (Vijay Kumar), target increased however to $102 from $66 or approx. 3% upside. (FactSet average target $87.56; range $65-107) PRCT downgraded to hold from buy at Truist (Richard Newitter), noting reduced confidence in company's procedure growth rate. Target cut to $25 from $30 or approx. 19% upside. (FactSet average PT $30; range $20-37) GKOS initiated buy at HC Wainwright (Yi Chen), target is $168 or approx. 13% upside. (FactSet average target $158; range $138-170) Post-close news M&A: VRTX to acquire CRNX for $85.00 per share. Shares of CRNX +101% in the after-hours; VRTX (0.5%) Corporate: ABBV discloses Q2 expected to include acquired IPR&D and milestones expense of $291M pre-tax, representing unfavorable impact of $0.17 to EPS. - 8-K RXST guides Q2 revenue $32-$34M vs FactSet $32.1M. Shares (11.6%) in the after-hours. Collaboration: ALC and RxSight announce collaboration to develop adjustable PCIOLs. On Deck: Jul 6-12 Regulatory calendar Tue 7-Jul: FDA PDUFA for VERA atacicept BLA for adults with IgA Nephropathy (IgAN) (MRK.GR) early Q3: CMS proposal of Physician Fee Schedule (PFS) for CY2027 REPL formal scheduling FDA Adcom for RP1 ahead of 'late July' event Corporate calendar Wed 8-Jul: MCRB hosting call to discuss topline results from IST with SER-155 in enterocolitis (8:30ET) NYXH.BB hosting Investor Day (10:00ET) early Q3 readouts: DFTX (ph3 GAD); CMPS (ph3 TRD); PMN (ph1 AD) Conference calendar Sun 12-Jul: AAIC 2026 meeting (Jul 12-15) Syndicate calendar / potential IPO pricing +TARX (Tarsier Pharma) - F-1A - clinical-stage biotech with focus on treating ocular diseases; lead product ph3 TRS01 Peek Ahead to next week Jul 13-19 Overview: Earnings season kicks off with JNJ pre-open on 15-Jul, UNH and ABT the next day. This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ALC, APTX.CN, AVTX, AZN, BIIB, CRNX, ENOV, GILD, GKOS, GSK, GSK.LN, MRK.GR, MRNA, NOVN.SW, NVO, NVS, PBLS, PFE, PHVS, PODD, PRCT, RGNX, RMD, ROP.SW, RXST, SLS, TWST, VERA, VRTX...(more)	show story hide story
06-Jul-2026 10:33	AZN.LN Transcript Intelligence: AstraZeneca Business Update Call Call Summary (Call Time: 06-Jul-26 09:30 ET): Ambition to reduce scope 1 and 2 emissions by 98% by December 2026, where addressable. Updated 2030 target aims for a 35% reduction in scope 3 emissions versus 2019, aligned with $80B revenue and 20 new medicines by 2030. Commitment to net zero emissions across the value chain by 2045 remains unchanged. Transition of pressurised metered dose inhalers to next-generation propellant with near-zero global warming potential to be completed by 2030. AZ Forest target revised to planting 100M trees by 2030, prioritizing high-quality projects over volume. Goal to reach 1B people through health equity programs, including 400M from underserved groups, by 2030. PHSSR (Partnership for Health System Sustainability and Resilience) to expand to over 40 countries by end of 2026, targeting 45 by 2030. AI-driven pharmaceutical development aims for 35% productivity improvement and 50% reduction in lead time by 2030. Supplier engagement to continue, with over 80% of supplier spend already with companies holding science-based targets; active decarbonization plans underway. Ongoing integration of sustainability by design in R&D, including green chemistry, circular solvent use, and recyclable packaging for future product launches. This summary was created with GenAI, optimized by StreetAccount. Early transcripts may contain phonetic spellings. Reference Link: Transcript	show story hide story
06-Jul-2026 08:45	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis M&A was the biggest story this morning, with NVS agreeing to acquire Myricx Bio for $1.1B upfront, plus up to $400M in milestone payments. The stock was simultaneously downgraded by Vontobel on valuation. HSBC updated its coverage of pharma names, including an upgrade for GSK, while Merck KGaA, Pfizer, and Roche were downgraded. Sector news flow is very quiet following the long holiday weekend. Earnings season begins on 15-Jul with JNJ reporting before the open, followed by UnitedHealth and Abbott the next day. Macro S&P futures up 0.5% and Nasdaq futures up 1.1% in Monday morning trading. Momentum bounce big story this morning with semis and memory outperforming. Nothing specific behind the move, though some discussion about the extent of the recent drawdown. In addition, despite some headline volatility, including the excess capacity scrutiny surrounding the recent META cloud foray speculation, broader capex narrative remains intact. Very quiet elsewhere. Pre-market trading update Trading higher +5.2% VERA ahead of PDUFA on Tuesday +4.7% ONC +2.3% ABVX ADRs were up +48% last week; shares were +6% on Friday +0.6% GILD upgraded at HSBC Trading lower -2.6% AZN shares traded down (1%) on Friday -2.2% MRNA shares were +19% last week -2.1% NVO shares traded down (2%) on Friday -1.7% ROP.SW in European trading; downgraded at HSBC -1.1% NVS acquires Myricx Bio for up to $1.5B; downgraded at Vontobel -0.6% MRK.GR in European trading; downgraded at HSBC -0.4% PFE downgraded at HSBC Pharma M&A: NVS agrees to acquire Myricx Bio for $1.1B upfront, with up to $400M in potential milestone payments. Research: GSK upgraded to hold from reduce at HSBC (Rajesh Kumar), target increased to 1,860p from 1,500p or approx. 8% downside. (FactSet average target 2139.76p; range 1700-2825p) NVS downgraded to hold from buy at Vontobel (Stefan Schneider), target remains CHF128. (FactSet average target CHF124.43; range CHF94.31-138.98) MRK.GR downgraded to hold from buy at HSBC (Rajesh Kumar), target increased however to €170 from €160 or approx. 30% upside. (FactSet average target €146.29; range €121-179) ROP.SW downgraded to hold from buy at HSBC (Rajesh Kumar), target remains CHF365 or approx. 5% upside. (FactSet average target CHF357.10; range CHF230-428) PFE downgraded to hold from buy at HSBC (Rajesh Kumar), target cut to $28 from $32 or approx. 15% upside. (FactSet average PT $29; range $24-36) Biotech Regulatory: PHVS announces FDA acceptance of NDA for deucrictibant IR for on-demand treatment of hereditary angioedema attacks. PDUFA date is 23-Apr-2027. Research: GILD upgraded to buy from hold at HSBC (Rajesh Kumar), target increased to $155 from $133 or approx. 18% upside. (FactSet average target $160.78; range $122-180) AVTX initiated outperform at Leerink Partners (Thomas Smith), target is $38 or approx. 102% upside. (FactSet average target $45.25; range $34-60) PBLS seeing initial sell-side coverage following IPO on 18-Jun. Shares have traded +48% since pricing at $16/shr - the largest HC IPO of the year raised $670M before the shoe. All buy-equivalent ratings so far today (BofA, Guggenheim, Leerink, LifeSci Capital) with an average PT $42 or approx. 41% upside; range $40-45. Life Science & MedTech Research: TECH downgraded to in line from outperform at Evercore ISI (Vijay Kumar), target remains $73 or approx. 3% upside. (FactSet average target $69.42; range $50-75) TWST downgraded to in line from outperform at Evercore ISI (Vijay Kumar), target increased however to $102 from $66 or approx. 3% upside. (FactSet average target $87.56; range $65-107) PRCT downgraded to hold from buy at Truist (Richard Newitter), noting reduced confidence in company's procedure growth rate. Target cut to $25 from $30 or approx. 19% upside. (FactSet average PT $30; range $20-37) GKOS initiated buy at HC Wainwright (Yi Chen), target is $168 or approx. 13% upside. (FactSet average target $157.50; range $138-170) On Deck: Jul 6-12 Tue 7-Jul: Regulatory: FDA PDUFA for VERA atacicept BLA for adults with IgA Nephropathy (IgAN) (MRK.GR) Wed 8-Jul: Corporate: MCRB hosting call to discuss topline results from IST with SER-155 in enterocolitis (8:30ET); NYXH.BB hosting Investor Day (10:00ET) Sun 12-Jul: Conference: AAIC 2026 meeting (Jul 12-15) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Editor's note: Corrected the price target details for Pfizer (PFE) downgrade at HSBC. Related: ABVX, AVTX, AZN, GILD, GKOS, GSK, MRK.GR, MRNA, NVO, NVS, ONC, PBLS, PFE, PHVS, PRCT, ROP.SW, TECH, TWST, VERA...(more)	show story hide story
02-Jul-2026 21:29	StreetAccount Sector Summary - China Healthcare June Recap June in Review: Hang Seng Innovative Drug (7.37%) vs Hang Seng Listed Biotech (4.7%) vs Hang Seng Index (9.91%) CSI300 Healthcare +3.04% vs CSI300 +2.79% Trending topics: China's CDMO giant WuXi AppTec, as well as Alibaba Group Holding declined on 9th after the Pentagon added them, along with several other Chinese companies from key emerging sectors, to a blacklist citing alleged military connections. WuXi AppTec fell 3.7% to HK$116.80, while Alibaba dropped 1.4% to HK$117.10. Other companies on the blacklist, such as electric vehicle manufacturer BYD and tech giant Baidu, largely ignored the action and saw gains after the market opened. The Hang Seng Index slipped 0.4%. WuXi AppTec's shares listed in Shanghai also fell 2.6%, closing at CNY93.48. The US Department of Defense updated its Section 1260H list of companies alleged to support the Chinese military, newly adding major Chinese enterprises including Alibaba, Baidu, and BYD Company. The updated list also reinstates YMTC, CXMT, WuXi AppTec, Robosense, and Unitree Robotics. The Pentagon expanded this blacklist to include 188 companies, highlighting concerns that China's military might leverage the country's private sector for technological advancements amid rising geopolitical tensions between Beijing and Washington. The Defense Department will be prohibited from contracting directly with listed companies starting later this month. While the list does not impose direct sanctions at this time, the DoD is progressively using it to limit these companies' access to US military contracts and research and development funding. This move occurred less than a month after U.S. President Trump met with China's Xi in Beijing, where the two leaders upheld a fragile truce on trade matters. Some argue that being placed on the list could result in WuXi being designated a "company of concern" under the Biosecure Act, a law that limits federal agencies from engaging in business with non-U.S. biotechnology firms. WuXi filed a lawsuit against the U.S. government on 11-Jun (HKT), challenging its placement on a list of Chinese companies that the U.S. Department of Defense has associated with the country's military. The complaint was submitted to the federal court in Washington, D.C., arguing that WuXi's inclusion on the list is arbitrary, capricious, unsupported by evidence, and driven by political pressure. The company also claimed that being labelled a national security threat has caused significant reputational and operational damage, without any legal or factual justification. The lawsuit seeks to have WuXi removed from the list. A spokesperson for the Pentagon stated that the agency does not comment on ongoing litigation (CNBC, SCMP, Guardian) HBM Holdings announced that a jury in the US District Court for the District of Delaware has delivered a verdict in the patent infringement lawsuit the company originally filed in 2021 against Amgen and its subsidiary, Teneobio, Inc. The jury found that Amgen willfully infringed the Grosveld patent and ruled that Harbour Antibodies, a member company of HBM Holdings, is entitled to damages amounting to $20.2037M. The company stated that, since the infringement was deemed willful, Harbour Antibodies may seek an enhancement of the damages from the court. The total damages awarded in this litigation could potentially reach approximately $60.6M. The group plans to conduct a thorough evaluation of the verdict, the possibility of enhanced damages, and other related litigation concerning its broader patent portfolio, with further legal actions to be taken at an appropriate time. StreetAccount notes that during the conference call held on 15-Jun, HBM Holdings stated that the impact of the compensation amount on net profit is likely to be reflected in the financial statements in H2 this year. It is worth noting that both parties in this patent infringement lawsuit retain the right to appeal. During the call, the company indicated that based on current situation, Amgen has not taken any action to appeal and has not expressed any intention to do so following the trial ruling. Harbour filed a lawsuit against Amgen in late 2021, shortly after Amgen made an upfront payment of $900M and agreed to pay up to $1.6B in milestone payments to acquire Teneobio. Harbour BioMed acquired Harbour Antibodies and its transgenic mouse platforms for antibody discovery in Dec-2016. Noticing the alleged infringement, Harbour revealed that it first contacted Teneobio's management in 2017 to discuss potential licensing terms, but this overture was declined. In its 14-Jun release, Harbour noted that the Delaware court had previously ruled against it on one patent, leading the company to concentrate initially on its U.S. Patent No. 10,906,970, which relates to an invention by Frank Grosveld, a founder of Harbour Antibodies. Harbour is currently appealing the other ruling to the Federal Circuit. The company highlighted that this patent carries significantly greater financial stakes, potentially up to ten times the damages awarded in the current case. As Chinese innovative drugs go global and actively engage in global competition, clashes between Chinese pharmas and MNCs over core patents, technology platforms, and commercial interests are becoming increasingly frequent. However, unlike before when Chinese biotechs were typically cast as defendants, many argue that the HBM-Amgen dispute tells a different story. Amgen is a multinational giant with a market-cap exceeding $200B yet that of HBM Holdings did not even reach HK$10B. Moreover, this case did not arise from a patent attack on a Chinese drug after going global (i.e. Abbvie's US patent dispute against BeOne on Brukinsa), instead, HBM proactively asserted its own technology platform patents and secured a full victory in a US jury trial (FiercePharma, STCN, Pharmacube, US district court historical record) Sector performance: Halfway through 2026, Hong Kong's pharma IPO market has been lively. 37 filed in the first half, with notable listings like Mabwell, Impact Therapeutics and TenNor Therapeutics, especially active in June. More than half of the healthcare companies in the pipeline are biopharma firms, covering nearly all cutting-edge fields such as oncology drugs, cell and gene therapy, radiopharmaceuticals, and peptides. Thanks to ongoing 18A policy support and improved market liquidity, demand for fundraising remains strong. However, the IPO boom hasn't guaranteed success - some stocks doubled on debut, while others dropped below their offering price, showing the market won't simply endorse every "18A" company. Ultimately, stock prices remain the truest test of market acceptance. StreetAccount notes that Chapter18A of the Hong Kong Stock Exchange (HKEX) Listing Rules allows pre-revenue and pre-profit biotech companies to go public. As of 30-Jun, 94 biotech firms have listed via this route, with 11 listing in H1 alone, raising a combined HK$12.486B. At this pace, it will take another three to four years to fully clear the backlog of companies waiting in the queue The speed of IPO approvals doesn't necessarily depend on when companies file. For example, Ture Health Medical Technology Development, which specializes in robotic puncture and ablation devices, filed on 31-May and secured listing approval within just two weeks. However, companies like Arkbiosciences and Genuine Biotech have not seen such progress in years. Industry experts believe the current wave of pharma IPOs isn't slowing down anytime soon. However, they also emphasize that who gets listed, when, and how well they perform ultimately boils down to the fundamental of the companies themselves. Regulatory actions: On 29-Jun, China's A/H pharmaceutical sector experienced a broad surge, with its index climbing over 6%. 20 stocks-including Sunshine Guojian Pharmaceutical, Fujian Cosunter Pharmaceutical and Biocytogen Pharmaceuticals all smashing the 20% ceiling. More than a dozen stocks, such as Asymchem, Sichuan Kelun and Haisco reached their 10% daily limit. Additionally, Remegen, InventisBio and Junshi Biosciences each rose over 10%. From a fundamentals standpoint, the pharmaceutical sector is seeing a range of strong tailwinds, of which the most direct trigger is the announcement of drug list that passed the 2026 NRDL initial screening: China's National Healthcare Security Administration (NHSA) issued a public notice on the list of drugs having passed the preliminary review for the 2026 adjustments to the National Reimbursement Drug List (NRDL) for basic health insurance and commercial Insurance Innovative Drug List. A total of 818 applications were received for this adjustment cycle, covering 674 generic drug names Basic National Reimbursement Drug List: among the 375 generic names applied for addition to the lists (excluding pre‑submitted varieties), 334 passed the preliminary review (drugmakers i.e. Otsuka Pharma,, J&J, GSK, Pfizer, AZ/Daiichi Sankyo, Astellas, Eisai, Roche, Kelun-Biotech, Beone, Zai Lab, Sino-Biopharmaceuticals, CSPC, JW Therapeutics,, Kelun-Biotech, Jiangsu Hengrui, Innovent) ; and among the 229 applied for adjustments within the lists/renewals (excluding pre‑submitted varieties), 223 passed the preliminary review Commercial Health Insurance Innovative Drug List: among the 57 generic names applied for addition to the list (excluding pre‑submitted varieties), 53 passed the preliminary review (i.e. AstraZeneca, GSK, Sanofi, Roche, Lepu Biopharma); and among the 1 applied for adjustment within the list/renewal, 1 passed the preliminary review. Drugs passing screening for both lists: i.e. NURTEC ODT of Pfizer, DAYVIGO of Eisai, COPAXONE of Teva, ZILBRYSQ of UCB China, Lisaftoclax (lisaftoclax ) of Ascentage Pharma, QUVIVIQ of Simcere Drug development and approvals: Clinical updates: BeOne Medicines announces Phase 3 MANGROVE study of BRUKINSA meets primary endpoint (link); Luye Pharma Group reports positive phase II results for LY03015 to treat TD (link); Akeso Inc presents Phase II trial results of ligufalimab (AK117) in combination with azacitidine and venetoclax in patients with treatment-naïve AML(link); Jazz Pharmaceuticals/ Luye/ PharmaMar reports phase 3 LAGOON trial of ZEPZELCA in 2L SCLC did not meet primary endpoint; the trial did not meet its primary endpoint of overall survival (OS) evaluating Zepzelca as monotherapy or in combination with irinotecan compared to investigators' choice of topotecan or irinotecan (link); InSilico Medicine Cayman TopCo completes first-in-human dosing in Phase I clinical study of ISM8969 in obese adult participants at risk of CVD (link); Kintor Pharmaceutical reports positive interim results of long-term human safety trial of KT-939, filed for registration application to NMPA (link) IND: FDA issues IND clearance to Ascletis Pharma's once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist ASC35 phase I trial for treatment of obesity (link); NMPA approves Shanghai Henlius Biotech's HLX3902 to phase I trial for treatment of mCRPC and other advanced solid tumors (link); Jiangsu Hengrui Pharmaceuticals obtains NMPA clinical trial approval for SHR-6914 injection for treatment of prostate cancer (link); Sichuan Biokin Pharmaceutical receives NMPA trial approval for BL-M14D1 combination therapy in ES-SCLC (link); Changchun High-Tech Industry (Group) Co. receives NMPA clinical trial approval for GenSci136 injection for oMG (link); NMPA approves Antengene's IND application for Phase I study of ATG-201 for treatment of B cell related autoimmune diseases (link); China's NMPA approves Huadong Medicine HDM2005 combination to clinical trial for treatment of Hodgkin lymphoma (link) Designations: Zai Lab receives EMA Orphan Drug Designation for zocilurtatug pelitecan (Zoci) in pulmonary neuroendocrine carcinomas (link); CSPC's SYS6043 granted breakthrough therapy designation by China's NMPA in platinum-resistant ovarian cancer, primary peritoneal cancer, and fallopian tube cancer (link) NDA acceptance: NMPA accepts Pierre Fabre's BRAFTOVI (encorafenib capsules) for review in combination with cetuximab and FOLFOX for first-line treatment of adult patients with BRAF V600E-mutant metastatic CRC. StreetAccount notes that the indication was granted priority review in April (link); Hybio Pharmaceutical has submitted the first experimental generic versions of tirzepatide for U.S. FDA review. The FDA accepted their ANDAs, targeting type 2 diabetes, weight loss, and obstructive sleep apnea (link); NMPA accepts marketing application for CSPC Pharmaceutical Group's SYH9056 to treat hypertension (link); NMPA accepts Hansoh Pharma's NDA of HS-10568 for treatment of secondary hyperparathyroidism (link); CSPC Pharmaceutical Group's second marketing authorisation application for Edaglutide Alpha Injection (Shanmeining) accepted by NMPA (link); CSPC Pharmaceutical Group's marketing authorisation application for biosimilar Secukinumab injection (COSENTYX biosimilar) accepted by NMPA (link); Everest Medicines announces China NMPA acceptance of the BLA for LEROCHOL in adults with hypercholesterolemia (link) NDA approvals: China approves Daiichi Sankyo's VANFLYTA for use in combination with standard cytarabine and anthracycline induction, cytarabine consolidation; and as monotherapy for AML (link); Gilead/Everest Medicines's TRODELVY approved by FDA as monotherapy and in combination with pembrolizumab for first-line treatment of TNBC (link); Akeso Inc's anti-IL-17 mAb gumokimab (AK111) approved by NMPA for moderate-to-severe plaque psoriasis (link); Jiangsu Hengrui Pharmaceuticals obtains NMPA new indication approval for CDK4/6 inhibitor dalpiciclib isethionate Tablets as adjuvant therapy in combination with endocrine therapy in patients with early-stage breast cancer who are HR positive, HER2 negative, and at high risk of recurrence (link); Eisai/Henlius Biotech receives NMPA NDA approval for HANSIZHUANG in combination with Oxaliplatin and S-1 for neoadjuvant treatment of resectable gastric cancer with tumor PD-L1 expression CPS≥ 5, followed by adjuvant monotherapy after surgery (link) License-in/out, co-development, M&A AstraZeneca enters a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across eight programmes. Under this agreement, the companies will initially progress four programmes, which utilise CSPC's advanced AI-driven peptide drug discovery platform and their proprietary LiquidGel once-monthly dosing platform technology AstraZeneca will receive exclusive global rights outside of China to CSPC's once-monthly injectable weight management portfolio, comprising one clinical-ready asset, SYH2082, a long-acting GLP1R/GIPR agonist progressing into Phase I and three preclinical programmes with differing mechanisms designed to provide extended therapeutic benefits for people living with obesity and weight-related conditions. For access to eight programmes, as well as the advanced AI molecular design capabilities and their proprietary LiquidGel once-monthly dosing platform technology, CSPC will receive an upfront payment of $1.2B from AstraZeneca. CSPC is also eligible to receive development and regulatory milestones of up to $3.5B across all programmes. CSPC will also be eligible for further commercialisation and sales milestones plus tiered royalties. The transaction is expected to close in Q2, subject to customary closing conditions and regulatory clearances. Under the agreement, CSPC will progress ongoing development of the four programmes through Phase I completion, alongside the four new programmes. Following successful completion of Phase I, AstraZeneca will be responsible for further development and commercialisation in all territories outside of China. CSPC retains all rights for China, Taiwan, Hong Kong and Macau, and following successful approval, AstraZeneca has the right to opt-in to co-commercialise these products. This agreement builds on existing strategic collaborations between AstraZeneca and CSPC. Shanghai Junshi Biosciences out-licenses JS005 in Greater China to Fosun Wanbang Pharmaceutical for CNY215M upfront. Under the license agreement, the company has granted Fosun Wanbang rights regarding the development, registration, manufacturing, and commercialization of Ruokaoqibai Monoclonal Antibody (JS005, an anti-IL-17A monoclonal antibody) in the Greater China region. Junshi will receive a non-creditable and non-refundable upfront payment of CNY215M and is eligible to receive development and sales milestone payments of up to CNY1.125B (inclusive of tax), as well as tiered royalties based on a double-digit percentage of net sales in the Greater China region. Abbisko Therapeutics enters potential $1.9B R&D deal with Eli Lilly. Under the terms of this agreement, Abbisko will utilize its early-stage drug discovery platform, innovative R&D ecosystem, and extensive development expertise to conduct discovery and early development activities for novel drug programs directed against disease targets selected by Lilly. Abbisko will receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments totaling up to approximately $1.9B. In addition, Abbisko will be eligible to receive tiered royalties based on annual net sales of products arising from this collaboration. In 2022, Abbisko and Lilly entered into a global collaboration and exclusive license agreement to collaborate on the discovery, development, and potential commercialization of a novel small-molecule therapeutic. Haisco Pharmaceutical Group announced that it has entered into an exclusive licensing agreement with Nuvectis, a U.S. biotechnology company. Under the agreement, Haisco has granted Nuvectis the exclusive rights to develop, manufacture, and commercialize its independently developed innovative drug HSK42360 worldwide, excluding Greater China, as well as its independently developed innovative drug HSK39297 worldwide, excluding Greater China, India, and certain Southeast Asia territories HSK42360 is a best-in-class BRAF paradoxical breaker inhibitor designed to overcome acquired resistance to current BRAF inhibitors. It demonstrates strong potential in primary brain tumors and brain metastases and is currently being evaluated in a Phase I clinical trial in China. HSK39297 is a best-in-class potential once-daily (QD) CFB inhibitor. Two NDA applications for PNH have been submitted in China, while several additional indications are advancing through Phase 2 and Phase 3 clinical development in China Under the terms of the agreement, Haisco will receive an upfront and near-term payment of $40M and is eligible to receive up to $1.421B in additional development, regulatory, and commercial milestone payments, as well as tiered royalties on future net sales. The first four milestones may be payable by Licensee in cash and/or common stock, provided that the equity consideration shall represent less than 40% of the total milestone value. If the Licensee sublicenses all or part of the rights to a third party, or if a change of control occurs during the restricted period, Haisco shall be entitled to share in the corresponding sublicense income and change-of-control payments. In addition, the effectiveness of the agreement is subject to certain financing conditions which Nuvectis is required to meet to ensure sufficient capital for the development of the licensed products. Everest Medicines enters into agreement with Dimerix to develop and commercialize DMX-200 in Greater China, South Korea and Southeast Asia. Under the terms of the agreement, Everest will pay Dimerix a $10M upfront payment, and up to $30M potential success-based development and regulatory milestone payments, as well as up to $300M in commercial milestone payments. In addition, Everest will pay tiered royalties between 10-15% of DMX-200 net sales in Greater China, South Korea, and certain Southeast Asian countries. DMX-200 is a small molecule inhibitor of the chemokine receptor 2 (CCR2) under development in a pivotal, Phase 3 study, ACTION3, for the treatment of Focal Segmental Glomerulosclerosis (FSGS). DMX-200 has received Orphan Drug Designations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) METiS TechBio , a leading AI-driven drug delivery innovation company, has entered into an exclusive global licensing agreement with Boulevard Bio, a U.S. biotechnology company backed by Deerfield Management, granting Boulevard worldwide development, manufacturing, and commercialization rights for MTS-128, a proprietary trispecific T-cell engager (TCE) program developed by METiS TechBio. METiS TechBio will receive a $20M upfront payment and is eligible to receive up to $1.6B in development, regulatory, and commercial milestone payments, in addition to tiered royalties on product sales. MTS-128 is a next-generation trispecific T-cell engager developed by METiS TechBio through its NanoForge platform. Unlike traditional antibody discovery approaches, MTS-128 is designed and optimized end-to-end through NanoForge-enabled AI-driven molecular engineering, representing a key example of AI-enabled therapeutic innovation at METiS TechBio. Everest Medicines has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd., for the development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across the Asia-Pacific region, including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR, and Taiwan region, China. Pursuant to the agreement, Everest Medicines will pay Vcare PharmaTech an upfront payment of CNY20M, along with subsequent milestone payments and commercial supply procurement. Sumecigrel is an antiplatelet agent and a new-generation oral P2Y12 receptor antagonist. It is being clinically developed for the treatment and prevention of atherothrombotic events such as acute coronary syndrome (ACS), ischemic stroke (IS) and peripheral arterial disease (PAD). As a novel antithrombotic drug developed by Vcare PharmaTech, the product is currently advancing preparations for NDA in China, the United States, Europe. See Related StreetAccount comments: 6/29/2026 11:39:51 AM - China announces preliminary results of 2026 NRDL adjustment, 557 passed for basic medical insurance, 54 passed for commercial insurance list Related: 000661.CH, 002422.CH, 002653.CH, 1093.HK, 1672.HK, 1877.HK, 1952.HK, 2096.HK, 2142.HK, 2493.HK, 2697.HK, 300122.CH, 4523.JP, 4568.JP, 600196.CH, 600276.CH, 603259.CH, 6160.HK, 6855.HK, 6872.HK, 688506.CH, 6996.HK, 7630.HK, 7666.HK, 9637.HK, 9939.HK, AZN.LN, LLY, TEVA...(more)	show story hide story
02-Jul-2026 17:10	+SCTX Scribe Therapeutics, Inc. files for Nasdaq IPO of indeterminate amount - S-1 We have applied to list our common stock on the Nasdaq Global Market, or Nasdaq, under the symbol "SCTX." Underwriters noted as Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities About: Scribe Therapeutics, Inc. engages in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Berkeley, CA. Financials: Year-End 31-Dec-25: Collaboration Revenue $27.4M vs prior-year $51.2M R&D $57.1M vs prior-year $60.8M Net Loss ($47.8M) vs prior-year ($21.8M) Quarter-End 31-Mar-26 Collaboration Revenue $2.2M vs prior-year $17.1M Lilly $2.2M vs prior year $16.8M Sanofi nil vs prior year $0.3M R&D $11.3M vs prior year $16.0M net Loss ($17.3M) vs prior year ($3.4M) Competitors: There are several companies utilizing CRISPR-Cas9 technology including CRISPR Therapeutics AG, Editas Medicine, Inc., Intellia Therapeutics, Inc. and Caribou Biosciences, Inc. In addition, companies using Cas attachment or novel nuclease technologies include Beam Therapeutics Inc., Prime Medicine, Inc., Tessera Therapeutics, Inc., Mammoth Biosciences, Inc., Arbor Biotechnologies, Inc., and Metagenomi Technologies, Inc., among others. More recently, several companies have emerged focusing on epigenetic modification to modulate protein expression without directly editing DNA, such as nChroma Bio, Inc., Epicrispr Biotechnologies, Inc. and Tune Therapeutics, Inc. We are aware of a number of genetic medicine companies with operations outside of the United States with active cardiometabolic programs, including AccurEdit Therapeutics, CorrectSequence Therapeutics, Epigenic Therapeutics Co., Ltd., Yoltech Therapeutics Co., Ltd., among others. Several additional companies utilize alternative nuclease-based epigenetic modification technologies, including ZFNs, engineered meganucleases and TALENs. In addition, we face competition from companies utilizing small interfering RNA, or siRNA, oligonucleotides, cell therapy therapeutic approaches and LNP delivery technologies to create therapeutics, including Corsera Health Inc. Our lead product candidate, STX-1150, and development programs, STX-1200 and STX-1400, target genetic risk factors of ASCVD. There are several approved products for LDL-C lowering or cardiovascular risk reduction, such as statins, ezetimibe, bempedoic acid, lomitapide, mipomersen and icosapent ethyl. There are also several approved products that target PCSK9 protein as a mechanism to lower LDL-C and reduce the risk of ASCVD, including evolocumab, which is a monoclonal antibody, or mAb, marketed as Repatha by Amgen Inc., alirocumab, which is marketed as PRALUENT by both Sanofi and Regeneron Pharmaceuticals, Inc., and inclisiran, which is a siRNA marketed as LEQVIO by Novartis. We are also aware of one other gene editing program targeting PCSK9 in development by Verve Therapeutics, a subsidiary of Eli Lilly and Company. Additionally, there are other investigational therapies targeting PCSK9, including Merck & Co., Inc.'s enlicitide and AstraZeneca PLC's laroprovstat. Related: 1853921, AMGN, AZN.LN, BEAM, CRBU, CRSP, EDIT, LLY, MGX, MRK, NOVN.SW, PRME, REGN, SAN.FP...(more) Reference Link: S-1 filing	show story hide story
02-Jul-2026 07:33	BBIO Acoramidis associated with first-ever early and sustained direct kidney-protective effects in ATTR-CM ($74.52) BBIO announced the publication of new analyses in Circulation: Heart Failure, examining kidney function in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with acoramidis. This publication was based on post-hoc analyses of data from randomized, double blind, placebo-controlled trials including the Phase 2 study and the Phase 3 ATTRibute-CM study. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer. The post-hoc analyses shared in the publication demonstrated that acoramidis initiation was associated with direct kidney-protective effects in patients with ATTR-CM, with both early and sustained improvements in kidney function, resembling the pattern seen with drugs acting directly on the kidney. Findings included: Acoramidis was associated with an early, reversible estimated glomerular filtration rate (eGFR) dip of 8.5±0.48 mL/min/1.73 m2 (95% CI: 7.57, 9.44), which was accompanied by a reduction in placebo-corrected urinary albumin to creatinine ratio (UACR) by 15.5% by Day 28 (P<0.05); such a reduction in UACR may suggest a direct impact on kidney health A sustained, improved chronic eGFR slope (+2.47 mL/min/1.73M²/year; p<0.001) and sustained UACR reduction (13.7%; p=0.026) were observed through Month 30, resembling the pattern seen with drugs acting directly on the kidney, such as ACE inhibitors, ARBs, and SGLT2 inhibitors The acute dip in eGFR following initiation of acoramidis may represent a beneficial kidney effect that could be relevant to the previously reported, observed early separation within the first 3 months between acoramidis and placebo in adverse clinical outcomes and the cumulative cardiovascular-related mortality or recurrent cardiovascular-related hospitalizations (CVH) curves, with a numerical difference in events within 1 month Participants with dips larger than the overall population median experienced a 58% lower risk of death or cardiovascular hospitalization (HR: 0.42; 95% CI, 0.22-0.78; P=0.006) and 66% lower risk of hospitalization alone (HR: 0.34; 95% CI, 0.17-0.66; P=0.002) in the first year of treatment. Within the placebo arm, eGFR dips were associated with worse outcomes Acoramidis is approved as ATTRUBY by the U.S. FDA and is approved as BEYONTTRA by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the Swiss Agency for Therapeutic Products, the UK Medicines and Healthcare Products Regulatory Agency, and the Brazilian Health Regulatory Agency (ANVISA) with all labels specifying near-complete stabilization of TTR. Editor's note: Corrected ticker for Alexion, now owned by AstraZeneca (AZN) Reference Link: Press release Related: AZN, BAYN.GR	show story hide story
02-Jul-2026 04:37	1093.HK CSPC Pharmaceutical Group enters collaboration and licensing agreement with AstraZeneca for siRNA drugs (HK$7.55) The collaboration, option and license agreement, will utilise the group's proprietary siRNA drug discovery platform and extrahepatic targeted delivery platform to develop novel small nucleic acid drug candidates. Under the terms of the agreement, the group and AstraZeneca will jointly discover and develop preclinical candidates for two targets, with the potential to treat renal diseases across multiple indications. For each PCC program, AstraZeneca will have the option to obtain the exclusive rights for the development, manufacturing and commercialisation globally or outside of China. The group will retain the rights to develop, manufacture and commercialise one of the PCCs in China. The group will receive an upfront payment of $30M and is also eligible to receive up to $540M in potential development milestone payments and up to $1.2B in potential sales milestone payments, plus potential single digit royalties based on the annual net sales of the products. Related: AZN.LN Attached Files PDF Document: Press release	show story hide story
02-Jul-2026 04:37	13.HK Hutchmed receives NMPA conditional approval for ORPATHYS for treatment of gastric caner with MET amplification (HK$17.60) ORPATHYS is approved for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments. Reference Link: Press release Related: AZN.LN	show story hide story
01-Jul-2026 17:23	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to slightly higher overall on Wednesday. Advancers beat decliners by nearly 5:1 on the XLV. Healthcare +0.52% vs S&P 500 +0.22%. Most major health groups were higher by 2% to 4% on the averages to begin July and H2 2026. Biotech and Pharma kept a lid on the sector overall however, the XBI (1.07%) and the DRG (0.93%) after recent and respective outperformance. ELV +7.6% and BIIB (2.9%) bracketed the XLV; just ten decliners on the XLV, mostly large-cap drugmakers. NVO +1.7% an outlier in the space, after reaffirming its participation in the Medicare GLP-1 Bridge demo, which began 1-Jul. The calendar turn also meant new reimbursement/coverage for GH +13.8% Shield at UNH +2.6%. Marketplace MCOs among the leading gainers, after CMS risk adjustment report on Tuesday. UBS sees earnings upside in Q2 for some MP-leveraged payers including OSCR +11.9%. For June 2026, Healthcare outperformed by more than 750bps, +6.46% vs S&P 500 (1.06%). At the half way mark of CY26, Healthcare climbed to eighth out of eleven sectors, on the back of Biotech and MCO strength in June. Just one more session in a holiday-shortened week. So far this week, Healthcare unable to maintain June's momentum, XLV tracking mildly lower as Pharma weighs. Beyond the long Holiday weekend, two weeks until JNJ kicks off Q2 earnings season, followed the next day by UnitedHealth and Abbott. Macro There were several moving parts in play today with another day of momentum unwinding as the big story. Semis/memory pulled back sharply after the group logged a record-breaking Q2; but also rotations in the mix with Mag7, software, financials, healthcare, food, apparel, restaurants, media, and staffing areas faring well. In terms of headlines, not much incremental out of Warsh's appearance at the Sintra conference, though he did argue inflationary pressures have diminished. Some positive takes on today's ISM manufacturing reading given big drop in prices-paid component and less pessimistic commentary (much attention pulled ahead to tomorrow's payrolls report). Geopolitics still a relative nonissue; reports suggest positive talks in Doha while reports Trump still reluctant to return to kinetic action. Corporate stories of note include MSFT job cuts, reports META moving toward long-expected sale of excess compute, ongoing NKE turnaround, and continued pickup in M&A activity. Notable Gainers +13.8% GH (Guardant Health): Leerink comments on UNH coverage of Shield +12.8% CARL (Carlsmed): initiation +11.9% OSCR (Oscar Health): UBS comments on CMS risk adjustment and earnings upside +10.3% ZBIO (Zenas BioPharma): best performer on XBI; unusual volume 3X daily +9.3% RGNX (REGENXBIO): on nearly 2X daily volume +8.4% HIMS (Hims & Hers Health): shares +16% YTD +7.6% ELV (Elevance Health): UBS comments on CMS risk adjustment and earnings upside; best performer on XLV +7.6% ALGN (Align Technology): shares green +2% WTD +6.5% CNC (Centene): UBS comments on CMS risk adjustment and earnings upside; 52-week high +6.3% TEM (Tempus AI): initiation +5.2% IQV (IQVIA Holdings): Baird comments, bullish pick +5.0% PODD (Insulet): shares remain (44%) YTD +4.7% HTFL (Heartflow): initiation; shares were (16%) yesterday Notable Decliners -10.1% SLS (SELLAS Life Sciences Group): worst performer on XBI; profit-taking; shares remain +252% YTD -9.5% PVLA (Palvella Therapeutics): off 52-week high (Monday) -8.1% TNGX (Tango Therapeutics): profit-taking; shares remain +224% YTD -7.6% TRAX (First Tracks Biotherapeutics Inc): shares were +18% yesterday -7.5% DNTH (Dianthus Therapeutics): off 52-week high; first decline in 10 days -3.0% AZN (AstraZeneca): on above average volume -2.9% BIIB (Biogen): worst performer on XLV; off 52-week high (Monday) Marketplace MCOs trade higher on Wednesday; CMS risk adjustment report cited Trading update (intraday): OSCR +11.3%, ELV 5.9%, CNC +5.1%, HUM +3.1%, UNH +2.5%, MOH +1.0% UBS analyst AJ Rice published research today highlighting the CMS release yesterday of the final 2025 risk adjustment summary report for Marketplace MCOs. Firm details the net positions for risk accruals, a key portion of earnings, and expects some to report favorable upside to Q2 EPS. Guardant Health mentioned positively at Leerink following UnitedHealthcare's coverage of Shield Leerink comments UNH's decision to cover Shield as an unambiguous 1L test, noting that the 1L category is a significant positive over the suggested 2L option Firm sees ASP and volume momentum from the decision Rating remains outperform, target $190 Analyst is Puneet Souda CMS issues press release for previously announced 1-Jul launch of GLP-1 Bridge Eligible Medicare beneficiaries may now get certain GLP-1 medications for $50 per month through the Medicare GLP-1 Bridge, a new Centers for Medicare & Medicaid Services (CMS) initiative designed to expand access to innovative treatments and test the impacts of increased access to GLP-1 drugs for weight management on the Medicare program. StreetAccount notes the GLP-1 Bridge demo was previously announced, extended in April 2026 when payers pushed back on the BALANCE model, and even more widely discussed in May 2026. (CNC, CVS, ELV, LLY, MOH, NVO, UNH) FDA approves Orca Bio's (private) BLA for Tregzi FDA approves Orca Bio's (private) BLA for Tregzi (formerly Orca-T) for hematologic malignancies. StreetAccount notes the PDUFA goal date was 6-Jul (extended from April). CEO tells STAT News the company is "well financed" for the launch and has no immediate plans for an IPO. Notable research in Healthcare today Biotech: ABVX upgraded to buy from hold at Jefferies (Faisal Khurshid), target increased to $158 from $108 or approx. 19% upside. (FactSet average PT $149; range $81-206) EYPT transferred buy at Chardan Capital (Andreas Argyrides), target increased to $65 from $29 or approx. 355% upside (FactSet average PT $37; range $20-68) GUTS initiated buy at Craig-Hallum Capital (Chase Knickerbocker), target is $4 or approx. 406% upside (FactSet average PT $5; range $2-8) KZIA initiated buy at BTIG (Kambiz Yazdi), target is $34 or approx. 141% upside (FactSet average PT $26; range $18-32) MedTech: ABT initiated outperform at Baird (David Rescott), target is $121 or approx. 33% upside. (FactSet average PT $116; range $92-135) CARL initiated buy at Needham (David Saxon), target is $17 or approx. 64% upside. (FactSet average PT $18; range $16-23) HTFL initiated buy at Freedom Capital (Gene Mannheimer), target is $37 or approx. 26% upside. (FactSet average PT $37; range $35-40) INSP initiated buy at Freedom Capital (Keith Hinton), target is $62 or approx. 39% upside. (FactSet average PT $51; range $39-65) LIVN initiated hold at Freedom Capital (Keith Hinton), target is $81 or approx. 1% downside. (FactSet average PT $83; range $72-95) TEM initiated hold at Freedom Capital (Gene Mannheimer), target is $59 or approx. 2% upside. (FactSet average PT $67; range $35-100) Operon Research analyst Jack Meehan (formerly of Nephron Research) initiates coverage on 20 names in the LST&D space. Services: CON initiated outperform at William Blair (Jared Haase) Post-close news Regulatory: CMS proposes +2.4% increase to payments in Home Health PPS for CY27 PR; Fact Sheet; Proposed Rule (269pp) Research: WAY initiated overweight at Keybanc (Scott Schoenhaus), target is $30 or approx. 40% upside. (FactSet average PT $34; range $25-44) On Deck: Jun 27 - Jul 5 Overview: A holiday shortened week, with US equity markets closed on Friday 3-Jul in observance of Independence Day. Very little on the sector calendar, the FDA cleared out most PDUFA goal dates in the prior week. Holiday calendar: Fri 3-Jul: Holiday (observed) - US equity markets closed for Independence Day StreetAccount Healthcare Reads Cigna's CEO Vows to Put Patients First. Wall Street Is Watching (1-Jul) Bloomberg FDA approves Orca Bio's T cell therapy for blood cancer patients (1-Jul) STAT News Medicare will start covering obesity drugs for the first time. Here's what patients should know (30-Jun) CNBC This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABT, ABVX, ALGN, AVAH, AZN, BIIB, BTSG, CARL, CHE, CNC, CON, CVS, DNTH, EHC, ELV, ENSG, EYPT, GH, GUTS, HIMS, HTFL, HUM, INSP, IQV, KZIA, LIVN, LLY, MOH, NVO, OPCH, OSCR, PNTG, PODD, PVLA, RGNX, SLS, TEM, TNGX, TRAX, UNH, WAY, ZBIO...(more)	show story hide story
30-Jun-2026 18:08	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mostly lower on Tuesday, final session of June/Q2/H1. Decliners beat advancers by more than 2:1 on the XLV. Healthcare (1.30%) vs S&P 500 +0.79%. Most major health groups ended lower on the session, and all underperformed the wider tape. Only Services group ended higher on the averages. XBI (0.04%) quietly ended its winning streak at eight days, after MRNA +0.5% unable to hold early gains. HUM +2.1% and ZBH (5.6%) bracketed the XLV. Pharma, DRG (1.46%), and MedTech dragged down the sector. LST stocks were lightly mixed following latest AI headlines on Tuesday afternoon - Claude Sciene launch in focus. Medical devices weak all session - we're told that a boutique midwest research firm had cautious comments on the orthopedic subgroup today. Otherwise no clear catalyst outside of today's rebound in Big Tech and Semis, unwinding the recent market rotations. Health sector news very quiet apart from the usual biotech din. Mixed regulatory newsflow overnight in Biotech. FDA approved Arcutis Biotherapeutics' sNDA and issued a CRL for Unicycive Therapeutics' NDA. Also trial results in ulcerative colitis and r/r DLBCL on the tape. For June 2026, Healthcare outperformed by 750bps, +6.46% vs S&P 500 (1.06%). At the half way mark of CY26, Healthcare climbed to eighth out of eleven sectors, on the back of Biotech and MCO strength in June. Looking ahead, just two more sessions in a holiday-shortened week, in which Healthcare is coming off its best week in four years, and fifth-best week ever for Pharma and tenth-best week ever for Biotech. Macro Momentum again took the lead in a session without many notable drivers; semis were broadly higher and SOX capped its best quarter since its 1993 inception. But there was some stalling of the broadening-out trade with S&P decliners leading advancers and equal-weight S&P lagging. Otherwise not much of note. Market looking ahead to Warsh remarks on Wednesday and NFP on Thursday. Latter expected to highlight the solid macro backdrop theme with another month of 100K+ payrolls growth. Also some focus on upcoming Q2 earnings season, which is expected to deliver second straight Q of 20%+ growth with tailwinds from AI capex boom and oil. Geopolitics on the backburner again; no updates yet out of Qatar negotiations though gaps likely to remain on nuclear policy and SoH tolls; however, issue not a market mover (energy or otherwise) amid ongoing tanker-traffic normalization. Notable Gainers +38.6% ABVX (Abivax): trial results in ulcerative colitis +18.3% TRAX (First Tracks Biotherapeutics Inc): best performer on XBI +8.8% RARE (Ultragenyx Pharmaceutical): shares +39% for the month +7.4% DMRA (Damora Therapeutics): shares +20% last week +6.8% NKTR (Nektar Therapeutics): shares +65% YTD vs XBI +30% +5.6% SRPT (Sarepta Therapeutics): FDA accepts sNDAs for Amondys 45 and Vyondys 53 +5.6% GMAB (Genmab): trial results in r/r DLBCL +2.1% HUM (Humana): best performer on XLV; 52W high; shares +30% for the month Notable Decliners -39.1% UNCY (Unicycive Therapeutics): FDA issues CRL for OLC -15.8% HTFL (Heartflow): Canaccord Genuity comments on plaque survey and evidence of competitive switching at the expense of HTFL -11.7% EVMN (Evommune): follow-through, downgraded at HC Wainwright -10.5% ACIU (AC Immune): trial results in Alzheimer's Disease -8.9% ATEC (Alphatec Holdings): spine/orthopedics weakness; cautious comments by midwest boutique firm, we're told -8.4% OCGN (Ocugen): worst performer on XBI; shares +11% for the month -6.1% EVH (Evolent Health): downgraded at Truist -6.0% ENOV (Enovis): brief mention at BTIG -5.9% GMED (Globus Medical): spine/orthopedics weakness; cautious comments by midwest boutique firm, we're told -5.6% ZBH (Zimmer Biomet Holdings): worst performer on XLV; acquires iovera from PCRX; BTIG comments on cryoneurolysis; broader orthopedics weakness; cautious comments by midwest boutique firm, we're told -5.6% OFIX (Orthofix Medical): spine/orthopedics weakness; cautious comments by midwest boutique firm, we're told -4.9% SNN (Smith & Nephew): broader orthopedics weakness; cautious comments by midwest boutique firm, we're told -4.5% PRAX (Praxis Precision Medicines): FDA extends PDUFA date by 3 months -4.5% SYK (Stryker): broader orthopedics weakness; cautious comments by midwest boutique firm, we're told -4.5% SLS (SELLAS Life Sciences Group, Inc.): shares remain +59% for the month -2.8% ALGN (Align Technology): EC antitrust investigation into aligners and scanners Anthropic launches Claude Science Anthropic today announced the availability of Claude Science. Building on Claude Life Sciences announced in October 2025, Science, "an AI workbench for scientists", it is "an app that integrates the tools and packages that researchers most commonly use, produces auditable artifacts, and provides flexible access to computing resources". Media coverage: STAT News; Bloomberg; Reuters Lawmakers open national security investigation into China drug trials - Reuters Reuters article cites letters dated Monday (29-Jun) sent from leaders of the China Select Committee of the US House of Representatives, to drugmakers Merck and AbbVie seeking details on their clinical trial sites in the Xinjiang region and military hospitals. Trial results in SMID-cap biotech ABVX.FP (ABVX) announced topline results from ABTECT Maintenance Part 2, the supplemental portion of its Phase 3 ulcerative colitis maintenance program evaluating obefazimod. GMAB.DC (GMAB) announced topline results from the phase 3 EPCORE DLBCL-4 trial evaluating epcoritamab (Epkinly, ABBV) and lenalidomide compared to SOC in adult patients with r/r DLBC who received at least one prior line of treatment. Study met its primary objective, stat sig and clinically meaningful improvement in PFS. Hazard Ratio 0.40 (US) and 0.44 (ex-US censoring rules). ACIU announced interim data from the first three cohorts in the Phase 1b/2 ABATE trial evaluating ACI-24 (Abeta) active immunotherapy for Alzheimer's Disease. Dose-response demonstrated with antibodies detected at all dose levels. Safe and well-tolerated. Study ongoing. Regulatory headlines in SMID-cap biotech ARQT announced that FDA approved Zoryve (AZN) sNDA in pediatric plaque psoriasis. FDA PDUFA was on Monday. UNCY announced that FDA issued a CRL for OLC NDA in hyperphosphatemia in CKD w/ dialysis. The CRL based on the same third party manufacturing deficiencies that were identified in the prior CRL (June 2025). PRAX announces that FDA extends PDUFA goal date by three months for relutrigine NDA. New PDUFA goal date is 27-Dec-2026. DBV.FP (DBVT) announced that following meetings with FDA, it will incorporate feedback and now anticipates BLA submission for Viaskin Peanut Patch in Q3 of 2026 - versus prior guidance for H1 of 2026. Notable research in Healthcare today Biotech: EVMN downgraded to neutral from buy at HC Wainwright (Mitchell Kapoor). REPL upgraded to outperform from underperform at BMO Capital Markets (Evan Seigerman), follows Q4 results (Monday AM). Target raised to $16 or approx. 43% upside. (FactSet average PT $8; range $1-17) ATHE initiated buy at Jones (Debanjana Chatterjee), target is $16 or approx. 227% upside. (FactSet average PT $16; range $9-33) PMN initiated overweight at Cantor Fitzgerald (Pete Stavropoulos), target is $25 or approx. 133% upside. (FactSet average PT $36; range $18-50) VTVT initiated buy at Rodman & Renshaw (Michael King), target is $67 or approx. 85% upside. (FactSet average PT $55; range $45-67) MedTech: ICLR upgraded to buy from hold at Truist (Jailendra Singh), sees upside to Street EBITDA and revenue estimates. Target increased to $207 from $159 or approx. 20% upside (FactSet average PT $180; range $150-207) EVH downgraded to hold from buy at Truist (Jailendra Singh), notes valuation and lack of near-term visibility. Target remains $7 or approx. 21% upside. (FactSet average PT $6; range $3-8) Post-close news Regulatory: FDA approves Orca Bio's (private) BLA for Tregzi (formerly Orca-T) for hematologic malignancies. StreetAccount notes the PDUFA goal date was 6-Jul (extended from April). Secondary offering: ABVX commences $600M offering of ADS. Research: ABVX upgraded to buy from hold at Jefferies (Faisal Khurshid), target increased to $158 from $108 or approx. 19% upside. (FactSet average PT $149; range $81-206) ABT initiated outperform at Baird (David Rescott), target is $121 or approx. 33% upside. (FactSet average PT $116; range $92-135) HTFL initiated buy at Freedom Capital (Gene Mannheimer), target is $37 or approx. 26% upside. (FactSet average PT $37; range $35-40) INSP initiated buy at Freedom Capital (Keith Hinton), target is $62 or approx. 39% upside. (FactSet average PT $51; range $39-65) LIVN initiated hold at Freedom Capital (Keith Hinton), target is $81 or approx. 1% downside. (FactSet average PT $83; range $72-95) TEM initiated hold at Freedom Capital (Gene Mannheimer), target is $59 or approx. 2% upside. (FactSet average PT $67; range $35-100) On Deck: Jun 27 - Jul 5 Overview: A holiday shortened week ahead, with US equity markets closed on Friday 3-Jul in observance of Independence Day. Very little on the sector calendar, the FDA cleared out most PDUFA goal dates in the prior week. Holiday calendar: Fri 3-Jul: Holiday (observed) - US equity markets closed for Independence Day This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABBV, ABT, ABVX, ABVX.FP, ACIU, ALGN, ARQT, ATEC, ATHE, AZN, DBV.FP, DMRA, ENOV, EVH, EVMN, GMAB, GMAB.DC, GMED, HTFL, HUM, ICLR, INSP, LIVN, NKTR, OCGN, OFIX, PMN, PRAX, RARE, REPL, SLS, SNN, SRPT, SYK, TEM, TRAX, UNCY, VTVT, ZBH...(more)	show story hide story
30-Jun-2026 08:52	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Mixed regulatory newsflow overnight in Biotech. FDA approved Arcutis Biotherapeutics' sNDA and issued a CRL for Unicycive Therapeutics' NDA. Also trial results in ulcerative colitis and r/r DLBCL on the tape. A holiday-shortened week in which Healthcare is coming off its best week in four years, and fifth-best week ever for Pharma and tenth-best week ever for Biotech. Biopharma M&A and market rotation were significant drivers las week. Macro S&P futures are little changed on Tuesday morning, off pre-market highs. No big directional drivers in play this morning. Near-term focus seems to be on outsized month/quarter-end selling estimates for equities, Warsh speech on Wednesday and NFP on Thursday. Also a pickup in focus on upcoming Q2 earnings season and expectations for a second straight Q of 20%+ growth. Elevated US corporate profit margins, Iran's continued push for control over SoH traffic, 40-year lows in Japanese yen, dampened pressure on ECB to raise rates, political pressure on BoJ not to tighten, slightly firmer China PMIs, cooler Eurozone inflation prints, memory price pressure spillover (China smartphone makers cutting shipment targets again), more headlines about US retailers frontloading orders and DeepSeek peak-use surcharge among the areas of discussion today. Pre-market trading update Trading higher +33.4% ABVX trial results in UC +7.5% GMAB trial results in r/r DLBCL +5.9% REPL double upgrade at BMO Capital Markets +1.2% ICLR upgraded at Truist +0.4% PRAX FDA extends PDUFA date by 3 months Trading lower -48.3% UNCY FDA issues CRL for OLC -15.0% ACIU trial results in AD -2.6% DBVT regulatory feedback, BLA submission now Q3 vs H1 -1.4% EVH downgraded at Truist -0.8% EVMN follow-through, downgraded at HC Wainwright Biotech Regulatory: ARQT announced that FDA approved Zoryve (AZN) sNDA in pediatric plaque psoriasis. FDA PDUFA was on Monday. UNCY announced that FDA issued a CRL for OLC NDA in hyperphosphatemia in CKD w/ dialysis. The CRL based on the same third party manufacturing deficiencies that were identified in the prior CRL (June 2025). PRAX announces that FDA extends PDUFA goal date by three months for relutrigine NDA. New PDUFA goal date is 27-Dec-2026. DBV.FP (DBVT) announced that following meetings with FDA, it will incorporate feedback and now anticipates BLA submission for Viaskin Peanut Patch in Q3 of 2026 - versus prior guidance for H1 of 2026. Trial results: ABVX.FP (ABVX) announced topline results from ABTECT Maintenance Part 2, the supplemental portion of its Phase 3 ulcerative colitis maintenance program evaluating obefazimod. GMAB.DC (GMAB) announced topline results from the phase 3 EPCORE DLBCL-4 trial evaluating epcoritamab (Epkinly, ABBV) and lenalidomide compared to SOC in adult patients with r/r DLBC who received at least one prior line of treatment. Study met its primary objective, stat sig and clinically meaningful improvement in PFS. Hazard Ratio 0.40 (US) and 0.44 (ex-US censoring rules). ACIU announced interim data from the first three cohorts in the Phase 1b/2 ABATE trial evaluating ACI-24 (Abeta) active immunotherapy for Alzheimer's Disease. Dose-response demonstrated with antibodies detected at all dose levels. Safe and well-tolerated. Study ongoing. Research: EVMN downgraded to neutral from buy at HC Wainwright (Mitchell Kapoor). REPL upgraded to outperform from underperform at BMO Capital Markets (Evan Seigerman), follows Q4 results (Monday AM). Target raised to $16 or approx. 43% upside. (FactSet average PT $8; range $1-17) ATHE initiated buy at Jones (Debanjana Chatterjee), target is $16 or approx. 227% upside. (FactSet average PT $16; range $9-33) PMN initiated overweight at Cantor Fitzgerald (Pete Stavropoulos), target is $25 or approx. 133% upside. (FactSet average PT $36; range $18-50) VTVT initiated buy at Rodman & Renshaw (Michael King), target is $67 or approx. 85% upside. (FactSet average PT $55; range $45-67) Life Science & MedTech Research: ICLR upgraded to buy from hold at Truist (Jailendra Singh), sees upside to Street EBITDA and revenue estimates. Target increased to $207 from $159 or approx. 20% upside (FactSet average PT $180; range $150-207) EVH downgraded to hold from buy at Truist (Jailendra Singh), notes valuation and lack of near-term visibility. Target remains $7 or approx. 21% upside. (FactSet average PT $6; range $3-8) On Deck:: Jun 27 - Jul 5 Overview: A holiday shortened week ahead, with US equity markets closed on Friday 3-Jul in observance of Independence Day. Very little on the sector calendar, the FDA cleared out most PDUFA goal dates in the prior week. Holiday calendar: Fri 3-Jul: Holiday (observed) - US equity markets closed for Independence Day This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABBV, ABVX, ABVX.FP, ACIU, ARQT, ATHE, AZN, DBV.FP, DBVT, EVH, EVMN, GMAB, GMAB.DC, ICLR, PMN, PRAX, REPL, UNCY, VTVT...(more)	show story hide story
29-Jun-2026 19:17	ARQT FDA approves Arcutis Biotherapeutics' sNDA to expand indication for ZORYVE (roflumilast) cream 0.3% for topical treatment of plaque psoriasis including intertriginous areas to children down to age 2 ($26.76) ZORYVE cream 0.3% was previously approved for the treatment of plaque psoriasis in adults and children down to age 6 Reference Link: Press release Related: 000963.CH, AZN.LN	show story hide story
29-Jun-2026 17:08	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to slightly higher overall on a mixed tape Monday. Decliners outnumbered advancers on the XLV. Healthcare +0.16% vs S&P 500 +1.18%. Major health groups ended widely mixed for the session, and only Biotech outperformed the wider tape. Biotech, XBI +1.89%, extended its winning to streak to eight days, and outperformance to six days, although newsflow was just incremental at best. One small M&A deal struck just below Friday's closing price: ZYME (0.2%) buying TBPH (3.2%) for ~$1B. VRDN +5.0% to challenge AMGN +0.6% following FDA approval in TED. Handful of downgrades out of BofA today, including BHVN (5.6%) to underperform. Pharma saw broad yet modest gains in a narrow band, with the DRG +1.16%. Today's bounce for Big Tech dominated any incremental sector news. Managed Care was a source of funds in a reversal of last week's dynamic. CRL +4.6% and ZTS (3.7%) bracketed the XLV on Monday. Fairly modest moves in between. VEEV +2.8% was back among leading advancers. In a holiday-shortened week, Healthcare is coming off its best week in four years, and fifth-best week ever for Pharma and tenth-best week ever for Biotech. Biopharma M&A and market rotation were significant drivers las week. Macro There were several large gainers in the big-tech space, though with no specific catalyst in view; followed mtd underperformance and some focus on depressed positioning. South Korean investment and AAPL China supply lobbying among the easiest excuses. Dampened oil/rate momentum (lower) might have been an overhang. However, geopolitics remained largely on the backburner with US and Iran agreeing to halt attacks and another round of technical discussions on tap for tomorrow. SCOTUS denied Trump stay request to remove Fed Governor Cook (though largely as expected and with no notable rate impact). Busy again in terms of M&A, though CMCSA spin (and potential to unleash more media M&A) seems to be the biggest corporate story. Busy macro week on tap with Warsh and NFP the highlights. Q2 earnings season kicks off in a couple of weeks with a second straight Q of 20%+ growth expected on the back of the AI capex boom and energy tailwind from the Middle East conflict. Notable Gainers +32.2% QDEL (QuidelOrtho): FT report - seeking to sell testing unit +24.7% SLS (SELLAS Life Sciences Group, Inc.): best performer on XBI; follow-through, shares +54% last week +16.8% CATX (Perspective Therapeutics): second-best on XBI; brief positive mention B Riley +15.5% VOR (Vor Biopharma): shares were +8% Friday on 8X average volume +14.2% ERAS (Erasca): shares were +7% Friday on 3X average volume +13.5% COAG (Hemab Therapeutics): follow-through, shares were +17% on Friday following pipeline updates and new FIH data +11.0% FDMT (4D Molecular Therapeutics): credit facility / financing agreement +8.5% PRME (Prime Medicine): upgraded at HC Wainwright +6.2% CYTK (Cytokinetics): upgraded at UBS +5.0% VRDN (Viridian Therapeutics): FDA approves Lumvoa for TED +4.6% CRL (Charles River Laboratories): best performer on XLV +4.0% NTRA (Natera): announces partnership with Aveta Biomics in HNSCC +3.6% MRNA (Moderna): second-best on XLV; 52-week high; shares were +13% on Friday +3.2% HNGE (Hinge Health, Inc.): 52-week high; seeking seventh straight weekly advance +3.0% LH (Labcorp Holdings): shares were +6% last week +2.8% VEEV (Veeva Systems): shares were +12% last week Notable Decliners -40.2% EVMN (Evommune): trial results in CSU; downgraded at William Blair -12.6% LRMR (Larimar Therapeutics): regulatory updates in Friedreich's Ataxia -10.0% CAPR (Capricor Therapeutics): worst performer on XBI; shares were (7%) last week -6.9% SEPN (Septerna): sympathy to EVMN -6.8% RGEN (Repligen Corp.): Bloomberg report on BLFS, Repligen a suitor; shares were +11% last week -5.8% ARDX (Ardelyx): shares were (8%) last week -5.6% BHVN (Biohaven): downgraded at BofA -5.2% AORT (Artivion): despite FDA approval AMDS Hybrid Prosthesis -4.9% AMPH (Amphastar Pharmaceuticals): downgraded at BofA -4.6% ALKS (Alkermes): downgraded at BofA -4.3% CNMD (CONMED): downgraded at BofA -3.9% LQDA (Liquidia): downgraded at BofA -3.7% ZTS (Zoetis): worst performer on XLV -3.7% REPL (Replimune Group): follows back-to-back +14% weeks -3.2% TBPH (Theravance Biopharma): acquired for $17.00/shr; closed Friday at $17.63/shr -2.8% IDXX (IDEXX Laboratories): second-worst on XLV -2.8% ALGN (Align Technology): shares were (2%) last week -2.6% MANE (VeraDermics, Inc.): shares were +35% last week -1.9% UNH (UnitedHealth Group): shares were +7% last week -1.8% CNC (Centene): shares were +8% last week -0.2% ZYME (Zymeworks): acquired TBPH for $929M cash Quidel higher following media report on PE bids QDEL FT reports that company is seeking to sell its testing unit, for up to $1.5B, bids coming in from private equity firms. One small M&A deal in biopharma TBPH acquired by ZYME for $17/shr total EV $928M in cash. Lead asset is Yuperli, a LAMA for COPD maintenance treatment. Full year sales of Yuperli in 2025 were $266.6M, or 12% growth from 2024. Viridian wins FDA approval for TED, seeks to challenge Amgen VRDN announced that FDA approved Lumvoa (veligrotug-vvze) BLA for the treatment of TED. PDUFA goal date was Tuesday 30-Jun. On the call: Announced pricing at parity with AMGN Tepezza - on a course of therapy basis. Lantheus Holdings lower following manufacturing-related CRL LNTH announced that FDA issued a CRL for '2501 (Gallium 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs). Agency solely cited third-party manufacturing-related conditions. PDUFA goal date was Monday 29-Jun. Larimar Therapeutics lower as safety questions remain key to review of FA treatment LRMR announced submission of first module of rolling BLA for nomlabufusp in Friedreich's Ataxia. Company also reported new data from open label study. Quick take: Leerink Partners (outperform) expects stock to trade down today, noting that safety questions persist - discontinuation rate, anaphylaxis rate, and lack of clarity on safety database. Notable research in Healthcare today Pharma: AMPH downgraded to underperform from neutral at BofA (Jason Gerberry), target cut to $20 from $25 or approx. 8% downside. (FactSet average PT $22; range $19-30) Biotech: ALKS downgraded to underperform from neutral at BofA (Jason Gerberry), target is $38 or approx. 31% downside. (FactSet average PT $49; range $34-65) BHVN downgraded to underperform from neutral at BofA (Dina Ramadane), target cut to $11 from $12 or approx. 31% downside. (FactSet average PT $22; range $9-50) CYTK upgraded to buy from neutral at UBS (Ashwani Verma), target increased to $115 from $69 or approx. 40% upside. (FactSet average PT $108; range $83-146) LQDA downgraded neutral from outperform at BofA (Jason Gerberry), target increased however to $79 from $64. (FactSet average PT $74; range $60-109) PRME upgraded to buy from neutral at HC Wainwright (Arthur He), target is $8 or approx. 133% upside. (FactSet average PT $7; range $4-11) MedTech: CNMD downgraded to underperform from neutral at BofA (Travis Steed), target remains $40 or approx. 11% upside. (FactSet average PT $40; range $39-40) Post-close news Regulatory: PRAX announces that FDA extends PDUFA goal date by three months for relutrigine NDA. New PDUFA goal date is 27-Dec-2026. Shares trading (5.9%) in the after-hours DBV.FP (DBVT) announced that following meetings with FDA, it will incorporate feedback and now anticipates BLA submission for Viaskin Peanut Patch in Q3 of 2026 - versus prior guidance for H1 of 2026. Conf. call at 17:00ET ADRs trading little changed in the after-hours Trial results: ABVX.FP (ABVX) announced topline results from ABTECT Maintenance Part 2, the supplemental portion of its Phase 3 ulcerative colitis maintenance program evaluating obefazimod. Conf. call at 16:30ET ADRs halted; to resume trading 17:00ET GMAB.DC (GMAB) announced topline results from the phase 3 EPCORE DLBCL-4 trial evaluating epcoritamab (Epkinly, ABBV) and lenalidomide compared to SOC in adult patients with r/r DLBC who received at least one prior line of treatment. Study met its primary objective, stat sig and clinically meaningful improvement in PFS. Hazard Ratio 0.40 (US) and 0.44 (ex-US censoring rules). ADRs trading +3.5% in the after-hours Research: ATHE initiated buy at Jones (Debanjana Chatterjee), target is $16 or approx. 227% upside. (FactSet average PT $16; range $9-33) ADRs trading +2.7% in the after-hours On Deck: Jun 27 - Jul 5 Overview: A holiday shortened week ahead, with US equity markets closed on Friday 3-Jul in observance of Independence Day. Very little on the sector calendar, the FDA cleared out most PDUFA goal dates in the prior week. Regulatory calendar Mon 29-Jun: FDA PDUFA for ARQT/AZN (Zoryve sNDA in pediatric plaque psoriasis) FDA PDUFA for UNCY (OLC NDA in hyperphosphatemia in CKD w/ dialysis) Holiday calendar: Fri 3-Jul: Holiday (observed) - US equity markets closed for Independence Day StreetAccount Healthcare Reads The ERs that can turn patients away - and are reaping millions (29-Jun) STAT News Pfizer, Innovent GLP-1 drugs clear China insurance hurdle (29-Jun) Reuters Medicare Advantage Company Pays $342M to Government in Midst of Billing Probe (26-Jun) KFF Health News This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 1801.HK, ABBV, ABVX.FP, ALGN, ALKS, AMGN, AMPH, AORT, ARDX, ARQT, ATHE, AZN, BHVN, CAPR, CATX, CNC, CNMD, COAG, CRL, CYTK, DBV.FP, ELV, ERAS, EVMN, FDMT, GMAB.DC, HNGE, IDXX, LH, LLY, LNTH, LQDA, LRMR, MANE, MRNA, NTRA, NUTX, NVO, PFE, PRAX, PRME, QDEL, REPL, RGEN, SEPN, SLS, TBPH, UNCY, UNH, VEEV, VOR, VRDN, ZTS, ZYME...(more)	show story hide story
29-Jun-2026 11:39	China announces preliminary results of 2026 NRDL adjustment, 557 passed for basic medical insurance, 54 passed for commercial insurance list On 29-Jun, China's National Healthcare Security Administration (NHSA) issued a public notice on the list of drugs having passed the preliminary review for the 2026 adjustments to the National Reimbursement Drug List (NRDL) for basic health insurance and commercial Insurance Innovative Drug List. A total of 818 applications were received for this adjustment cycle, covering 674 generic drug names. Basic National Reimbursement Drug List: among the 375 generic names applied for addition to the lists (excluding pre‑submitted varieties), 334 passed the preliminary review; and among the 229 applied for adjustments within the lists/renewals (excluding pre‑submitted varieties), 223 passed the preliminary review. Commercial Health Insurance Innovative Drug List: among the 57 generic names applied for addition to the list (excluding pre‑submitted varieties), 53 passed the preliminary review; and among the 1 applied for adjustment within the list/renewal, 1 passed the preliminary review. Overall, this year: The number of submitted drugs has further increased. A total of 818 application were received, covering 674 generic names, representing an increase of 100 applications and 41 generic names vs. that of 2025 The pass rate for initial screening has improved significantly. Excluding pre‑submitted varieties, the overall pass rate for the preliminary screening stood at 92%, up by 8% from last year, indicating that most pharmaceutical companies were able to accurately understand the adjustment work plan and submit applications in compliance with the specified conditions The majority of submitted drugs are new drugs. In particular, the number of drugs submitted under Condition 1 for addition to the list, i.e., new drugs approved within the past five years, is 343. On the whole, both the number of submitted applications and the proportion that passed the initial screening are higher than in previous years. The NHSA stated that, for the pre‑submitted drugs, it has simultaneously requested the relevant authorities to verify the completion timeline of the technical review, and will release the formal review results together after the applicants submit supplementary materials StreetAccount note that pre-submission is a new mechanism introduced by NHSA in 2026. It allows pharmaceutical companies to submit application materials for inclusion in NRDL before their product has officially received a formal marketing approval from the National Medical Products Administration (NMPA) Traditionally, a drug had to be fully approved by the cut-off date (30-Jun) to be eligible for that year's adjustment. If approval came just one day late, the applicant would have to wait another full year (China Daily). The pre‑submission mechanism bridges this timing gap by allowing innovative drugs that have already completed the technical review at the Center for Drug Evaluation (CDE) to get into the queue early According to NHSA, the drug must have completed the technical review (e.g., NDA or ANDA review) by the CDE no later than 10-Jun. After that, the applicant must supply the formal drug registration certificate and approved package no later than 3-Jul. Only after these supplementary documents are submitted will the formal review results be published together with those of regular submissions. StreetAccount notes that with the NHSA announcement as a direct trigger, today the pharmaceutical sector in both A/H markets saw a long-awaited surge, with innovative drugs, CRO, and healthcare services leading the gains. The limit-up board was densely packed with pharmaceutical stock names, such as Sunshine Guojian Pharmaceutical, Fujian Cosunter Pharmaceutical, all smashing the 20% ceiling. Jiangsu Hengrui Pharmaceutical soared more than 8% intraday, while Pien Tze Huang jumped over 5%. Even Alebund Pharmaceuticals, who debuted today in Hong Kong, rocketed 103.54% higher on its first day, pushing market cap straight to HK$15.6B. Related: 000661.CH, 000963.CH, 1093.HK, 1177.HK, 1530.HK, 1801.HK, 2126.HK, 4523.JP, 4568.JP, 4578.JP, 512.HK, 600276.CH, 6160.HK, 6855.HK, 6990.HK, 9637.HK, 9688.HK, 9966.HK, AZN.LN, GSK, LLY, SAN.FP...(more)	show story hide story
29-Jun-2026 09:01	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Healthcare equities coming off their best week in four years, and fifth-best week ever for Pharma and tenth-best week ever for Biotech. Viridian Therapeutics won FDA approval for Lumvoa in Thyroid Eye Disease, including a broad label, where it is expected to compete with Amgen's Tepezza. Shares of VRDN +11% in the pre-market. Handful of downgrades at BofA on the tape today, including new Biohaven to underperform. Shares of BHVN (8%) in the pre-market. Macro S&P futures are up +0.9% on Monday morning. Mag 7 bounce the tailwind this morning. Nothing specific behind the move. Some focus on memory price backlash and big investment pledges from Samsung and SK Hynix overnight. Oil higher but market seemingly able to largely ignore geopolitics despite recent ramp in kinetic activity as US and Iran agreed on Sunday to stop attacks ahead of fresh talks on Tuesday. Some other notable themes in the weekend/Monday press revolved around China's matching of Anthropic in cybersecurity, proliferation of leveraged equity funds, Fed reaction function uncertainty, pull-forward of imports amid expectations of higher costs from Middle East conflict and new tariffs, and Japan-China trade tensions. Pre-market trading update Trading higher +16.0% QDEL FT report - seeking to sell testing unit +11.1% PRME upgraded at HC Wainwright +10.6% VRDN FDA approves Lumvoa for TED; call at 8ET +7.7% SLS follow-through, shares +54% last week +3.7% BBIO publication for achondroplasia in NEJM (low volume) +2.8% CYTK upgraded at UBS +0.3% LQDA downgraded at BofA Trading lower -21.0% LRMR regulatory updates in Friedreich's Ataxia; call at 745ET -8.4% BHVN downgraded at BofA -1.9% CNMD downgraded at BofA -1.8% ALKS downgraded at BofA -2.2% AMPH downgraded at BofA -0.6% ABBV sympathy to VRDN -0.4% AMGN sympathy to VRDN (low volume) Pharma Regulatory: ABBV announced that FDA approved Skyrizi sBLA to include pediatric use (children six and older) in psoriatic diseases. A new 55mg prefilled syringe has also been approved. (+BOEHRINGER) Research: AMPH downgraded to underperform from neutral at BofA (Jason Gerberry), target cut to $20 from $25 or approx. 8% downside. (FactSet average PT $22; range $19-30) Biotech Regulatory: VRDN announced that FDA approved Lumvoa (veligrotug-vvze) BLA for the treatment of TED. StreetAccount notes the PDUFA goal date was Tuesday 30-Jun Conference call at 8:00ET On the call: Announced pricing at parity with AMGN Tepezza - on a course of therapy basis. LNTH announced that FDA issued a CRL for '2501 (Gallium 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs). Agency solely cited third-party manufacturing-related conditions. StreetAccount notes the PDUFA goal date was Monday 29-Jun LRMR announced submission of first module of rolling BLA for nomlabufusp in Friedreich's Ataxia. Company also reported new data from open label study. Quick take: Leerink Partners (outperform) expects stock to trade down today, noting that safety questions persist - discontinuation rate, anaphylaxis rate, and lack of clarity on safety database. Research: ALKS downgraded to underperform from neutral at BofA (Jason Gerberry), target is $38 or approx. 31% downside. (FactSet average PT $49; range $34-65) BHVN downgraded to underperform from neutral at BofA (Dina Ramadane), target cut to $11 from $12 or approx. 31% downside. (FactSet average PT $22; range $9-50) CYTK upgraded to buy from neutral at UBS (Ashwani Verma), target increased to $115 from $69 or approx. 40% upside. (FactSet average PT $108; range $83-146) LQDA downgraded neutral from outperform at BofA (Jason Gerberry), target increased however to $79 from $64. (FactSet average PT $74; range $60-109) PRME upgraded to buy from neutral at HC Wainwright (Arthur He), target is $8 or approx. 133% upside. (FactSet average PT $7; range $4-11) Life Science & MedTech Media report: QDEL FT reports that company is seeking to sell its testing unit, for up to $1.5B, bids coming in from private equity firms. Research: CNMD downgraded to underperform from neutral at BofA (Travis Steed), target remains $40 or approx. 11% upside. (FactSet average PT $40; range $39-40) On Deck: Overview: A holiday shortened week ahead, with US equity markets closed on Friday 3-Jul in observance of Independence Day. Very little on the sector calendar, the FDA cleared out most PDUFA goal dates in the prior week. Corporate R&D Day for ARWR (11:30ET) Regulatory FDA PDUFA today for ARQT/AZN (Zoryve sNDA in pediatric plaque psoriasis) FDA PDUFA today for UNCY (OLC NDA in hyperphosphatemia in CKD w/ dialysis) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABBV, ALKS, AMGN, AMPH, ARQT, ARWR, AZN, BBIO, BHVN, CNMD, CYTK, LNTH, LQDA, LRMR, PRME, QDEL, SLS, UNCY, VRDN...(more)	show story hide story
29-Jun-2026 02:37	4568.JP AstraZeneca and Daiichi Sankyo's Enhertu obtains EU approval for previously treated HER2-positive metastatic solid tumors (¥2614) Approval covers adults with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior treatment and have no satisfactory treatment options; companies describe Enhertu as the first tumor-agnostic HER2-directed therapy and ADC approved in the EU. No new safety concerns identified; AstraZeneca owes Daiichi Sankyo a $25M milestone payment following approval. Reference Link: Press release Related: AZN.LN	show story hide story
29-Jun-2026 02:05	AstraZeneca and Daiichi Sankyo's Datroway recommended for approval in EU for TNBC ($2594.50 +$59.00) AstraZeneca and Daiichi Sankyo's DATROWAY (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the 1st-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02 Phase III trial, which were presented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. In the trial, Datroway demonstrated a statistically significant and clinically meaningful 5.0-month improvement in median overall survival (OS) (hazard ratio [HR] 0.79; 95% confidence interval [CI] 0.64-0.98; p=0.0291) compared to chemotherapy as 1st-line treatment in this patient population. Median OS was 23.7 months for patients treated with Datroway versus 18.7 months for those treated with chemotherapy. Datroway reduced the risk of disease progression or death by 43% compared to chemotherapy (HR 0.57; 95% CI 0.47-0.69; p<0.0001) as assessed by blinded independent central review (BICR). Datroway was also associated with more robust treatment responses, including an objective response rate (ORR) of 62.5% compared to an ORR of 29.3% with chemotherapy.1 The safety profile of Datroway in TROPION-Breast02 was consistent with previous clinical trials of Datroway in breast cancer. Datroway was approved in the US in May 2026 for the treatment of adult patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy. Additional reviews are underway in China and Japan, as well as Australia, Canada, Singapore and Switzerland as part of Project Orbis. Datroway is a specifically engineered TROP2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo. Reference Link: Press release Related: 4568.JP, AZN.LN	show story hide story
28-Jun-2026 16:29	AZN.LN AstraZeneca reports positive results from the MULBERRY Phase III trial presented at ICCBH (14318p) late-breaking results were presented today in an oral session at the 12th International Conference on Children's Bone Health (ICCBH) in Montreal, Canada In the MULBERRY trial, patients treated with efzimfotase alfa achieved an observed median RGI-C Score of 1.67 at week 25 compared to an observed median score of 0 in the placebo group, with a median difference of 1.67 (95% CI: 0.66, 2.00; p=0.0003). The study also met its key secondary endpoint in bone health as measured by Rickets Severity Score (RSS), demonstrating a statistically significant improvement at week 25, with an observed median of -1.00 in the efzimfotase alfa group compared to 0 in the placebo group and a median difference of -1.00 (95% CI: -2.00, -0.33; p=0.0008). In the CHESTNUT trial, efzimfotase alfa demonstrated a similar incidence of treatment-emergent adverse events (TEAEs) at week 25 in children (2 to <12 years of age) who switched from Strensiq (90.5%) compared to those who remained on Strensiq (86.4%) with a favourable safety profile. Key secondary endpoints showed that bone health was maintained in children who received efzimfotase alfa after switching from Strensiq at week 25, including an observed median difference in RGI-C Score of 0 in the efzimfotase alfa group compared to the Strensiq group and an observed median RSS of 0 in the efzimfotase alfa group compared to -0.08 in the Strensiq group (median difference 0.08; 95% CI: -0.17, 0.32). Full results from the HICKORY Phase III trial in adolescents and adults (12 years of age and older) with HPP who have not been previously treated with Strensiq will be shared at a forthcoming medical meeting See Related StreetAccount comments: 3/31/2026 2:07:25 AM - AstraZeneca announces efzimfotase alfa Phase III clinical programme demonstrates positive results	show story hide story
26-Jun-2026 19:48	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities finished stronger into the weekend, XLV saw its best day in fourteen months. A fifth straight day of significant gains across the sector, and the best week in over four years for the XLV. Advancers beat decliners by 7:1 on the session. Healthcare +3.16% vs S&P 500 (0.05%). Broad momentum continued for Healthcare equities. All major health groups ended with very strong gains on the session, led by Pharma and Managed Care. DRG +3.69%, higher for a fifth straight day, and cleared a +9.29% week - fifth best all time. XBI +2.50% on the day, up for a seventh straight day, and cleared +10.42% week - tenth best all-time. MRNA +12.6% today with more constructive takeaways from yesterday's R&D Day, and ZTS (2.2%) bracketed the XLV today. ACAD +9% another top performer on the XBI, winning a re-examination at EMA's CHMP for Daybu, albeit for a narrower indication. New-look FDA plans to reinstate advisory committee meetings; shares of CAPR (13.0%) and REPL +4.5% will face expert panel reviews next month. Macro: Stock indexes were little changed to end the week, though notable movement under the surface. Momentum a laggard again with semis, memory both off by more than 5%. Technical/mechanical dynamics easy excuse though a number of other pieces in play (South Korea selloff overnight, possible delay of OpenAI IPO, Samsung/SK Hynix investment announcements, concerns over demand destruction, elevated memory GM sustainability, US government requesting OpenAI limit release of next model, open-source/China competition). Software, select Big Tech names beneficiaries of rotation out of AI trade, though other recent rotational beneficiaries (consumer groups, cyclicals) didn't do much. Yields firmer again on back of latest oil selloff (WTI crude back below $70, lowest close since day before war began), unfazed by latest hawkish Iran developments (Iran attacks on ships in SoH, Trump saying Iran violated ceasefire). Other areas of focus included some more flattening of Fed rate path outlook (~28 bp of hikes through year-end, down from Monday peak of 42 bp), Russell rebalancing, month/quarter-end flows, resilient macro, M&A pickup. Notable Gainers on Friday: +17.7% SLS - follow-though, speculation after change in control amendments to exec E'e agreements; best performer on XBI; shares +54% for the week +12.6% MRNA - takeaways from Science Day; best performer on XLV; second-best on XBI +8.4% VEEV - shares remain (2%) MTD and (23%) YTD +7.0% LLY - 52-week high +7.0% BIIB - Reuters report on Apellis pipeline focus; 52-week high +6.7% ACAD - EMA CHMP positive opinion for Daybu +6.7% ABSI - follow-through, shares +44% WTD +5.8% INCY - EMA CHMP positive opinion for Opzelura; 52-week high +4.8% VERA - follow-through, shares +21% for the week +4.5% REPL - FDA accepts BLA resubmission for RP1, Adcom planned for late July +4.4% TNGX - upgraded to buy at Jefferies Notable Decliners on Friday: -19.1% OMER - EMA CHMP negative opinion for Yartemlea -13.0% CAPR - FDA Adcom to review deramiocel BLA on 29-Jul; worst performer on XBI -12.0% TMDX - Stifel comments post-ATC, lowers estimates -8.4% ARDX - on 5X avg volume; Jefferies commented on ruling in CMS appeal and risk to Ibsrela Q2 guidance -7.2% KYMR - shares +20% for the week and +33% MTD -2.3% ZTS - worst performer on XLV; shares down (3%) for the week Week in Review: Healthcare equities outperformed for the week. The S&P 500 Healthcare Index +7.90% vs the S&P 500 Index (1.95%). Outperformers: Biotech, Pharma, MedTech, Managed Care, Services Underperformers: none Major health groups were all higher by MSD to LDD on the averages. Best week for the XLV in exactly four years (week-ended 24-Jun-2022). Confluence of tailwinds boosted all groups simultaneously, and significantly - the XLV closed higher all five days, and culminated with its best day on Friday - also the best day in more than a year for the XLV. Biotech momentum built on more high-premium M&A, AbbVie confirmed on Monday that it would acquire Apogee Therapeutics for $10.9B. Another slightly larger deal surprised on Thursday, in the Life Sciences subgroup, when Merck KGaA announced a deal to acquire BioTechne for $11.3B. Market rotation away from Big Tech sought value in both Pharma and Managed Care. The DRG +9.29% for its fifth best week all-time. Year-to-date, Healthcare +3.74% vs the S&P 500 +7.43%. Healthcare up three spots now eighth out of eleven major sectors in CY26. Energy +19.47% and Consumer Discretionary (3,76%) bracket them all. Notable movers for the week: Gainers: DFTX +83.6% - phase 3 trial results with a psychedelic in major depressive disorder APGE +46.7% - acquired by ABBV for $10.9B MANE +35.2% - stock closed higher 7 straight days RCUS +27.5% - stock closed higher 7 straight days ORKA +25.2% - sympathy to APGE VKTX +25.2% - sympathy to APGE TECH +22.5% - acquired by MRK.GR for $11.3B; best performer on XLV ALKS +22.4% - stock closed higher 7 straight days KYMR +19.6% - accelerated timeline by 6 months for BROADEN2 study in AD MOH +17.6% - shares +32% YTD and an 11-month high ABBV +17.0% - acquired APGE for $10.9B in cash CRL +16.6% - sympathy to ICLR; shares green +8% YTD ICLR +16.3% - earnings PRAX +16.1% - FDA granted Breakthrough Therapy Designation INCY +15.8% - resolves litigation with CMS; EMA CHMP positive opinion IQV +13.9% - sympathy to ICLR; shares remain (15%) YTD NTRA +13.2% - NCCN guidelines; approval in Japan for Signatera for CRC RVTY +13.0% - sympathy to TECH MRK +13.0% - stock higher all 5 days; FDA approval of Keytruda-Trodelvy combo in TNBC VEEV +11.8% - best week in 13 months; shares remain (2%) MTD and (23%) YTD JNJ +11.5% - stock higher all 5 days; best week since mid-Oct 2008 Decliners: TMDX (13.1%) - Stifel lowers estimates post-ATC and management meetings SPRY (11.5%) - provided payer update on neffy and updated outlook for FY26-27; worst performer on XBI PFE (3.6%) - 8-month low; CFO Denton announced as next CFO at Nike; key laggard vs DRG and worst performer on XLV Week Ahead (Sat - Sun): Jun 27 - Jul 5 Overview: A holiday shortened week ahead, with US equity markets closed on Friday 3-Jul in observance of Independence Day. Very little on the sector calendar, the FDA cleared out most PDUFA goal dates in the prior week. Corporate calendar Mon 29-Jun: Investor call - VRDN to discuss FDA approval and launch of Lumvoa in TED (8:00ET) (ABBV); R&D Day for ARWR (11:30ET) Regulatory calendar Mon 29-Jun: FDA PDUFA for ARQT/AZN (Zoryve sNDA in pediatric plaque psoriasis); FDA PDUFA for UNCY (OLC NDA in hyperphosphatemia in CKD w/ dialysis) Holiday calendar: Fri 3-Jul: Holiday (observed) - US equity markets closed for Independence Day Related: ABBV, ABSI, ACAD, ALKS, APGE, ARDX, ARQT, ARWR, AZN, BIIB, CAPR, CRL, DFTX, ICLR, INCY, IQV, JNJ, KYMR, LLY, MANE, MOH, MRK, MRNA, NTRA, OMER, ORKA, PFE, PRAX, RCUS, REPL, RVTY, SLS, SPRY, TECH, TMDX, TNGX, UNCY, VEEV, VERA, VKTX, VRDN, ZTS...(more)	show story hide story
26-Jun-2026 12:46	StreetAccount Summary: Notable Drug Events expected for the week of 28-Jun Preface: The FDA PDUFA date for SOBI.SS Nanoecapsulated Sirolimus plus Pegadricase (NASP) (formerly SEL-212) BLA in gout is expected on Saturday 27-Jun. Generally, weekend PDUFA dates tend to be Friday announcements. Mon 29-Jun Regulatory decisions: ARQT FDA PDUFA for Zoryve sNDA in plaque psoriasis in children ages 2 to 5 AZN.LN is eligible for milestones and royalties LNTH FDA PDUFA for LNTH-2501 BLA for PET imaging of SSTR+ NETs in adult and pediatric patients Extended three months from March 2026 UNCY FDA PDUFA for Oxylanthanum Carbonate (OLC) NDA resubmission in hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis 'OLC' formerly known as 'RenaZorb' Investor event: ARWR hosting R&D Day (11:30ET) Tue 30-Jun Regulatory decision: VRDN FDA PDUFA for veligrotug BLA in thyroid eye disease (TED) ABBV, via acquistion of ImmunoGen, is eligible for milestones and royalties during June 2026 Trial results: CGON (Ph3 NMIBC), EVMN (Ph2 CSU), ALLO (Ph 1 autoimmune diseases), TVRD (Ph1 HVs/HCC) Related: ABBV, ALLO, ARQT, ARWR, AZN, CGON, EVMN, LNTH, SOBI.SS, TVRD, UNCY, VRDN...(more)	show story hide story
26-Jun-2026 08:51	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis EMA CHMP published a raft of positive opinions - six new medicines and eleven extensions of indication - however three negative opinions as well. Shares of ACAD +14% in the pre-market, OMER (26%) in the pre-market. Notable week for both Biotech group and Life Science Tools subgroup, both on track for broad HSD gains. Sector strength extends to MSD gains elsewhere. Macro S&P futures are down (0.5%) on Friday morning - Nasdaq futures are down (1.1%). Momentum trade under pressure again following another selloff in Asia. Still a lot of focus on market structure/concentration issues, though expected Samsung/SK Hynix investment announcements, concerns about demand destruction (via price hikes)/elevated GM sustainability, potential delay in OpenAI IPO until 2027, US government request for OpenAI to limit release of next model and open-source competition all flagged as well. Pretty quiet outside of tech. Oil under renewed pressure following a brief reprieve on Thursday as SoH reopening traction narrative remains intact despite Iran's missile strike on Thursday. Oil selloff also seems to be helping to push rates lower again (Warsh as a Fed inflation credibility tailwind mentioned in press). Fed's Williams said policy in right place to bring inflation back to target. Russell rebalancing and month/quarter-end flows another area of focus today. Pre-market trading update Trading higher +13.7% ACAD EMA CHMP positive opinion for Daybu +3.7% TNGX upgraded to buy at Jefferies +2.5% VERA follow-through, shares +15% WTD +2.3% INSM follow-through, shares +9% WTD +0.3% TWST follow-through, shares +10% WTD and on-track for sixth straight weekly gain (five by double-digits) Trading lower -26.3% OMER EMA CHMP negative opinion for Yartemlea -2.5% ZTS shares down (1%) WTD -2.5% HIMS follow-through, shares (8%) WTD -2.4% ABSI follow-through, shares +38% WTD EMA CHMP publishes summary of opinions for June 2026 meeting Summary here. EMA recommends six (6) new medicines for approval, including two (2) biosimilar applications. Also recommends label expansions for eleven (11) more medicines. Three (3) negative opinion issued. Positive opinions for MAA include: Sequiris (CSL.AU) Aujemflu (influenza virus, inactivated) Zambon (private) Hopledo (levodopa /carbidopa) Note: EU rights in-licensed from Amneal (AMRX) Eli Lilly (LLY) Onswik (insulin efsitora alfa) Acadia Pharma (ACAD) Daybu (trofinitide) - following a re-examination - MAA granted but for a restricted indication - Daybu is indicated for the treatment of neurobehavioural symptoms of Rett syndrome in adults and paediatric patients aged 5 years and older Negative opinion for MAA: Netherlands Cancer Institute (private) Tacquell (autologous melanoma-derived TILs) Omeros (OMER) Yartemlea (narsoplimab) Maat Pharma (MAAT.FP) Xervyteg (allogenic faecal microbiota) Extensions of indication were recommended for: Imvanex (BAVA.DC), Datroway (4568.JP / AZN), Jaypirca (LLY), Leqvio (NOVN.SW / ALNY), Menquadfi (SAN.FP), Opzelura (INCY), Rezolsta (JNJ), Rinvoq (ABBV), Stelara (JNJ), Symtuza (JNJ) and Tecvayli (JNJ / GMAB) Also concluded review of Tavneos (AMGN) and recommended that MAA be revoked as benefits no longer outweigh the risks. Biotech Regulatory: REPL announced that FDA has accepted for review its BLA resubmission for RP1 (vusolimogene oderparepvec) in combo with Opdivo (BMY) for advanced melanoma. Class 1 response, the FDA expects to make a decision by 2-Aug-2026 following an Adcom in late July. Research: TNGX upgraded to buy from hold at Jefferies (Maury Raycroft), target increased to $60 from $27 or approx. 99% upside. (FactSet average PT $40; range $24-69) CNTB initiated overweight at Piper Sandler (Biren Amin), target is $7 or approx. 238% upside. (FactSet average PT $7; range $4-10) DYN initiated buy at TD Cowen (Joseph Thome) EPRX initiated outperform at Oppenheimer (Jay Olson), target is $17 or approx. 165% upside. (FactSet average PT $16; range $10-25) FTH initiated outperform at Baird (Jack Allen), target is $57 or approx. 131% upside. (FactSet average PT $54; range $50-60) Life Science & MedTech Research: Bernstein analyst Eve Burstein resumes coverage on eight names in the LST&D space. Outperform ratings on four (A, GH, NTRA, WAT) and market perform on four (AVTR, ILMN, RVTY, TMO) Services & Hospitals Research: NUTX initiated buy at B Riley Securities (Anderson Schock), target is $290 or approx. 94% upside. (FactSet average PT $236; range $175-300) On Deck: Regulatory on Sat 27-Jun: SOBI.SS FDA PDUFA for SEL-212 BLA in gout Peek Ahead to next week (Jun 29 - Jul 5) Mon 29-Jun: FDA PDUFAs for ARQT, LNTH, and UNCY Tue 30-Jun: FDA PDUFA for VRDN/ABBV Fri 3-Jul: Holiday (observed)- US equity markets closed This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4568.JP, A, ABBV, ABSI, ACAD, ALNY, AMGN, AMRX, ARQT, AVTR, AZN, BAVA.DC, BMY, CNTB, CSL.AU, DYN, EPRX, FTH, GH, GMAB, HIMS, ILMN, INCY, INSM, JNJ, LLY, LNTH, MAAT.FP, NOVN.SW, NTRA, NUTX, OMER, REPL, RVTY, SAN.FP, SOBI.SS, TMO, TNGX, TWST, UNCY, VERA, VRDN, WAT, ZTS...(more)	show story hide story
26-Jun-2026 08:34	EMA CHMP publishes summary of opinions for June 2026 meeting Summary here. EMA recommends six (6) new medicines for approval, including two (2) biosimilar applications. Also recommends label expansions for eleven (11) more medicines. Three (3) negative opinion issued. Positive opinions for MAA include: Sequiris (CSL.AU) Aujemflu (influenza virus, inactivated) Zambon (private) Hopledo (levodopa /carbidopa) Note: EU rights in-licensed from Amneal (AMRX) Eli Lilly (LLY) Onswik (insulin efsitora alfa) Acadia Pharma (ACAD) Daybu (trofinitide) - following a re-examination - MAA granted but for a restricted indication - Daybu is indicated for the treatment of neurobehavioural symptoms of Rett syndrome in adults and paediatric patients aged 5 years and older Negative opinion for MAA: Netherlands Cancer Institute (private) Tacquell (autologous melanoma-derived TILs) Omeros (OMER) Yartemlea (narsoplimab) Maat Pharma (MAAT.FP) Xervyteg (allogenic faecal microbiota) Extensions of indication were recommended for: Imvanex (BAVA.DC), Datroway (4568.JP / AZN), Jaypirca (LLY), Leqvio (NOVN.SW / ALNY), Menquadfi (SAN.FP), Opzelura (INCY), Rezolsta (JNJ), Rinvoq (ABBV), Stelara (JNJ), Symtuza (JNJ) and Tecvayli (JNJ / GMAB) Also concluded review of Tavneos (AMGN) and recommended that MAA be revoked as benefits no longer outweigh the risks. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: 4568.JP, ABBV, ACAD, ALNY, AMGN, AMRX, AZN, BAVA.DC, CSL.AU, GMAB, INCY, JNJ, LLY, MAAT.FP, NOVN.SW, OMER, SAN.FP...(more)	show story hide story
26-Jun-2026 07:11	AZN.LN EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for AstraZeneca's Leqvio (13966p -96p) The marketing authorisation holder for this medicinal product is Novartis Europharm Limited. The CHMP adopted an extension to the existing indication as follows: LEQVIO is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet, and in paediatric patients aged 12 years and older with heterozygous familial hypercholesterolaemia (HeFH): in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. Reference Link	show story hide story
26-Jun-2026 07:06	4568.JP EU's CHMP adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Datroway (¥2535.5) The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Datroway . The marketing authorisation holder for this medicinal product is Daiichi Sankyo Europe GmbH. The CHMP adopted a new indication as follows: Datroway as monotherapy is indicated for the first-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy (see section 5.1). Related: AZN.LN Reference Link	show story hide story
26-Jun-2026 07:03	EU's CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for Ascend GmbH's medicinal product Denosumab Ascend The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Denosumab Ascend, intended for the prevention of bone complications in adults with advanced cancer involving bone and for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone. The applicant for this medicinal product is Ascend GmbH. Denosumab Ascend is a biosimilar medicinal product. It is highly similar to the reference product Xgeva (denosumab) which was authorised in the EU on 13-Jul-11. Data show that Denosumab Ascend has comparable quality, safety and efficacy to Xgeva. The full indication is: Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1). Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Denosumab Ascend should be administered under the responsibility of a healthcare professional. Related: 4568.JP, 500124.IN, AZN.LN, ONC, 0FWFVM-E Reference Link	show story hide story
18-Jun-2026 14:21	StreetAccount Summary: Notable Drug Events expected for the week of 21-June Sat 20-Jun Regulatory decisions: ACHV FDA PDUFA for Tabex NDA in smoking cessation Tris Pharma FDA PDUFA for TRN-257 (low-sodium oxybate) NDA in idiopathic hypersomnia (ALKS, JAZZ) Mon 22-Jun Regulatory meeting: EMA CHMP monthly meeting (June 22-25) Conferences: BIO International Convention (June 22-25) Presentations: American Transplant Congress: NTRA (June 22-24) Tue 23-Jun Investor event: VSTM to present preliminary data for VS-7375 TARGET-D (16:30ET) Conferences: Jefferies German and Swiss Conference (June 23-24) Thu 25-Jun Investor event: MRNA hosting Science Day (9:00ET) Fri 26-Jun Regulatory decisions: EMA CHMP opinions on MAA (June 2026 meeting) Sat 27-Jun Regulatory decision: SOBI.SS FDA PDUFA for SEL-212 BLA in gout later during June 2026 Regulatory decisions: ARQT/AZN.LN (Zoryve sNDA, 29-Jun), LNTH (LNTH-2501 BLA, 29-Jun), UNCY (Oxylanthanum Carbonate NDA and RenaZorb NDA, 29-Jun), IONS/SOBI.SS (Tryngolza sNDA, 30-Jun), ABBV/VRDN (Veligrotug BLA, 30-Jun) Trial results: CGON (Ph3 NMIBC), DFTX (Ph3 MDD), EVMN (Ph2 CSU), ALLO (Ph 1 autoimmune diseases), TVRD (Ph1 HVs/HCC), KTTA (Ph1 solid tumors) Related: ABBV, ACHV, ALKS, ALLO, ARQT, AZN, CGON, DFTX, EVMN, IONS, JAZZ, KTTA, LNTH, MRNA, SOBI.SS, TVRD, UNCY, VRDN, VSTM...(more)	show story hide story
18-Jun-2026 09:04	AIM AIM ImmunoTech achieves clinical milestone as final subject receives first dose in Phase 2 DURIPANC study in metastatic pancreatic cancer ($0.40) AIM ImmunoTech announced that the final subject has received their first dose in the Phase 2 DURIPANC clinical trial evaluating Ampligen (rintatolimod) in combination with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor IMFINZI (durvalumab) for the treatment of metastatic pancreatic cancer. With this final subject, Primary Endpoint analysis is anticipated to begin in December 2026 and topline results are anticipated in Q1 2027. DURIPANC's primary endpoint is Clinical Benefit Rate, defined as the proportion of patients achieving stable disease, partial response or complete response at 24 weeks following initiation of combination therapy. Analysis of Secondary Endpoints is expected to begin in June 2027, or 49 weeks after this final subject received their first dose. DURIPANC's Secondary Endpoints include Overall Survival - the gold standard in oncology trials - as well as progression-free survival and immune profiling analysis that could potentially help identify subsets of future pancreatic cancer patients likely to experience the best survival results, which could be critical to the design of a pivotal Phase 3 clinical trial. Reference Link: Press release Related: AZN.LN	show story hide story
16-Jun-2026 08:19	Market Voices: Plain English podcast on GLP-1s, Cancer Breakthroughs, and the Future of Drug Development Summary: On the Plain English with Derek Thompson, guest Matthew Herper, Senior Writer at STAT News, discusses what he calls a potential "miracle month" for medicine, highlighting breakthroughs in obesity drugs, cancer therapies, gene editing, and AI-driven drug development. While remaining optimistic about the industry's long-term trajectory, he emphasizes that many of the most promising advances remain early-stage and will require years of validation and commercialization. Eli Lilly continues to widen its lead in obesity and metabolic disease: Herper describes Lilly's retatrutide as one of the most powerful obesity drugs developed to date, citing nearly 28% weight loss in clinical trials versus roughly 15% for semaglutide-based therapies. He believes GLP-1 drugs are becoming one of the most important pharmaceutical categories in decades. The GLP-1 market is expanding well beyond weight loss: Obesity reduction appears to drive benefits across cardiovascular disease, diabetes, sleep apnea, fatty liver disease, inflammation, and potentially other conditions. Herper expects future versions, including oral therapies, to significantly expand patient adoption. Revolution Medicines may have delivered one of the biggest pancreatic cancer advances in years: The company's RAS-targeting therapy demonstrated encouraging results in pancreatic cancer, a disease long viewed as one of oncology's most difficult targets. Herper calls it one of the most promising developments to emerge from the current wave of targeted cancer therapies. Targeted oncology remains one of healthcare's most attractive long-term opportunities: The discussion highlights how companies are increasingly developing therapies against previously "undruggable" targets, building on earlier successes from drugs such as Gleevec and newer targeted therapies from Pfizer and others. AI could become a major catalyst for drug discovery and clinical development: Companies such as Xaira, Genentech, OpenAI partners, and Nvidia are investing heavily in AI-enabled biology platforms. Herper sees the greatest near-term value in improving target identification, patient recruitment, and clinical-trial efficiency rather than replacing the scientific process altogether. Verve's gene-editing platform could transform cardiovascular prevention: Early data suggest Verve's PCSK9-editing therapy may permanently lower LDL cholesterol through a single treatment. While still early, Herper views PCSK9 as one of the most validated targets in medicine given decades of genetic and clinical evidence. The cholesterol market remains highly competitive despite new technologies: Established therapies from Regeneron, Amgen, Merck, AstraZeneca, and generic statins continue to dominate treatment today. Gene editing may eventually expand the market, though broad adoption remains years away and will require significant safety validation. Drug pricing and clinical-trial costs remain major industry challenges: Herper argues that accelerating clinical-trial enrollment, improving patient identification, and reducing development costs may ultimately be as important as discovering new medicines. He suggests government involvement in drug development and clinical-trial infrastructure could help address some of these bottlenecks. Overall outlook: Herper remains highly optimistic on biotechnology and pharmaceutical innovation, arguing that advances in GLP-1s, gene editing, precision oncology, and AI are creating one of the most promising periods in modern medicine. However, he cautions that commercialization, access, pricing, and clinical validation remain critical hurdles before many of these breakthroughs can achieve their full impact. Companies in focus: Eli Lilly and Company, Revolution Medicines, Verve Therapeutics, NVIDIA, Genentech, Regeneron Pharmaceuticals, Amgen, Merck & Co., AstraZeneca, Pfizer, Xaira Therapeutics. This summary was optimized by StreetAccount using GenAI. Related: AMGN, AZN, LLY, MRK, PFE, ROP.SW, RVMD, 0SBXPR-E, 0ZCZW9-E...(more) Reference Link	show story hide story
15-Jun-2026 02:17	AZN.LN AstraZeneca announces supplemental Biologics License Application for Ultomiris (ravulizumab) has been accepted and granted Priority Review by FDA for the treatment of adults with immunoglobulin A nephropathy (13462p) The sBLA is based on results from a prespecified interim analysis of the I CAN Phase III trial, which were recently presented at the 2026 European Renal Association (ERA) Congress. Reference Link: Press release Related: XNCR	show story hide story
15-Jun-2026 02:01	AZN.LN AstraZeneca's Truqap approved in US for prostate cancer (13462p) AstraZeneca's TRUQAP (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a FDA-authorised test. The approval by the US FDA was based on positive results from the CAPItello-281 Phase III trial, presented at the 2025 European Society for Medical Oncology (ESMO) Congress and published in Annals of Oncology. Prostate cancer is the second most prevalent cancer in men and the fifth leading cause of male cancer death globally, with more than 1.4M people diagnosed each year. Of these, ~200,000 patients worldwide, including 35,000 in the US, are diagnosed with mAPMN/S prostate cancer annually.4 One in four of these patients have PTEN-deficient tumours, which fuels the growth of cancer cells and defines an aggressive form of the disease associated with poor outcomes. PTEN deficiency is an independent risk factor regardless of other clinical characteristics, and can be identified by immunohistochemistry testing at time of diagnosis. Reference Link: Press release	show story hide story
12-Jun-2026 15:18	ROP.SW Roche confirms FDA approval for Ventana PTEN approval for prostate cancer companion Dx (CHF 330.00) Roche announced that the VENTANA PTEN (SP218) RxDx Assay is the first immunohistochemistry (IHC) companion diagnostic test to receive FDA approval for determining PTEN protein loss, also known as PTEN deficiency, in tumours of patients with prostate adenocarcinoma. These patients may now be eligible for treatment with AstraZeneca's targeted therapy TRUQAP (capivasertib). Reference Link: Press release See Related StreetAccount comments: 6/12/2026 2:49:06 PM - Follow-up: FDA approves Truqap and a companion diagnostic for mHSPC Related: AZN.LN	show story hide story
12-Jun-2026 14:49	AZN.LN Follow-up: FDA approves Truqap and a companion diagnostic for mHSPC (13462p) StreetAccount notes that the approved companion diagnostic appears to be the VENTANA PTEN (SP218) RxDx from Roche, as referenced in the ODAC briefing materials from 30-Apr review of Truqap. Editor's Note: This comment was revised to correct the ticker for Roche. (12-Jun-2026, 14:49 ET) See Related StreetAccount comments: 6/12/2026 2:05:49 PM - AstraZeneca's Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer 4/30/2026 4:44:27 PM - FDA ODAC panel votes 7-1-1 to support AstraZeneca's TRUQAP sNDA in prostate cancer 4/28/2026 3:04:40 PM - FDA releases briefing materials ahead of Thursday adcom (earlier, timing uncertain) Related: ROP.SW	show story hide story
12-Jun-2026 14:40	StreetAccount Summary: Notable Drug Events expected for the week of 14-June (cont.) Industry meetings with clinical data: European Hematology Association (EHA) Congress (June 11-14) (INCY, DMRA, AGIO, LLY, AAPG, ALNY, AMGN, ARGX, BBIO, FULC, LEGN, REGN, RIGL) European Academy of Allergy and Clinical Immunology (EAACI) Congress (June 12-15) (NTLA) ENDO 2026 (June 13-16) (AZN.LN, RYTM, CRNX, CORT, LLY) Sun 14-Jun Industry meeting with clinical data: SLEEP 2026 (Jun 14-17) (ALKS) Mon 15-Jun Investor event: IRON business update call at EHA (8:00ET) Tue 16-Jun FDA briefing materials: MRNA VRBPAC to publish materials ahead of the 18-Jun meeting for MFLUSIA Investor event: IRD R&D day (10:00ET) Wed 17-Jun Investor event: OCUL investor day (14:00ET) Thu 18-Jun Regulatory decision: SPRO/GSK FDA PDUFA for Orapenem NDA in complicated urinary tract infection Regulatory meeting: FDA Adcom - VRBPAC to discuss MRNA MFLUSIA BLA for season flu (8:30ET) Sat 20-Jun Regulatory decisions: ACHV FDA PDUFA for Tabex NDA in smoking cessation Tris Pharma FDA PDUFA for TRN-257 NDA in idiopathic hypersomnia later during June 2026 Regulatory decisions: FDA PDUFAs: SOBI.SS (NASP BLA, 27-Jun), ARQT/AZN.LN (Zoryve sNDA, 29-Jun), LNTH (LNTH-2501 BLA, 29-Jun), UNCY (Oxylanthanum Carbonate NDA and RenaZorb NDA, 29-Jun), IONS/SOBI.SS (Tryngolza sNDA, 30-Jun), ABBV/VRDN (Veligrotug BLA, 30-Jun); EMA CHMP opinions on MAA (26-June) Regulatory meeting: EMA CHMP monthly meeting (June 22-25) Trial results: CGON (Ph3 NMIBC), NMRA (Ph3 MDD), DFTX (Ph3 MDD), QNRX (Ph 2/3 NS), EVMN (Ph2 CSU), EWTX (Ph2 HCM), CNTX (Ph1 solid tumors), ALLO (Ph 1 autoimmune diseases), TVRD (Ph1 HVs/HCC), KTTA (Ph1 solid tumors) Related: AAPG, ABBV, ACHV, AGIO, ALKS, ALLO, ALNY, AMGN, ARGX, ARQT, AZN.LN, BBIO, CGON, CNTX, CORT, CRNX, DFTX, DMRA, EVMN, EWTX, FULC, GSK, INCY, IONS, IRD, KTTA, LEGN, LLY, LNTH, MRNA, NMRA, NTLA, OCUL, QNRX, REGN, RIGL, RYTM, SOBI.SS, SPRO, TVRD, UNCY, VRDN...(more)	show story hide story
12-Jun-2026 14:05	AZN.LN AstraZeneca's Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer (13462p) AstraZeneca's TRUQAP (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a FDA-authorised test. Concurrently with this approval, the FDA also approved a companion diagnostic test to detect PTEN deficiency in tumours of patients with prostate adenocarcinoma. A regulatory application for the Truqap combination in this setting is under review in the EU based on the CAPItello-281 Phase III trial. Reference Link	show story hide story
10-Jun-2026 11:37	^ESG StreetAccount ESG Research Round Up Overview Recent thematic Street Research highlights improvement in sustainable fund performance in Q2, with grid and renewable names leading thematic sectors. Investors are awaiting upcoming high profile thematic IPOs in SpaceX, OpenAI, and Anthropic. In analyst actions, clean hydrogen names in focus due to data center opportunities for clean energy. Certain uranium miners received positive attention from analysts as interest in nuclear energy expansion grows. Sector research points to GLP-1 research updates for various drug manufacturers. Truist analysts highlighted cybersecurity names expected to benefit from various AI rollouts, contradicting previous expectations that the industry would be displaced from emerging technology. Highlighted research RBC (9-Jun) Thematic fund flows remain strong in clean energy, transition materials, sustainable infrastructure and technology segments though performance has reversed somewhat in AI/datacenter exposed themes. Sustainable fund performance improving in Q2 as widely held ESG names outperform ESG laggards. Scorecard favors grid, renewables, pollution/water names currently though most themes score positively. BMO (5-Jun) Governance review for mega IPOs includes Musk as CEO, CTO, Board Chair of SpaceX while holding 85% of voting rights. OpenAI is governed non-profit foundation and for-profit PBC. Foundation has 26% equity stake with special voting rights to control board membership. Eight member board includes PBC's CEO Sam Altman. Anthropic has a long-term benefit trust which controls it's PBC board. The CEO does not sit on the non-commercial entity's board. Also, a supermajority of investors can terminate the trust and remove directors. Analyst Actions Uranium miners receiving positive analyst attention as growing global energy needs improve outlook for nuclear reactors; Deep Yellow (DYL.AU) was upgraded to buy at Jefferies following recent pullback in share price. Paladin Energy (PDN.AU) was upgraded to buy at Argonaut, though analyst lowered PT; following visit to Langer Heinrich Mine earlier this year. Clean Hydrogen names also in focus as analysts weigh data center opportunity; FuelCell Energy (FCEL) was upgraded to buy at Canaccord Genuity, with PT increased despite disappointing 2Q26 earning report as analysts see several lucrative catalysts. In contrast, British fuel cell maker Ceres Power (CWR.LN) was downgraded to sell at Panmure Liberum, though analyst raised PT. Elsewhere, Tesla (TSLA) was upgraded to neutral at JPMorgan, ending a bearish run as coverage of the EV maker changes hands; Erste Group also upgraded stock to hold. European Wind names Vestas (VWS.DC) and Nordex (NDX1.GR) upgraded at Kepler Cheuvreux and mwb Research, respectively. Cybersecurity firm Crowdstrike (CRWD) among few downgrades this week, being lowered to hold at Berenberg on valuation. Sector research Energy BMO (9-Jun) Wood Mackenzie's Global Solar Tracker Market Share report noted that NexTracker's (NXT) market share in the US has materially expanded from 46% in CY24 and 55% in CY25. Data and estimates for NexTracker and Array Technologies (ARRY) implies that the companies' US ASPs were -18% and largely unchanged y/y respectively. While the US ASP trends for NXT were weaker than expected, ROW ASPs were resilient, implying an ability to effectively compete outside of the US market. Healthcare Cantor (7-Jun, 9-Jun) Discussion of some developments from recent ADA conference. Sees Structure Therapeutics (GPCR) as able to further differentiate on efficacy with its aleniglipron (aleni) drug; notes half-life of its oral amylin is very long, making once-weekly dosing likely, making it an important strategic differentiator. Meanwhile, AstraZeneca (AZN.LN) disclosed positive phase III trial data for its oral GLP-1 elecoglipron/eleco treatment, which delivered results similar to Eli Lilly's (LLY) and Structure's oral GLP-1 drugs; analyst does not see AstraZeneca's candidate as a difference maker, though its focus is on opportunities outside the US, where it likely will be more competitive. KeyBanc Capital Markets (3-Jun) USDA confirmed New World screwworm in Texas. Notes Elanco Animal Health (ELAN) and Zoetis (ZTS) have approved meds to prevent, treat the pest in livestock, though Elanco to see larger benefit if outbreak became severe, as it has a higher percenter of US livestock revenues. Technology Truist (8-Jun) Anthropic Claude Mythos and Daybreak rollout is redefining cybersecurity landscape (faster threat detection, autonomous defense, AI-drive vulnerability discovery). Cybersecurity demand seeing acceleration, not displacement, from AI. Favors leaders like CrowdStrike (CRWD), Cloudflare (NET), Palo Alto (PANW), and Zscaler (ZS). Data and identify security beneficiaries include Commvault (CVLT), Rubrik (RBRK), Okta (OKTA), and SailPoint (SAIL). If you are interested in company level ESG level alerts for your portfolio(s) please click here. For less frequent updates, click here to sign up for summary content including: daily headlines, weekly ESG press and company digests, and monthly Round Up pieces. Related: ARRY, AZN.LN, CRWD, CVLT, CWR.LN, DYL.AU, ELAN, FCEL, GPCR, NDX1.GR, NET, NXT, OKTA, PANW, PDN.AU, RBRK, SAIL, TSLA, VWS.DC, ZS, ZTS...(more)	show story hide story
10-Jun-2026 03:09	Trump's pharma offensive puts Europe's drug pricing under the microscope: Trump administration wants Europe to pay more for medicines, using tariffs, investment threats and bilateral deal-making to dismantle what Washington calls decades of foreign free-riding on US pharmaceutical innovation (Politico). Pressure reshaping drug pricing politics from London to Berlin. Opening salvo was US-UK agreement of Dec-2025, in which UK committed to raising net prices for new medicines by 25%, lifting NICE cost-effectiveness thresholds and doubling medicines spending as a share of GDP to 0.6% by 2036. In return, UK pharmaceutical exports secured zero tariffs for three years. Critics in London, however, are scathing. ING estimated deal could add between £2B and £3.5B annually to NHS costs by 2036, while campaigners argue Britain permanently weakened price controls in exchange for temporary relief from tariffs that barely existed. Germany now squarely in Washington's crosshairs (Politico). Secret talks between US health officials and German ministers have been underway, with investment serving as primary lever. Eli Lilly has halved a planned €2.3B German investment, while Boehringer Ingelheim scrapped €900M in committed spending (Biospace). US embassies across Europe are being mobilised to encourage governments to follow Britain's example. Yet resistance remains formidable (Reuters). EU health budgets under severe strain, trade policy remains a Brussels competence rather than a national one, and many governments fear that conceding to industry pressure will simply invite further demands. As one European health official bluntly put it, higher drug prices across the continent remain "financially unsustainable." For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: AZN.LN, BAYN.GR, GSK.LN, MRK.GR, NOVN.SW, ROG.SW...(more)	show story hide story
09-Jun-2026 16:51	AZN.LN Transcript Intelligence: AstraZeneca at American Diabetes Association Scientific Session Conference Presentation Summary (Presentation Time: 09-Jun-26 11:00 ET): Company-focused: Ambitious Phase 3 program for oral GLP-1 Elicoglirvar to launch in H2 2026. Three-pronged Phase 3: obesity (Embold), type 2 diabetes (Illuminate), and outcomes in heart failure/CKD (Elevate). Flexible titration and dose escalation strategies in Phase 3 to optimize tolerability. Combination therapies with Dapagliflozin and other small molecules are a key differentiation strategy. Additional assets in development: oral PCSK9, amylin agonist, dual/triple agonists, and monthly injectables. No unexpected safety signals in Phase 2; bilirubin elevations deemed clinically irrelevant. Global commercial footprint and pricing strategy to drive access, especially outside the U.S. Targeting five CVRM franchises with >$5B peak sales each by 2030. Macro: Obesity and overweight projected to affect over 3B people globally by 2035. Less than 5% of eligible obesity patients currently receive treatment worldwide. This summary was created with GenAI, optimized by StreetAccount. Early transcripts may contain phonetic spellings. Editor's Note: This transcript summary was edited to correct CVRM in the final company-focused bullet from the previously reported CBRAM. We apologize for the acronym error. (10-Jun-2026, 08:38 ET) Reference Link: Transcript	show story hide story
09-Jun-2026 09:32	Premarket themes include continued AI hardware rebound (9-Jun) AI-related names higher in early US trading following rebound yesterday. Chips among the leaders again including AMD +2%, ARM +4%, MRVL +4%, INTC +3%. Comes as US lawmakers urge stricter rules on TSM +0% and other contract chipmakers to prevent China sales. Meanwhile, China plans for $295M buildout over five years where 80% of chips expected to be sourced domestically. Data Center / HPC names led higher by APLD +13% on $5B long-term hosting deal with US hyperscaler. Memory segment higher including MU +5%. Pure Plays mostly higher including Transition Materials where SGML +8% saw favorable Brazil court ruling and NB +4% was initiated buy at B Riley. Energy Storage, Solar, eVTOL (EVTL +4%, prototype flight) segments also among the leaders. Space supported by ASTS +6% launch announcement for Bluebird satellites. Laggards include Cybersecurity (TENB -2%) alongside other AI-Impacted Software plays. EH earnings miss a negative spot in Drones segment. UEC -4% results weighing on Uranium names. GLP-1 segment mostly higher with GPCR +9% as analysts at Cantor note AZN +0% trial results leave room for Structure Therapeutics to differentiate on efficacy. For more themes and market movers see StreetAccount Themes and Gainers & Decliners. For the latest updates on this story and all top news, please visit the Themes Today's Top News page. Related: AMD, APLD, ARM, ASTS, AZN, EH, EVTL, GPCR, INTC, MRVL, MU, NB, SGML, TENB, TSM, UEC...(more)	show story hide story
09-Jun-2026 08:32	StreetAccount Themes Headlines (9-Jun) Iran Iran and Israel pause strikes after Trump calls for both sides to cease attacks President Trump claims Iran war deal possible within days, reopening Strait of Hormuz immediately AI US lawmakers urge stricter rules on contract chipmakers, such as TSMC, to prevent them making AI chips for China subsidiaries China preparing $295B in data center buildout funding in next five years; majority of chips to come from domestic suppliers Chip stocks recover as OpenAI files for US IPO; sources suggest offering could come as early as September, targeting $1T valuation SpaceX IPO order books to close Wednesday, deal said to be well oversubscribed; Musk says SpaceX's AI satellites will use mostly existing tech; MSCI confirms early index inclusion rules, clearing way for SpaceX to join Nvidia CEO Huang said to have turned down Sen. Warren invitation to speak at congress AI development hearing, NBC reports Apple will not roll out new Siri AI tool in EU after unsuccessful request for exemption from interoperability rules; says Apple Intelligence features will not be available in China Applied Digital signs $5.2B long-term data center deal with US hyperscaler Databricks in talks to raise funds at over $165B valuation, sources say Private Credit Apollo, Blackstone finalize $35B private credit package for Anthropic to expand AI infrastructure, lease Google chips Other Themes US judge tosses White House bid to restrict renewable energy tax credits, though provision sunsetting begins next month regardless Technip, Safran, Airbus, Tereos to form JV for development of large-scale SAF production in France AstraZeneca obesity pill helped patients lose >10% of their body weight over 26 weeks in mid-stage trial; drug not expected to launch before 2027 Environment COP31 host Turkey to seek support for target of meeting 35% of world's energy needs with electricity by 2035 EU member states back adjusted Transition exclusions for SFDR 2.0; fossil fuel companies could be included if they allocate a certain percentage of capex to taxonomy aligned activities Social & Governance UK officially opens probe into Warner/Paramount deal; initial decision deadline is 7-Aug; Paramount offered concessions to stave off California-led states' antitrust litigation Apple expands parental controls, allowing better device management for children amid global social media bans Stellantis recalling >1.3M Jeep Wranglers, Gladiators worldwide due to electrical issue which could result in vehicle fire For the latest updates on this story and all top news, please visit the Themes Today's Top News page. Related: 2330.TT, AAPL, AIR.FP, APLD, APO, AZN.LN, BX, GOOGL, NVDA, PSKY, SAF.FP, STLAM.IM, TE.FP, WBD, +ANTHROPIC, +DATABRICKS, +OPENAI, +PERPLEXITY, +SPACEX, 09ZQ1J-E...(more)	show story hide story
09-Jun-2026 06:26	Insurance, food/beverage, media and banks the top performers; energy and healthcare lag: Insurance leads sector gains, supported by consolidation developments in Italy's financial sector. Unipol (UNI.IM) surges after being identified as a beneficiary of Intesa Sanpaolo (ISP.IM)'s proposed acquisition of Banca Monte dei Paschi di Siena (BMPS.IM), while broader strength in Italian financials lifts sentiment across the group. Generali (G.IM) also advances as investors assess the implications of potential ownership reshuffling involving UniCredit (UCG.IM) and Delfin's stake in MPS. Banks outperform on Italian M&A activity, with Monte dei Paschi (BMPS.IM), Banco BPM (BAMI.IM), Intesa Sanpaolo (ISP.IM) and UniCredit (UCG.IM) all higher amid competing takeover and stake-building speculation. Elsewhere, UBS (UBSG.SW) gains after reports Swiss lawmakers are considering softer capital requirements, potentially reducing the regulatory burden on the lender. Sector also broadly supported by hawkish pricing of central bank rate outlooks amid renewed inflation risk. Food & Beverage supported by strong stock-specific moves, with Fevertree Drinks (FEVR.LN) rallying after positive AGM update, increased buyback plans and continued momentum from its partnership with Molson Coors. Nestlé (NESN.SW) also edges higher amid ongoing interest in its water business disposal process. Media benefits from broker support, with advertising names WPP (WPP.LN) and Publicis (PUB.FP) advancing after favorable initiations highlighting their positioning to benefit from AI-driven changes in the advertising industry. On the downside, Health Care underperforms as heavyweight pharmaceuticals weigh on the sector. GSK (GSK.LN) falls after agreeing to acquire US-based Nuvalent (NUVL) in a $10.6B deal, while AstraZeneca (AZN.LN) also declines despite advancing its obesity drug program into Phase III trials. Oil & Gas lags as crude prices ease following the pause in hostilities between Israel and Iran. BP (BP.LN) also weaker amid ongoing investor scrutiny surrounding recent management changes, as reported by the FT. Basic Resources underperform despite uptick in broader industrial metals complex on easing Middle East tensions, pressured by weakness in Boliden (BOL.SS) following a broker downgrade that highlighted operational risks at its Garpenberg mine. Autos & Parts see mixed performance, with Valeo (FR.FP) supported by AI-related data-center cooling developments, while Renault (RNO.FP) higher after FT report outlining a measured approach to expanding its defence-related activities. For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: AZN.LN, BAMI.IM, BMPS.IM, BOL.SS, BP.LN, FEVR.LN, FR.FP, G.IM, GSK.LN, ISP.IM, NESN.SW, PUB.FP, RNO.FP, UBSG.SW, UCG.IM, UNI.IM...(more)	show story hide story
09-Jun-2026 06:07	StreetAccount Macro Headlines: Iran conflict: Israeli and Iran agree to halt attacks on each other (Reuters, Bloomberg) Trump claims again Iran war deal possible within days, reopening Strait of Hormuz immediately (CNBC, Bloomberg ) Trump warned Netanyahu in call that US might not aid Israel if it resumes war with Iran (Axios, FT , NY Times ) US Apache helicopter crashes near Strait of Hormuz; crew safely rescued, cause unclear (NY Times , Reuters ) Energy: Iraq and UAE expedite oil pipeline expansions to compensate for lost Strait of Hormuz capacity (CNBC ) Oil market defies summer supply crunch predictions as crude prices remain below $100 per barrel (FT ) Morgan Stanley forecasts LNG prices to rise due to Asian demand and European restocking (Bloomberg) Corporate: SpaceX IPO invites scrutiny of Elon Musk's business portfolio amid concerns about government risks, conflicts of interest (Bloomberg) SpaceX's IPO said to be well oversubscribed; order books to close Wednesday afternoon (Bloomberg) Up to $1T of SpaceX IPO is based on series of ambitious "moonshot" goals (FT) Apple iOS 27 and software updates hint at future development of foldable phones (Bloomberg, FT ) Apple says Apple Intelligence features will not be available in China (Nikkei) Apple unable to launch Siri AI in EU amid standoff with European Commission over compliance with Digital Markets Act (Bloomberg) Apple expands parental controls, allowing better device management for children amid global social media bans (Bloomberg ) Databricks in talks to raise funds at over $165B valuation, sources say (The Information ) Waymo acquires autonomous vehicle testing facility in Arizona from Route 14 Investment Partners linked to Apple(TechCrunch ) GSK in talks to acquire Nuvalent for over $10.6B (FT) AstraZeneca advances weight-loss pill to take aim at obesity leaders (FT, Bloomberg ) Paramount Skydance offers concessions to California AG to secure support for Warner Bros. Discovery merger (Bloomberg ) Paramount criticizes Netflix for attempting to sabotage its Warner Bros. Discovery acquisition, documents reveal (Politico ) Nintendo led Japan gaming selloff in 2026 as memory cost pressures bite, investors reallocate to AI stocks (Nikkei) AI: OpenAI confidentially files for IPO with potential listing as soon as this fall (Bloomberg, Axios ) Apollo and Blackstone finalize a $35B private credit financing package for Anthropic (FT ) Perplexity CEO says startup plans to go public in 2028, regardless of outcomes for Anthropic or OpenAI (CNBC ) Applied Digital signs $5.2B long-term data center deal with US hyperscaler (Reuters ) 'Pick and shovel' companies reap massive profits from AI data center buildout (FT) ASML CEO repeats warning against EU intervention to direct supply of chips (FT) Nvidia CEO Huang declines Sen. Warren's request to testify at AI hearing on China's business (NBC ) White House debates AI profits distribution but hasn't yet invited major tech companies (Politico ) White House negotiates federal preemption of some state AI laws for support of tech policy priorities (Axios ) China plans to invest $295B in data centers to boost its AI infrastructure buildout (Bloomberg ) Markets: South Korean stocks surge 8.2% Tuesday as chip shares rebound on dip buying (Bloomberg ) Treasury market signaling to Kevin Warsh that interest rates need to be higher (Bloomberg ) Wall Street rushes to fund the AI boom through debt deals and IPOs as tech firms keep raking in investor cash (link ) Citi says traders building short positions in US stocks, risking market stability amid stretched tech sector bets (Bloomberg ) BofA advises investors take profits with US stocks displaying red flags and bear market signs (Bloomberg) Japan Finance Minister Katayama repeats preparedness to take bold action in FX markets when necessary (Bloomberg) Economy: China export growth accelerates on front-loading effects, tech product demand (Bloomberg, CNBC ) UK consumer spending rebounds in May but travel slumps for third month amid Iran war caution (Reuters) CBI cuts UK growth forecast, predicts highest unemployment in over a decade amid Iran war fallout (Reuters) German consumers more pessimistic than European average, hoard savings over inflation and energy costs (Reuters) German industrial production beats consensus but exports advance remains modest (Bloomberg, Reuters ) South Korea Q1 GDP revised up from initial estimate, driven by upgrades to facilities investment, private consumption (Bloomberg) Australian consumer confidence declines due to cost-of-living and tax policy uncertainties impacting businesses (Reuters, Reuters) Trade/Tariffs: Pentagon accuses Chinese companies including Alibaba, Baidu and BYD of aiding China's military (Bloomberg) US asks China to resume rare earths exports to Japan as shortage reduces supply of Japanese high-tech products (Nikkei) Central banks: BOJ reportedly set to hike next week, halt JGB purchase reductions in FY27 (Nikkei) Washington: Some Republicans seek Pulte's withdrawal for intelligence role amid Democratic opposition to FISA extension (Semafor ) Federal judge rejects Trump's $100K H-1B visa application fee, deeming it an unauthorized tax (AP) USDA Secretary Rollins labels Texas Agriculture Commissioner Miller as "unserious" over screwworm concerns (CNBC , NY Times ) Susan Collins accuses Democrats of not negotiating funding bills before September shutdown deadline (Politico ) US Trade Representative Greer to visits California to promote Trump administration's job onshoring efforts (Semafor ) Trump formally nominates Todd Blanche for AG role, but faces uncertain Senate confirmation battle ahead (Washington Post ) Poll shows Trump's approval rating remains near low as Americans expect rising gasoline prices amid Iran conflict (Reuters/Ipsos ) Related: 7974.JP, AAPL, APLD, ASML.NA, AZN.LN, BABA, BIDU, BX, GSK.LN, NFLX, NUVL, NVDA, PSKY, WBD, +ANTHROPIC, +DATABRICKS, +OPENAI, +PERPLEXITY, +SPCX...(more)	show story hide story
09-Jun-2026 03:57	StreetAccount Summary - Trading higher/lower: EU mid-morning Trading Higher: +307.2% ALZCUR.SS (AlzeCure Pharma SEK5.56, +4.26) -- enters into a collaboration and out-licensing agreement with Eli Lilly for ACD680 +6.9% ZEAL.DC (Zealand Pharma DKK268.30, +17.40) +5.8% AUS.GR (AT & S Austria Technologie & Systemtechnik €148.60, +8.00) +5.7% FEVR.LN (Fevertree Drinks £7.94, +0.43) -- AGM trading statement +5.7% GIVN.SW (Givaudan CHF3,068.00, +168.00) -- Deutsche Bank upgrade +5.3% HVO.LN (hVIVO plc £0.09, -0.00) +5.2% WPP.LN (WPP Group £2.76, +0.14) -- initiated buy at Berenberg +5.2% UNI.IM (Unipol Gruppo €22.70, +1.13) -- Unicredit eyes Delfin ~17.5% stake in MPS to block Intesa Sanpaolo takeover plan - Quotidiano Nazionale +3.8% BPE.IM (BPER Banca €12.77, +0.47) -- +1.9% BAMI.IM (Banco BPM €13.60, +0.25) -- +4.8% ATEME.FP (ATEME €13.10, +0.60) +4.7% ELN.IM (El.En. €16.73, +0.75) -- initiated buy at Stifel +4.2% ATS.AV (AT & S Austria Technologie & Systemtechnik €148.00, +5.80) +4.1% BREE.LN (Breedon Group £2.80, +0.11) -- completes acquisition of Falling Springs Quarry for enterprise value $120M +4.0% OTB.LN (On The Beach Group £1.58, +0.06) +3.9% INSTAL.SS (Instalco SEK38.54, +1.46) -- order +3.1% DEMANT.DC (Demant DKK259.80, +7.80) -- BofA upgrade +3.1% CLAS.B.SS (Clas Ohlson SEK393.60, +11.80) -- initiated buy at Nordea +2.9% CEM.IM (Cementir Holding €13.68, +0.40) -- announces agreement with Danish Energy Agency to receive carbon capture subsidy for ACCSION +2.8% BNZL.LN (Bunzl £25.56, +0.70) -- BNP Paribas Exane upgrade +2.7% ABDN.LN (Aberdeen Group £2.44, +0.06) +2.6% JLP.LN (Jubilee Metals Group £0.03, -0.00) -- updates on Molefe Mine operation +2.4% IDIA.SW (Idorsia CHF4.35, +0.10) -- announces up to CHF 250M loan from Pharmakon +2.3% AZM.IM (Azimut Holding €35.68, +0.82) -- May net inflows +2.3% IG.IM (Italgas €10.49, +0.23) -- Citi upgrade +2.2% IFX.GR (Infineon Technologies €80.41, +1.73) +2.2% AVAP.LN (Avation £1.38, +0.03) +2.0% ABI.BB (Anheuser-Busch InBev €68.68, +1.34) +1.9% KLR.LN (Keller Group £25.02, +0.48) -- contract Trading Lower: -8.0% OXIG.LN (Oxford Instruments £29.40, -2.48) -- FY earnings -6.7% OHB.GR (OHB SE €385.00, -27.40) -5.7% VBK.GR (Verbio €36.64, -2.12) -5.5% MGN.NO (Magnora NOK27.45, -1.50) -4.8% IDR.SM (Indra Sistemas €54.58, -2.72) -- German and France agree to abandon development of the joint fighter aircraft under the Future Combat Air System (FCAS) defense program - Reuters -4.7% SDF.GR (K+S AG €13.12, -0.65) -- launches an offering of ~€300M convertible bonds due 2031 -4.3% LPK.GR (LPKF Laser & Electronics €20.60, -0.90) -3.7% NANO.LN (Nanoco Group £0.03, -0.00) -- notes Glass Lewis recommends voting for delisting resolution at next week's general meeting -3.4% GNFT.FP (GENFIT €8.69, -0.30) -3.3% BOL.SS (Boliden SEK524.80, -17.60) -- initiated sell at Goldman Sachs -3.3% CAML.LN (Central Asia Metals £1.30, -0.04) -3.2% EVK.GR (Evonik Industries €15.18, -0.50) -- RAG-Stiftung launches an offering of bonds exchangeable into shares of company -3.1% DATA.LN (GlobalData £0.99, -0.03) -- initiated neutral at JPMorgan -3.0% NDX1.GR (Nordex €39.60, -1.22) -- order -2.8% GSK.LN (GSK Plc £18.42, -0.54) -- confirms it has entered an agreement to acquire Nuvalent, Inc. for $124 per share in cash in a $10.6B deal -2.7% GLEN.LN (Glencore £5.86, -0.16) -- Larvotto Resources signs binding offtake agreement with company for gold concentrate from Hillgrove Antimony-Gold Project in NSW -2.4% LSL.LN (LSL Property Services £2.06, -0.05) -2.4% EKT.GR (EnergieKontor €42.05, -1.05) -2.3% GLE.LN (MJ Gleeson £2.32, -0.06) -- updates on major land sale expected to close in 2027 -2.2% NOKIA.FH (Nokia €12.78, -0.28) -2.2% KOG.NO (Kongsberg Gruppen NOK315.60, -6.90) -2.0% BSL.GR (Basler €26.65, -0.55) -2.0% ZAL.NO (Zalaris NOK99.00, -2.00) -- Kona BidCo AS completes cash tender offer for company at NOK100/share -2.0% NKR.NO (Nekkar NOK14.55, -0.30) -1.8% SOI.FP (SOITEC €158.55, -2.75) -1.8% RDC.GR (Redcare Pharmacy €48.30, -0.90) -1.7% AZN.LN (AstraZeneca £135.06, -2.40) -- announces elecoglipron moves to Phase III program Related: ABDN.LN, ABI.BB, ALZCUR.SS, ATEME.FP, ATS.AV, AUS.GR, AVAP.LN, AZM.IM, AZN.LN, BAMI.IM, BNZL.LN, BOL.SS, BPE.IM, BREE.LN, BSL.GR, CAML.LN, CEM.IM, CLAS.B.SS, DATA.LN, DEMANT.DC, EKT.GR, ELN.IM, EVK.GR, FEVR.LN, GIVN.SW, GLE.LN, GLEN.LN, GNFT.FP, GSK.LN, HVO.LN, IDIA.SW, IDR.SM, IFX.GR, IG.IM, INSTAL.SS, JLP.LN, KLR.LN, KOG.NO, LPK.GR, LSL.LN, MGN.NO, NANO.LN, NDX1.GR, NKR.NO, NOKIA.FH, OHB.GR, OTB.LN, OXIG.LN, RDC.GR, SDF.GR, SOI.FP, UNI.IM, VBK.GR, WPP.LN, ZAL.NO, ZEAL.DC...(more)	show story hide story
09-Jun-2026 02:02	European macro headlines: Geopolitics: Zelensky reports positive call with US envoys as Europe backs proposed Putin meeting for ceasefire (France24) Macron to host G7 video call with China on global trade imbalances ahead of Evian summit (Politico) France and Germany scrap joint next-generation fighter jet project (CNN) UK: UK consumer spending rebounds in May but travel slumps for third month amid Iran war caution (Reuters) CBI cuts UK growth forecast, predicts highest unemployment in over a decade amid Iran war fallout (Reuters) Starmer vows to fight leadership challenge as Makerfield by-election looms (Politico) UK government to reimburse visa fees for tech and scale-up firms to attract talent (Bloomberg) Investors warn Scotland against long-term bonds over independence risk premium (FT) Germany: German consumers more pessimistic than European average, hoard savings over inflation and energy costs (Reuters) Corporate: ASML CEO warns EU against direct intervention in semiconductor supply chains (FT) Renault to cap defence revenue at 5% as it pushes into drone making (FT) BP investors demand clarity over ousting of chairman (FT) GSK in talks to buy cancer biotech Nuvalent for more than $9B (FT) AstraZeneca advances weight-loss pill to take aim at obesity leaders (FT) Swiss lawmakers consider softening UBS capital requirements to ease regulatory burden (Reuters) For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: ASML.NA, AZN.LN, BP.LN, GSK.LN, RNO.FP, UBSG.SW...(more)	show story hide story
08-Jun-2026 20:17	AZN.LN Transcript Intelligence: AstraZeneca at American Diabetes Association Scientific Session Conference Presentation Summary (Presentation Time: 08-Jun-26 19:00 ET): Company-focused: Phase 3 program for oral GLP-1 agonist to commence in H2 2026. Obesity, type 2 diabetes, and heart failure trials to be included in Phase 3 program. Peak sales potential for multiple assets projected at $3–5B each. Five franchise launches with >$5B peak sales each anticipated by 2030. Oral GLP-1 agonist demonstrated clinically meaningful weight loss and glycemic control in Phase 2. Combination therapies and flexible dosing strategies prioritized for future differentiation. Safety profile consistent with GLP-1 class; no unexpected safety signals in Phase 2. Portfolio expansion includes once-weekly and monthly injectables, and novel combinations in pipeline. First Phase 3 readouts for dyslipidemia and hypertension assets expected in 2027. Macro: Obesity epidemic projected to affect over 3B people globally by 2035. This summary was created with GenAI, optimized by StreetAccount. Early transcripts may contain phonetic spellings. Reference Link: Transcript	show story hide story
08-Jun-2026 16:23	AZN.LN AstraZeneca announces elecoglipron moves to Phase III program (13796p) Positive results from the VISTA and SOLSTICE Phase IIb trials of elecoglipron, an oral small molecule GLP-1 receptor agonist (GLP-1 RA), unlock the next chapter in AstraZeneca's ambition to develop therapies that improve cardiometabolic and kidney health and reduce weight-related complications. These results, presented today at the 2026 Scientific Sessions of the American Diabetes Association (ADA) and simultaneously published in The Lancet, mark an important step in building AstraZeneca's differentiated weight management portfolio of monotherapies and combinations, supported by the company's broad CVRM pipeline and global commercial expertise. AstraZeneca is advancing elecoglipron into an extensive Phase III programme in obesity and type 2 diabetes, including cardiovascular and kidney outcome trials.	show story hide story
08-Jun-2026 08:50	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis ADA Scientific Sessions ongoing and source of obesity treatment headlines over the weekend. Eli Lilly presented its triple G agonist retatrutide seen affirming its leadership in the space. Novo Nordisk took a backseat. Shares of LLY +2% in the pre-market; ADRs for NVO down (1%) in the pre-market. Biopharma M&A returns on Monday morning with Incyte acquiring privately-held Vega Therapeutics in a deal worth up to $2B. Shares of INCY slightly higher in the pre-market. Early-stage trial results in pancreatic cancer, evalating the combination of PRMT5 and RAS(ON) inhibitors - Tango Therapeutics and Revolution Medicines are the originators, respectively. Greater than 90% ORR in the ongoing study. Shares of TNGX +46% in the pre-market, and RVMD +2%. Macro S&P futures are up +0.7% on Monday morning. US equities resilient in the face of latest escalation in military tensions in the Middle East and spillover of a late-week tech selloff to Asia. Nothing specific behind the resilience, though comments from Trump throughout the weekend fit with expectations US remains focused on a diplomatic solution. When it comes to tech, stretched positioning and sentiment seems to be getting the bulk of the blame as the compute/capex demand narrative remains firmly intact. Broadening out trade dynamics also somewhat underpinned by the solid macro backdrop theme highlighted by the high-profile May economic data that surprised to the upside last week. Pre-market trading update Trading higher +45.9% TNGX trial results in PDAC; call at 8ET +15.0% NRIX announces collaboration with Roche with up to $3B +9.6% ADCT follow-through, downgraded at HC Wainwright +4.9% ATAI on 40K shares +3.7% GMRS initiations (low volume) +3.6% CMPS on 58K shares +2.3% INCY acquires Vega Therapeutics for up to $2B +2.0% RVMD sympathy to TNGX (combo trial in PDAC) +1.5% LLY obesity presentations at ADA +1.5% BIIB upgraded at Needham +1.1% TFX upgraded at Piper Sandler Trading lower -1.3% LAB to merge with Treeline Biosciences, divest Lab businesses -0.8% NVO obesity presentations at ADA Pharma Trial results at ADA: LLY presented additional results from the pivotal phase 3 trials of triple G agonist retatrutide in obesity and in common obesity-related conditions. TRIUMPH-1 and TRANSCEND-T2D-1 trials were presented at ADA. Quick take: Sell-side painted the data as clean and reinforcing the company's leadership position in the metabolics field. (NVO) Biotech Trial results: TNGX announced initial data from its ongoing Phase 1/2 study of PRMT5 inhibitor vopimetostat in 2L and 3L PDAC, in combo with RAS(ON) inhibitors from Revolution Medicine (RVMD). 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response. In addition, company notes upcoming data readouts for vopimetostat single agent in lung cancer and TNG456 in GBM. M&A: INCY confirmed an earlier media report (FT) with an announcement of the acquisition of privately-held Vega Therapeutics in a deal worth up to $2.0B, including $1.25B upfront. Deal adds monoclonal antibody VGA 039 to the hematology pipeline. Collaboration agreement: NRIX and ROP.SW announced a global collaboration for the development of BTK degrader bexobrutideg across broad range of indications from malignant hematology to immune-mediated diseases. Deal worth up to $3.0B, including $700M upfront. Research: BIIB upgraded to buy from hold at Needham (Ami Fadia), notes strength of pipeline. Target is $255 or approx. 31% upside. (FactSet average PT $220; range $150-300) ADCT downgraded to neutral from buy at HC Wainwright (Robert Burns). Life Science & MedTech M&A: LAB Standard BioTools and Treeline Biosciences announced all-stock merger agreement. Combined company to focus on Treeline's drug discovery and development organization, and trade on the Nasdaq as TRLN. Standard BioTools exploring divestitures of its core businesses. Research: TFX upgraded to overweight in transfer of coverage at Piper Sandler (Jason Bednar), target increased to $160 from $140 or approx. 23% upside. (FactSet average PT $144; range $135-155) Services & Hospitals Research: GMRS seeing initial sell-side coverage following IPO on 13-May. Shares have traded down (27%) since pricing at $15/shr. Nearly unanimous buy-rating on the stock today, seven buy-equivalent ratings (Barclays, BofA, Citi, Evercore, Goldman Sachs, JPMorgan, UBS) and one hold-equivalent (Morgan Stanley). Average PT $19, range $14-35, or approx. 78% upside. BTSG initiated buy at Goldman Sachs (Scott Fidel), target is $71 or approx. 24% upside. (FactSet average PT $63; range $49-71) OPCH initiated neutral at Goldman Sachs (Scott Fidel), target is $22 or approx. 7% upside. (FactSet average PT $29; range $22-39) On Deck: Conference (cont.) ADA Scientific Sessions (Jun 5-8) Goldman Sachs Healthcare Conference (Jun 8-10) Corporate ARTV investor meeting (8:15ET) ROP.SW virtual ADA investor event (11:00ET) AZN.LN ADA virtual investor meeting (17:00ET) on Tue 9-Jun: Investor meeting SN.LN (SNN) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ADCT, ARTV, ATAI, AZN, BIIB, BTSG, CMPS, GMRS, INCY, LAB, LLY, NRIX, NVO, OPCH, ROP.SW, RVMD, SNN, TFX, TNGX, TRLN...(more)	show story hide story
08-Jun-2026 08:40	AIM AIM ImmunoTech provides interim clinical progress from Ph2 study of Ampligen in combination with Imfinzi in Pancreatic Cancer ($0.52) AIM recently announced enrollment of the final patient in the clinical trial, barring any disqualifying pre-treatment circumstances. The company remains on track for a planned December 2026 evaluation of the clinical trial's primary endpoint, Clinical Benefit Rate, defined as stable disease, partial response or complete response (progression-free disease) at 6 months (24 weeks) after start of combination therapy. DURIPANC is a follow-up to a 57-subject Named Patient Program of Ampligen as a monotherapy in late-stage pancreatic cancer, where Ampligen was associated with median survival of 19.7 months, which is an extension of median overall survival of 8.6 months when compared to the standard of care. The EAP subjects also reported improved quality of life. Reference Link: Press release Related: AZN.LN	show story hide story
06-Jun-2026 09:48	AZN.LN AstraZeneca announces Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo in adults with immunoglobulin A nephropathy at 34 weeks in I CAN Phase III trial (13858p) Results from a prespecified interim analysis of the I CAN Phase III trial evaluating Ultomiris (ravulizumab) demonstrated a statistically significant and clinically meaningful reduction in proteinuria from baseline, based on 24-hour urine protein creatinine ratio (UPCR), compared to placebo at week 34 in adults with immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. Ultomiris demonstrated a 46.6% reduction in 24-hour UPCR from baseline (95% confidence interval [CI]: 39.0%, 53.2%) at week 34, compared to 5.6% (95% CI: -4.9%, 15.0%) in patients receiving placebo, resulting in a placebo-adjusted treatment effect of 43.4% (95% CI: 33.5%, 51.8%; p<0.0001). The reduction in proteinuria was rapid, observed as early as week 10 with Ultomiris (36.7% [95% CI: 30.2%, 42.6%]) and sustained through 34 weeks, compared to placebo (8.5% [95% CI: 0.5%, 15.8%]). These results were consistent across patient subgroups, reflecting diverse demographic and baseline clinical characteristics and disease severity. The safety profile observed in this trial was consistent with the known profile of Ultomiris and generally well tolerated, with no new safety concerns identified. The most common adverse events (AE) reported were upper respiratory tract infection (11.3%), nasopharyngitis (9.2%) and infusion-related reactions (8.4%) in those treated with Ultomiris; and upper respiratory tract infection (10.2%), nasopharyngitis (9.0%) and hypertension (6.6%) in those receiving placebo. These results were presented today at the 63rd European Renal Association (ERA) Congress in Glasgow, Scotland. The trial's primary endpoint of change from baseline in estimated glomerular filtration rate (eGFR) will be measured at week 106 Reference Link: Press release Related: XNCR	show story hide story
05-Jun-2026 18:04	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities ended higher overall on Friday. Advancers outnumbered decliners nearly 2:1 on the XLV. Healthcare +0.65% vs the S&P 500 (2.64%). Most major health groups were higher, with little in the way of sector-specific catalysts. Biotech was the outlier, with the XBI (3.53%), and MedTech more mixed. COO shares +8.6% after a beat, and as management updates on a strategic review outweighed a lowered FY guide. Elsewhere, Goldman Sachs initiated coverage across several MedTech names, assigning Buy ratings to GH and SHC, while launching GRAL and NTRA at Neutral. Macro: Big story today was sharp selloff in semi/AI space. No specific catalyst to selling pressure, though followed underwhelming AVGO results/guidance yesterday, seemingly exacerbated by technical dynamics amid the barrage of momentum superlatives. Big bond yield backup (through key levels) another overhang and may be dampening some of the rotation reprieve seen in the prior session (though defensives still doing well today). However, move a function of further support for the solid macro backdrop narrative in the wake of the stronger May employment report. No help for risk sentiment today from weaker oil. Pretty quiet in terms of Middle East developments with US-Iran deal expectations and skepticism both elevated. Equity supply back in focus with report META stock offering. Notable Gainers on Friday: +8.6% COO - earnings; best performer on XLV +3.0% ARDX - best performer on XBI +1.7% CON - initiation +1.7% AMRX - trial results in Parkinson's disease +1.2% VRTX - trial results in CF +0.3% SHC - initiation Notable Decliners on Friday: -23.0% EDSA - trial results in acute kidney injury -13.7% FDMT - worst performer on XBI -9.9% GRAL - initiation -8.0% MRNA- worst performer on XLV -5.6% GH - initiation -4.6% STTK - upgraded at Citi -3.3% CLYM - trial results -3.1% NTRA - initiation -3.0% LFST - initiation -0.6% TNDM - announced CE mark for expanded indications of AID systems Week in Review: Healthcare equities outperformed for the week. The S&P 500 Healthcare Index +2.31% vs the S&P 500 Index (2.59%). Outperformers: Pharma, MedTech, Services, Managed Care Underperformers: Biotech Most major health groups were higher for the week, biotech the negative outliner, XBI (5.87%). Year-to-date, Healthcare (1.44%) vs the S&P 500 +7.86%. Healthcare 9th out of eleven major sectors in CY25. Energy +27.4% and Financials (4.8%) bracket them all. Notable movers for the week: Gainers: LEGN +20.1% - LBA at EHA 2026 for CAR-T therapy LB2501 MMED +18.2% - earnings, guidance HUM +14.6% - regFD disclosure, reaffirmed FY EPS guidance MDT +10.7% - earnings, guidance; upgraded at BTIG OSCR +10.3% - upgraded at Wells Fargo MOH +9.9% - MCO sector move TGTX +5.9% - trial results for subQ Briumvi Decliners: CELC (33.6%) - trial results in breast cancer PRAX (27.4%) - trial results in FOS MLYS (24.8%) - repurchased royalty obligations; secondary priced ABVX (23.5%) - trial results in UC; safety signal; downgraded at Jefferies, upgraded at Wedbush NUVL (17.6%) - presented ALKOVE-1 data at ASCO GRAL (16.3%) - trial results for Galleri (MCED) at ASCO SMMT (15.8%) - presentation of HARMONi-6 (NSCLC) at ASCO MDLN (8.1%) - FDA publishes Warning Letter for Illinois site BTSG (6.9%) - secondary offering, priced RVMD (5.2%) - presentation of RASolute 302 (PDAC) at ASCO Week Ahead (Sat - Sun): Jun 6 - Jun 14 Conference calendar (cont.) ADA Scientific Sessions (Jun 5-8) Mon 8-Jun: Goldman Sachs Healthcare Conference (Jun 8-10) Thu 11-Jun: EHA 2026 Congress (Jun 11-14) Regulatory calendar Wed 10-Jun: FDA PDUFA for CAMX.SS Oczyesa in acromegaly Corporate calendar Sat 6-Jun:LLY investor event from ADA (19:00ET); PFE trial results for PF'3944 in obesity at ADA Mon 8-Jun: ARTV investor meeting (8:15ET); ROP.SW virtual ADA investor event (11:00ET); AZN.LN ADA virtual investor meeting (17:00ET) Tue 9-Jun: Investor meeting SN.LN (SNN) Fri 12-Jun: MBX Investor day (8:00ET) Related: ABVX, AMRX, ARDX, ARTV, AVGO, AZN.LN, BTSG, CAMX.SS, CELC, CLYM, CON, COO, EDSA, FDMT, GH, GRAL, HUM, LEGN, LFST, LLY, MBX, MDLN, MDT, META, MLYS, MMED, MOH, MRNA, NTRA, NUVL, OSCR, PFE, PRAX, ROP.SW, RVMD, SHC, SMMT, SNN, STTK, TGTX, TNDM, VRTX...(more)	show story hide story
05-Jun-2026 13:55	StreetAccount Summary: Notable Drug Events expected for the week of 7-June (cont.) Industry meeting with clinical data: American Diabetes Association (ADA) Scientific Sessions (June 5-8) (PFE, LLY, NVO, GPCR, AZN.LN) Mon 8-Jun Investor event: ARTV investor meeting (8:15ET) ROP.SW virtual ADA investor event (11:00ET) AZN.LN ADA virtual investor meeting (17:00ET) Wed 10-Jun Regulatory decision: CAMX.SS FDA PDUFA for Oczyesa NDA in acromegaly Trial results: CGEM initial data from Ph1 study of CLN-978 in RA and Ph1 study of velinotamig in SLE (webcast 8:30ET) Thu 11-Jun Industry meeting with clinical data: European Hematology Association (EHA) Congress (June 11-14) (CCCC, COGT, INCY, DMRA, ELVN, AGIO, ONC, LLY, NRIX, AAPG, ABBV, ALNY, AMGN, ARGX, BBIO, CRSP, FULC, JAZZ, LEGN, REGN, RIGL) Fri 12-Jun Investor Event: MBX Investor day (8:00ET) later during June 2026 Regulatory decisions: FDA PDUFAs: SPRO/GSK (Orapenem NDA, 18-Jun), XSPRAY.SS (Nilopki NDA, 18-Jun), MRK (Welireg sNDA and Keytruda+Keytruda QLEX sBLA, 19-Jun), ACHV (Tabex NDA, 20-Jun), Tris Pharma (TRN-257, 20-Jun), SOBI.SS (NASP BLA, 27-Jun), ARQT/AZN.LN (Zoryve sNDA, 29-Jun), LNTH (LNTH-2501 BLA, 29-Jun), UNCY (Oxylanthanum Carbonate NDA and RenaZorb NDA, 29-Jun), IONS/SOBI.SS (Tryngolza sNDA, 30-Jun), ABBV/VRDN (Veligrotug BLA, 30-Jun); EMA CHMP opinions on MAA (26-June) Regulatory meeting: EMA CHMP monthly meeting (June 22-25) Trial results: NMRA (Ph3 MDD), DFTX (Ph3 MDD), HUMA (Ph3 ESRD), QNRX (Ph 2/3 NS), EVMN (Ph2 CSU), EWTX (Ph2 HCM), CNTX (Ph1 solid tumors), ALLO (Ph 1 autoimmune diseases), TVRD (Ph1 HVs/HCC), KTTA (Ph1 solid tumors) Related: AAPG, ABBV, ACHV, AGIO, ALLO, ALNY, AMGN, ARGX, ARQT, ARTV, AZN.LN, BBIO, CAMX.SS, CCCC, CGEM, CNTX, COGT, CRSP, DFTX, DMRA, ELVN, EVMN, EWTX, FULC, GSK, HUMA, INCY, IONS, JAZZ, KTTA, LEGN, LLY, LNTH, MBX, MRK, NMRA, NRIX, ONC, QNRX, REGN, RIGL, ROP.SW, SOBI.SS, SPRO, TVRD, UNCY, VRDN, XSPRAY.SS...(more)	show story hide story
05-Jun-2026 02:09	StreetAccount Sector Summary - China Healthcare May Recap May in Review: Hang Seng Innovative Drug (11.16%) vs Hang Seng Listed Biotech (8.85%) vs Hang Seng Index (2.3%) CSI300 Healthcare (7.93%) vs CSI300 1.76% Trending topics: The 2026 ASCO Annual Meeting concluded on 2-June. The most closely watched Chinese biopharma is no doubt Akeso, the only one selected for the Plenary Session. 12 Chinese companies, including BeOne, Biokin Pharmaceutical Pharmaceutical, Dizal, Kelun-Biotech, Legend Biotech and 3SBio, together secured 13 late-breaking abstracts (LBAs). Moreover, oral or rapid oral presentations led by Chinese researchers reached a record high of 95. StreetAccount notes that this year, Chinese companies reported extensive late-stage clinical data, including several large global phase 3 trials - allowing the industry to better judge whether the drug is just a proof-of-concept product or one that truly holds commercial value. For example, Biokin's bispecific ADC BL-B01D1 (targeting EGFRxHER3) has been selected for a late-breaking abstract (LBA) for its pivotal phase III clinical study in TNBC. Meanwhile, the phase III study in ESCC was also disclosed as an oral presentation. Both studies showed positive results on the dual primary endpoints of PFS and OS; Kelun-Biotech, on the other hand, was leading the game in ADC space. Their phase III OptiTROP-Lung05, presented at ASCO, demonstrated that in first-line PD-L1-positive advanced NSCLC, Keytruda plus the TROP2 ADC (SKB264) significantly extended PFS and reduced the risk of progression or death versus Keytruda alone. The core advantage is a robust benefit across the overall population, with meaningful breakthroughs in patients with low-to-moderate PD-L1 expression and non-squamous cancers, addressing a major clinical need. That said, OS data are still immature and require longer-term follow-up. However, alongside the cheers in Chicago was a rather lukewarm reaction from the stock market. On the first day of 1-June, Hong Kong-Stock Connect innovative drugs stocks saw significant volatility. More than 10 stocks posted intraday moves above 10%, among which Akeso was particularly volatile, surging over 10% in the morning but closing down 1.86%, with a 16.43% amplitude and HK$7.04B in turnover. At the same time, Cstone dropped 32.42% (data not up to expectation), Biokin and Dizal were both down more than 10%. With Akeso having disclosed more than 40 clinical research results in ASCO, the market reactions reflected a fact that we may have overlooked: clinical data do not translate directly into stock performance, despites that Akeso announced the positive results in plenary session - the highest impact session at ASCO. Each year, from thousands of global submissions, only 4-5 breakthrough studies with the potential to change clinical practice are ultimately selected. On the day of the session, it is broadcast live to over 35,000 oncologists in the audience. However, the market apparently places greater emphasis on the feasibility and certainty of clinical research advancement, progress overseas and the outlook for commercialization. Ivonescimab is the one in the spotlight. In HARMONi-6 study, ivonescimab combined with chemotherapy as first-line treatment for advanced squamous cell lung cancer reduced the risk of death by 34% compared with tislelizumab plus chemotherapy, with a hazard ratio of 0.66. OS positive, and since the control arm is also arranged with PD-1 inhibitor plus chemotherapy, the data are recognized to be more comparable. Yet the stock market response was not particularly enthusiastic. Akeso failed to hold its early gains, and its partner Summit Therapeutics also dropped 10.49% on the same day. The US biotech sector was weak, with XBI down 2.24% and IBB down 1.64%. Individual stock performance was, however, mixed. We can see that this time during ASCO, market reactions among oncology innovation assets showed clear divergence. Aside from clinical data, BD transactions are more likely to be priced in by the market in this year's innovative drug landscape. The aforementioned set of data has clinical value, but high expectations are already priced in. As a blockbuster or rather a representative for Chinese innovative drugs going global, Ivonescimab had already driven a revaluation of Summit's stock around its overseas rights. With the results out, the market has recognized the efficacy, but remains cautious about the overseas filing pathway ahead. The drop in Summit's stock largely corresponds to colling expectations for overseas commercialization. While HARMONi-6 proved its efficacy, it does not provide enough to directly underpin sales assumptions for the US market. For more than two years, Akeso and Summit have seen their stock prices swing up and down, with all the suspense revolving one problem: can the PFS benefit ultimately translate into an OS benefit? This is not only the biggest unanswered question in the PD-1/VEGF bispecific antibody space - it also carries implications far beyond Akeso's own gains or losses. Now that Pfizer, Merck, and BMS have all joined race, this has become an arena for the big pharma players. Sector performance: At noon on 27-May, CSPC Pharmaceutical Group released its unaudited Q1 results, reporting revenue of CNY6.47B, (7.8%) y/y, and net profit attributable of CNY860M, a sharp decline of 41.8% y/y. The stock price immediately plunged when trading resumed in the afternoon, falling more than 10% intrady before closing at HK$7.04/share, down 5.38%. The giant now faces grim reality of a third straight year of declining NI attributable and second straight year of falling revenue: Price cut of core products: Speaking of CSPC's growth drive in the past years, what pops up in people's mind are usually three drugs: NBP for stroke, Duomeisu for cancer, and jinyouli for boosting white blood cell counts. At one point, these three made up nearly half of the company's finished drug revenue, transforming the company into a blue-chip stock in Hong Kong market. But then came the centralized procurement. Piece by piece, the foundation started to crumble. in 2025, NBP saw sales drop after it had to take a price cut for China's National Reimbursement Drug List (NRDL) renewal. Then Shu-Anling injection was included by the 10th round of national bulk purchasing program with a significant drop of price that further weighed on the neurology segment. As a result, neurology drug revenue fell 19% y/y to CNY7.82B. In the same round, Duomeisu won the bid at the lowest price, around 90% below the ceiling price, going as low as CNY98/vial (jiemian). Meanwhile, Jinyouli was affected by the expansion of Beijing-Tianjin-Hebei 3+N alliance's procurement, with its price reduced by 58%. The sharp price collapse of core products directly caused the oncology business revenue to be cut in half, from CNY4.4B in 2024 to CNY2.2B in 2025, down 50% y/y. One thing led to another, pretty soon the entire finished drug business was shrinking across the board. BD-licensing as a double-edged sword: on one hand, it signals a leap in innovation capability and global competitiveness; on the other hand, it makes profits more volatile. quarterly earnings pike sharply when upfront payments come in, and plunge just as sharply during off-seasons with no such receipts. Meanwhile, there has also been growing fatigue in the secondary market toward BD deals. This year, several pharmaceutical companies, including CSPC have seen their share prices decline rather than rise after announcing BD transactions. For example, after CSPC revealed its $18.5B partnership with AstraZeneca, its stock fell more than 10% on the same day. Shares of its holding subsidiary, Shineway Pharmaceutical Group also dropped sharply by 15.72%. StreetAccount notes that since 2025, CSPC has completed five out-licensing deals, with a total value of up to $28.21B. The biggest headline grabber was the strategic partnership with AstraZeneca in Jan-26, with a total potential value of up to $18.5B, setting a record for a single out-licensing deal in Chinse biopharma, including a $1.2B upfront payment. And even before that, the two parties had already reached another licensing deal for AI-driven oral small molecule drugs, with a total potential value exceeding $5.3B StreetAccount notes that overseas product registration and establishment of sales networks will take time. As a results, follow-up payments from such licensing deals tend to be slow, and related revenue is often marked by periods of weak growth. Judging from the fact that BG-89894 licensed by CSPC to BeOne was later downgraded and removed from the core pipeline portfolio, out-licensing products under development is far from a smooth R&D path. The prospects for overseas commercialization remain unclear. Increasing R&D investment and low R&D efficiency: Over the past five years, the company has steadily increased its investment in innovative drugs, attempting to complete its strategic shift before generic drug prices hit rock bottom. In FY25 , CSPC's R&D expenses reached CNY5.81B, +11.9% y/y, accounting for 28.2% of its finished drug revenue, a level that rivals Hengrui Medicine. In Q1 this year, R&D expense continued to climb to CNY1.4B, up 7.7% y/y, representing 26.8% of finished drug revenue for the period. Currently, the company has over 130 products in its pipeline, with marketing applications submitted for 11 indications and nearly 30 key products undergoing registrational clinical trials. The combined number of innovative drugs and novel formulations in development exceeds 200, including more than 90 large molecules, over 60 small ones and 50+ novel formulations. However, the key issue is not the size of the pipeline, it's whether they can commercialize the candidates fast enough to outrun the decline of legacy businesses. Innovation takes quarters and years. Yet for centralized procurement price cuts, the cycle from announcement to implementation can be squeezed down to months, or even less. What's even more worrying is the R&D efficiency. The R&D investment has yet to translate into matching performance growth Departure of key executives: just ahead of the company's earnings release, reports circulated in the market that Hei Yongjiang, CSPC's Executive President and Global Chief Medical Officer, had recently resigned. In Dec-24, Liu Yongjun, a prominent expert in immunology, oncology, and translational medicine, joined CSPC as Executive President and Global Head of R&D. However, he left the company after only three months to pursue his own venture. Some market observers suggest that the departures of these two executives may be linked to a generational leadership transition within the Cai family at CSPC. Others attribute the issue to challenges within the company's organizational structure. At the end of 2025, Cai Lei, son of CSPC founder Cai Dongchen, replaced long-time executive Zhang Cuilong as Vice Chairman of the board and CEO (Huaxia Times, National Business Daily, China Economic Net, company reports) Drug development and approvals: Clinical updates: BeOne disclosed clinical data of phase 1 study of BGB-B2033 monotherapy in patients with selected advanced or metastatic solid tumours. Treatment-related treatment-emergent adverse events occurred in 44.3% of patients, with Grade ≥3 events reported in 8.2%, and one dose-limiting toxicity that resolved after dose reduction. In 59 efficacy-evaluable patients with hepatocellular carcinoma, the confirmed objective response rate was 20.3%, with 12 partial responses (link); Genscript associate Legend Biotech announces late-breaking oral presentation at EHA 2026 showcasing initial Phase 1 in vivo CAR-T data with LB2501 in non-Hodgkin lymphoma (NHL). At dose level DL2, ORR is 100% with CR 83.3% among 6 patients (link); CSPC Pharmaceutical presents phase I clinical data of SYS6043 at 2026 ASCO. It demonstrated favourable anti-tumour activity in patients across multiple tumour types. Among the 533 efficacy-evaluable patients, the ORR was 41.8%, DCR was 81.4%, and the mDoR was 6.9 months(link); Antengene receives approval from NMPA for Phase III study of ATG-022 for CLDN18.2+ advanced gastric or GEJ adenocarcinoma (link) IND: Sichuan Biokin Pharmaceutical receives NMPA clinical trial approval for BL-M08D1 injection (link); Mabwell Bioscience receives NMPA clinical trial approval for 9MW5211 injection for treatment of inflammatory bowel disease (link); Jiangsu Hengrui Pharmaceuticals obtains NMPA trial approval for SHR-1819 in atopic dermatitis (link); TransThera Sciences (Nanjing) receives NMPA trial approval for Tinengotinib combination therapy (link); Jiangsu Hengrui Pharmaceuticals obtains NMPA clinical trial approval for HRS-1635 tablets in B-cell malignant tumors (link), and SHR-5421 in multiple myeloma (link); Designations: NMPA accepts Innovent Biologics' IBI343 NDA with priority review for advanced gastric cancer. It is the world's first CLDN18.2 ADC to be accepted for regulatory review (link); China's NMPA to grant breakthrough therapy designation to Roche's siRNA drug zilebesiran for hypertension patients to reduce the risk of major adverse cardiovascular events (link); Merck's IDVYNSO to be included in priority review list by China's NMPA, a complete, tenofovir-free, two-drug combination designed as a switch therapy for virologically suppressed patients who have no history of treatment failure (link); Sino Biopharmaceutical's TQB3454 tablet "IDH1 inhibitor" included in NMPA priority review (link) NDA acceptance: NMPA accepts Shanghai Bao Pharma's NDA of KJ103 for desensitization therapy in highly sensitized kidney transplant patients (link); InnoCare Pharma receives NMPA acceptance notice for orelabrutinib's NDA application for treatment of ITP (link); NMPA accepts CF PharmTech's marketing authorization application for tiotropium bromide inhalation powder (link) NDA approvals: Haisco Pharmaceutical Group subsidiary receives FDA NDA approval for Cipepofol Injection CYPSEDO 50mg:20ml for induction of general anethesia in adults undergoing surgery (link); NMPA approves marketing of CSPC Pharmaceutical and Alphamab Oncology's Ennituo (anbenitamab, KN026) to be combined with chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma (link); Jiangsu Hengrui Pharmaceuticals obtains NMPA drug registration approval for SHR4640 (link); CSPC Innovation Pharmaceutical obtains China NMPA approval for ustekinumab injection (link); Sino Biopharmaceutical Limited's ZONGERTINIB receives NMPA approval for first-line treatment of HER2-MUTANT non-small cell lung cancer (link); China's NMPA approves marketing of Junshi Biosciences's JS001 to be combined with disitamab vedotin for urothelial carcinoma with HER2 expression (link) License-in/out, co-development, M&A On 1-June, Haisco Pharmaceutical Group and Eli Lilly sign drug R&D partnership worth up to $3.05B. Haisco's wholly owned subsidiary signed a licensing and R&D collaboration agreement with Eli Lilly to jointly develop small-molecule drugs across multiple disease areas. Under the agreement, Haisco will be responsible for drug discovery and early-stage research for up to five novel drug targets selected by Eli Lilly. Eli Lilly will receive global exclusive rights, or ex-China exclusive rights, to the partnered programs, while Haisco retains exclusive rights in Greater China for certain projects. Haisco is eligible to receive up to $87M in upfront and near-term payments tied to the progress of the five discovery programs. The company could earn up to $2.97B in additional clinical, regulatory, and commercial milestone payments. Innovent and Pfizer have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new breakthrough early-stage and de novo cancer medicines. The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates (ADCs) with novel differentiated payloads and multi-specific antibodies with differentiated immune-engaging features and unique designs. According to the agreement, Innovent will conduct development of these programs through Phase 1, powered by its proprietary discovery engine and robust early clinical capabilities, after which Pfizer will lead future global development. The agreement also sets out the following licensing and commercialization structure: Pfizer will receive an exclusive global license for four programs, and will be responsible for the global development costs; Pfizer will receive an exclusive license outside Greater China for four programs, and will be responsible for the majority of the development costs; and Pfizer and Innovent will co-develop four programs globally and share the development costs. The companies will co-commercialize in the United States and Europe *, and share the profits. Innovent will retain Greater China rights to these programs. Under the financial terms of the agreement, Innovent will receive a $650M upfront payment and is eligible for up to $9.85B in development, regulatory and commercial milestone payments. Additionally, Innovent will receive up to double-digit royalties on sales of each licensed product if approved. For the 'co-developed, co-commercialized' programs, the two companies will share the profits in the U.S. and Europe. The transaction is expected to close in the third quarter subject to fulfillment of required regulatory approvals. On 12-May, Bristol Myers Squibb and Hengrui Pharma announced the companies have entered into global strategic collaboration and license agreements to advance a portfolio of 13 early stage programs in oncology, hematology and immunology, with the goal of accelerating discovery and development of innovative medicines for the benefit of patients worldwide. The agreements include four oncology/hematology assets from Hengrui, four immunology assets from BMS, and five innovative assets to be jointly discovered and developed by both companies, leveraging Hengrui's discovery engine and platform technologies across several innovative modalities. Hengrui has the option to co-develop select assets and the potential to conduct certain commercialization activities globally with BMS. Under the collaboration, BMS obtains exclusive worldwide rights to the Hengrui‑originated assets outside Chinese mainland, Hong Kong SAR, and Macau SAR, while Hengrui obtains exclusive rights to the BMS‑originated assets within the Hengrui territory, with BMS retaining rights for the rest of the world. Hengrui will be fully responsible for early clinical development to accelerate clinical proof of concept for these programs. BMS will pay Hengrui up to $950M, including a $600M upfront payment, a $175M first anniversary payment, and a second contingent anniversary payment of $175M in 2028. The potential total value of the agreement is up to approximately $15.2B, including the exercise of available options for the joint discovery programs and the achievement of applicable development, regulatory, and commercial milestones for all programs. In addition, Hengrui is eligible to receive tiered royalties on net sales of products commercialized outside the Hengrui territory. The parties expect that the agreement will close in the third quarter of 2026. Related: 000538.CH, 000661.CH, 000963.CH, 002422.CH, 002653.CH, 1093.HK, 1177.HK, 1548.HK, 1801.HK, 1877.HK, 2359.HK, 2607.HK, 2616.HK, 2617.HK, 600196.CH, 600276.CH, 688062.CH, 688506.CH, 6990.HK, 9926.HK, 9966.HK, 9969.HK, AZN.LN, BMY, LEGN, LLY, ONC, SMMT...(more)	show story hide story
02-Jun-2026 22:32	AZN.LN NICE recommends AstraZeneca's Imfinzi with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma in adults (13214p) Durvalumab can be used, within its marketing authorisation, as an option for neoadjuvant and adjuvant treatment with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy, then alone as adjuvant treatment, for resectable gastric or gastro-oesophageal junction adenocarcinoma in adults. Reference Link: Press release	show story hide story
02-Jun-2026 08:04	AZN.LN AstraZeneca announces that Camizestrant combination delayed time to first progression by 55% and to second progression by 37% in patients with advanced hr-positive breast cancer with An emergent ESR1 Tumor mutation in SERENA-6 trial (13376p -58p) Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor - palbociclib, ribociclib or abemaciclib - maintained its progression-free survival (PFS) benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival (PFS2), demonstrating sustained benefit beyond initial treatment. Additionally,exploratory analyses showed that the camizestrant combination profoundly reduced total circulating tumor DNA (ctDNA) and enabled substantially more patients to achieve total ctDNA clearance. The trial evaluated switching to the camizestrant combination before progression in the 1st-line setting versus continuing standard-of-care treatment with an aromatase inhibitor (AI) (anastrozole or letrozole) in combination with a CDK4/6 inhibitor following detection of an ESR1 mutation in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer. SERENA-6 met its primary endpoint of PFS at the interim analysis, with results first presented at last year's American Society of Clinical Oncology (ASCO) and simultaneously published in The New England Journal of Medicine.1 The updated results will be presented today during the 2026 ASCO Annual Meeting in Chicago, IL (abstract LBA1007). The updated results showed the camizestrant combination reduced the risk of disease progression or death by 55% versus an AI plus a CDK4/6 inhibitor (based on a hazard ratio [HR] of 0.45; 95% confidence interval [CI] 0.34-0.59; p<0.00001). Median PFS was 16.8 months for the camizestrant combination compared with 9.2 months for the AI combination, representing a median improvement of 7.6 months. Importantly, the PFS benefit observed with the camizestrant combination was sustained beyond initial progression. For the key secondary endpoint of PFS2, a measure of treatment durability beyond first progression, the final PFS2 analysis showed that the camizestrant combination reduced the risk of second disease progression or death by 37% versus the comparator arm (HR 0.63; 95% CI 0.46-0.86; p=0.00373), indicating that the benefit of switching to camizestrant plus a CDK4/6 inhibitor was maintained even after patients received subsequent therapies. Median PFS2 was 25.7 months for the camizestrant combination compared with 19.1 months for the AI combination. The camizestrant combination also demonstrated substantially greater reductions in total ctDNA in blood than continued treatment with an AI plus a CDK4/6 inhibitor at week 4 and/or week 8 after randomization. Patients who switched to the camizestrant combination had a median 99% reduction in total ctDNA by week 8, with 51% achieving total ctDNA clearance, compared with a median 64% increase in total ctDNA by week 8, and 1.9% total ctDNA clearance among patients who remained on the AI combination. These results show the early effect of switching to camizestrant on ctDNA which is linked to tumor burden reduction. Clearance of total ctDNA during treatment has been associated with long-term clinical benefit including improved overall survival (OS) across tumor types, including in patients with HR-positive, HER2-negative advanced breast cancer receiving endocrine-based therapy plus a CDK4/6 inhibitor.2,3 In an exploratory analysis pooled across both arms in SERENA-6, total ctDNA clearance was associated with OS benefit (HR 0.39; 95% CI 0.19-0.73), consistent with other studies. Data for the key secondary endpoint of OS showed a numerical trend favoring the camizestrant combination (HR 0.87; CI 0.57-1.30) at 30% maturity. The trial will continue to final analysis to assess OS. Reference Link: Press release	show story hide story
02-Jun-2026 07:53	AZN.LN Transcript Intelligence: AstraZeneca at American Society of Clinical Oncology Meeting Conference Presentation Summary (Presentation Time: 01-Jun-26 19:30 ET): Company-focused: Recent approvals for Baxendale and CHMP positive opinion for Camizestrant in Europe; FDA discussions ongoing. EMERALD-3 trial met primary endpoint; blockbuster potential anticipated globally upon approval. Overall survival data for EMERALD-3 to mature in 2027, expected to further support adoption. Multiple phase 3 readouts, including Avanza and Solutions, scheduled for H2 2026 and 2027. Weight management and PCSK9 portfolios advancing rapidly, with new agents entering phase 3. Breakthrough Therapy Designation for Puxisom in endometrial cancer; phase 3 trials underway. Radioligand therapy for prostate cancer (Actinium-225) has entered phase 3; data expected later this year. Strong D-b09 launch in breast cancer; robust early uptake and deeper responses than prior standards. Camizestrant safety profile remains favorable; over 10,000 patients treated with low discontinuation rates. Regulatory engagement ongoing for Ancelle-imab in rare disease; confidence in global path despite missed primary endpoint. Macro: Global regulatory landscape evolving, with faster approvals in UAE and Saudi Arabia than historically. Non-viral etiology now predominant in Japan, influencing regional regulatory and clinical strategies. Industry-wide momentum in antibody drug conjugates and bispecifics expected to reshape cancer care standards. This summary was created with GenAI, optimized by StreetAccount. Early transcripts may contain phonetic spellings. Reference Link: Transcript	show story hide story
01-Jun-2026 08:05	AZN.LN AstraZeneca announces IMFINZI (durvalumab) plus IMJUDO (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial (13686p -116p) Positive results from the EMERALD-3 Phase III trial showed AstraZeneca's IMFINZI (durvalumab) in combination with IMJUDO (tremelimumab-actl), lenvatinib and transarterial chemoembolization (TACE), demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus TACE alone for patients with unresectable hepatocellular carcinoma (HCC) eligible for embolization. Patients in the investigational arms were treated with the STRIDE regimen (Single Tremelimumab-actl Regular Interval Durvalumab), with or without lenvatinib, prior to TACE and then in combination with TACE thereafter. These results will be presented today in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL (abstract #LBA4000). In a planned interim analysis, the STRIDE regimen combined with lenvatinib and TACE demonstrated a 30% reduction in the risk of disease progression or death versus TACE alone (based on a PFS hazard ratio [HR] of 0.70; 95% confidence interval [CI] 0.57-0.86; p=0.0007). The median PFS was 13.0 months for this regimen versus 9.8 months for TACE. The PFS improvement was broadly consistent across key prespecified patient subgroups. For the secondary endpoint of overall survival (OS), a positive trend was observed in favor of the STRIDE regimen with lenvatinib and TACE versus TACE alone (HR 0.84; 95% CI 0.65-1.09; p=0.1814). Although not formally tested at this analysis, the key secondary endpoints of PFS and OS for the treatment arm evaluating the STRIDE regimen plus TACE versus TACE alone showed a clinically meaningful improvement in PFS (HR 0.71; 95% CI 0.56-0.91; nominal p=0.0062) and OS (HR 0.70; 95% CI 0.51-0.95; nominal p=0.0233) versus TACE alone. Median PFS was 12.9 months for STRIDE plus TACE versus 8.1 months for TACE alone. In a pre-planned exploratory analysis comparing the two investigational arms, a PFS improvement was observed favoring the lenvatinib-containing arm in patients with non-viral etiology (HR 0.70; 95% CI 0.44-1.09). The trial will continue to assess OS and other key secondary endpoints in both investigational arms. The safety profile for each combination was consistent with the known profiles of each medicine. Grade 3 or higher adverse events from all causes occurred in 71.4% of the patients in the STRIDE plus lenvatinib and TACE arm, and 64% of the patients in the STRIDE plus TACE arm, versus 28.6% in the TACE-only arm. Reference Link: Press release Related: PFE	show story hide story
29-May-2026 14:11	StreetAccount Summary: Notable Drug Events expected for the week of 31-May (cont.) American Society of Clinical Oncology (ASCO) Meeting (May 29-Jun 2) (BCAX, CRBP, KPTI, 9926.HK, SMMT, RVMD, MRK, BMY, BNTX, JNJ, PFE, LLY, ABBV, GILD, OLMA, IDYA, COGT, CATX, NUVL, SNDX, JAZZ, MRNA, URGN, NUVL, BDTX, VSTM, ONC, EXEL, IMCR, IMNM, CMPX, BCYC, CRDF, RIGL, ROP.SW, VCYT, LEGN, NUVB) Sun 31-May Investor meetings: LEGN ASCO investor event (19:00ET) RVMD to discuss Ph 3 RASolute 302 trial in PDAC (19:00ET) Mon 1-Jun Investor meetings: SMMT to discuss updates to its Ph3 HARMONi-6 trial in Squamous NSCLC (7:00ET) CRBP to discuss updated CRB-701 monotherapy data in HNSCC (7:30ET) ONC ASCO investor event (20:00ET) MRK ASCO investor event (20:00ET) Tue 2-Jun Trial results: CRDF Ph3 data for Onvansertib in RAS-Mutated mCRC (webcast 8:30ET) Abstracts release: EHA late-breaking abstracts available online (9:30ET) Wed 3-Jun Industry meetings with clinical data: European Renal Association (ERA) Congress (June 3-6) (JBIO, NOVN.SW) European Cystic Fibrosis Society (ECFS) Conference (June 3-6) (SION) European Alliance of Associations for Rheumatology (EULAR) Congress (June 3-6) (IMM.AU, ZBIO, ARTV, CGEM, UCB.BB, ZEAL) Investor meetings: KURA to discuss data from the FIT-001 clinical trial in solid tumors (15:15ET) CRDF to review updated data from CRDF-004 in mCRC (8:30ET) Fri 5-Jun Industry meeting with clinical data: American Diabetes Association (ADA) Scientific Sessions (June 5-8) (PFE, LLY, NVO, GPCR, AZN) Sat 6-Jun Investor event: LLY ADA investor event (19:00ET) Trial results: PFE Ph2 data for PF'3944 in obesity at ADA later during June 2026 Regulatory decisions: FDA PDUFAs: CAMX.SS (Oczyesa NDA, 10-Jun), 4507.JP (Xocova NDA, 16-Jun), SPRO/GSK (Orapenem NDA, 18-Jun), XSPRAY.SS (Nilopki NDA, 18-Jun), MRK (Welireg sNDA and Keytruda+Keytruda QLEX sBLA, 19-Jun), ACHV (Tabex NDA, 20-Jun), Tris Pharma (TRN-257, 20-Jun), SOBI.SS (NASP BLA, 27-Jun), ARQT/AZN.LN (Zoryve sNDA, 29-Jun), LNTH (LNTH-2501 BLA, 29-Jun), UNCY (Oxylanthanum Carbonate NDA and RenaZorb NDA, 29-Jun), IONS/SOBI.SS (Tryngolza sNDA, 30-Jun), ABBV/VRDN (Veligrotug BLA, 30-Jun); EMA CHMP opinions on MAA (26-June) Regulatory meeting: EMA CHMP monthly meeting (June 22-25) Industry meeting with clinical data: European Hematology Association (EHA) Congress (June 11-14) Trial results: NMRA (Ph3 MDD), ADCT (Ph3 DLBCL), OCS (Ph3 DME), DFTX (Ph3 MDD), ABVX (Ph3 UC), HUMA (Ph3 ESRD), PRAX (Ph2/3 FOS), QNRX (Ph 2/3 NS), EVMN (Ph2 CSU), EWTX (Ph2 HCM), CNTX (Ph1 solid tumors), ALLO (Ph 1 autoimmune diseases), TVRD (Ph1 HVs/HCC), KTTA (Ph1 solid tumors) Related: 4507.JP, 9926.HK, ABBV, ABVX, ACHV, ADCT, ALLO, ARQT, ARTV, AZN, AZN.LN, BCAX, BCYC, BDTX, BMY, BNTX, CAMX.SS, CATX, CGEM, CMPX, CNTX, COGT, CRBP, CRDF, DFTX, EVMN, EWTX, EXEL, GILD, GPCR, GSK, HUMA, IDYA, IMCR, IMM.AU, IMNM, IONS, JAZZ, JBIO, JNJ, KPTI, KTTA, KURA, LEGN, LLY, LNTH, MLTX, MRK, MRNA, NMRA, NOVN.SW, NUVB, NUVL, NVO, OCS, OLMA, ONC, PFE, PRAX, QNRX, RIGL, ROP.SW, RVMD, SION, SMMT, SNDX, SOBI.SS, SPRO, TVRD, UCB.BB, UNCY, URGN, VCYT, VRDN, VSTM, XSPRAY.SS, ZBIO, ZEAL.DC...(more)	show story hide story
29-May-2026 08:22	1093.HK CSPC Pharmaceutical Group receives $1.2B upfront from AstraZeneca under agreement announced 30-Jan See Related StreetAccount comments: 1/30/2026 2:10:02 AM - AstraZeneca to pay $1.2B upfront in multi-billion-dollar CSPC Pharmaceuticals obesity collaboration Related: 300765.CH, AZN.LN Attached Files PDF Document: Press release	show story hide story
29-May-2026 08:09	AZN.LN AstraZeneca announces that CARES Phase III clinical programme did not meet primary endpoint in overall light chain amyloidosis population, but, demonstrated anselamimab as potential first anti-fibril therapy in kappa light chain amyloidosis (13864p +128p) The global CARES Phase III clinical programme showed that treatment with anselamimab , a potential first-in-class anti-fibril therapy, resulted in nominally statistically significant and highly clinically meaningful benefit in adults with advanced kappa light chain (AL) amyloidosis as first-line therapy added to standard of care plasma cell dyscrasia (PCD) treatments, compared to placebo. In the overall population of patients with AL amyloidosis, treatment with anselamimab did not meet the primary endpoint, defined as a hierarchical combination of time to all-cause mortality (ACM) and frequency of cardiovascular hospitalisations (CVH), as previously disclosed. In a prespecified subgroup analysis of patients with kappa predominant light chain isotype, anselamimab improved survival by 62%, measured by ACM (hazard ratio 0.38; 95% confidence interval [CI] 0.17, 0.86; nominal p=0.012), and reduced the frequency of CVH by 71% (incidence risk ratio 0.29; 95% CI 0.10, 0.87; nominal p=0.028), compared to placebo in the subgroup with kappa AL amyoidosis. The reduction in the risk of ACM in the kappa subgroup was also observed in both trials comprising the CARES Phase III clinical programme among patients with kappa isotype with Mayo stage IIIa disease (75%) and Mayo stage IIIb disease (48%). No differences in ACM and CVH were observed among patients with lambda predominant light chain isotype. At 50 weeks, numerical improvements favoring anselamimab were observed in key secondary endpoints, including quality of life, as measured by the Kansas City Cardiomyopathy Questionnaire-Overall Score (Hodges-Lehmann median difference [HLMD]: 10.37 [95% CI -9.38, 25.56; p=0.113), and functional capacity, as measured by the Six-Minute Walk Test ([HLMD]: 18.00 [95% CI -71.60, 95.92; p=0.145), in patients with kappa light chain amyloidosis who received anselamimab, compared to placebo. Related: FBIO Reference Link	show story hide story
29-May-2026 06:18	300765.CH CSPC Innovation unit receives $420M (CNY2.85B) upfront payment from AstraZenca as part of long-acting peptide medicine license agreement (CNY 26.76) Editor's note (added at 18:20 HKT): This comment was revised to add AstraZenca as a secondary ticker without generating an email alert. See Related StreetAccount comments: 1/29/2026 7:04:52 PM - CSPC Pharmaceutical enters into strategic collaboration and license agreement with AstraZeneca regarding long-acting peptide medicines Related: AZN.LN Attached Files PDF Document: Press release	show story hide story
29-May-2026 02:29	StreetAccount Summary - European pre-market trading update StreetAccount notes that the pre-market levels mentioned are taken from various market sources Trading Higher +5% to +7% EVD.GR (CTS Eventim) -- Q1 earnings +5% UQA.AV (UNIQA Insurance Group) -- Q1 earnings +2% to +5% DBG.FP (Derichebourg) -- H1 earnings +1% to +5% OCDO.LN (Ocado Group) -- and Asda enter partnership to develop Asda's online business across UK; not expected to have material financial impact in FY26 +1% AZN.LN (AstraZeneca) -- FDA approves Imfinzi combo with BCG for NMIBC +0.5% DG.FP (VINCI SA) -- Fletcher Building completes sale of construction division to VINCI; deal announced 20-Jan-26 (NZT) +0.25% RWE.GR (RWE) -- RWE considering buying further stake in Amprion; seller would likely be consortium led by Ärzteversorgung Westfalen-Lippe -- Handelsblatt, citing sources Trading Lower -5% ACR.NO (Axactor) -- Q1 earnings -2% BRG.NO (Borregaard) -- comments on investment in Alginor -1% GETI.B.SS (Getinge) -- subsidiary Maquet Cardiovascular receives negative jury verdict in a patent infringement case against Abiomed in the US Gap (GPS) earnings sympathy -1% HM.B.SS (H&M Hennes & Mauritz) -1% ITX.SM (Inditex) Related: ACR.NO, AZN.LN, BRG.NO, DBG.FP, DG.FP, EVD.GR, GETI.B.SS, HM.B.SS, ITX.SM, OCDO.LN, RWE.GR, UQA.AV...(more)	show story hide story
28-May-2026 13:35	AZN.LN Follow-up: AstraZeneca confirms Imfinzi + BCG induction and maintenance therapy approved in the US for NMIBC (13736p) AstraZeneca's IMFINZI (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). Regulatory submissions based on the POTOMAC results are under review in the European Union (EU), Japan and several other countries. See Related StreetAccount comments: 5/28/2026 12:56:30 PM - FDA approves Imfinzi combo with BCG for NMIBC Reference Link	show story hide story
28-May-2026 12:56	AZN.LN FDA approves Imfinzi combo with BCG for NMIBC (13736p) FDA announced it has approved IMFINZI (durvalumab) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). Application was granted standard review. StreetAccount notes that PDUFA was guided for H1 of 2026. See Related StreetAccount comments: 10/17/2025 8:28:35 AM - AstraZeneca's Imfinzi regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial 5/9/2025 2:05:11 AM - AstraZeneca announces Imfinzi regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial Reference Link	show story hide story
28-May-2026 04:40	StreetAccount Summary - Trading higher/lower: EU mid-morning Trading Higher: +25.0% PPH.LN (PPHE Hotel Group £20.35, +4.03) -- update on strategic review and formal sale process +20.9% SOI.FP (SOITEC €176.60, +32.30) -- earnings +10.1% EDR.SM (eDreams ODIGEO €3.74, +0.35) -- earnings +9.7% DIA.LN (Dialight £3.75, +0.35) +8.5% GRE.SM (Grenergy Renovables €128.00, +10.20) -- target up at RBC Capital Markets +7.9% SFER.IM (Salvatore Ferragamo €9.21, +0.68) -- buyback +6.6% JIN.NO (Jinhui Shipping & Transportation NOK6.40, +0.40) -- ex-div today +6.1% BIOVIC.B.SS (Biovica International SEK0.33, +0.02) -- new phase III data +5.7% MTRO.LN (Metro Bank Holdings £1.67, +0.09) -- target up at RBC Capital Markets +5.5% POS.AV (PORR €38.40, +2.00) +5.0% SAAB.B.SS (Saab SEK557.80, +26.80) -- partnership +4.4% RHM.GR (Rheinmetall €1,276.20, +54.60) -- order +4.3% ALFOR.FP (Forsee Power €0.31, +0.01) -- MoU +3.9% TRMED.NO (Thor Medical NOK4.69, +0.18) -- partnership +3.9% NVM.GR (Novem Group €2.68, +0.10) -- prelim earnings +3.8% IDR.SM (Indra Sistemas €54.56, +2.04) +3.7% HEX.NO (Hexagon Composites NOK10.22, +0.37) -- target up at SEB +3.4% PEN.NO (Panoro Energy NOK32.05, +1.05) -- Danske Bank upgrade +3.1% KAP.LN (Kazatomprom £77.30, +2.30) +3.0% HUBN.SW (HUBER+SUHNER CHF270.50, +8.00) +2.9% COSH.NO (Constellation Oil Services Holding NOK143.00, +4.00) -- earnings +2.8% CCC.LN (Computacenter £42.98, +1.20) -- acquisition +2.4% BESI.NA (BE Semiconductor Industries €282.80, +6.60) +2.4% ELUX.B.SS (Electrolux SEK29.56, +0.69) +2.4% HO.FP (Thales €238.00, +5.50) +2.4% IFX.GR (Infineon Technologies €78.50, +1.85) +2.2% AM.FP (Dassault Aviation €300.80, +6.40) +2.2% STMPA.FP (STMicroelectronics €58.99, +1.25) +2.0% SDF.GR (K+S AG €15.19, +0.30) +1.9% WAF.GR (Siltronic €94.65, +1.75) +1.6% SGL.GR (SGL Carbon €4.73, +0.08) -- initiated neutral at Oddo +1.5% SOP.FP (Sopra Steria Group €144.60, +2.10) -- acquisition +1.4% ULTP.LN (Ultimate Products £0.53, +0.01) -- trading update Trading Lower: -13.7% EKTA.B.SS (Elekta SEK54.85, -8.40) -- earnings -5.0% HAFNI.NO (Hafnia NOK72.10, -3.80) -- Pareto downgrade -3.6% DHER.GR (Delivery Hero €37.74, -1.41) -- Uber (UBER) increases stake in Delivery Hero SE to ~36.8% from prior ~25.1% -- filing -3.4% FRES.LN (Fresnillo £31.00, -1.11) -3.4% IQE.LN (IQE £0.50, -0.02) -- earnings -3.3% UMG.NA (Universal Music Group €19.07, -0.64) -3.3% NKT.DC (NKT A/S DKK1,066.00, -36.00) -- DNB Carnegie downgrade; chairman sells shares -3.2% VIG.AV (Vienna Insurance Group €60.60, -2.00) -- earnings -3.2% BT.A.LN (BT Group £2.10, -0.07) -- UK would oppose any attempt from Bharti Enterprises to increase stake in BT - FT -3.0% AZN.LN (AstraZeneca £136.64, -4.16) -2.9% OCDO.LN (Ocado Group £2.03, -0.06) -2.9% DEC.LN (Diversified Energy £10.80, -0.32) -2.9% AGN.NA (Aegon €7.24, -0.21) -- agreement -2.8% 9Q9.GR (Azerion Group €1.03, -0.03) -- earnings -2.8% BSLN.SW (Basilea Pharmaceutica CHF51.70, -1.50) -- further funding -2.8% GMAB.DC (Genmab DKK1,676.50, -48.00) -- NICE recommendation -2.7% VIV.FP (Vivendi €2.24, -0.06) -2.7% NORION.SS (Norion Bank SEK58.20, -1.60) -- fine -2.6% TEP.FP (Teleperformance €59.40, -1.56) -2.6% HEIA.NA (Heineken €69.10, -1.84) -- Deutsche Bank downgrade -2.5% WRT1V.FH (Wartsila €35.69, -0.90) -- UBS downgrade -2.4% EVN.AV (EVN AG €28.65, -0.70) -- earnings -2.2% SCHO.DC (Schouw & Co DKK668.00, -15.00) -- BioMar (BIOMAR.DC) IPO -2.1% ROP.SW (Roche Holding CHF324.40, -6.90) -2.0% GNC.LN (Greencore Group £2.15, -0.04) -2.0% ADYEN.NA (Adyen €942.30, -19.00) -- CFO steps down -1.6% 1AST.GR (ASTA Energy Solutions AG €72.40, -1.20) -- earnings Related: 1AST.GR, 9Q9.GR, ADYEN.NA, AGN.NA, ALFOR.FP, AM.FP, AZN.LN, BESI.NA, BIOVIC.B.SS, BSLN.SW, BT.A.LN, CCC.LN, COSH.NO, DEC.LN, DHER.GR, DIA.LN, EDR.SM, EKTA.B.SS, ELUX.B.SS, EVN.AV, FRES.LN, GMAB.DC, GNC.LN, GRE.SM, HAFNI.NO, HEIA.NA, HEIO.NA, HEX.NO, HO.FP, HUBN.SW, IDR.SM, IFX.GR, IQE.LN, JIN.NO, KAP.LN, MTRO.LN, NKT.DC, NORION.SS, NVM.GR, OCDO.LN, PEN.NO, POS.AV, PPH.LN, RHM.GR, ROP.SW, SAAB.B.SS, SCHO.DC, SDF.GR, SFER.IM, SGL.GR, SOI.FP, SOP.FP, STMPA.FP, TEP.FP, TRMED.NO, ULTP.LN, UMG.NA, VIG.AV, VIV.FP, WAF.GR, WRT1V.FH...(more)	show story hide story
27-May-2026 02:05	AZN.LN AstraZeneca announces US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data (13960p) FDA has informed AstraZeneca that it will extend the Prescription Drug User Fee Act (PDUFA) date to review additional data requested to support the New Drug Application (NDA) for camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumours have an emergent ESR1 mutation. The NDA is based on positive results from the pivotal SERENA-6 Phase III trial presented at the 2025 ASCO Annual Meeting and simultaneously published in The New England Journal of Medicine. The FDA granted Breakthrough Therapy Designation for the camizestrant combination in this setting in May 2025. StreetAccount notes in Apr, FDA's Oncologic Drugs Advisory Committee did not reach a majority vote in favour of the benefit of switching to camizestrant in combination with a CDK4/6 inhibitor after detection of an ESR1 mutation in circulating tumour DNA (ctDNA) prior to radiographic progression, based on the SERENA-6 Phase III trial. On 22-May, EU's CHMP adopted a positive opinion recommending approval of the camizestrant combination in this setting based on the results of the SERENA-6 Phase III trial. Reference Link: Press release See Related StreetAccount comments: 5/22/2026 8:02:28 AM - EU's CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for AstraZeneca's Etcamah 5/1/2026 2:06:42 AM - FDA Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote in favor of the benefit risk profile of AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor 4/30/2026 12:02:56 PM - FDA ODAC Panel votes 6-3 against AstraZeneca's camizestrant in combination with CDK4/6 inhibitor in breast cancer patients	show story hide story
25-May-2026 00:21	4272.JP Nippon Kayaku Co. enters agreement to take over Japan marketing authorization for AstraZeneca's Zoladex 3.6mg/10.8mg depot (¥2140.5 +¥50) Agreement covers transfer of manufacturing/marketing authorization for Zoladex 3.6mg depot / LA 10.8mg depot in Japan; timing of transfer to be announced once fixed. Editor's note (added at 17:47 JT/09:47 BST): We have deleted a comment posted at 17:43 JT/09:43 BST that was a duplicate of this one. Related: AZN.LN Attached Files PDF Document: Press release	show story hide story
22-May-2026 14:22	StreetAccount Summary: Notable Drug Events expected for the week of 24-May Preface: The FDA PDUFA for IRWD/ABBV for Linzess sNDA in functional constipation patients aged 2 to 5 years is expected Sunday, 24-May. Generally, weekend PDUFA dates tend to be Friday announcements. Tue 26-May Trial results: CRBP Ph1/2 data for CRB-701 in HNSCC and cervical cancer (7:00ET) Wed 27-May Investor meetings: AKTS AKY-2519 clinical imaging and dosimetry data call (8:00ET) EQ investor day (11:00ET) BHVN R&D Day Industry meeting with clinical data: European Association for the Study of the Liver (EASL) Congress (May 27-30) (MNPR, GSK/IONS, ASMB, GILD, VIR, MIRM, MDGL, ALT, AZN) Thu 28-May Investor meeting: GSK review of Ph3 bepirovirsen data (9:00ET) Fri 29-May Abstracts release: ADA 2026 abstracts release online Regulatory decision: MNKD FDA PDUFA for Afreeza sBLA for label expansion in pediatric patients with with type I or type II diabetes Industry meeting with clinical data: American Society of Clinical Oncology (ASCO) Meeting (May 29-Jun 2) (BCAX, CRBP, KPTI, 9926.HK, SMMT, RVMD, MRK, BMY, BNTX, JNJ, PFE, LLY, ABBV, GILD, OLMA, IDYA, COGT, CATX, NUVL, SNDX, JAZZ, MRNA, URGN, NUVL, BDTX, VSTM, ONC, EXEL, IMCR, IMNM, CMPX, BCYC, CRDF, RIGL, ROP.SW) Sun 31-May Regulatory decision: CING FDA PDUFA for dexmethylphenidate NDA in ADHD during May 2026 Trial results: PTGX/JNJ Ph3 results for icotrokinra in psoriatic arthritis Related: 9926.HK, ABBV, AKTS, ALT, ASMB, AZN, BCAX, BCYC, BDTX, BHVN, BMY, BNTX, CATX, CING, CMPX, COGT, CRBP, CRDF, EQ, EXEL, GILD, GSK, IDYA, IMCR, IMNM, IONS, IRWD, JAZZ, JNJ, KPTI, LLY, MDGL, MIRM, MNKD, MNPR, MRK, MRNA, NUVL, OLMA, ONC, PFE, PTGX, RIGL, ROP.SW, RVMD, SMMT, SNDX, URGN, VIR, VSTM...(more)	show story hide story
22-May-2026 09:41	4568.JP Daiichi Sankyo receives FDA approval for Datroway for first-line treatment of patients with metastatic triple negative breast cancer who are not PD-1/PD-L1 inhibitor candidates (¥2649.5) Daiichi Sankyo and AstraZeneca's Datroway (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval follows Priority Review by the FDA based on results from the TROPION-Breast02 phase 3 trial. Reference Link: Press release See Related StreetAccount comments: 2/3/2026 2:37:50 AM - Daiichi Sankyo and AstraZeneca's sBLA for DATROWAY has been accepted and granted priority review in US for triple negative breast cancer Related: AZN.LN	show story hide story
22-May-2026 08:59	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Annual data dump known as ASCO abstract release on Thursday night. Thousands of regular abstracts published online simultaneously - several key Late Breakers won't be released until day of their presentation (May 29 - Jun 2). Early positives include TROP2 ADC and PD-1/VEGF bispecific in the lung cancer space. Shares of MRK up +3% in the pre-market; shares of BNTX +2%. Sell-side gets more bearish on Summit and the opportunity for ivonescimab. Shares of SMMT down (7%) in the pre-market. Today: EMA CHMP publishes opinions on MAA from the May 2026 monthly meeting. EMA recommends eight (8) new medicines including three (3) hybrid applications and one (1) biosimilar application. Also recommends label expansions for thirteen (13) more medicines. One (1) negative opinion issued. Three-day weekend ahead to digest all the new data - US equity markets closed on Monday for Memorial Day holiday. Macro S&P futures are up +0.2% on Friday morning. Quiet heading into the long weekend holiday in the US. Lots of moving pieces surrounding the higher-profile areas of interest, particularly when it comes to the Middle East. Biggest positive continues to be the lack of appetite for renewed escalation, though nuclear and Strait of Hormuz still big sticking points in resolution talks. While recent rate stabilization has helped sentiment, still a big pickup in headlines about structural upward pressure on yields and negative correlation between rates and equities. AI compute and infrastructure demand still the most important theme for the market and remains supported on multiple fronts, though related momentum trade has already come a long way (even with recent unwind). S&P less than 1% below ATH and on track for an eighth straight weekly gain, but sentiment looks in check with HF short positioning elevated and AAII bull-bear spread back in negative territory. Busy week of consumer-facing earnings has been largely supportive of the consumer resilience theme, though some cracks continue to emerge, particularly when it comes to inflation/affordability pressures. Pre-market trading update Trading higher +12.1% IMRX ASCO abstracts (MEK inhibitor in pancreatic cancer) +7.6% RLAY follow-through, shares +12% WTD +5.4% BBNX new timeline for patch pump +3.3% HAE upgraded at BofA +2.6% BNTX ASCO abstracts (bispecific in lung cancer w BMY); initiation +2.5% MRK ASCO abstracts (TROP2 ADC in lung cancer) Trading lower -7.0% SMMT downgraded at HC Wainwright; initiation -3.0% ZLAB immediate departure of COO -2.9% DNLI trial results with LRRK2 in Parkinson's Disease w BIIB -2.9% GH follow-through, shares +24% WTD -2.8% INSP downgraded at BofA -0.8% BIIB trial results with LRRK2 in Parkinson's Disease w DNLI EMA CHMP publishes summary of opinions for May 2026 meeting Summary here. EMA recommends eight (8) new medicines for approval, including three (3) hybrid applications and one (1) biosimilar application. Also recommends label expansions for thirteen (13) more medicines. One (1) negative opinion issued. Positive opinions for MAA include: Boehringer Ingelheim (+BOEHRINGER) Jascayd (nerandomilast) Novartis (NOVN.SW) Vojoice (alpelisib) AbbVie (ABBV) Boey (trenibotulinumtoxinE) AstraZeneca (AZN.LN) Etcamah (camizestrant) Negative opinion for MAA: Cis Bio International (owned by Curium (private)) Deqtynet (copper (64Cu) oxodotreotide) Extensions of indication were recommended for: Braftovi (Pierre Fabre / PFE), Enhertu (AZN.LN / 4568.JP), Erbitux (MRK.GR), Fasenra (AZN), Hetronifly (Accord Health), Iclusig (INCY), Keytruda (MRK), Maviret (ABBV), Padcev (4503.JP), Palynziq (BMRN), Sogroya (NOVO.B.DC), Tepkinly (ABBV) and Trodelvy (GILD) Also recommended an extension for oral Wegovy (NOVO.B.DC) - first oral use GLP-1 in Europe Withdrawal of appllication include: Laboratoires Delbert (private) Orblid (bevacizumab) Celltrion (068270.KS) Veblocema (infliximab) Pharma ASCO-related: MRK partner Kelun Biotech (6990.HK) reported interim results for the phase 3 OptiTROP-Lung05 study in China. In the study, ADC sacituzumab tirumotecan (sac-TMT) plus Keytruda reduced the risk of disease progression by 65% compared with Keytruda alone. Survival data not yet mature, but preliminary hazard ratio indicates OS improvement 45%. Abstract here. Biotech ASCO-related: IMRX reported a 17.3-month median overall survival (OS) in first-line metastatic pancreatic cancer patients treated in its Phase 2a clinical trial evaluating atebimetinib. Abstract here. ~BNTX and BMY showed data from the interim analysis from the global Phase 2/3 ROSETTA Lung-02 clinical trial, evaluating pumitamig plus chemotherapy in 1L NSCLC. Abstract here. Trial results: DNLI and BIIB announced the discontinuation of BIIB122 (DNL151) in idiopathic Parkinson's Disease following topline results from the phase 2B LUMA study did not slow the progression compared to placebo. StreetAccount notes other public companies developing LRRK2 in PD include ARVN (ARV-102) and AMRX (KFRX06) Research: SMMT downgraded to neutral from buy at HC Wainwright (Mitchell Kapoor) SMMT initiated underperform at Bernstein (Jeffrey Walch), target is $7.70 or approx. 56% downside. (FactSet average PT $29; range $7.70-45) BNTX initiated market perform at Bernstein (Jeffrey Walch) INCY initiated market perform at Bernstein (Jeffrey Walch) JAZZ initiated market perform at Bernstein (Jeffrey Walch) NBIX initiated outperform at Bernstein (Jeffrey Walch) NUVL initiated outperform at Bernstein (Jeffrey Walch) QTTB initiated outperform at Mizuho Securities (Joseph Catanzaro) RVMD initiated market perform at Bernstein (Jeffrey Walch) SABS initiated buy at Citi (Samantha Semenkow) SNSE initiated buy at Citi (Geoff Meacham) Life Science & MedTech Corporate: BBNX announced that it now expects to commercialize its patch pump by the end of Q2 2027. Updated timeline factors include FDA's feedback on the company's ACE pump 510(k) application, and progress in scaling of manufacturing. This compares to recent guidance for "by the end of 2027". (PODD) Research: HAE upgraded to buy from neutral at BofA (Travis Steed), target increased to $80 from $72 or approx. 29% upside. (FactSet average PT $81; range $62-104) INSP downgraded to underperform from neutral at BofA (Travis Steed), target cut to $39 from $53 or approx. 13% downside. (FactSet average PT $52; range $39-65) BSX removed from the Top Pick list at UBS. Firm believes the recent sell-off is overdone, but sees no near-term catalyst to keep on the list. On Deck: May 16 - 24 All clear into the long weekend Peek Ahead to the following week (May 25 - 31) on Mon 25-May - US equity markets closed for Memorial Day Holiday on Wed 27-May - EASL 2026 annual meeting (May 27-30); Stifel Jaws & Paws (May 27-28); Earnings after Agilent (A) on Thu 28-May: Earnings after HQY on Fri 29-May - ASCO 2026 annual meeting (May 29 - Jun 2); ADA 2026 abstracts release online (meeting is Jun 5-8) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 068270.KS, 4503.JP, 4568.JP, 6990.HK, ABBV, AMRX, ARVN, AZN, AZN.LN, BBNX, BIIB, BMRN, BMY, BNTX, BSX, DNLI, GH, GILD, HAE, IMRX, INCY, INSP, JAZZ, MRK, MRK.GR, NBIX, NOVN.SW, NOVO.B.DC, NUVL, PFE, PODD, QTTB, RLAY, RVMD, SABS, SMMT, SNSE, ZLAB...(more)	show story hide story
22-May-2026 08:27	AZN.LN AstraZeneca's Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours (14008p +2p) Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which showed clinically meaningful responses across a broad range of tumours. If approved, Enhertu would become the first HER2 -directed therapy and antibody drug conjugate to receive a tumour agnostic indication in the EU. AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumours who have received prior treatment and who have no satisfactory treatment options. Reference Link: Press release Related: 4568.JP	show story hide story
22-May-2026 08:19	EMA CHMP publishes summary of opinions for May 2026 meeting Summary here. EMA recommends eight (8) new medicines for approval, including three (3) hybrid applications and one (1) biosimilar application. Also recommends label expansions for thirteen (13) more medicines. One (1) negative opinion issued. Positive opinions for MAA include: Boehringer Ingelheim (+BOEHRINGER) Jascayd (nerandomilast) Novartis (NOVN.SW) Vojoice (alpelisib) AbbVie (ABBV) Boey (trenibotulinumtoxinE) AstraZeneca (AZN.LN) Etcamah (camizestrant) Negative opinion for MAA: Cis Bio International (owned by Curium (private)) Deqtynet (copper (64Cu) oxodotreotide) Extensions of indication were recommended for: Braftovi (Pierre Fabre / PFE), Enhertu (AZN.LN / 4568.JP), Erbitux (MRK.GR), Fasenra (AZN), Hetronifly (Accord Health), Iclusig (INCY), Keytruda (MRK), Maviret (ABBV), Padcev (4503.JP), Palynziq (BMRN), Sogroya (NOVO.B.DC), Tepkinly (ABBV) and Trodelvy (GILD) Also recommended an extension for oral Wegovy (NOVO.B.DC) - first oral use GLP-1 in Europe Withdrawal of appllication include: Laboratoires Delbert (private) Orblid (bevacizumab) Celltrion (068270.KS) Veblocema (infliximab) For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: 068270.KS, 4503.JP, 4568.JP, ABBV, AZN, AZN.LN, BMRN, GILD, INCY, MRK, MRK.GR, NOVN.SW, NOVO.B.DC, NVS, PFE, +BOEHRINGER...(more)	show story hide story
22-May-2026 08:13	AZN.LN EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for AstraZeneca's Fasenra (14026p +20p) EU's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Fasenra The marketing authorisation holder for this medicinal product is AstraZeneca AB. The CHMP adopted a new indication as follows: Asthma Fasenra is indicated as an add‑on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long‑acting β‑agonists (see section 5.1). Eosinophilic granulomatosis with polyangiitis (EGPA) Fasenra is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (see section 5.1). Hypereosinophilic syndrome (HES) Fasenra is indicated as an add‑on treatment for adult and adolescent patients aged 12 years and older weighing at least 35 kg with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause Reference Link	show story hide story
22-May-2026 08:02	AZN.LN EU's CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for AstraZeneca's Etcamah (14024p +18p) The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Etcamah, intended for the treatment of ER-positive, HER2-negative locally advanced or metastatic breast cancer in patients with ESR1 gene mutations. Etcamah will be available as 75 mg film-coated tablets. The active substance of Etcamah is camizestrant , an anti-oestrogen endocrine therapy (ATC code:L02BA05). The full indication is: Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1‑mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor (for biomarker based patient-selection, see section 4.2 and 5.1). In pre- or peri-menopausal women and in men, Etcamah plus a CDK4/6 inhibitor should be combined with a luteinizing hormone releasing hormone (LHRH) agonist or antagonist. Treatment with Etcamah should be initiated and supervised by a physician experienced in the use of anticancer medicinal products. Reference Link Attached Files PDF Document: Press release	show story hide story
22-May-2026 02:04	AZN.LN AstraZeneca to showcase Phase III data at ASCO 2026 (14006p) AstraZeneca advances its ambition to eliminate cancer as a cause of death and transform outcomes for people living with rare diseases with new data across its diverse, industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, 29 May to 2-Jun-26. EMERALD-3 late-breaking presentation will showcase benefit of Imfinzi and Imjudo in early liver cancer Phase III data from SERENA-6, DESTINY-Breast09 and TROPION-Breast02 span all three major subtypes of metastatic breast cancer CARES Phase III results will demonstrate highly clinically meaningful benefit of anti-fibril therapy, anselamimab, for kappa light chain amyloidosis	show story hide story
21-May-2026 20:04	13.HK HUTCHMED to present savolitinib phase II gastric/GEJ MET amp data at ASCO 2026 (HK$18.87) Rapid oral: pivotal phase II registration study of savolitinib in MET-amplified gastric/GEJ adenocarcinoma in China meets primary endpoint IRC-assessed ORR 32.3% (95% CI 21.2%-45.1%) at Oct-08, 2025 cutoff. Reference Link: Press release Related: AZN.LN	show story hide story
20-May-2026 20:31	AZN.LN NICE recommends AstraZeneca's Tagrisso to treat EGFR mutation-positive unresectable locally advanced NSCLC after platinum-based chemoradiotherapy (13950p) Osimertinib can be used, within its marketing authorisation, as an option to treat unresectable locally advanced (stage 3) non-small-cell lung cancer (NSCLC) in adults. It is an option when: the tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, and the cancer has not progressed during or after platinum-based chemoradiotherapy. Reference Link: Press release	show story hide story
18-May-2026 17:14	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished modestly higher overall on Monday. Advancers beat decliners by nearly 3:1 on the XLV. Healthcare +0.42% vs S&P 500 (0.07%). Major health groups ended mostly higher on their averages, led by MedTech group coming off last week's pullback. Fairly uneventful bounce across both LifeSci and Medical Devices subgroups. BIO +13.9% reportedly attracting activist attention. BSX +6.2% leading all gainers on the XLV, an opportunistic $2B share repurchase, combined with some strategic M&A, taking a minority stake in MiRus with option to acquire. Shares of BSX remain (41%) YTD. Managed Care group an early decliner, underpinned by UNH (0.7%) after the Berkshire Hathaway exit disclosed via 13F filing. Biotech group the only significant decliner, XBI (2.36%) just one-day after falling (3%). Turmoil at the FDA continues to spark volatility, plus REGN (9.8%) or around ($7B) hit to market cap after the pipeline setback in melanoma. In a Friday night dish of disappointment, clinical trial with LAG-3/PD-1 combo failed to beat Keytruda monotherapy in melanoma. MRK +1.1% also had positive oncology news of its own with sac-TMT. First of many pivotal readouts for the ADC. Health-related newsflow was relatively busy over the weekend: from Ebola-stricken Americans, to HELP Chair Cassidy denied a third-term, and more FDA turmoil. Macro US/Iran war narrative continues to offer a lot of headline volatility, little progress toward a resolution. Late afternoon social media post by Trump said Middle East leaders from Qatar, UAE, Saudi Arabia, asked for US to hold off on planned military attack on Iran, which Trump said was scheduled for tomorrow. Earlier updates continued to vacillate between diplomacy vs possible US strikes. Rate stabilization a key focus in Monday trading following upward pressure on Treasury yields last week, though global bond yield break continues to get flagged as key headwind for risk sentiment, with Japan and Uk the notable areas of scrutiny. AI trade (semis, memory), Mag 7 also under pressure in Monday trading, extending recent momentum unwind. Other bearish pieces of narrative include growing fears around rapidly deteriorating energy inventory buffers, further upward pressure on energy prices and global supply chain spillover effects, still-extended positioning and sentiment, CTAs likely selling in neutral scenarios in near-term, and hawkish Fed outlook (market pricing ~15 bp of hikes through year-end). Bullish pieces include M&A tailwinds (latest in utilities sector), buyback boosts, activist headlines, BRK.B positioning update. However, market waiting for signals later this week with NVDA, retail earnings. Notable Gainers +13.9% BIO (Bio-Rad Laboratories): media report - Elliott building stake +8.5% OSCR (Oscar Health): stock higher last 7 weeks +7.8% VCYT (Veracyte): best performer on XBI; shares are +28% MTD +6.2% BSX (Boston Scientific): best performer on XLV; $2B share repurchase; M&A +5.6% DXCM (Dexcom): shares were +7% on Friday +4.7% ZTS (Zoetis): shares remain (32%) MTD +4.2% MTD (Mettler-Toledo International): shares remain (16%) MTD +3.4% PODD (Insulet): shares remain (11%) MTD +3.4% ATAI (AtaiBeckley): psychedelic stocks broadly higher; Reuters story +3.3% NTRA (Natera): follow-through, MRD approval in MIBC Notable Decliners -25.5% DSGN (Design Therapeutics): trial results in Friedreich's Ataxia -18.7% GENB (Generate Biomedicines): despite stake disclosed by NVDA -11.0% HIMS (Hims & Hers Health): proposes convertible note offering -9.8% REGN (Regeneron): trial results in melanoma; downgraded at Citi and at Leerink; worst performer on XLV and XBI -8.0% VERA (Vera Therapeutics): shares were (6%) on Friday -7.8% QURE (uniQure NV): sympathy to FDA turmoil headlines -7.2% NTLA (Intellia Therapeutics): fourth-worst session of CY26 -6.6% MIRM (Mirum Pharmaceuticals): shares were (8%) on Friday -6.5% SYRE (Spyre Therapeutics): hit 52-week high last week -6.4% PRAX (Praxis Precision Medicines): hit 52-week high last week -5.0% SMMT (Summit Therapeutics): shares were (7%) on Friday Regeneron lower after LAG-3/PD-1 combo fails to beat Keytruda monotherapy REGN late on Friday night announced that the phase 3 trial evaluating LAG-3 combo with PD-1 in melanoma did not reach stat sig for the primary endpoint of PFS, compared against MRK Keytruda monotherapy. A separate head-to-head with fianlimab against BMY Opdualag is ongoing. Stock downgraded in reaction Boston Scientific higher; share repurchase and M&A on the tape BSX announced the investment of $1.5B for a 34% stake in privately-held MiRus LLC, developer of proprietary biomaterials, implants and procedural solutions for CV and Ortho diseases. BSX announced new $2B share repurchase agreement, part of the $5B authorization. Following completion, company will have $3B remaining under the plan. UnitedHealth Group lower on Berkshire Hathaway exit Friday was the 13F deadline for significant holders, and some notable changes in ownership during Q1. Berkshire Hathaway exited its stake in UNH, and Appaloosa cut its stake in half. Eli Lilly trading lower; pivotal readout for oral GLP-1 in China cited LLY trading lower by as much as (2%) on Monday morning, vs DRG flat. Follows pivotal phase 3 announcement by Vincentage Pharma (private) for their oral GLP-1 VCT220 (CX11), demonstrating dose-dependent weight loss between 12.2% and 12.4%, and tolerability similar to existing GLP-1s. Plans NDA submission in China. Says partner Corxel on track to report global trial data later this year. Quick take: UBS analyst Michael Yee notes read-across to orfoglipron (LLY Foundayo), with weight loss "exactly inline". Firm expects results from Vincentage's global partner Corxel in the coming weeks. Merck higher after endometrial cancer trial meets primary endpoint MRK announced on Monday morning that the pivotal phase 3 TroFuse-005 trial evaluating TROP2-directed ADC sac-TMT, at a pre-specified interim analysis, met its primary endpoint of OS and PFS in patients with advanced or recurrent endometrial cancer. The TroFuse program consists of 17 ongoing global Phase 3 trials across multiple tumor types. Design Therapeutics lower following update in Friedreich's Ataxia DSGN announced biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia (FA). Data support advancement toward registrational development. AstraZeneca wins quick approvals in Breast Cancer indication AZN / 4568.JP FDA approved two new indications for Enhertu in HER2+ early stage breast cancer, one based on DESTINY-Breast11 and another based on DESTINY-Breast05. The agency also approved two companion diagnostics, both made by Roche (ROP.SW). FDA PDUFA for the Breast11-backed sBLA was 18-May; FDA PDUFA for the Breast05 sBLA was during Q3 of 2026. Psychedelic drug stocks higher on Monday, catalyst unclear Reuters story today on psychedelic drug development accelerating since Trump EO. The article breaks no real news. White House to Announce TrumpRx Expansion With Mark Cuban - Bloomberg Bloomberg reports that Mark Cuban will attend the oval office announcement later on Monday afternoon. Cost Plus Drug Company markets a range of generic drugs. StreetAccount notes no drugmakers or products specified in the initial media report, tickers for distribution purposes only. Notable research in Healthcare today Biotech: REGN downgraded to neutral from buy at Citi (Geoff Meacham), target cut to $700 from 900 (FactSet average PT $853; range $700-1057) REGN downgraded to market perform from outperform at Leerink Partners (David Risinger), target cut to $641 from $792 or approx. 8% downside. (FactSet average PT $853; range $700-1057) AARD downgraded to underperform from buy at BofA, target is $4 or approx. 12% downside. (FactSet average PT $18; range $3-45) OTLK downgraded to neutral from buy at BTIG (Julian Harrison), notes lack of visibility into path for US approval. RVMD assumed buy at Truist (Gregory Renza), target increased to $179 from $116 or approx. 23% upside. (FactSet average PT $181; range $116-263) RCUS assumed buy at Truist (Supawat Thongthip), target increased to $35 from $30 or approx. 47% upside. (FactSet average PT $35; range $22-47) QTTB initiated overweight at Cantor Fitzgerald (Imogen Mansfield) NTHI initiated buy at Maxim Group (Jason McCarthy), target is $20 or approx. 264% upside. KRRO initiated buy at Citi (Yigal Nochomovitz), target is $21 or approx. 106% upside. (FactSet average PT $20; range $8-30) MedTech: ICLR resumed sector perform at RBC Capital Markets (Ryan Halsted), prior rating was outperform. Target is $123 (prior $263) or approx. 6% upside. (FactSet average PT $132; range $90-180) PMI initiated neutral at HC Wainwright (Yi Chen) Post-close news Research: ALNY initiated buy at Citi (Eric Joseph), target is $380 or approx. 33% upside. (FactSet average PT $445; range $330-550) ASND initiated buy at Citi (Eric Joseph), target is $355 or approx. 49% upside. (FactSet average PT $290; range $251-342) BBIO initiated neutral at Citi (Eric Joseph), target is $82 or approx. 26% upside. (FactSet average PT $106; range $76-157) BMRN initiated buy at Citi (Eric Joseph), target is $75 or approx. 51% upside. (FactSet average PT $89; range $50-120) CYTK initiated buy at Citi (Eric Joseph), target is $99 or approx. 32% upside. (FactSet average PT $105; range $69-146) IONS initiated buy at Citi (Eric Joseph), target is $115 or approx. 59% upside. (FactSet average PT $106; range $74-130) On Deck: Conference (cont.) ATS 2026 (May 15-20) HC Wainwright BioConnect Investor Conference RBC Global Healthcare Conference (May 19-20) on Wed 20-May: Cantor Fitzgerald Oncology Symposium; B Riley Securities Investor Conference (May 20-21) on Thu 21-May: ASCO abstract release online (17:00ET) Regulatory (cont.): EMA CHMP monthly meeting (May 18-21) Earnings on Wed 20-May: before ROIV (call at 8:00ET), IMVT (call at 8:00ET) after BLTE (call at 16:30ET) Corporate on Wed 20-May: TMO Investor Day (9:00ET) StreetAccount Healthcare Reads The China question is tearing biotech apart (18-May) STAT News Trump Bought Stock in Drugmaker as His Government Boosted Its Obesity Drugs (18-May) KFF Health News Mangione Judge Allows Gun, Notebook But Tosses Other Evidence (18-May) Bloomberg WHO Declares Ebola Outbreak a Global Health Emergency (17-May) NY Times Sen. Bill Cassidy loses primary as race heads to run-off in win for Trump (17-May) STAT News This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4568.JP, AARD, ALNY, ASND, ATAI, AZN, BBIO, BIO, BLTE, BMRN, BMY, BSX, CYTK, DSGN, DXCM, GENB, HIMS, ICLR, IMVT, IONS, KRRO, LLY, MIRM, MRK, MTD, NTHI, NTLA, NTRA, OSCR, OTLK, PMI, PODD, PRAX, QTTB, QURE, RCUS, REGN, ROIV, ROP.SW, RVMD, SMMT, SYRE, TMO, VCYT, VERA, ZTS...(more)	show story hide story
18-May-2026 12:17	White House to Announce TrumpRx Expansion With Mark Cuban - Bloomberg Bloomberg reports that Mark Cuban will attend the oval office announcement later on Monday afternoon. Cost Plus Drug Company markets a range of generic drugs. StreetAccount notes no drugmakers or products specified in the initial media report, tickers for distribution purposes only. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: ABBV, AMGN, AZN, JNJ, LLY, MRK, NVS, PFE...(more)	show story hide story
18-May-2026 09:09	BMRN BioMarin provides update on Phase 3 trial for BMN 401 in children aged 1-12 with ENPP1 Deficiency ($51.81) BioMarin Pharmaceutical announced results from the pivotal Phase 3 ENERGY 3 trial evaluating BMN 401 in children aged 1-12 with ENPP1 deficiency. The study met one co-primary endpoint, showing treatment with BMN 401 resulted in statistically significant increases in plasma PPi through week 52 compared to the conventional therapy control arm in children with ENPP1 deficiency. However, the study did not meet its other co-primary endpoint as there was no corresponding improvement in Radiographic Global Impression of Change (RGI-C) scores, an important measure of treatment impact in children with rickets. Additionally, no positive trends were observed across secondary endpoints, including Rickets Severity Score (RSS) and growth Z-score (height/body length and weight). BMN 401 was generally well-tolerated with no new safety signals reported. Management comments: 'We are disappointed that the significant increases in plasma PPi observed with BMN 401 did not translate into meaningful clinical improvements for children with ENPP1 deficiency,' said Greg Friberg, M.D., EVP and Chief Research & Development Officer at BioMarin. 'We are actively evaluating these data to determine the appropriate next steps. ENPP1 deficiency is a devastating disease, particularly for infants, where mortality rates remain high and new treatment options are urgently needed. We are deeply grateful to the children, families, investigators and study teams who are participating in this trial.' Detailed results from the ENERGY 3 study will be presented at an upcoming medical meeting Reference Link: Press release Related: AZN	show story hide story
18-May-2026 08:58	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Senate HELP committee will be getting a new majority Chair after Bill Cassidy failed to reach the Louisiana run-off. FDA leadership also changing - CBER acting director joins the list of high-level appointees exiting. Late on Friday night, Regeneron announced that LAG-3 combo in melanoma failed to achieve its primary endpoint. Downgrades at Citi and at Leerink in reaction. Shares down (12%) in the pre-market. Friday was the 13F deadline for CQ1 - Berkshire exited UnitedHealth stake, and Appaloosa cut stake in the insurer. Shares of UNH (3%) in the pre-market. Macro S&P futures are down (0.1%) on Monday morning. No real change in the market narrative coming out of the weekend. Big story as of late has been the backup in global bond yields on inflation and fiscal worries (JGBs remain ground zero with latest supplementary budget headlines out of Japan). Technical headwinds on a ferocious momentum trade that has been driven by the AI compute/capex demand narrative another area of scrutiny, though fundamental drivers remain intact and will be on display this week with NVDA earnings. Nothing particularly incremental when it comes to the US-Iran conflict, though Trump warned Tehran over the weekend that the clock is ticking and there has been a pickup in headlines about US consideration of a re-escalation of military activities. Strait of Hormuz stalemate continues to drive a flurry of headlines about rapidly deteriorating buffers, potential for further upward pressure on energy prices and global supply chain spillover effects. Global growth worries also in focus today with the softer-than-expected April activity data out of China. Pre-market trading update Trading higher +14.6% CMPS psychedelic stocks higher in the pre-market; Reuters story +12.0% DSGN trial results in Friedreich's Ataxia +7.6% BIO media report - Elliott building stake +7.6% GHRS psychedelic stocks higher in the pre-market; Reuters story +7.9% ATAI psychedelic stocks higher in the pre-market; Reuters story +5.2% NTRA +3.3% IBRX announces patents for ANKTIVA +3.0% RCUS assumed buy at Truist +2.5% BSX share repurchase +0.8% AZN FDA approves two Enhertu sBLAs in breast cancer +0.3% MRK sympathy to REGN Trading lower -12.1% REGN trial results in melanoma; downgraded at Citi and at Leerink -3.4% HIMS proposes convertible note offering -3.0% UNH Berkshire Hathaway liquidated stake in 1Q 13F Notable 13F filings in Healthcare (CQ1 2026) ACHC stake increased +10% to 4.5M at Greenlight BDX stake decreased (32%) to 636K at Starboard CNC stake increased +4% to 2.7M at Greenlight CTEV stake decreased (70%) to 44K at Third Point DHR stake decreased (13%) to 525K at Third Point DVA stake decreased (5%) to 30.1M at Berkshire Hathaway GENB stake initiated 833K at NVIDIA HSIC stake increased +28% to 599K at Greenlight IMVT stake initiated 94K at Greenlight IQV stake liquidated at Appaloosa PCVX stake initiated 800K at Baupost Group ROIV stake increased +4% to 2.2M at Greenlight SHC stake increased +348% to 2.1M at Greenlight SPRY stake increased +80% to 1.0M at Third Point TEVA stake decreased (5%) to 2.9M at Greenlight UNH stake decreased (55%) to 90K at Appaloosa UNH stake liquidated at Berkshire Hathaway VTRS stake initiated 1.8M at Greenlight Pharma Regulatory: AZN / 4568.JP FDA approved two new indications for Enhertu in HER2+ early stage breast cancer, one based on DESTINY-Breast11 and another based on DESTINY-Breast05. The agency also approved two companion diagnostics, both made by Roche (ROP.SW). FDA PDUFA for the Breast11-backed sBLA was 18-May; FDA PDUFA for the Breast05 sBLA was during Q3 of 2026. Biotech Trial results: REGN late on Friday night announced that the phase 3 trial evaluating LAG-3 combo with PD-1 in melanoma did not reach stat sig for the primary endpoint of PFS, compared against MRK Keytruda monotherapy. A separate head-to-head with fianlimab against BMY Opdualag is ongoing. Stock downgraded in reaction DSGN announced biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia (FA). Data support advancement toward registrational development. Conf. call at 8:00ET Regulatory: FDA CBER acting director also departing the agency - STAT News Katherine Szarama, Tracy Beth Høeg, and Marty Makary all out in a span of three days. Research: REGN downgraded to neutral from buy at Citi (Geoff Meacham), target cut to $700 from 900 (FactSet average PT $853; range $700-1057) REGN downgraded to market perform from outperform at Leerink Partners (David Risinger), target cut to $641 from $792 or approx. 8% downside. (FactSet average PT $853; range $700-1057) AARD downgraded to underperform from buy at BofA, target is $4 or approx. 12% downside. (FactSet average PT $18; range $3-45) OTLK downgraded to neutral from buy at BTIG (Julian Harrison), notes lack of visibility into path for US approval. RVMD assumed buy at Truist (Gregory Renza), target increased to $179 from $116 or approx. 23% upside. (FactSet average PT $181; range $116-263) RCUS assumed buy at Truist (Supawat Thongthip), target increased to $35 from $30 or approx. 47% upside. (FactSet average PT $35; range $22-47) QTTB initiated overweight at Cantor Fitzgerald (Imogen Mansfield) NTHI initiated buy at Maxim Group (Jason McCarthy), target is $20 or approx. 264% upside. KRRO initiated buy at Citi (Yigal Nochomovitz), target is $21 or approx. 106% upside. (FactSet average PT $20; range $8-30) Media report: Reuters story on psychedelic drug development accelerating since Trump EO. Life Science & MedTech M&A: BSX announces the investment of $1.5B for a 34% stake in privately-held MiRus LLC, developer of proprietary biomaterials, implants and procedural solutions for CV and Ortho diseases. Corporate: BSX announces new $2B share repurchase agreement, part of the $5B authorization. Following completion, company will have $3B remaining under the plan. Research: ICLR resumed sector perform at RBC Capital Markets (Ryan Halsted), prior rating was outperform. Target is $123 (prior $263) or approx. 6% upside. (FactSet average PT $132; range $90-180) PMI initiated neutral at HC Wainwright (Yi Chen) Managed Care and Services Regulatory: HHS / CMS finalized the 2027 Notice of Benefit and Payment Parameters. The final rule reduces federal Exchange user fees to help lower premiums, establishes new safeguards to prevent improper enrollments, ensures subsidies go only to eligible individuals, increases consumer choice, affordability, access and protections, and expands state flexibility to manage Exchange operations. Press release; Fact Sheet; Final Rule (1121 pp) On Deck: Conference (cont.) AUA 2026 (May 15-18) (cont.) ATS 2026 (May 15-20) on Tue 19-May: HC Wainwright BioConnect Investor Conference; RBC Global Healthcare Conference (May 19-20) Regulatory EMA CHMP monthly meeting (May 18-21) HHS/CMS Healthcare Advisory Committee (14:00ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4568.JP, AARD, ACHC, ATAI, AZN, BDX, BIO, BMY, BSX, CMPS, CNC, CTEV, DHR, DSGN, DVA, GENB, GHRS, HIMS, HSIC, IBRX, ICLR, IMVT, IQV, KRRO, MRK, NTHI, NTRA, OTLK, PCVX, PMI, QTTB, RCUS, REGN, ROIV, ROP.SW, RVMD, SHC, SPRY, TEVA, UNH, VTRS...(more)	show story hide story
18-May-2026 06:51	Autos, construction, travel and banks the biggest decliners; energy and defensive sectors the top gainers: Autos & Parts led the declines, amid broader risk aversion and renewed pressure on cyclicals. Luxury-linked autos and consumer names weaken alongside Chinese EV stocks, as concerns around intensifying price competition resurface. Construction & Materials underperform as rising rates raise worries on project pipelines and margins, with Crest Nicholson (CRST.LN) dropping amid broader UK homebuilder weakness. Travel & Leisure also big decliners with airlines bearing the brunt after Ryanair (RYA.ID) warns over geopolitical uncertainty and rising fuel, saying maintenance and wage costs could weigh on peak summer demand. Banks also down as worries over higher-for-longer rates stoke fears of rising funding costs and slower loan growth. Of note, some Italian banks downgraded at Deutsche Bank after strong Q1s, with mixed outlooks as risk premiums rise. Health Care see steady weakness despite positive corporate news. Sartorius (SRT3.GR) higher, aided by Elliott's investment in Bio-Rad (BIO), while Sonova (SOON.SW) rises after it delivers upbeat FY guidance and raises its dividend. AstraZeneca (AZN.LN) announced its hypertension treatment receives US regulatory approval, while CNBC reports Novo Nordisk (NOVO.B.DC) says it sees significant growth opportunities for weight-loss drugs outside the US. Oil & Gas the clear outperformer as crude prices continue to climb with Brent trading around $110 on escalating geopolitical tensions. Repsol (REP.SM) higher after a rating upgrade, while Shell (SHEL.LN) and BP (BP.LN) advance after positive broker commentary and rating upgrades tied to stronger oil price assumptions and buyback potential. Defensive and yield sectors like Telecom, Food & Beverage and Utilities benefit from risk-off rotation and renewed inflation protection. Media outperforming, led by Publicis (PUB.FP) stock surging after announcing acquisition of LiveRamp (RAMP) for €1.86B in cash, raising growth and revenue targets for 2027/2028. Sentiment for advertising names is bolstered by deal activity and upbeat outlooks. Insurance also higher on defensive tilt and M&A speculation after Hiscox (HSX.LN) stock extends Friday's strength after Canada's Intact Financial Corp (IFC.CN) reports to be exploring a potential takeover. For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: AZN.LN, BP.LN, CRST.LN, HSX.LN, NOVO.B.DC, PUB.FP, REP.SM, RYA.ID, SHEL.LN, SOON.SW, SRT3.GR...(more)	show story hide story
18-May-2026 02:08	AZN.LN AstraZeneca's Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer (13632p) AstraZeneca and Daiichi Sankyo'sEnhertu (trastuzumab deruxtecan) has been approved by the FDA for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer based on results from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials, respectively. In the neoadjuvant setting, Enhertu followed by a taxane, trastuzumab, and pertuzumab (THP) has been approved for the treatment of adult patients with HER2-positive Stage II or Stage III breast cancer. In the adjuvant setting, Enhertu has been approved for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease following trastuzumab (with or without pertuzumab) and taxane-based treatment. Reference Link: Press release Related: 4568.JP	show story hide story
18-May-2026 02:03	AZN.LN AstraZeneca's Baxfendy approved in the US for hypertension (13632p) AstraZeneca's Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood pressure in adults who are not adequately controlled. There are 1.4B people worldwide living with hypertension.1 In the US, ~50% of patients living with hypertension who are already taking multiple antihypertensive medications still struggle with persistently elevated blood pressure,2 which is a leading risk factor for cardiovascular disease and premature death.3,4 Hypertension is the most prevalent and significant modifiable cardiovascular risk factor worldwide, accounting for more deaths and disability than any other modifiable risk.5-7 Baxfendy is a first-in-class, highly selective and potent ASI designed to lower blood pressure in a new way by specifically inhibiting the production of aldosterone,8 a hormone that raises blood pressure to unhealthy levels and increases the risk of heart and kidney problems.9-11 The approval by the FDA was based on positive results from the BaxHTN Phase III trial,12 with Baxfendy demonstrating statistically significant and clinically meaningful seated systolic blood pressure reduction at both 2Mg and 1Mg doses in patients with uncontrolled and resistant hypertension on two or more medications. Baxfendy was generally well-tolerated with no unanticipated safety findings. Reference Link: Press release	show story hide story
16-May-2026 00:08	Post-close news (Friday) Trial results: REGN announced that the phase 3 trial evaluating LAG-3 combo with PD-1 in melanoma did not reach stat sig for the primary endpoint of PFS, compared against MRK Keytruda monotherapy. A separate head-to-head with fianlimab against BMY Opdualag is ongoing. Regulatory: AZN / 4568.JP FDA approved two new indications for Enhertu in HER2+ early stage breast cancer, one based on DESTINY-Breast11 and another based on DESTINY-Breast05. The agency also approved two companion diagnostics, both made by Roche (ROP.SW). FDA PDUFA for the Breast11-backed sBLA was 18-May; FDA PDUFA for the Breast05 sBLA was during Q3 of 2026. HHS / CMS finalized the 2027 Notice of Benefit and Payment Parameters. The final rule reduces federal Exchange user fees to help lower premiums, establishes new safeguards to prevent improper enrollments, ensures subsidies go only to eligible individuals, increases consumer choice, affordability, access and protections, and expands state flexibility to manage Exchange operations. Press release; Fact Sheet; Final Rule (1121 pp) FDA CBER acting director also departing the agency - STAT News Katherine Szarama, Tracy Beth Høeg, and Marty Makary all out in a span of three days. 13F filings: ACHC stake increased +10% to 4.5M at Greenlight BDX stake decreased (32%) to 636K at Starboard CNC stake increased +4% to 2.7M at Greenlight CTEV stake decreased (70%) to 44K at Third Point DHR stake decreased (13%) to 525K at Third Point DVA stake decreased (5%) to 30.1M at Berkshire Hathaway GENB stake initiated 833K at NVIDIA HSIC stake increased +28% to 599K at Greenlight IMVT stake initiated 94K at Greenlight IQV stake liquidated at Appaloosa ROIV stake increased +4% to 2.2M at Greenlight SHC stake increased +348% to 2.1M at Greenlight SPRY stake increased +80% to 1.0M at Third Point TEVA stake decreased (5%) to 2.9M at Greenlight UNH stake decreased (55%) to 90K at Appaloosa UNH stake liquidated at Berkshire Hathaway VTRS stake initiated 1.8M at Greenlight For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: 4568.JP, ACHC, AZN, BDX, BMY, CNC, CTEV, DHR, DVA, GENB, HSIC, IMVT, IQV, MRK, REGN, ROIV, ROP.SW, SHC, SPRY, TEVA, UNH, VTRS...(more)	show story hide story
15-May-2026 20:15	FDA CBER acting director Katherine Szarama also leaving the agency - STAT News STAT writes that "the agency is now facing an extreme leadership vacuum. The Trump administration will need to select a permanent FDA commissioner, deputy commissioner, drug center director, and biologics center director." Citing an internal email from acting Commissioner Kyle Diamantas, not only is CDER acting director Tracy Beth Høeg leaving the agency, but also CBER acting director Katherine Szarama. Karim Mikhail, who joined the FDA in 2025 as a senior adviser in the office of the commissioner, will replace Szarama. Michael Davis, deputy director has been named acting director of CDER to replace Høeg. News comes three days after Marty Makary resigned as FDA Commissioner, and just two weeks after Szarama was elevated from deputy to fill the vacancy left by Vinay Prasad. See Related StreetAccount comments: 5/15/2026 11:53:38 AM - FDA Center for Drug Evaluation & Research (CDER) Acting Director Tracy Beth Hoeg expected to depart from agency - Reuters, citing sources 5/12/2026 3:40:20 PM - Trump confirms prior report, puts Kyle Diamantas in the Acting position after FDA Commissioner Marty Makary leaves - Truth Social post Related: AZN, BMY, BNTX, GSK, MRK, MRNA, NVAX, PCVX, PFE, QURE, REPL...(more) Reference Link: STAT News	show story hide story
15-May-2026 18:01	AZN.LN FDA approves sBLA for Enhertu; two new indications for adults with HER2+ early-stage breast cancer (13632p) FDA approved Enhertu (T-DXd, fam-trastuzumab deruxtecan-nxki) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for the neoadjuvant treatment of adults with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test, followed by taxane, trastuzumab, and pertuzumab (THP). The second indication is for the treatment of adults with HER2-positive (IHC3+ or ISH+) breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment. FDA also approved two companion diagnostic devices, the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody and the VENTANA HER2 Dual ISH DNA Probe Cocktail, both for identifying HER2-positive (IHC3+ or ISH+) patients for treatment with T-DXd, consistent with the approved drug labeling. StreetAccount notes the PDUFA date for the AstraZeneca / Daiichi Sankyo drug was Monday 18-May for the sBLA based upon DESTINY-Breast11 study. The PDUFA date for the second indication, HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment, was expected during Q3 of 2026. Both companion diagnostics made by Roche (ROP.SW). See Related StreetAccount comments: 5/15/2026 3:09:59 PM - StreetAccount Summary: Notable Drug Events expected for the week of 17-May 3/9/2026 2:37:06 AM - AstraZenca's Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer 10/1/2025 7:42:54 AM - Daiichi Sankyo and AstraZeneca's sBLA for ENHERTU followed by THP accepted for FDA review in HER2 patients Related: 4568.JP, ROP.SW Reference Link	show story hide story
15-May-2026 15:09	StreetAccount Summary: Notable Drug Events expected for the week of 17-May (cont.) Industry meetings with clinical data: American Urological Association (AUA) Meeting (May 15-18) (ENGN, CADL) American Thoracic Society (ATS) International Conference (May 15-20) (WVE, TRVI, GSK, UTHR, INSM, ENTA) Mon 18-May Regulatory decision: AZN FDA PDUFA for Enhertu sBLA (DESTINY-Breast11) in breast cancer Regulatory meeting: EMA CHMP monthly meeting (May 18-21) Tue 19-May Industry meeting with clinical data: International Society for the Study of Vascular Anomalies (ISSVA) World Congress (May 19-22) (RLAY, TARA, PVLA) Investor event: TARA investor meeting discussing TARA-002 in LMs (16:30ET) Thu 21-May Investor event: TWST investor day (14:00ET) Abstracts release: ASCO regular abstracts release (17:00ET) Fri 22-May Regulatory decision: EMA CHMP opinions on MAA later during May 2026 Regulatory decisions: FDA PDUFAs: MNKD (Afreeza sBLA, 29-May), CING (dexmethylphenidate NDA, 31-May) Industry meetings with clinical data: EASL Congress (May 27-30); American Society of Clinical Oncology (ASCO) Meeting (May 29-Jun 2) Trial results: SMMT (Ph3 NSCLC), PTGX (Ph3 PsA), BNTX (Ph2 NSCLC), BDTX (Ph2 NSCLC), CRBP (Ph1/2 solid tumors), CATX (Ph1 NETs) Related: AZN, BDTX, BNTX, CADL, CATX, CING, CRBP, ENGN, ENTA, GSK, INSM, MNKD, PTGX, PVLA, RLAY, SMMT, TARA, TRVI, TWST, UTHR, WVE...(more)	show story hide story
15-May-2026 09:04	AZN.LN FDA approves sBLA for Fasenra; new indication in hypereosinophilic syndrome (HES) (13620p -120p) According to FDA.gov, and the approval letter linked below, on 13-May the agency approved an efficacy supplement (sBLA) for FASENRA (benralizumab), to add the indication for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause. StreetAccount notes supportive data from the NATRON trial were presented at ACAAI 2025 (see linked comment). See Related StreetAccount comments: 11/7/2025 9:08:29 AM - AstraZeneca announces NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA (benralizumab) met the primary endpoint Reference Link: Approval letter Reference Link	show story hide story
15-May-2026 08:45	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis DexCom reached an agreement with activist holder Elliott Investment Management, to identify two new independent directors. Shares +5% in the pre-market. Conference season shifts from broker meetings into industry meetings with AUA 2026 and ATS 2026. Also less than one week until the annual data dump for ASCO 2026. US Supreme Court preserves access to mifepristone while the Louisiana lawsuit proceeds. Macro S&P futures are down (1.0%) on Friday morning. Risk off to end the week with upward pressure on global yields, stretched positioning in pockets of tech, lack of deliverables out of the Trump-Xi summit and worries about potential for renewed escalation of military activity in the Middle East among the areas of concern. While AI momentum has been the big story again for much of the week, it has also triggered worries that the latest buying waves have been more mechanical/forced in nature. In addition, it has exacerbated the scrutiny surrounding weak breadth/concentration. Rates another big area of worry given the flurry of headlines and data points (including latest from Japan overnight) highlighting price pressure. Status-quo out of the US-China summit not really surprising but also a bit underwhelming in the face of hope for some deal announcements. Pre-market trading update Trading higher +4.6% DXCM board member agreement with Elliott; Investor Day updates +4.2% STRO earnings; upgraded at Wedbush +2.2% AVAH upgraded at Stephens Trading lower -30.8% AARD full clinical hold on ARD-101; downgraded at Morgan Stanley -8.7% ALMS earnings; downgraded at HC Wainwright -4.0% OSCR on 78K shares; shares +9% WTD -3.7% TNYA trial results in arrhythmogenic right ventricular cardiomyopathy -3.3% IMVT on light volume -2.9% PHR downgraded at Barclays -0.9% TNDM terminates Chief Commercial Officer -0.6% TNGX downgraded at Piper Sandler Biotech Trial results: TNYA announced presented at ASGCT interim data from the ongoing phase 1/2 RIDGE-1 trial of investigational gene therapy TN-401. In adults with arrhythmogenic right ventricular cardiomyopathy (ARVC), caused by mutations in the PKP2 gene, treatment with a single infusion of TN-401 resulted in consistent and deep reductions in premature ventricular contractions (PVCs) in all six Cohort 1 and 2 patients. Conf. call at 10:30ET Regulatory: AARD announced that FDA has placed a full clinical hold on the IND for ARD-101. Follows the voluntary pause previously announced. Stock downgraded in reaction. 13F filing: PCVX 800K share stake initiated at Baupost Group during 1Q 2026. Research: AARD downgraded to underweight from equal-weight at Morgan Stanley (Michael Ulz), follows clinical hold. Target cut to $3 from $7 or approx. 55% downside. (FactSet average PT $18; range $3-45) AARD downgraded to neutral from buy at BTIG (Jeet Mukherjee), follows clinical hold. ALMS downgraded to neutral from buy at HC Wainwright (Mitchell Kapoor), follows earnings. Target remains $25. JSPR downgraded to hold from buy at TD Cowen (Yaron Werber), follows earnings. STRO upgraded to outperform at Wedbush Securities (David Nierengarten), follows earnings. TNGX downgraded to neutral from overweight at Piper Sandler (Kelsey Goodwin). Cites lack of clarity on when mono data will be updated. Target increased however to $24 from $16 or approx. 3% downside. (FactSet average PT $31; range $16-55) ORIC rated buy at Goldman Sachs (Corinne Johnson), target is $15 or approx. 80% upside. PRLD rated buy at Goldman Sachs (Corinne Johnson) BIIB resumed outperform at Evercore ISI (Umer Raffat) SLGL initiated outperform at LifeSci Capital (Patrick Dolezal) Life Science & MedTech Corporate: DXCM announced that it will work with Elliott Investment Management to identify two new independent board members. Disclosed new $1B share repurchase program, replacing an existing program which had $250M remaining. Held Investor Day meeting after the close on Thursday. (Slides). TNDM discloses the termination of Chief Commercial Officer Mark Novara without cause. Company's strategy and 2026 goals remain unchanged. Research: AVTR resumed sector perform at RBC Capital Markets (Dan Leonard), target is $9 or approx. 13% upside. BIO resumed outperform at RBC Capital Markets (Dan Leonard), target is $320 or approx. 30% upside. DHR resumed outperform at RBC Capital Markets (Dan Leonard), target is $200 or approx. 20% upside. ILMN resumed outperform at RBC Capital Markets (Dan Leonard), target is $170 or approx. 19% upside. RGEN resumed outperform at RBC Capital Markets (Dan Leonard), target is $160 or approx. 55% upside. TECH resumed outperform at RBC Capital Markets (Dan Leonard), target is $62 or approx. upside. TMO resumed sector perform at RBC Capital Markets (Dan Leonard), target is $490 or approx. 9% upside. SOLV initiated outperform at Wedbush Securities (Mike Piccolo), target is $94 or approx. 26% upside (FactSet average PT $82; range $60-100) On Deck: Conference AUA 2026 (May 15-18) ATS 2026 (May 15-20) Peek Ahead to next week (May 18 - 24) Mon 18-May - HHS/CMS Healthcare Advisory Committee (14:00ET); FDA PDUFA for AZN Enhertu sBLA (DESTINY-Breast11) Tue 19-May - HC Wainwright BioConnect Investor Conference; RBC Global Healthcare Conference (May 19-20) Wed 20-May - Cantor Fitzgerald Oncology Symposium; B Riley Securities Investor Conference (May 20-21); TMO Investor Day; earnings before ROIV, IMVT after BLTE Thu 21-May - ASCO abstract release online (17:00ET); TWST Investor Day This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AARD, ALMS, AVAH, AVTR, AZN, BIIB, BIO, DHR, DXCM, ILMN, IMVT, JSPR, ORIC, OSCR, PCVX, PHR, PRLD, RGEN, SLGL, SOLV, STRO, TECH, TMO, TNDM, TNGX, TNYA...(more)	show story hide story
14-May-2026 16:55	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to slightly lower overall on Thursday. Decliners narrowly outnumbered advancers on the XLV. Healthcare (0.08%) vs S&P 500 +0.77%. Most major health groups ended lower on their averages, however most declines were modest. Nearly all groups lagged the broader tape; Services group just inline. HSIC +4.6% and BIIB (6.4%) bracketed the XLV. Latter with midstage trial results with tau antibody for Alzheimer's Disease. Initial takeaways were mixed at best, pointing to failure of the primary endpoint, and questioning what exactly gives Biogen the confidence to advance into phase 3. XBI (0.74%) left clinging to a very small weekly gain +0.10%. SMID-cap bitech, led by gene-editing stocks, continued to weigh on the ETF today, the final day of ASGCT. Sector newsflow fairly quiet, final day of the BofA conference a primary source of updates. Biogen announced midstage data from its Tau targeting ASO for Alzheimer's Disease, in-licensed from Ionis Pharma. CELIA study demonstrated reduction in Tau across all doses. Detailed data expected at AAIC. Biogen will advance into a phase 3 trial. After the close today, DexCom hosting an Investor Day meeting, and 13F filing deadline. Macro A fairly quiet session with the latest AI-related enthusiasm the biggest driver to today's upside. Latest updates include strong CSCO earnings takeaways, big rally in CBRS after its IPO debut, and some dovish updates on NVDA AI chip sales to China (around H200 chips, though Chinese approval remains pending). Fairly quiet elsewhere, with few takeaways around Trump's summit with Chinese President Xi. Not much incremental around Iran. US and China agreed on opposition of Strait of Hormuz toll, though reports said tankers increasingly crossing strait in recent days. Also not much change around other market stories (narrow breadth concerns, extended positioning and sentiment in momentum and AI names, retail investors, consumer spending concerns reflected by recent weakness in discretionary stocks). Rates stabilized Thursday, though this week's hotter inflation takeaways remain key overhang (market pricing ~10 bp of rate hikes through year-end) Notable Gainers +13.6% SLS (SELLAS Life Sciences Group, Inc.): second-best performer on XBI; shares +48% WTD +10.8% PGEN (Precigen): earnings +9.9% AVAH (Aveanna Healthcare Holdings): earnings +8.9% STAA (STAAR Surgical): earnings; upgraded at Wedbush +8.2% CELC (Celcuity): announces updates to VIK-2 trial +7.7% ANTX (AN2 Therapeutics): upgraded at Leerink +7.0% ALEC (Alector): sympathy to BIIB (tau) +4.6% HSIC (Henry Schein): best performer on XLV; presented at BofA late yesterday +4.3% CAH (Cardinal Health): shares +6% WTD and (5%) YTD +3.4% SLDB (Solid Biosciences): sympathy to RGNX +2.3% VRDN (Viridian Therapeutics): insider buying +2.2% VYGR (Voyager Therapeutics): sympathy to BIIB (tau) Notable Decliners -37.8% RGNX (REGENXBIO): trial results in DMD; earnings; worst performer on XBI -21.1% IVVD (Invivyd): earnings -14.7% MBOT (Microbot Medical): short report from White Diamond Research -13.8% CRVS (Corvus Pharmaceuticals): presented data in atopic dermatitis -9.4% ALHC (Alignment Healthcare): presented at BofA yesterday -8.3% NTLA (Intellia Therapeutics): risk-off / gene-editing / XBI weakness -8.2% ALLO (Allogene Therapeutics): earnings -7.3% BEAM (Beam Therapeutics): risk-off / gene-editing / XBI weakness -6.4% BIIB (Biogen): trial results in Alzheimer's Disease; worst performer on XLV -5.6% AMPH (Amphastar Pharmaceuticals): downgraded at Wells Fargo -3.5% SMMT (Summit Therapeutics): on low volume, shares flat WTD -2.8% DVA (DaVita): shares are +24% MTD and +70% YTD -2.5% TNGX (Tango Therapeutics): earnings; downgraded at Jefferies -2.5% IONS (Ionis Pharmaceuticals): trial results in Alzheimer's Disease -2.1% DNLI (Denali Therapeutics): sympathy to BIIB (tau) Tau thesis intact says Biogen; analysts await detailed data BIIB and IONS announced topline results from the phase 2 CELIA study evaluating diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease. Robust reductions in tau pathology were observed across all studied doses, with results generally consistent with those observed in the Phase 1b study. Data will be presented at AAIC 2026. Quick Take: Discussion points to heightened uncertainty given the absence of a clear dose response, though most are not surprised by the missed primary endpoint given the likely limited statical power of the study. Cantor Fitzgerald cautions that the results may redirect investor/company focus toward this higher-risk AD program rather than other lower-risk assets in the R&D pipeline. However, most are encouraged by the decision to advance the program into Phase 3, and note an upbeat tone from management on the call. Analysts look for more detailed data at AAIC in July. The CELIA results are viewed as a meaningful step forward in the development of tau-targeted therapies for Alzheimer's disease; discussion points to positive read-through to DNLI, ALEC, PRTA, VYGR, and DYN. REGENXBIO lower on DMD update; safety trumps efficacy in AFFINITY trial RGNX announced topline and interim functional data from the pivotal Phase III portion of the AFFINITY DUCHENNE trial of gene therapy RGX-202 in DMD. Trial achieved its primary endpoint with 93% of patients reaching at least 10% microdystrophin expression at week 12. Study also demonstrated stat sig correlation between MD expression and interim functional improvement. Two SAEs were reported (myocarditis and liver injury) - "both were easily managed and resolved within weeks". STAAR Surgical higher on wide Q1 beat STAA reports Q1 EPS $0.10 vs FactSet $0.03 on revenue $93.5M vs FS $78.7M, adj EBITDA $24.4M vs FS $6.9M. Stock upgraded at Wedbush in reaction Aveanna Healthcare higher on Q1 beat-and-raise, easing Home Health worries AVAH reports Q1 EPS $0.18 ex-items vs FactSet $0.13 on revenue $647.9M vs FS $613.2M, adj EBITDA $84.4M vs FS $71.6M. Raises FY26 revenue guidance by $20M / adj EBITDA by $10M, at the midpoints. Earnings in SMID-cap biotech PGEN reported Q1 results including cash & equivalents $56.7M as of 31-Mar. CEO comments: "thrilled with the strength of the PAPZIMEOS launch" TNGX reported Q1 results including cash & equivalents $379.8M as of 31-Mar. Stock downgraded after the print Notable research in Healthcare today Pharma: AMPH downgraded to equal weight from overweight at Wells Fargo Securities (Benjamin Burnett), target cut to $19 from $30 or approx. 4% upside. (FactSet average PT $23; range $19-30) Biotech: ANTX upgraded to outperform from market perform at Leerink Partners (Joseph Schwartz), notes optimism around company's move into polycythemia vera, target increased to $9 from $1 or approx. 109% upside. TNGX downgraded to hold from buy at Jefferies (Maury Raycroft), noting valuation. Target increased however to $27 from $18 or approx. 6% upside. (FactSet average PT $26; range $16-40) ANL initiated buy at Jones (Boris Peaker), target is $22 or approx. 58% upside. (FactSet average PT $28; range $20-46) KLRS initiated outperform at Wedbush Securities (Yun Zhong), target is $17 or approx. 252% upside. (FactSet average PT $19; range $7-27) MPLT initiated outperform at LifeSci Capital (Francois Brisebois), target is $45 or approx. 47% upside. (FactSet average PT $36; range $28-45) MedTech: ILMN upgraded to outperform from neutral at Daiwa (Narumi Nakagiri), target increased to $155 from $128 or approx. 7% upside. (FactSet average PT $141; range $95-175) MDXH downgraded to market perform from outperform at William Blair (Andrew Brackman) STAA *upgraded* to outperform from neutral at Wedbush Securities (Michael Piccolo), target increased to $40 from $26 or approx. 36% upside. (FactSet average PT $27; range $18-33 Post-close news Corporate: DXCM announces that it will work with Elliott Investment Management to identify two new independent board members. Investor Day meeting started at 16:15ET Shares trading +4.6% in the after-hours Regulatory: AARD announced that FDA has placed a full clinical hold on the IND for ARD-101. Follows the voluntary pause previously announced. Shares trading (9.4%) in the after-hours 13F filing: PCVX 800K share stake initiated at Baupost Group during 1Q 2026. Research: RBC Capital Markets (Dan Leonard) resumes coverage of seven names in LST&D. Outperform ratings on BIO, DHR, ILMN, RGEN and TECH. Sector perform on TMO and AVTR On Deck: Conference AUA 2026 (May 15-18) ATS 2026 (May 15-20) Peek Ahead to next week (May 18 - 24) Mon 18-May - HHS/CMS Healthcare Advisory Committee (14:00ET); FDA PDUFA for AZN Enhertu sBLA (DESTINY-Breast11) Tue 19-May - HC Wainwright BioConnect Investor Conference; RBC Global Healthcare Conference (May 19-20) Wed 20-May - Cantor Fitzgerald Oncology Symposium; B Riley Securities Investor Conference (May 20-21); TMO Investor Day; earnings before ROIV, IMVT after BLTE Thu 21-May - ASCO abstract release online (17:00ET); TWST Investor Day StreetAccount Healthcare Reads Biogen Advances Alzheimer's Drug on Suggestion of Benefit (14-May) Bloomberg US cancer clinics scramble to get experimental pancreatic cancer drug (14-May) Reuters 'No drama' Diamantas should serve biotech well as acting FDA chief (14-May) STAT News (Opinion) Trump Taps Don Jr.'s 38-Year-Old Turkey-Hunting Pal to Lead FDA (13-May) Rolling Stone Bill Cassidy risked his legacy. It may not be enough to save his career (13-May) STAT News Why Marty Makary was the worst FDA commissioner in 25 years (12-May) STAT News (Opinion) Makary's Exit From FDA Gives Biotech Hope the 'Circus' Is Over (12-May) Bloomberg This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AARD, ALEC, ALHC, ALLO, AMPH, ANL, ANTX, AVAH, AVTR, AZN, BEAM, BIIB, BIO, BLTE, CAH, CELC, CRVS, DHR, DNLI, DVA, DXCM, DYN, HSIC, ILMN, IMVT, IONS, IVVD, KLRS, MBOT, MDXH, MPLT, NTLA, PCVX, PGEN, PRTA, RGEN, RGNX, ROIV, RVMD, SLDB, SLS, SMMT, STAA, TECH, TMO, TNGX, TWST, VRDN, VYGR...(more)	show story hide story
14-May-2026 02:02	AZN.LN AstraZeneca PLC announces Imfinzi + EV improves EFS & OS in bladder cancer (13766p) High-level results from a planned interim analysis of the VOLGA Phase III trial showed perioperative treatment with IMFINZI (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in event-free survival (EFS) and overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus standard of care. Patients were ineligible for or had declined cisplatin-based chemotherapy. Patients in the comparator arm had a radical cystectomy (surgery to remove the bladder) with or without approved adjuvant treatment. Perioperative Imfinzi plus Imjudo (tremelimumab) in combination with neoadjuvant EV demonstrated a statistically significant and clinically meaningful improvement in EFS and a favourable trend for OS; however, the OS data were not statistically significant at this planned interim analysis and will be formally reassessed at a subsequent analysis. Approximately one in four patients with bladder cancer has muscle-invasive disease, where the tumour invades the muscle wall of the bladder, without distant metastases. As many as 50% of patients are ineligible for cisplatin-based chemotherapy due to impaired renal function or comorbidities. The standard treatment for these patients has historically been radical cystectomy alone but, despite undergoing this major surgery, patients experience high rates of recurrence and have a poor prognosis. Reference Link: Press release	show story hide story
12-May-2026 07:13	AZN.LN AstraZeneca discloses further results from CALYPSO Phase III trial; shows eneboparatide maintained clinical benefits through week 52 with some use of oral supplements (13486p -16p) These late-breaking results were presented today at the European Congress of Endocrinology Positive results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601) met its composite primary endpoint, demonstrating a statistically significant and clinically meaningful normalisation of albumin-adjusted serum calcium (sCa) levels and independence from active vitamin D and oral calcium supplements in adults with chronic hypoparathyroidism (HypoPT) at week 24. In the trial, 31.1% of patients treated with eneboparatide met the composite primary endpoint, achieving sCa within normal range (8.3-10.6 mg/dL) and independence from oral supplements at week 24, compared with 5.9% of patients in the placebo group (eneboparatide: n=41/132; placebo: n=4/68; p=0.0001). Immunogenicity was observed in the majority of patients, resulting in reduced treatment effects in some patients. sCa was controlled with the aid of supplements and up-titration of eneboparatide. CALYPSO also met all key secondary endpoints at week 24, including normalisation of urinary calcium (uCa) excretion in patients with hypercalciuria at baseline. After week 24, patients continued eneboparatide (ENB/ENB group) or were switched to eneboparatide from placebo (PBO/ENB group) for an additional 28-week open-label extension (OLE) period. In the ENB/ENB group, clinical benefits were maintained through week 52 with some use of oral supplements, as assessed by OLE efficacy endpoints. See Related StreetAccount comments: 3/17/2025 3:12:41 AM - AstraZeneca's Phase III CALYPSO trial of eneboparatide meets primary endpoint Reference Link	show story hide story
07-May-2026 10:52	^ESG StreetAccount ESG Press Digest Summary ESG-related regulations continue be streamlined in US and EU, with the SEC proposing semi-annual corporate filings and a formal end to climate disclosure rules, while the EU trims its ESRS framework, drafts changes to SFDR, and proposes dropping leather goods from EUDR requirements. The IEA's Global Methane Tracker report detailed that the energy sector accounts for roughly 40% of methane emissions from human activity. Antitrust enforcement in focus in social and governance; Alphabet (GOOGL) seeks to appease the EU and avoid additional antitrust fines by offering to adjust how it displays news across its search engines while card issuers, PayPal (PYPL) face anticompetition probe in the UK. Market In the US, corporate disclosures in focus after the SEC formally proposed a rule change that would permit semi-annual corporate filings on a new 10-S form in lieu of traditional quarterly reporting on 10-Qs, though a full annual report would still be required. Meanwhile, the agency has proposed to formally end Biden-era corporate climate disclosures rules, which were never implemented. Proxy advisors facing continued challenges at state level, with Glass Lewis following ISS in pursuing legal action against an upcoming Indiana law which would require written financial analysis to support recommendations against management. In the EU, the European Commission finalized updates to its corporate sustainability reporting rules, ESRS, opting against alignment with ISSB standards, meaning companies may have to undertake additional reporting in order to meet requirements for both frameworks. Meanwhile, draft changes to SFDR rules, which would strengthen anti-greenwashing provisions, have been put forward as a starting point for legislative talks; EU member states are debating a carveout for sovereign bonds in transition funds, aiming to table a draft compromise on 18-May. The Commission released its simplification review for anti-deforestation rules, saying efforts have already cut compliance costs for companies by 75% while proposing the exemption of leather imports. Elsewhere, investor engagement initiative CA100+ has discontinued it benchmark indicator on climate-disclosures assessing alignment with TCFD and ISSB standards, citing regulatory developments mandating such disclosures. Environment In global news, the IEA concluded that methane emissions from the energy sector remained at near record levels in 2025; Australian coal mines' methane emissions are more than double what officials have estimated. The EU is drafting plans to suspend penalties for oil and gas companies that breach its methane emissions law. An auction in Germany began to offer up to €5B in subsidies to help heavy industries cut carbon emissions. Thailand rescinded an agreement with Cambodia for joint offshore energy exploration following border conflicts. Environmental groups say investmen ts of Taiwan government's four major funds are misaligned with Taiwan's net zero carbon emissions goal. In the US, onshore wind developments have been stalled by the Dept. of Defense in the latest effort to stymie US wind energy. CA officials are probing the Trump administration's deal with Golden State Wind to cancel a project off the state's coast. Social & Governance In tech regulation, Alphabet (GOOGL) offered concessions to EU regulators in a news search antitrust case. Meta facing probe in Ireland over consumer right to select content feeds on social media platforms, and pressure domestically as Senate committee backs bill to stop minors from using chatbots. The UK FCA opened an antitrust probe into Mastercard (MA), Visa (V), and PayPal (PYPL) while Morgan Stanley under investigation in the US over allegations it use unlicensed junior bankers in Hungary on deals. In healthcare and consumer safety, the FDA scrutinized AstraZeneca (AZN) over a cancer drug and also proposed policies that would exclude Novo Nordisk (NVO) and Eli Lilly (LLY) from bulk compounding lists. Bayer (BAYN.GR) faced judicial pushback as judge criticizing a $72.5B Roundup settlement proposal. In labor, Samsung Biologics (207940.KS) estimated strike-related losses exceeding $100M. QBE Insurance (QBE.AU) faced investor pressure over climate risk disclosures. US regulators targeted beef processors in an expanding antitrust investigation. Elsewhere, Paramount Global (PARA) and Warner Bros. Discovery (WBD) hit with consumer lawsuit over their proposed deal. If you are interested in company level ESG level alerts for your portfolio(s) please click here. For less frequent updates, click here to sign up for summary content including: daily headlines, weekly ESG press and company digests, and monthly Round Up pieces. Related: 207940.KS, AZN, BAYN.GR, GOOGL, MA, NVO, PSKY, PYPL, QBE.AU, V, WBD...(more)	show story hide story
05-May-2026 21:36	StreetAccount Sector Summary - China Healthcare April Recap April in Review: Hang Seng Innovative Drug (7.14%) vs Hang Seng Listed Biotech (5.07%) vs Hang Seng Index 1.91% CSI300 Healthcare (1.97%) vs CSI300 6.21% Trending topics: On 20-Mar, the core patent for Novo Nordisk's semaglutide in China expired. This means that pharmaceutical companies in China can now use the molecular structure of semaglutide for production. Previously stalled due to patent protection, the marketing applications for domestically produced semaglutide have now entered the formal review and approval process. By the time, China's National Medical Products Administration (NMPA) had accepted at least 10 applications for domestic semaglutide biosimilars, with another 10-plus projects still in phase III study (nature-scientific reports, ChiCTR). The market is eagerly waiting to see which company's biosimilar will be the first to receive approval. However, a month has passed with no updates from the regulator side. To date, not a single semaglutide has been approved yet. Jiuyuan Gene Engineering revealed the reason in FY report: their JY29-2 (jiyoutai) involves data protection requirements under an agreement with another country, the review of this product is thus suspended currently. This detail sparked widespread discussion in the market (Jianshiju, Pharmacube). Industry insiders concluded that Novo Nordisk likely leveraged the China-Switzerland Free Trade Agreement (FTA) to extend semaglutide's protection period by another year. If the claim holds true, then the launch of domestic semaglutide biosimilars will be delayed until after Apr-27. Those having filed for marketing such as Jiuyuan Gene, Livzon and Huadong Medicine will have to wait another year. The cost is obvious. StreetAccount notes that according to NMPA, when semaglutide was approved in China in April-2021, the marketing authorization holder was not its Danish parent company, Novo Nordisk A/S, but rather a Swiss-registered subsidiary, Novo Nordisk Pharma AG. Highly likely that with this very detail, the industry quickly linked the current situation to the China-Switzerland FTA (signed in 2013 and into force in 2014) data protection regulation, based on which both contracting parties shall protect undisclosed pharmaceutical test data in accordance with the TRIPS agreement, and for at least six years from the date of marketing approval, other applicants are prohibited from relying on such data to apply for market approval. Therefore, semaglutide, who received approval in Apr-21, will have its data protection window extended until April-27. This may explain why, despite the patent having already expired, the market still has to wait another year (J Public Health Policy, European IP Review) Jiuyuan Gene recently told reporters from Cailian Press, who called in as investors, that the core reason for not obtaining the approval certificate is that relevant data is still under protection. Meanwhile, Livzon Group confirmed that, due to the FTA, the company's semaglutide approval process is currently suspended. Sector performance: Looking back at the pharmaceutical industry in 2025, Chinese drugmakers are facing both opportunities and challenges. On one hand, centralized procurement and strong regulatory oversight continue as the norm; on the other hand, this year also marks a milestone year for Chinese innovative drugs going global. China has surpassed the United States to become the world's top country in terms of out-licensing deal value for innovative drugs. Leading pharmaceutical companies such as BeOne, Hengrui, Hansoh and CSPC have made significant breakthroughs in out-licensing deals. Compared with previous years: Those recognized for high innovation such as Hengrui, BeOne, Hansoh and Sino Biopharmaceuticals demonstrated stronger growth resilience. CR Sanjiu which focuses primarily on self-medication drugs and is less affected by centralized procurement, also maintained solid growth through continuous M&As. Fosun, CSPC and Shanghai Pharma continued to fact pressure. Among them, CSPC's finished drug business revenue declined by 13.3% y/y, as the impact of centralized procurement persists R&D investment: among the eight leading domestic pharmaceutical companies, BeOne ranks first, spending CNY15.508B, with an R&D intensity of 40.57%. Hengrui invested CNY8.724B (27.58%), followed by Sino-Biopharm (CNY6.317B, 19.8%), Fosun Pharma (CNY5.913B, 14.19%), CPSC (CNY5.809B, 28.2%), Hansoh, Shanghai Pharma and CR Sanjiu. According to SWS industry classification, in the A-share listed pharmaceutical and biotech sector, 18 companies had R&D expenses exceeding CNY1B in FY25 (16 pharmas, 2 medical devices). 46 had expenses exceeding CNY500M. 40 out of the top 100 saw a decline in R&D investment, as companies adjust their strategies in response to changing market competition dynamics and their own strategic priorities. StreetAccount notes that investment among market leaders continued to grow, with particularly faster growth seen among innovative drug companies and those undergoing transformation toward innovation Intense competition is concentrated in CCV diseases and oncology sectors. The oncology area has become the primary growth driver for most companies, with BeOne, Hansoh, Hengrui, Sino-Biopharmaceuticals and Fosun Pharma all driving a relatively high share of their revenue from oncology; in the CCV space, two paths - M&A and innovation are emerging. CR Sanjiu, through its acquisition of Tasly, achieved explosive growth in its prescription drug business, which is centered on CCV. Drugmakers such as CSPC and Fosun Pharma, however, are facing pressures from reimbursement price reduction or market competition (news.cn, SinaFinance, Mic366, yaozhi, STCN, Global Pharma Navigator, cnpharm) By 21-Apr, according to incomplete statistics, among innovative biotechs listed on the HKEX and China's STAR Market, at least 17 were profitable in 2025, an increase of nearly 55% compared with 2024. BeOne, Innovent Biologics, Innocare, Lepu Biotech, Hua Medicine, Qyuns Therapeutics, and Mabwell Pharmaceuticals all made it across the break-even line for the first time. Meanwhile, Henlius, Hutchmed, Allist, Betta, HBM Holding, Shanghai Yizhong, and Sunshine Guojian have already maintained their profitability status for more than three years. Some made their profits thicker by relying on blockbusters, and others pushed net profit into positive territory through licensing collaborations, contract-related earnings, or one-time revenue recognition (company reports, mic366, yaozhi, pharmacube,21jingji) BeOne, Innovent and InnoCare are most closely watched in the industry as they finally turned income statement profitable after years of investment, among which InnoCare achieved its first full-year profitability as it marked its 10th anniversary Time matters: the average time to first profitability was about 11.4 years, reflecting the reality that innovation drug development typically requires a decade, plus of R&D and commercialization building Core driver is products: 2/3 of the profitable firms relied on product sales as the main profit source, especially those with blockbusters. For example, BeOne's product revenue was $5.28B, accounting for more than 90% of total FY revenue (likewise for Innovent and Mabpharm). Brukinsa generated global sales of $3.93B, up 48.6%, making it the largest contributor to the company's revenue. It has been approved in more than 75 markets worldwide with sales in US reaching $2.8B. With such momentum, turning a profit is just a matter of time. At the same time, TEVIMBRA recorded $737.3M in global sales. Other products that drove profitability include orelabrutinib tablets of InnoCare, Elunate of Hutchmed, Allist's third generation EGFR-TKI Airuikang (furmonertinib), to name a few. Profitablility vs sustainability: among the seven firms that reported first-time profitability, five saw their stock prices rise one week later, with gains ranging from 1.46% to 19.61%. Hua Medicine, Innovent, and Lepu each rose by more than 10%. However, we see pullbacks and declines in multiple drugmakers a week or even a month later. BeOne saw its stock drop 17% one week later, with a cumulative decline of over 23% after one month. Mabpharm also fell by double digits one week after announcing results. Only Lepu continued to rise, expanding its gains to 26.6%. Apparently what ultimately matters for the market are the source of earnings, the sustainability of growth, and whether the valuation matches expectations StreetAccount notes that market is concerned that some companies' BD momentum, once slows down, will raise the question of whether profitability can continue to grow relying on product sales alone; others moved from losses to profit because the turnaround depended on BD-driven income-such as licensed-in/out deals that served as the direct catalyst (i.e. CNY723.4M out of the total CNY807M sales of Qyuns Therapeutics was contributed from BD activities). Since these earnings are often one-off, they are inherently non-replicable, making long-term stable profitability difficult to sustain. Regulatory actions: On 15-Apr, the Chinese government rolled out guidelines on improving the drug price formation mechanism, with the aim of keeping drug prices within a reasonable range. These guidelines, issued by the State Council, stress the need to refine the market-oriented mechanism for drug price formation, propose optimizing the initial pricing mechanism for newly marketed drugs, including innovative drugs. StreetAccount notes that both mainland China A-shares and Hong Kong-listed innovative drug stocks have surged the next day following the announcement of the guideline. A-share pharmaceutical index and the innovative drug index both rose by more than 2%. More than 25 stocks gained over 5%. In Hong Kong, the innovative drug index jumped 3.94%, and several market leaders increased by more than 7%. The document said patented innovative drugs would be supported through value-based pricing, while the prices of generic drugs will be reduced via market competition and volume-based procurement. StreetAccount notes that reasonable pricing is the foundation for pharmas to recoup their R&D costs and continue investing in innovation. Previously, strict price caps limited the pricing room for most novel drugs after they entered the market, making it difficult to realize their innovative value and greatly undermining pharma's motivation to develop and invest in R&D. It allows biotech companies to set higher prices in the private market, including private hospitals, retail pharmacies, and online channels while urging commercial insurance to play a bigger role in financing innovative drugs Drug development and approvals: According to Yaozhi-database, In 2026, the Chinese market is expected to complete the review of 103 new drug registration applications. Based on historical data showing an approximately 80% domestic novel drug approval success rate, it is estimated that this year, 82 new drugs may be approved for market launch. Drug types: Several major first-in-class drugs are expected to launch in China in 2026. For example, Amgen's tarlatamab (CD3/DLL3 bispecific T-cell engager): the drug received FDA accelerated approval in May-24 for second-line treatment of adults with ES-SCLC that has progressed after platinum-based chemotherapy, and it is the first approved DLL3-targeting therapy in the world. The drug won approval from China's NMPA this month indicated for adults in ES-SCLC (BeOne) ; AstraZeneca's lupus drug anifrolumab (Saphnelo, type I interferon pathway targeting) is under regulatory review in China (Yicai): it is the first type I interferon pathway targeted therapy approved for SLE. Therapeutic areas: Oncology/autoimmune diseases are popular therapeutic areas. Domestic oncology R&D has entered a more refined era of targeted therapy. Taking cholangiocarcinoma as an example, FGFR inhibitors have become a key focus of development. NDAs include drugs such as tinengotinib, tasurgratinib and fanregratinib tartrate. It is also worth noting that, in oncology, ADCs and bispecific antibodies are reshaping the landscape for solid tumor treatment. GSK's BCMA-targeted ADC, Blenrep has already been approved in multiple countries worldwide for the treatment of multiple myeloma. For Her2-targeted therapies, anbenitamab (KN026) has shown strong clinical significance in two major cancer types - gastric cancer and breast cancer. Target/checkpoints: among the 103 drug candidates, two classic oncology targets - EGFR and Her2 remain popular especially in high-incidence malignancies such as lung cancer and breast cancer. In addition, GLP-1R is also poised for upcoming launches, with two innovative GLP-1R drugs from Changshan Pharma and CSPC; there's also signs of R&D crowding in targets such as IL-4RA and IL-17 Drugmakers: local pharma companies are already the main force behind drug launches in 2026. Traditional large pharmaceutical companies are shifting toward the innovation-drug track, and Jiangsu Hengrui stands out as a role model. Hengrui bags several innovative drugs that may launch in 2026, including ruzinurad, a highly selective URAT1 inhibitor for gout treatment and oral GnRH antagonist SHR-7280 for assisted reproduction. At the same time, MNCs in China are steadily accelerating the introduction and localization of major global innovative drugs. Companies such as AstraZeneca, Novartis, and GSK are making efforts in shortening the lag between global innovation approvals and market entry in China (Sina-Medicine, CDE-NMPA, NMPA announcement on accelerating approvals for overseas-marketed drugs addressing urgent clinical needs) Clinical updates: Sino Biopharmaceutical completes enrollment of the first patient in phase III study of tecotabart vedotin (LM-302) for GC/GEJC adenocarcinoma (link); Innovent Biologics presents preclinical data of IBI3055 targeting autoimmune diseases (link); Sino Biopharmaceutical presents pre-clinical data for LM-364 and LM-338 at AACR 2026 (link) IND: Livzon Pharmaceutical Group obtains NMPA clinical trial approval for P-CAB JP-1366 tablets for helicobacter pylori (link); Jiangsu Hengrui receives NMPA trial approval for HRS9531 injection in adolescents aged over 12 and under 18 years who are overweight or obese (link); Shanghai Allist Pharmaceuticals receives approval from NMPA to launch clinical trial for additional indication of furmonertinib tablet vs osimertinib or afatinib as first-line treatment in patients with locally advanced or metastatic NSCLC harbouring rare EGFR P-loop and aC helical compression (PACC) mutations (link); NMPA approves trial of Changchun High-Tech Industry unit's GenSci161 for NIU (link); NMPA approves phase 1 trial of Henlius Biotech's HLX05-N for mCRC (link) Designations: NMPA includes Jiangsu Hengrui's SHR-A1811 into breakthrough therapy product list for the treatment of HER2-positive recurrent or metastatic breast cancer patients (link); NMPA includes Hengrui's SHR-A2102 into breakthrough therapy product list in recurrent or metastatic cervical cancer (link); Hansoh Pharmaceutical Group receives NMPA breakthrough-therapy-designation for ADC HS-20093 in metastatic castration-resistant prostate cancer previously treated with novel endocrine therapy and taxane-based chemotherapy (link); NMPA grants priority review for Hutchmed's NDA for sovleplenib (HMPL-523) to treat wAIHA (link) NDA acceptance: China's NMPA accepts submission of Simcere Pharmaceutical's NDA for rademikibart for atopic dermatitis (link); Bayer AG's Asundexian Marketing Application accepted in China for stroke prevention after positive Phase III results (link); Haisco Pharmaceutical Group receives NMPA acceptance notice for HL231 for treatment of chronic obstructive pulmonary disease (link) NDA approvals: AstraZeneca/Pfizer receives NMPA approval for IMFINZI in combination with IMJUDO as first-line treatment of advanced or unresectable HCC (link); Immunotech Biopharm's conditional new drug application for EAL rejected by NMPA (link); RemeGen obtains NMPA new indication approval for RC48 combined with toripalimab for urothelial carcinoma (link); NMPA approves marketing of combination treatment of Sino Biopharmaceutical's benmelstobart and anlotinib for ASPS (link); LEO Pharma announces NMPA approval of Enstilar to treat adult patients in China living with plaque psoriasis (link) License-in/out, co-development, M&A On 10-Apr, IASO Bio establishes international partnership with Instituto Butantan to develop CAR-T cell therapy for hematological cancer in Brazil. The technology uses the patient's own immune cells to treat the disease. Under the agreement, the cells will be developed and manufactured at the Advanced Therapies Center of São Paulo (Nutera-SP), a facility coordinated by Butantan that has specific equipment for cell therapies On 20-Apr, Biogen enters into agreement with TJ Biopharma for felzartamab assets in the greater China region. Under the terms of the agreement, TJ Bio will receive a $100M upfront payment and is eligible to receive up to $750M in potential commercial and sales milestone payments, for a total potential consideration of up to $850M, plus mid-single-digit to low-double-digit percentage of royalties on potential net sales in the Greater China Region. The upfront payment is expected to be recorded by Biogen as an Acquired In-Process Research and Development expense in Q2. With this transaction, Biogen will assume responsibilities for milestone payment and royalty obligations under the prior MorphoSys (a wholly-owned subsidiary of Novartis) licensing agreement. On 17-Apr, Xcovery Holdings, Inc., (sub of Betta Pharmaceuticals) announced an agreement with EVERSANA, a leading provider of commercialization services to the global life sciences industry, to support and expand the U.S. commercial launch of ENSACOVE™ (ensartinib), the company's novel therapy for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Under the agreement, EVERSANA will provide comprehensive end‑to‑end commercialization services for Xcovery, including but not limited to agency of record, market access, commercial and medical teams to support the company's strategy to make Ensacove available to more patients across the U.S. On 16-Apr, Evive Biotech announced a strategic agreement granting Molteni Farmaceutici exclusive rights to commercialize RYZNEUTA (efbemalenograstim alfa) in Italy and Poland. Under the terms of the agreement, Molteni Farmaceutici will lead regulatory, market access, and commercialization activities across the licensed territories, capitalizing on its established leadership and track record in oncology supportive care. RemeGen receives $650M (CNY4.43B) upfront payment from AbbVie under RC148 exclusive license agreement. On 12-Jan, the company entered into an exclusive license agreement with AbbVie for RC148, which became effective on 10-Mar. Pursuant to the agreement, AbbVie would obtain exclusive rights to develop, manufacture and commercialize RC148 outside Greater China. In consideration, the company would receive an $650M upfront payment and is eligible to receive additional development, regulatory and commercial milestone payments of up to $4.95B, as well as tiered double-digit royalty payments based on net sales of RC148 outside Greater China. Hansoh Pharmaceutical Group enters novation, transfer agreement with KiOmed and Jiangsu Hengrui; transfer price CNY131M. Pursuant to the agreement, the Hansoh Parties shall assign and transfer all of their rights, duties and obligations under the KiOmed license agreement to Hengrui who shall accept, perform and discharge all liabilities and obligations and be substituted in place of the Hansoh Parties as the licensee thereunder, with KiOmed consenting to such substitution. Related: 000538.CH, 000661.CH, 000999.CH, 1093.HK, 1177.HK, 13.HK, 1513.HK, 1530.HK, 1801.HK, 2096.HK, 2142.HK, 2157.HK, 2181.HK, 2196.HK, 2509.HK, 2552.HK, 2607.HK, 300558.CH, 3692.HK, 600276.CH, 603259.CH, 6618.HK, 688578.CH, 6990.HK, 9969.HK, 9995.HK, AZN.LN, BIIB, GSK, NOVN.SW, NOVO.B.DC, ONC...(more)	show story hide story
05-May-2026 08:08	CVS CVS Caremark expands biosimilar adoption through formulary updates ($82.01) CVS announced updates to its most common commercial template formularies that will expand the use of lower-cost biosimilars across multiple therapeutic categories, including changes effective 1-Jul-26, that will prefer interchangeable biosimilars over select reference brands. As part of these updates, CVS Caremark will transition from STELARA (ustekinumab) on its most common commercial template formularies to preferring lower-cost, interchangeable biosimilar alternatives- PYZCHIVA and YESINTEK . With this change, most members will pay $0 out-of-pocket for their therapy. In addition to changes involving Stelara, CVS Caremark is expanding biosimilar coverage across select specialty categories, including treatments for multiple sclerosis and rare blood disorders, such as biosimilar alternatives to therapies like TYSABRI (with biosimilars BRIUMVI and TYRUKO ) and SOLIRIS (biosimilar EPYSQLI ). Reference Link: Press release Related: 000230.KS, 0126Z0.KS, 532523.IN, AZN, BIIB, JNJ, RPRPX, TEVA, UCB.BB...(more)	show story hide story
01-May-2026 08:09	StreetAccount Themes Headlines (1-May) Iran Oil prices little changed despite US-Iran tensions intensifying; Tehran threatens painful response should US renew attacks, vows to protect nuclear and missile capabilities; UAE says Iran cannot be trusted over Hormuz Trump backs extended naval blockade, betting it will collapse Iran's economy Chevron reported strong Q1 beat (though profits down from last year) due to war-driven surge in oil prices; CEO warns global energy systems are under extreme stress Exxon beat Q1 estimates, though unadjusted profit dropped to five-year low on shipment disruptions AI SanDisk, Western Digital post strong quarterly results as data center build out helps drive SSD/HDD demand; stocks dipped in extended trading in apparent profit-taking OpenAI CEO says company is meeting objectives, seeing big demand; follows recent reports company was not meeting internal targets Nvidia, Microsoft, Reflection AI, AWS all entered new agreements with Dept. of Defense to expand AI tools for classified military networks Huawei sees strong demand for latest Ascend chip; poised to capture market share from Nvidia Memory Apple warned of intensifying memory constraints; expects increasing impact on business from memory prices Mobility Tesla sales rebound continues in France, Denmark, Netherlands in April; BYD chipping away at market share Rivian says US DoE loan to be about $2B lower than previously approved, though funds will be drawn earlier than planned Nissan cancels plans for electric SUV factory in Mississippi amid waning US EV demand Other Themes SEC approves Nasdaq proposal to trade stock market prediction instruments tied to major index First Solar reports rise in quarterly sales, boosted by demand from third parties in India Study says Novo Nordisk Wegovy helped people with alcoholism reduce their drinking ESG CA100+ discontinues benchmark climate-disclosure indicator assessing alignment with TCFD, ISSB standards; cites regulatory developments Bayer's $7.25B Roundup cancer settlement criticized by US judge who fears ruling may legally bind future claimants Consumers sued in federal court to block Warner Brothers acquisition of Paramount; says it would limit competition FDA votes against approving AstraZeneca's new experimental cancer drug For the latest updates on this story and all top news, please visit the Themes Today's Top News page. Related: 7201.JP, AAPL, AMZN, AZN.LN, BAYN.GR, CVX, FSLR, MSFT, NVDA, NVO, PSKY, RIVN, SNDK, TSLA, WBD, WDC, XOM, +HUAWEI, +OPENAI, +REFLECTIONAI...(more)	show story hide story
01-May-2026 07:24	Banks, utilities and healthcare the main UK underperformers; media outperforms: European equity markets closed Friday, except UK stocks which are trading lower, with defensives and rate-sensitive pockets lagging. Media provided modest offset, supported by Pearson (PSON.LN) after solid Q1 update, with underlying sales +4% and guidance reaffirmed. Banks underperformed, led by NatWest (NWG.LN) post-results. While FY26 income guidance was nudged to top end of the £17.2-17.6B range, this still sits below consensus, with Shore Cap flagging downside risk to estimates following an ex-notables Q1 miss. Health Care the weakest sector, dragged by AstraZeneca (AZN.LN) after an FDA advisory panel failed to back the benefit-risk profile of camizestrant in combination therapy-raising uncertainty around the asset's regulatory path. Utilities also lagged with United Utilities (UU.LN) falling on a discounted equity placing, while Citi downgraded both UU.LN and Severn Trent (SVT.LN), citing limited near-term valuation upside and growing sensitivity to UK rate uncertainty. In Mining, spotlight on Rotork (ROR.LN) Q1 mixed with order intake declining while revenues grew modestly vs same period last year. For the latest updates on this story and all top news, please visit the Europe Today's Top News page. Related: AZN.LN, NWG.LN, PSON.LN, ROR.LN, SVT.LN, UU.LN...(more)	show story hide story
01-May-2026 06:25	^EUSECTORS StreetAccount Summary - EU Sector Highlights: FTSE 350 (0.6%), Media outperforms due to Pearson; Banks weighed down by NatWest Note: Most European markets closed today for Labor Day holidays with the exception of UK and Denmark UK Sector performance (vs FTSE 350) Media +0.9% outperforming with Pearson (PSON.LN) +2.2% up on back of its Q1 trading update; underlying sales +4%; on track to deliver FY26 guidance. Banks (1.0%) underperforming with NatWest (NWG.LN) down (3.7%) following Q1 results with mixed takeaways. While the bank upgraded FY26 income guidance to the top end of its previously guided range of £17.2 - 17.6B, this was noted to be below current consensus. Analysts at Shore Cap mention this suggests potential modest downside risk to consensus income forecasts, particularly given the Q1 miss at the ex-notable level. Healthcare (1.9%) worst performer with AstraZeneca (AZN.LN) down (2.5%). FDA Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote in favour of the benefit risk profile of AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor. Utilities (0.9) underperforming. United Utilities (UU.LN) (3.1%) placing result: 60.6M new shares priced at 1,312p/share through Deutsche Bank and J.P. Morgan Securities. Separately, Citi downgrades both UU.LN and Severn Trent (SVT.LN) (3.0%) to neutral from buy. Citi says it continues to see an unjustifiable valuation gap (P/E, dividend yield, premium to RAB) between UK regulated energy networks versus water and expect this to close through to the end of this decade. Despite this relative preference, firm now sees limited absolute valuation upside on a 12m view given much of the RAB growth is backend loaded for the waters. Citi also sees increasing near-term risk around UK rates give the uncertain political outlook. Related: AZN.LN, NWG.LN, PSON.LN, SVT.LN, UU.LN	show story hide story
01-May-2026 03:55	StreetAccount Summary - Trading higher/lower: EU mid-morning Trading Higher: +10.0% PRTC.LN (PureTech Health £1.40, +0.13) -- founded entity Seaport Therapeutics announces pricing of upsized initial public offering +5.7% ECEL.LN (Eurocell £1.11, +0.06) +5.4% PSON.LN (Pearson £11.41, +0.58) -- Q1 trading update +5.0% AOJ.B.DC (Brødrene A & O Johansen DKK90.90, +4.30) -- Q1 earnings +4.7% SCHO.DC (Schouw & Co DKK675.00, +31.00) -- Q1 earnings; BioMar announces intention to IPO on Nasdaq Copenhagen +3.9% GLE.LN (MJ Gleeson £2.38, +0.09) -- trading update +3.8% RWS.LN (RWS Holdings £0.91, +0.03) +2.2% ROR.LN (Rotork £3.17, +0.07) -- Q1 trading update +1.9% RCN.LN (Redcentric £1.33, +0.03) -- completes previously announced sale of Redcentric Data Centre to Stellanor Datacenters Group +1.7% GN.DC (GN Store Nord DKK97.18, +1.66) Trading Lower: -14.5% PRO.LN (ProService Building Services Marketplace plc £0.03, -0.01) -- FY trading update -12.0% STX.LN (Shield Therapeutics £0.07, -0.01) -- Q1 earnings -4.5% FLS.DC (FLSmidth & Co. DKK451.80, -21.20) -- investigates potential non-compliance with sanctions regulations and takes steps to enhance compliance measures -3.3% FRES.LN (Fresnillo £31.36, -1.08) -3.2% NWG.LN (NatWest Group £5.64, -0.19) -- Q1 earnings -3.0% UU.LN (United Utilities Group £14.10, -0.44) -- announces placing result; Citi downgrade -2.4% SVT.LN (Severn Trent £31.96, -0.79) -- Citi downgrade -2.4% GENL.LN (Genel Energy £0.53, -0.01) -2.0% PAGE.LN (PageGroup £1.32, -0.03) -- Citi downgrade -1.9% AZN.LN (AstraZeneca £137.18, -2.66) -- ODAC) did not reach a majority vote in favor of the benefit risk profile of group's camizestrant; PineTree Therapeutics (private) announces that the company exercised option for bispecific degrader program -1.8% IQE.LN (IQE £0.42, -0.01) -1.6% PNN.LN (Pennon Group £5.40, -0.09) -1.5% ACSO.LN (accesso Technology Group £2.61, -0.04) -- CEO to step down Related: ACSO.LN, AOJ.B.DC, AZN.LN, ECEL.LN, FLS.DC, FRES.LN, GENL.LN, GLE.LN, GN.DC, IQE.LN, NWG.LN, PAGE.LN, PNN.LN, PRO.LN, PRTC.LN, PSON.LN, RCN.LN, ROR.LN, RWS.LN, SCHO.DC, STX.LN, SVT.LN, UU.LN...(more)	show story hide story
01-May-2026 02:06	AZN.LN FDA Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote in favor of the benefit risk profile of AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (13948p) The FDA's (FDA) Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote in favor of the benefit risk profile of AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumours have an emergent ESR1 mutation, based on the SERENA-6 Phase III trial. The Committee voted 3 to 6. In July 2025, the FDA accepted the New Drug Application (NDA) for camizestrant in combination with a CDK4/6 inhibitor based on positive results from the pivotal SERENA-6 Phase III trial presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The New England Journal of Medicine. The FDA granted Breakthrough Therapy Designation (BTD) for the camizestrant combination in this setting in May 2025. The FDA is not bound by the Committee's guidance but takes its advice into consideration. AstraZeneca will continue to work with the FDA as it completes its review of the application. Reference Link: Press release	show story hide story
30-Apr-2026 21:44	AZN.LN AstraZeneca issues press release on FDA ODAC panel's vote supporting TRUQAP sNDA in prostate cancer (13948p) StreetAccount reported the vote earlier. Editor's note (added at 05:23 ET/10:23 BST): We have deleted a duplicate of this comment that was posted at 02:02 ET/07:02 BST. Reference Link: Press release See Related StreetAccount comments: 4/30/2026 4:44:27 PM - FDA ODAC panel votes 7-1-1 to support AstraZeneca's TRUQAP sNDA in prostate cancer	show story hide story
30-Apr-2026 18:09	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished split yet higher overall on Thursday. Advancers beat decliners by more than 2:1 on the XLV. Healthcare +2.20% vs S&P 500 +1.02%. Most major health groups ended materially higher on the session. Gainers led by Pharma, with MedTech and Biotech not far off. DRG +3.73% for its best one-day gain this year (and in 7 months). Payers and providers ended a tad weaker amidst heavy earnings and intrasector rotation. MCOs saw yet another MLR beat, although shares of CI pressured (0.6%) on the ACA marketplace exit. Large-cap earnings reports were scattered throughout the sector, however LC drugmakers highlight the earnings calendar, and LLY +9.8% top of the XLV following today's big beat-and-raise quarter, shares jumping higher on the call with bullish commentary on the Foundayo launch. BMY +5.2% and MRK (1.6%) the other two pharma reports with varying success. CAH (4.9%) leading decliner on the XLV following fiscal Q3 beat and raise (rev just reaffirmed). INCY (3.9%) pullback on unusual volume; shares red similar YTD. Avalyn Pharma (AVLN) the eighth biotech IPO in CY2026, off to a strong debut on the Nasdaq. President Trump nominates another Fox News contributor as the next Surgeon General, after vaccine stance beset Means' nomination. Merck reported Q1 earnings muddled by an acquisition-related charge, however revenue beat widely with strength in Keytruda, Gardasil, and Winrevair. Guidance revision viewed underwhelming. Bristol Myers middle of the fairway with a beat-and-reaffirm, although legacy products carried Q1. Macro Earnings seemingly the big tailwind today as Q1 metrics continue to look very strong. Mag 7 names in focus and while takeaways mixed, results supportive of the most important theme for the market: insatiable compute demand and massive capex. However, this theme has already provided a meaningful tailwind for the market in recent weeks with growth and momentum up ~20% in April. Elsewhere, oil and rates pullback another positive for stocks today. However, nothing specific behind the move amid continued Middle East stalemate and ramp in energy supply disruption concerns. Busy day of economic data and leading central bank decisions have not seemed to have much impact on equities. While there were a number of moving pieces, data still fit with the solid macro backdrop narrative. No notable broader market impact from month-end dynamics, which had been flagged as a headwind. Looking ahead, May brings more positive seasonality with the S&P up nearly 1.5% on average over the last ten years. Corporate buyback activity also expected to pick up. Notable Gainers +63.8% AVLN (Avalyn Pharma): day one, biotech IPO #8 +27.5% NVCR (Novocure): earnings +22.8% GKOS (Glaukos): earnings +19.2% QURE (uniQure NV): UK regulatory update in HD; best performer on XBI +16.9% ERAS (Erasca): follow-through, shares (50%) WTD +10.7% PRCT (PROCEPT BioRobotics): earnings +10.1% ZBIO (Zenas BioPharma): insider buying (CEO) +9.8% LLY (Eli Lilly): earnings; bulks list proposal; best performer on XLV +9.6% GRAL (GRAIL, Inc.): on below average volume +7.7% INDV (Indivior Pharmaceuticals): earnings +7.6% PODD (Insulet): responds to FDA misstatements on recall; shares were (13%) yesterday +5.2% BMY (Bristol Myers Squibb): earnings +4.8% NVO (Novo Nordisk): sympathy to LLY; bulks list proposal +4.4% GH (Guardant Health): FDA panel rejects AZN treatment in breast cancer +4.0% BAX (Baxter International): earnings +3.6% ABBV (AbbVie): upgraded at BofA +3.4% NVS (Novartis): update on US manufacturing +3.2% HIMS (Hims & Hers Health): bulks list proposal +3.0% SMMT (Summit Therapeutics): STAT News story on Akeso at ASCO Notable Decliners -24.3% OPCH (Option Care Health): earnings -15.4% WAY (Waystar Holding): earnings -8.4% ACHC (Acadia Healthcare): earnings -7.1% MANE (VeraDermics, Inc.): secondary offering priced -7.0% TFX (Teleflex): appoints new CEO -4.9% CAH (Cardinal Health): earnings; worst performer on XLV -3.9% INCY (Incyte): worst performer on XBI; on heavy volume; shares +1% WTD -2.6% BIIB (Biogen): follow-through, shares were +6% yesterday Earnings in large-cap pharma LLY reports Q1 non-GAAP EPS $8.55 vs FactSet $6.97 on revenue $19.80B vs FS $17.82B. Raises FY26 EPS guidance by $2/shr, revenue guidance by $2B, and margin by 100bps. Mounjaro $8.66B vs SA $7.26B, +125.5% y/y; Zepbound $4.16B vs SA $4.04B, +79.9% y/y; Jardiance $1.11B vs SA $799.8M, +9.8% y/y. Quick Take: Discussion following the print is broadly positive, highlighting notable strength in Mounjaro and Zepbound, which drove the EPS beat, though this was partially offset by lower realized prices across the portfolio. Discussion also points to share gains across the GLP-1 portfolio, with particular strength in Mounjaro's international sales and more favorable pricing in the U.S. Commentary suggests guidance points to sustained momentum, reinforcing the GLP-1 franchise's leading position. MRK reports Q1 EPS ($1.28) ex-items vs FactSet ($1.47) -- includes charge of $3.62 for the acquisition of Cidara-- on revenue $16.29B vs FS $15.85B. Raises FY26 EPS guidance 2.5c at the midpoints, raises low-end of FY26 revenue guidance by $300M. Keytruda $8.03B vs StreetAccount $7.78B, +11.5% y/y; Winrevair $525M vs SA $487.0M, +87.5% y/y. Quick Take: Initial takeaways view the results as broadly positive, with Keytruda strength easing concerns around softness. Winrevair, Animal Health, and Gardasil strength also attributed to the top-line beat, partly offset by a widely expected miss from Ohtuvayre. The guidance revision is viewed as underwhelming given the size of the beat and the already conservative initial guidance, though some point out that it does not include the one-time EPS hit from charges related to the TERN acquisition. Focus remains on 2026 clinical updates, though some caution the stock already prices in high pipeline expectations. BMY reports Q1 EPS $1.58 ex-items vs FactSet $1.42 on revenue $11.49B vs FS $10.93B. Reaffirms FY26 guidance, both top and bottom lines trending toward the upper-end. Opdivo $2.15B vs FactSet $2.29B, (5.3%) y/y; Eliquis $4.14B vs FS $3.82B, +16% y/y. Quick take: Takeaways have been generally constructive around the print, highlighting much of Q1 upside was driven by legacy strength on Eliquis and Pomalyst beats - though Camzyos continued launch trajectory was also a noted tailwind. Discussion also leaned bullish around near term catalysts, including: phase 3 milvexian in Afib and SSP (H2 2026), phase 3 Cobenfy in Alzheimer's in psychosis (H2 2026) and phase 3 admilparant in IPF (H2 2026). Some suggesting current modeling largely discounts revenue contribution from these assets, with upside potential should they see positive outcomes. Earnings in Services & Hospitals and Managed Care CI reports Q1 EPS $7.79 ex-items vs FactSet $7.60 on revenue $68.49B vs FS $66.29B. MLR 79.8%, ahead of StreetAccount consensus by 120bps. Raises FY26 EPS outlook by 10c and reiterates FY MLR. CAH reports Q3 EPS $3.17 ex-items vs FactSet $2.79 on revenue $60.94B vs FS$62.10B. Raises FY26 EPS outlook by 50c at the midpoints. Reaffirms revenue growth by segment. LH reports Q1 EPS $4.25 vs FactSet $4.11 on revenue $3.54B vs FS $3.51B. Organic growth +3.1% vs StreetAccount +2.4%. Adj OM 14.4% vs SA 14.2%. Raises FY26 EPS outlook by 12.5c at the midpoints. Raises revenue outlook by $2.5M at the midpoints. THC reports Q1 adjusted EBITDA $1.16B vs FactSet $1.12B, EPS $4.82 ex-items vs FS $4.17, on revenue $5.37B vs FS $5.39B. Raises FY26 EPS outlook by 20c at the midpoints, reiterates revenue and adj EBITDA. OPCH reports Q1 adjusted EBITDA $104.8M vs FactSet $103.0M, EPS $0.40 ex-items vs FS $0.37, on revenue $1.35B vs FS $1.40B. Lowers FY26 revenue outlook by $175M at the midpoints, reaffirms adj EBITDA and EPS. ACHC reported Q1 EPS $0.37 ex-items vs FactSet $0.26 on revenue $828.8M vs FS $823.5M, adj EBITDA $144.2M vs FS $132.9M. Guides Q2 below consensus from top to bottom lines. Raises FY26 EPS guidance by $0.05 at the midpoints, raises adj EBITDA outlook by $5M, and reaffirms FY26 revenue outlook. Earnings in Life Science & MedTech ALGN reported Q1 EPS $2.58 ex-items vs FactSet $2.30 on revenue $1.04B vs FS $1.02B. Reiterates FY26 guidance to bottom. Guides Q2 revenue below at the midpoint, and volume up sequentially and y/y, ASP flat sequentially and y/y. BAX reports Q1 EPS $0.36 ex-items vs FactSet $0.31 on revenue $2.70B vs FS $2.62B. Reiterates FY26 guidance top and bottom. GKOS reported Q1 EPS ($0.18) vs FactSet ($0.28) on revenue $150.6M vs FS $137.0M. Raises FY26 revenue outlook by $17.5M at the midpoints. WAY reported Q1 EPS $0.42 ex-items vs FactSet $0.39 on revenue $313.9M vs FS $311.7M, and adj EBITDA $135.4M vs FS $128.5M. Reaffirms FY26 guidance. ITGR reports Q1 EPS $1.20 ex-items vs FactSet $1.19, adj EBITDA $85.1M vs FS $81.9M, on revenue $440M vs FS $426.5M. Announces strategic review to maximize shareholder value. No deadline or definitive timeline given. Broadly lowers FY26 financial guidance. Earnings in Biotech ALNY reports Q1 EPS $1.51 vs FactSet $0.90 on revenue $1.17B vs FS $1.12B. Reiterates FY26 guidance. VKTX reported Q1 results including cash and equivalents $603M. VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled. VK2735 Maintenance Dosing Study Ongoing; Data Expected 3Q26. Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26 KYMR reports Q1 results including cash & equivalents $1.55B, which it expects to provide runway into 2029 and beyond multiple inflection points in its pipeline. Surgeon General pick Means out, Saphier in On Thursday, President Trump withdrew his nomination of Casey Means - confirmation beset by her stance on vaccines - and nominated Dr Nicole Saphier, another frequent contributor to Fox News, and author of books including "MAHA: How Bad Behavior and Big Government Caused a Trillion Dollar Crisis" and "Panic Attack: Playing Politics with Science in the Fight Against COVID-19". Insulet clarifies the FDA on SAEs, stock bouncing from Wednesday slide PODD post-close on Wednesday commented via 8-K and clarified the earlier FDA report of '476 serious injuries' is actually 476 Medical Device Reports and 29 confirmed serious adverse events HHS formally files appeal of preliminary injunction in CDC ACIP case On 29-Apr, the HHS (defendant) filed a Notice of Appeal in AAP v Kennedy (1:25-cv-11916). The preliminary injunction was ordered on 16-Mar. Biotech IPO #8 of CY26 ALVN (Avalyn Pharma) 16.7M-share IPO priced at $18/sh -- upsized and at high-end of the expected range, proceeds $300M vs $200M at the midpoints. Clinical-stage biotech focused on inhaled therapies for pulmonary fibrosis. Lead candidate is AP01 (inhaled pirfenidone), the active ingredient in Esbriet (Legacy Pharma in US / ROP.SW globally). Also AP02 (inhaled nintedanib), the active ingredient in Ofev (+Boehringer) - S-1/A Shares opened on the Nasdaq at $26.00, and currently trading +55%. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from 503B bulks list In a Federal Register notice today, the FDA provides notice that the agency is evaluating substances that have been nominated for inclusion on a list of bulk drug substances (active pharmaceutical ingredients) for which there is a clinical need for outsourcing facilities to use in compounding (the 503B Bulks List). This notice identifies three bulk drug substances that FDA has considered and proposes not to include on the 503B Bulks List: semaglutide, tirzepatide, and liraglutide. Additional bulk drug substances nominated for inclusion on this list are under consideration and may be the subject of future notices. Docket open for comments through 29-Jun-2026 - FDA press release Pre-market trading update: LLY +5.5% (earnings), NVO +2.9%, HIMS +1.7% Notable research in Healthcare today Pharma: ABBV upgraded to buy from neutral at BofA (Jason Gerberry), target increased to $234 from $226 or approx. 15% upside. (FactSet average PT $253; range $205-294) MedTech: GEHC downgraded to neutral from buy at Goldman Sachs (David Roman), target cut to $65 from $81 or approx. 9% upside. (FactSet average PT $80; range $65-110) Post-close news Trial update: MRK Merck trading higher. Within Summit's Q1 earnings report, company disclosed that HARMONi-3 study of ivonescimab in squamous non-small cell lung cancer will continue as planned to the 'final PFS analysis' at the interim analysis in H2 of 2026. Follows the recommendation of IDMC after an 'early interim' PFS analysis. Study remains blinded. Shares of SMMT trading (21.6%) in the after-hours; MRK +2.6% and BNTX (6.9%) in reaction. Regulatory: AZN.LN FDA ODAC votes to support TRUQAP sNDA in prostate cancer. The vote was 7 yes, 1, no, 1 abstain. ADRs trading +1.4% in the after-hours Katherine Szarama elevated to FDA CBER Director to fill position last held by Vinay Prasad, reports Politico. Szarama was hired last year as Deputy Director under Prasad. S&P 500 Index change: VEEV to replace Coterra Energy (CTRA) in the S&P 500 Index following the acquisition by Devon (DVN). Share of VEEV +9.0% in the after-hours Earnings: AMGN reports Q1 EPS $5.15 ex-items vs FactSet $4.77 on revenue $8.62B vs FS $8.58B. Repatha, Tepezza, Uplizna all beat; Prolia, Tezspire, Enbrel all miss. Raises FY26 EPS guidance by 10c, and revenue by $100M, all at the midpoints. Conf. call at 16:30ET Shares trading (1.8%) in the after-hours SYK reports Q1 EPS $2.60 ex-items vs FactSet $2.98 on revenue $6.02B vs FS $6.34B. Organic growth +2.4% vs StreetAccount +8.3%. Reaffirms FY26 EPS guidance, and maintains FY26 revenue growth range. Conf. call at 16:30ET Shares trading (1.4%) in the after-hours RMD reports Q3 EPS $2.88 ex-items vs FactSet $2.80 on revenue $1.43B vs FS $1.42B. Reiterates FY26 guidance. Announces retirement of CFO Brett Sandercock, effective 4-May. Aaron Bloomer, formerly at Exact Sciences, appointed as next CFO. Conf. call at 16:30ET ADRs trading (2.7%) in the after-hours DXCM reports Q1 EPS $0.56 ex-items vs FactSet $0.47 on revenue $1.19B vs FS $1.17B. Topline beat driven by International, and offset by US miss. Reaffirms FY26 revenue guidance, and NG gross profit margin. Raises NG operating margin by 75bp at the midpoints. Conf. call at 16:30ET Shares trading (6.2%) in the after-hours ILMN reports Q1 EPS $1.15 ex-items vs FactSet $1.05 on revenue $1.09B vs FS $1.07B. Raises FY26 EPS guidance by 10c and revenues by $20M, all at the midpoints. Guides Q2 EPS midpoint below FS, revenue outlook ahead. Conf. call at 16:30ET Shares trading (3.0%) in the after-hours EHC reports Q1 adj EBITDA $348.8M vs FactSet $338.5M on revenue $1.59B vs FS $1.57B, and EPS $1.60 ex-items vs FS $1.49. Raises low-end of FY26 EBITDA guidance; Narrows outlook for EPS and midpoint raised 9.5 cents. Conf. call tomorrow at 10:00ET Shares trading +3.0% in the after-hours BIO reports Q1 EPS $1.89 ex-items vs FactSet $1.97 on revenue $592.1M vs FS $589.9M. Lowers FY26 revenue growth outlook - now expects decline of (3%) to growth +0.5% vs prior growth +0.5-1.5%. Also lowered OM outlook. Conf. call at 17:00ET Shares trading (6.5%) in the after-hours Research: EVMN initiated buy at Stifel (Alex Thompson), target is $54 or approx. 127% upside. (FactSet average PT $52; range $48-55) SEPN initiated buy at Stifel (Alex Thompson), target is $43 or approx. 81% upside. (FactSet average PT $44; range $35-60) On Deck: Regulatory during April: INBX submission of BLA for ozekibart SRPT submission of sNDAs to convert accelerated approvals (AA) to full approvals Earnings tomorrow morning: MRNA (call at 8:00ET) BTSG (call at 8:30ET) Conference on Sat 2-May: Digestive Disease Week (DDW) 2026 (May 2-5) on Sun 3-May: Assn for Research in Vision and Ophthalmology (ARVO) 2026 (May 3-7) Syndicate calendar / potential IPO pricing tonight: +COAG (Hemab Therapeutics) - S-1/A - clinical-stage biotech focus in blood coagulation disorders. Lead asset sutacimig (HMB-001) +SPTX (Seaport Therapeutics) - S-1/A - clinical-stage biotech focus in neuro and CNS disorders. Lead asset GlyphAllo (SPT-320) StreetAccount Healthcare Reads Trump pulls nomination for stalled surgeon general nominee Means and says he'll put forth Saphier (30-Apr) AP One of the world's most common knee surgeries does not help and may even be harmful (29-Apr) U of Helsinki / AAAS Your Doctor Is Using A.I. to Take Notes. What Could Go Wrong? (28-Apr) NY Times Health system CEOs get off easy at Congressional hearing on affordability (28-Apr) STAT News Rectal cancer deaths rising up to three times faster in specific age group, study finds (27-Apr) Fox News This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABBV, ACHC, ALGN, ALNY, AMGN, AVLN, AZN.LN, BAX, BIIB, BIO, BMY, BTSG, CAH, CI, DXCM, EHC, ERAS, EVMN, GEHC, GH, GKOS, GRAL, HIMS, ILMN, INBX, INCY, INDV, ITGR, KYMR, LH, LLY, MANE, MRK, MRNA, NVCR, NVO, NVS, OPCH, PODD, PRCT, QURE, RMD, ROP.SW, SEPN, SMMT, SRPT, SYK, TFX, THC, VEEV, VKTX, WAY, ZBIO, +COAG, +SPTX...(more)	show story hide story
30-Apr-2026 16:44	AZN.LN FDA ODAC panel votes 7-1-1 to support AstraZeneca's TRUQAP sNDA in prostate cancer (13948p) Panel vote: 7 Yes, 1 No, 1 Abstain Full question: Based on the CAPItello-281 results, does the benefit of adding capivasertib [TRUQAP] to abiraterone and prednisone outweigh the risk for the proposed indication? See Related StreetAccount comments: 4/30/2026 12:02:56 PM - FDA ODAC Panel votes 6-3 against AstraZeneca's camizestrant in combination with CDK4/6 inhibitor in breast cancer patients 4/28/2026 3:04:40 PM - FDA releases briefing materials ahead of Thursday adcom (earlier, timing uncertain)	show story hide story
30-Apr-2026 12:19	AZN.LN PineTree Therapeutics (private) announces that AstraZeneca exercised option for bispecific degrader program (19:00ET, 29-Apr) (13948p) Pinetree Therapeutics, Inc. (0MBNHF-E) announced that AstraZeneca has exercised its option under the companies' previously announced agreement to obtain an exclusive global license to develop and commercialize PTX-299, a first-in-class bispecific antibody degrader targeting EGFR. AstraZeneca will pay $25M fee and assume responsibility for global development and commercialization of the therapeutic candidate. Pinetree is also eligible to receive potential future development, regulatory, and commercial milestone payments and tiered royalties on global net sales if the product is successfully developed and commercialized. The total potential value of the agreement exceeds $500M. See Related StreetAccount comments: 7/23/2024 11:26:41 AM - Pinetree Therapeutics (private) announces exclusive option and global license agreement for preclinical EGFR degrader candidate with AstraZeneca (AZN.LN) Related: 0MBNHF-E Reference Link	show story hide story
30-Apr-2026 12:02	AZN.LN FDA ODAC Panel votes 6-3 against AstraZeneca's camizestrant in combination with CDK4/6 inhibitor in breast cancer patients (13948p) Editor's Note: This comment was revised to include distribution for Guardant Health (GH) (30-Apr-2026, 12:12 ET) See Related StreetAccount comments: 28-Apr-26 - FDA releases briefing materials ahead of Thursday adcom (earlier, timing uncertain) 06-Mar-26 - FDA panel to host meeting on 30-Apr to review AstraZenecas camizestrant and capivasertib 01-Jun-25 - AstraZeneca announces results from the SERENA-6 Phase III trial at ASCO 2025 Related: GH Reference Link Reference Link	show story hide story
30-Apr-2026 08:53	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings calendar ramp continues, with major pharma's turn today. Eli Lilly, Merck, and Bristol Myers on the tape, plus large-caps from every major group. Eli Lilly reported big beat-and-raise with diabesity drugs leading the charge. Shares are up +6% in the pre-market; Novo Nordisk also higher by +3% in reaction. Merck reported Q1 earnings muddled by an acquisition-related charge, however revenue beat widely with strength in Keytruda, Gardasil, and Winrevair. Guidance revision viewed underwhelming. Shares of MRK +1% in the pre-market. Bristol Myers middle of the fairway with a beat-and-reaffirm, although legacy products carried Q1. Shares are flattish in the pre-market. Eighth biotech IPO of the year priced overnight. Avalyn Pharma, with a focus on inhaled treatments for IPF, priced an upsized offering at $18/shr. Macro S&P futures are up +0.4% on Thursday morning, near best levels of the morning. Market not doing much following the flurry of big tech earnings after the close on Wednesday. Results supportive of the broader AI narrative surrounding insatiable compute demand and elevated capex, though they also came with some of the familiar concerns surrounding ROI/monetization and sustainability. As was the case with the OpenAI story earlier this week, bigger overhang may be the extent of the tailwind already provided by the AI trade in recent weeks. In addition, market has to deal with upward pressure on oil and yields stemming from the stalemate in the Middle East, along with the related complications for monetary policy. Technical dynamics have also shifted with the fading of the mechanical bid from CTA re-risking and estimates for outsized month-end selling of equities. Pre-market trading update Trading higher +15.4% GKOS earnings +11.5 PRCT earnings +9.9% QURE regulatory update in UK for Huntington's Disease +9.5% ALNY earnings +8.4% INDV earnings +6.3% LLY earnings +5.1% BAX earnings +2.9% NVO sympathy to LLY +2.8% NVS update on US manufacturing +2.4% GSK Health Canada files HepB treatment +1.7% ABBV upgraded at BofA +1.1% MRK earnings Trading lower -25.8% OPCH earnings -12.6% TDOC earnings -3.8% ACHC earnings (low volume) -1.5% CNC follow-through -0.6% THC earnings Pharma Earnings: LLY reports Q1 non-GAAP EPS $8.55 vs FactSet $6.97 on revenue $19.80B vs FS $17.82B. Raises FY26 EPS guidance by $2/shr, revenue guidance by $2B, and margin by 100bps. Mounjaro $8.66B vs SA $7.26B, +125.5% y/y; Zepbound $4.16B vs SA $4.04B, +79.9% y/y; Jardiance $1.11B vs SA $799.8M, +9.8% y/y. Conf. call at 10:00ET MRK reports Q1 EPS ($1.28) ex-items vs FactSet ($1.47) -- includes charge of $3.62 for the acquisition of Cidara-- on revenue $16.29B vs FS $15.85B. Raises FY26 EPS guidance 2.5c at the midpoints, raises low-end of FY26 revenue guidance by $300M. Keytruda $8.03B vs StreetAccount $7.78B, +11.5% y/y; Winrevair $525M vs SA $487.0M, +87.5% y/y. Quick Take: Initial takeaways view the results as broadly positive, with Keytruda strength easing concerns around softness. Winrevair, Animal Health, and Gardasil strength also attributed to the top-line beat, partly offset by a widely expected miss from Ohtuvayre. The guidance revision is viewed as underwhelming given the size of the beat and the already conservative initial guidance, though some point out that it does not include the one-time EPS hit from charges related to the TERN acquisition. Focus remains on 2026 clinical updates, though some caution the stock already prices in high pipeline expectations. Conf. call at 10:00ET BMY reports Q1 EPS $1.58 ex-items vs FactSet $1.42 on revenue $11.49B vs FS $10.93B. Reaffirms FY26 guidance, both top and bottom lines trending toward the upper-end. Opdivo $2.15B vs FactSet $2.29B, (5.3%) y/y; Eliquis $4.14B vs FS $3.82B, +16% y/y. Conf. call at 10:00ET Research: ABBV upgraded to buy from neutral at BofA (Jason Gerberry), target increased to $234 from $226 or approx. 15% upside. (FactSet average PT $253; range $205-294) Biotech Earnings: ALNY reports Q1 EPS $1.51 vs FactSet $0.90 on revenue $1.17B vs FS $1.12B. Reiterates FY26 guidance. Conf. call at 8:30ET VKTX reported Q1 results including cash and equivalents $603M. VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled. VK2735 Maintenance Dosing Study Ongoing; Data Expected 3Q26. Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26 KYMR reports Q1 results including cash & equivalents $1.55B, which it expects to provide runway into 2029 and beyond multiple inflection points in its pipeline. Conf. call at 8:30ET Trial update: ALEC announces the discontinuation of phase 2 PROGRESS-AD trial evaluating nivisnebart (GSK.LN) following a pre-specified futility analysis by IDMC. IPO priced: ALVN (Avalyn Pharma) 16.7M-share IPO priced at $18/sh -- upsized and at high-end of the expected range, proceeds $300M vs $200M at the midpoints. Clinical-stage biotech focused on inhaled therapies for pulmonary fibrosis. Lead candidate is AP01 (inhaled pirfenidone), the active ingredient in Esbriet (Legacy Pharma in US / ROP.SW globally). Also AP02 (inhaled nintedanib), the active ingredient in Ofev (+Boehringer) - S-1/A Life Science & MedTech Earnings: ALGN reported Q1 EPS $2.58 ex-items vs FactSet $2.30 on revenue $1.04B vs FS $1.02B. Reiterates FY26 guidance to bottom. Guides Q2 revenue below at the midpoint, and volume up sequentially and y/y, ASP flat sequentially and y/y. BAX reports Q1 EPS $0.36 ex-items vs FactSet $0.31 on revenue $2.70B vs FS $2.62B. Reiterates FY26 guidance top and bottom. Conf. call at 8:30ET GKOS reported Q1 EPS ($0.18) vs FactSet ($0.28) on revenue $150.6M vs FS $137.0M. Raises FY26 revenue outlook by $17.5M at the midpoints. WAY reported Q1 EPS $0.42 ex-items vs FactSet $0.39 on revenue $313.9M vs FS $311.7M, and adj EBITDA $135.4M vs FS $128.5M. Reaffirms FY26 guidance. ITGR reports Q1 EPS $1.20 ex-items vs FactSet $1.19, adj EBITDA $85.1M vs FS $81.9M, on revenue $440M vs FS $426.5M. Announces strategic review to maximize shareholder value. No deadline or definitive timeline given. Broadly lowers FY26 financial guidance. Conf. call at 9:00ET Corporate update / regulatory: PODD post-close on Wednesday commented via 8-K and clarified the earlier FDA report of '476 serious injuries' is actually 476 Medical Device Reports and 29 confirmed serious adverse events Research: GEHC downgraded to neutral from buy at Goldman Sachs (David Roman), target cut to $65 from $81 or approx. 9% upside. (FactSet average PT $80; range $65-110) Services & Hospitals Earnings: CAH reports Q3 EPS $3.17 ex-items vs FactSet $2.79 on revenue $60.94B vs FS $62.10B. Raises FY26 EPS outlook by 50c at the midpoints. Reaffirms revenue growth by segment. Conf. call at 8:30ET LH reports Q1 EPS $4.25 vs FactSet $4.11 on revenue $3.54B vs FS $3.51B. Organic growth +3.1% vs StreetAccount +2.4%. Adj OM 14.4% vs SA 14.2%. Raises FY26 EPS outlook by 12.5c at the midpoints. Raises revenue outlook by $2.5M at the midpoints. Conf. call at 9:00ET THC reports Q1 adjusted EBITDA $1.16B vs FactSet $1.12B, EPS $4.82 ex-items vs FS $4.17, on revenue $5.37B vs FS $5.39B. Raises FY26 EPS outlook by 20c at the midpoints, reiterates revenue and adj EBITDA. Conf. call at 10:00ET OPCH reports Q1 adjusted EBITDA $104.8M vs FactSet $103.0M, EPS $0.40 ex-items vs FS $0.37, on revenue $1.35B vs FS $1.40B. Lowers FY26 revenue outlook by $175M at the midpoints, reaffirms adj EBITDA and EPS. Conf. call at 8:30ET ACHC reported Q1 EPS $0.37 ex-items vs FactSet $0.26 on revenue $828.8M vs FS $823.5M, adj EBITDA $144.2M vs FS $132.9M. Guides Q2 below consensus from top to bottom lines. Raises FY26 EPS guidance by $0.05 at the midpoints, raises adj EBITDA outlook by $5M, and reaffirms FY26 revenue outlook. Conf. call at 9:00ET Managed Care Earnings: CI reports Q1 EPS $7.79 ex-items vs FactSet $7.60 on revenue $68.49B vs FS $66.29B. MLR 79.8%, ahead of StreetAccount consensus by 120bps. Raises FY26 EPS outlook by 10c and reiterates FY MLR. Conf. call at 8:30ET On Deck: Regulatory FDA Adcom to discuss AZN camizestrant NDA in breast cancer (GH)(AM session) (8:00-12:00ET) FDA Adcom to discuss AZN Truqap (capivasertib) sNDA in prostate cancer (PM session) (13:00-17:00ET) FDA PDUFA for AXSM Auvelity (AXS-05) sNDA in Alzheimer's Disease Agitation During April: INBX submission of BLA for ozekibart; SRPT submission of sNDAs to convert accelerated approvals (AA) to full approvals Earnings after the close today AMGN (call at 16:30ET), SYK (call at 16:30ET), RMD (call at 16:30ET), DXCM (call at 16:30ET), ILMN (call at 16:30ET), EHC (call Fri at 10:00ET), BIO (call at 17:00ET), ALHC (call at 17:00ET), MMSI (call at 16:30ET), IRTC (call at 16:30ET) Earnings tomorrow morning MRNA (call at 8:00ET), BTSG (call at 8:30ET) Conference on Sat 2-May: Digestive Disease Week (DDW) 2026 (May 2-5) on Sun 3-May: Assn for Research in Vision and Ophthalmology (ARVO) 2026 (May 3-7) Syndicate calendar / potential IPO pricing: Thu 30-Apr post-close: +COAG (Hemab Therapeutics) - S-1/A - clinical-stage biotech focus in blood coagulation disorders. Lead asset sutacimig (HMB-001) +SPTX (Seaport Therapeutics) - S-1/A - clinical-stage biotech focus in neuro and CNS disorders. Lead asset GlyphAllo (SPT-320) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABBV, ACHC, ALEC, ALGN, ALHC, ALNY, ALVN, AMGN, AXSM, AZN, BAX, BIO, BMY, BTSG, CAH, CI, CNC, DXCM, EHC, GEHC, GH, GKOS, GSK, GSK.LN, ILMN, INBX, INDV, IRTC, ITGR, KYMR, LH, LLY, MMSI, MRK, MRNA, NVO, NVS, OPCH, PODD, PRCT, QURE, RMD, ROP.SW, SRPT, SYK, TDOC, THC, VKTX, WAY, +ALVN, +BOEHRINGER...(more)	show story hide story
30-Apr-2026 06:50	AZN.LN Street Takeaways - AstraZeneca Q1 earnings (13844p +152p) Overview: AstraZeneca shares are currently trading +0.9% higher and closed lower (1.5%) yesterday after it reported Q1 earnings on Wednesday morning. The Q1 print saw core EPS $2.58 vs consensus $2.54, total revenue $15.29B vs consensus $14.95B, and core operating profit $5.35B vs consensus $5.23B. For 2026, the company confirmed total revenue and Core EPS guidance for FY26 at CER, based on the average foreign exchange rates through 2025. Total Revenue is expected to increase by a mid-to-high single-digit percentage, Core EPS is expected to increase by a low double-digit percentage and Core Tax rate is expected to be between 18-22%. Analysts were mostly positive following the print, highlighting results ahead of expectations across the board and confirming guidance for 2026. Analysts also flagged the company's healthy project pipeline with upcoming drug launches with strong possible earnings catalysts. Therefore, most analyst reaffirmed their confidence in the company and its ability to deliver growth over the coming year, with an analyst at Oddo indicating that the group remains well positioned to deliver above-industry earnings growth. However, Deutsche Bank questioned the quality of the results, attributing the earnings beat to one drug or segment, and noted minor negative R&D newsflow. Sell-side ratings (32): Buy 81% Hold 13% Sell 6% The average target increased +0.3% to £165.53, implying 19.6% upside Consensus Estimate Revisions: FY2026: Revenues +0.2% to $63.46B, and EPS +$0.02, +0.2%, to $10.29. FY2027: Revenues +0.2% to $67.93B, and EPS +$0.03, +0.2%, to $11.65. Analyst Commentary: UBS analyst Matthew Weston Notes that AstraZeneca reported a solid Q1 with sales and Core EPS c.2% ahead of expectations. Outperformance was seen in rare diseases and parts of Oncology. Cost and margin trends were in line with expectations. The analyst continues to see AZN as best-placed among EU Major Pharma to drive sector-leading growth to 2030E and to have the breadth and depth of pipeline replacement power to address the significant patent expiries the whole industry will see from 2029+. looks to eplontersen in ATTR-CM, tozorakimab in COPD and the mid-term potential of elecoglipron in weight management as key data sets in 2H26. Flags that Dato-DXd in the AVANZAR study is a high risk incremental opportunity in lung cancer, where the analyst and market expectations are low. Also sees the potential for camizestrant to build in ER+ breast cancer, but notes that data in the largest adjuvant indications are an opportunity 2028+. Continues to see AZN as a core portfolio holding for mid-term growth and innovation. Rating is buy with a price target of £176 Oddo analyst Florent Cespedes Notes that these results underpin the analyst's positive rating on the stock. Flags that the share price was volatile yesterday and thinks that the market is nervous because consensus expectations are already high. But in the analyst's view, AZN remains well positioned to deliver above-industry earnings growth (double-digit versus mid- to high single digit), thanks to growing established franchises, recent and upcoming drug launches, and despite patent losses (which we deem manageable). Rating is outperform with a price target of £165 JPMorgan analyst Richard Vosser Notes that the group reported results with Q1 Revenues, Core Operating Profit and Core EPS coming in 2% ahead of Consensus. Flags that for 2026, the company reiterated guidance for "mid-to-high single-digit % CER" Revenue growth with a "low single-digit FX tailwind", together with "low-double-digit % CER" Core EPS growth with a neutral FX impact. Assuming 7% CER Revenue growth, combined with a 2% FX tailwind, implies Total Revenues of $64,108m, c.2% ahead of Company Consensus at $63,127m. Highlights that on Core EPS, assuming 12% CER Core EPS growth and 0% FX, implies Core EPS of $10.26, in-line with Consensus at $10.27. Therefore, expects limited changes to Consensus Core EPS on the back of the results, though the sales forecasts could increase by 1-2%. Points out that on the back of the results, the analyst made minor changes to the forecasts, increasing 2027-2030 Revenue, Core Operating Profit and Core EPS forecasts by c.1-2% through 2027-30. Rating is overweight with a price target of £160 DNB Carnegie analyst Erik Hultgård Notes that Q1 confirmed to the analyst that the company is on track to meet the 2026 guidance and its long-term targets. Remains focused on upcoming pipeline news flow, particularly the AVANZAR and SERENA-4 read-outs in H2 - both USD5bn+ peak sales opportunities. Rating is buy with a price target raised to SEK1950 from SEK1920 Deutsche Bank analyst Emmanuel Papadakis Notes that the group's Q1 is nominally a 2% beat all the way down with a guide reiteration, but quality is very mixed, with Farxiga accounting for most of the revenue beat and a number of key brands missing, whilst OOI accounted for all of the core EBITA beat. Flags that there is minor negative R&D newsflow. Rating is sell with a price target of £115 See Related StreetAccount comments: 4/29/2026 2:13:19 AM - StreetAccount Metrics Recap - AstraZeneca Q1 Earnings 4/29/2026 2:08:42 AM - AstraZeneca reports Q1 core EPS $2.58 vs consensus $2.54; reconfirms FY26 total revenue and core EPS guidance	show story hide story

Download StreetAccount for iOS from the App Store.
All times are in (UTC-05:00) Eastern Time (US & Canada) unless otherwise specified.
Copyright ©2026 FactSet Research Systems Inc.

Terms and Conditions Disclaimer Sitemap Privacy Policy Careers

Week \| Month \| Quarter
Start:
End:
Enter dates in mm/dd/yyyy format